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Abstract 
Introduction: Drug-target binding kinetics are major determinants of the time course of drug action for 
several drugs, as clearly described for the irreversible binders omeprazole and aspirin. This supports the 
increasing interest to incorporate newly developed high-throughput assays for drug-target binding kinetics 
in drug discovery. A meaningful application of in vitro drug-target binding kinetics in drug discovery requires 
insight in the relation between in vivo drug effect and in vitro measured drug-target binding kinetics. 
 
Areas covered: In this review, the authors discuss both the relation between in vitro and in vivo measured 
binding kinetics and the relation between in vivo binding kinetics, target occupancy and effect profiles.  
We conclude that more scientific evidence is required for the rational selection and development of drug-
candidates on basis of in vitro estimates of drug-target binding kinetics. 
 
Expert opinion: To elucidate the value of in vitro binding kinetics measurements, it is necessary to obtain 
information on system-specific properties which influence the kinetics of target occupancy and drug effect. 
Mathematical integration of this information enables the identification of drug-specific properties which 



















Abbreviations: GPCR: G-Protein Coupled Receptor, HTRF: Homogeneous Time-Resolved Fluorescence, NA: 
Not Available, PET: Positron Emission Tomography, SAW: Surface Acoustic Wave, SPECT: Single Photon 
Emission Computed Tomography, SPR: Surface Plasmon Resonance, TO: target occupancy. 
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1. Introduction 
The rates of drug-target association and dissociation are essential determinants of the time course of target 
binding and drug effect. This is most clearly illustrated by the irreversible binders aspirin and omeprazole, 
which have shown a long-lasting effect in clinical practice [1–3]. Numerous other examples confirm that 
drug-target binding kinetics are important drug characteristics, as reviewed by others [4–6]. 
The relevance of drug-target binding arises from their connecting role between pharmacokinetics and 
pharmacodynamics. More precisely, for a given drug concentration profile, the kinetics of drug-target 
binding determine the time course of target occupancy and thus the time course of drug effect. The basic 
concepts of target equilibration kinetics are well established. The simplest mechanism to describe drug-
target binding is depicted in equation 1,   
 
(1) 
in which T = target concentration, L = ligand concentration, kon = the second order association rate constant, 
and koff = the first order dissociation rate constant. However, more complex mechanisms have been 
described in which target activation and G-protein binding (for GPCR’s) are incorporated [5,7]. Affinity, the 
ratio of the dissociation and association rate constants (KD = koff/kon), is related to binding kinetics, but 
informs only on the extent of binding at equilibrium and gives no information on the required time to reach 
a new equilibrium. 
The important role of drug-target binding kinetics as a determinant of target occupancy profiles has been 
known for long, and both in vitro and in vivo measurements of association and dissociation kinetics have 
been reported from the eighties of last century [8–10]. However, with the development of high-throughput 
in vitro methods for binding kinetics, such as SPR, the interest in the use of binding kinetics in drug discovery 
has been rising in the past ten years. This has also led to the development of structure-kinetics relationships 
(SKR’s) for some drug classes [11,12]. The recent attention for binding kinetics in drug discovery focuses 
mostly on the drug-target dissociation rate, since a slow dissociation rate is expected to give a prolonged 
duration of drug action and improved efficacy [5,6,13–16].  
While most recent publications express an expected benefit of incorporating drug-target binding kinetics in 
drug discovery, more critical studies have also been published. On basis of basic 
pharmacokinetic/pharmacodynamic simulations, Dahl and Akerud indicated that the relevance of binding 
kinetics in drug treatment depends on a drug’s pharmacokinetics [15]. Several other studies have indicated 
that multiple other physiological processes can influence the impact of drug-target binding kinetics on drug 
effect, including endogenous competition, diffusion-limited binding and signal transduction [17–19]. While 
these simulations might contain oversimplifications and cannot be applied to all cases of drug treatment, it 
is important to realize that the impact of drug-target binding kinetics on drug action depends on multiple 
kinetic processes in the human body. 
To incorporate the role of drug-target binding kinetics in this complexity of kinetic processes, mathematical 
models have been developed to describe and predict the time profile of drug effects for several drugs and 
targets [20–26]. These models have been used to estimate drug-target binding kinetics on basis of 
pharmacokinetic and pharmacodynamic data, which supports the relevance of drug-target binding kinetics 
for drug action. 
In summary, the available literature indicates a growing interest in the application of screening techniques 
for binding kinetics in drug discovery and a context dependency for the impact of drug-target binding 
kinetics on drug effect. This poses the question under which conditions the in vitro screening of binding 
kinetics would further drug discovery and development. To answer this question, this review aims to 
investigate the value of in vitro binding kinetics measurements for the prediction of in vivo target occupancy 
and drug effect, using available literature with emphasis on two questions: 
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• What is the relation between in vitro measured binding kinetics and in vivo measured binding 
kinetics? 
• To what extent do binding kinetics contribute to target occupancy and drug effect profiles in vivo? 
To that end, first, the available methods to measure drug-target binding kinetics both in vitro and in vivo will 
be addressed and discussed. Second, we will discuss to what extent the estimates of these in vitro and in 
vivo methods provide comparable results, and what experimental conditions are required to enable 
translation of in vitro to in vivo binding kinetics. Third, we will discuss binding kinetics in a broader 
perspective, i.e. in the context of the other determinants of target occupancy and drug effect. Finally, the 
integration of all kinetic processes will be discussed, as well as their implementation in the various phases of 
drug discovery and development. 
2. In vitro methodological approaches to measure binding kinetics 
2.1 Labeled-ligand assays  
Various methods are available to determine in vitro kinetic binding parameters of compounds of interest at 
their respective target. In this review, we will use “ligand” to refer to compounds of interest (either labeled 
or unlabeled) and we will use “tracer” to refer to labeled or unlabeled compounds with known binding 
characteristics intended to inform about the binding of compounds of interest. The methods as discussed 
below are summarized in table 1.  
 
2.1.1 Radiolabel-based assays 
The most commonly used and straightforward method to characterize target binding is the use of 
radioligand binding assays. These assays use a radiolabeled ligand and can directly measure the association 
and dissociation rates of the radiolabeled ligand. In addition to traditional association and dissociation 
experiments, other kinetic radiolabel-based binding assays such as a competition association assay are 
emerging. This type of assay is an indirect assay based on a theoretical model developed by Motulsky & 
Mahan in 1984 by which one can quantitatively determine the binding kinetics of unlabeled ligands in a 
competitive assay using only one radiotracer [16,27–29]. The competition association assay can also be used 
in a higher-throughput fashion with the recently developed dual-point competition association assay. Only 
two timepoints are selected here to measure radiotracer binding; the ratio of binding at both time points 
gives a qualitative measure of the ligands’ dissociation kinetics. This makes this simplified assay a suitable 
method for screening potential drug candidates with favorable dissociation kinetics [30]. 
 
2.1.2 Fluorescent label-based assays 
Similarly, instead of using a radiolabeled tracer in a competition assay the tracer can also be fluorescently 
labeled and used in homogeneous time-resolved fluorescence (HTRF) assays. Similar to the radioligand 
competition assay, only one fluorescently labeled tracer is required and the binding kinetics of competitive 
ligands can be determined in an indirect fashion. This method is homogeneous since it requires no physical 
separation of bound and free ligand which enables continuous measurements and increases the 
throughput. HTRF assays are successfully applied in the determination of binding kinetics of dopamine D2 
receptor antagonist spiperone [31] and more recently for histamine H1 receptor ligands [32] and GnRH 
receptor agonists [Nederpelt et al., 2015, submitted for publication]. Of note, in addition to a fluorescently 
labeled tracer a fluorescently labeled receptor is needed for this method, as opposed to wild-type receptors 
for radioligand and radiotracer binding.  
  
10 
Table 1. Overview of in vitro methods to measure drug-target binding kinetics. 
 In vitro methods 
Technique radioligand radiotracer HTRF SPR SAW Organ bath Washout 
Throughput 
rate 

































































SAW: Surface Acoustic Wave, HTRF: Homogenous Time-Resolved Fluorescence, SPR: Surface Plasmon Resonance 
 
2.2 Label-free assays 
Several label-fee methods can be applied for kinetic target binding measurements without the need of a 
labeled ligand or labeled tracer.  
2.2.1 Surface plasmon resonance 
The most instilled label-free measurement is surface plasmon resonance (SPR) spectroscopy [33]. This 
method has the potential to be medium-throughput and the capability to measure real-time quantitative 
binding kinetics of ligands for membrane proteins using relatively small quantities of protein. The traditional 
SPR method needs one immobilized binding component on a coated gold sensor chip during which the 
ligand in solution is flowed over the sensor chip. This induces a real time change in the refractive index on 
the sensor surface which is linear to the number of molecules bound [33–35].  
2.2.2 Acoustic wave biosensor 
Another label-free technology is the surface acoustic wave biosensor [36]. This methodology captures real-
time mass changes on the surface, which result in a shifted phase and/or changed amplitude of a sound 
wave signal [37]. A disadvantage of these biophysical approaches for G protein-coupled receptors is that 
these receptors are integral membrane proteins that rapidly disintegrate when taken out of their natural 
environment, which is a prerequisite for these approaches. However, recent advances are made to 
overcome this problem [33].  
 
2.3 Functional assays 
Another way to determine drug-target binding kinetics is by use of functional assays. These assays provide 
an indirect measurement of binding kinetics by characterizing the time profile of drug effect. Although the 
use of functional assays is generally limited due to the indirect nature of these measurements, functional 
assays are valuable for the measurement of enzyme binding kinetics because of the direct relation between 
enzymatic product generation rates and enzyme inhibitor binding. Functional assays can be carried out in 





2.3.1 Organ bath 
An organ bath experiment is only suitable to qualitatively examine binding kinetics of antagonists and 
requires pre-incubation of cells/tissues with antagonists prior their challenge with an agonist. With this 
method the distinction between so-called surmountable and insurmountable antagonists can be made, 
where the level of insurmountability by an antagonist is related to its receptor dissociation kinetics 
[18,38,39].  
2.3.2 Washout 
Functional washout experiments are suitable for predicting binding kinetics of both agonists and 
antagonists. In this type of experiments, the rate of decrease in effect after removal of the free ligand by 
repeated washing (washout) is measured. Agonists with fast dissociation kinetics will readily wash out and 
will show a right-ward shift in their potency, whereas agonists with slow dissociation kinetics will show 
insignificant shifts in their potency, and vice versa for antagonists. It should be stated that control 
experiments are necessary to confirm that the long-lasting effect of the ligand is due to long target binding 
versus other effect-prolonging factors (such as exo-site binding, membrane partitioning, rebinding or signal 
transduction [40–42].  
 
3.1 In vivo methodological approaches to measure binding kinetics 
3.1.1 General principle of target occupancy measurements 
To obtain drug-target binding kinetics in vivo, target occupancy and target site concentrations are required. 
For most in vivo and ex vivo approaches, the target occupancy of a drug is measured indirectly by using a 
tracer. The administered drug competes at the same target site with the tracer and the reduction in specific 
binding of the tracer is used to calculate the target occupancy of the drug. The tracer can be an antagonist 
(more common) or agonist to the target, and can be radiolabeled (more common) or non-radiolabeled. The 
advantages and disadvantages of each approach will be briefly discussed, and the characteristics of each 
approach are summarized in table 2. We focus here mainly on methods which are in use for measurement 
of binding kinetics in the brain, since most methods have been used primarily for the brain targets. 
3.1.2 Tissue homogenate method with radiolabeled tracer 
The traditional way of measuring CNS target occupancy in preclinical animals is the brain homogenate 
method. At a pre-determined time point after radiotracer administration, the animal is sacrificed and the 
brain regions of interest (e.g. striatum for D2 receptors) and the reference region (e.g. cerebellum which has 
relatively low D2 receptor density, for the correction of non-specific binding of radiotracer to and uptake in 
brain tissue) are collected. These brain regions are then dissolved in a scintillation cocktail and the drug-
induced change in radioactivity of the tracer is measured by a liquid scintillation counter. Literature reports 
suggest that the target occupancy values obtained by this method are comparable to that obtained by 
positron emission tomography (PET) imaging [43]. Compared with PET/SPECT (single-photon emission 
computed tomography) imaging, this method is associated with much lower costs and allows higher 
throughput in screening different compounds or different doses of a single compound. Nevertheless, since 
this method involves the terminal use of animals, a continuous target occupancy time profile within the 
same animal cannot be obtained, and multiple animals are needed for a single target occupancy time 
profile. Moreover, in addition to the receptors expressed on the membrane surface, intracellular or 
internalized receptors would also become accessible to the tracer when the tissue is homogenized, which 






Table 2. Overview of in/ex vivo methods to measure drug-target binding kinetics. 
 In vivo methods 
 
Ex vivo methods 
 




















































































































































PET: Positron Emission Tomography, SPR: Surface Plasmon Resonance, SPECT: Single Photon Emission 
Computed Tomography, TO: target occupancy 
3.1.3 Tissue homogenate method with non-radiolabeled tracer using LC/MS assays 
The procedures of this method are the same as that with radiolabeled tracer as described above, except 
that a non-radiolabeled tracer (cold tracer) is administered to the animal and the absolute amount of the 
tracer in the brain tissues is quantified by LC/MS. The first report was presented by Phebus and colleagues, 
in which the drug-induced target occupancy of D2, serotonin 2A and NK-1 receptors in rat was quantified 
using non-radiolabeled tracers [45]. They also demonstrated in rats that for the eight D2-antagonists they 
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had investigated, the doses required to achieve 50% target occupancy using this LC/MS method (cold 
raclopride as tracer) are comparable to those using the traditional brain homogenate method 
([3H]raclopride as tracer) [46]. This method offers several advantages; first, the parent, intact tracer in the 
brain tissue can be differentiated from the tracer metabolites, thus increasing the accuracy of tracer 
quantification. Second, the costs and hazards associated with radioactivity are avoided. Third, it allows 
separation and quantification of different tracers in one sample, and thus enables the simultaneous 
assessment of the target occupancy of different receptors [47].  
The greatest concern of this method is the relatively high dose of the tracer that needs to be administered. 
Since the sensitivity of an LC/MS assay is lower than that of radioactivity counting, a much higher dose of 
the tracer is administered in order to achieve a quantifiable tissue concentration. This high tracer dose 
might distort the drug-induced target occupancy and might exert pharmacodynamics effects [48,49]. 
3.1.4 PET/SPECT imaging  
PET and SPECT imaging are the most common approaches to measure drug target occupancy in living 
humans and other primates. After the administration of a very small dose of radiotracer for the desired 
target, scans are carried out by the PET or SPECT scanner before and after administration of the competing 
drug. The radioactivity at the region of interest is measured, from which the density of receptors (Bmax) and 
the radiotracer binding affinity (KD) are derived. The ratio of Bmax and KD is termed the binding potential. The 
target occupancy of the drug is calculated as the percentage reduction in binding potential after drug 
administration. Binding kinetic parameters (kon, koff) can be derived if the target occupancy and free drug PK 
at the binding site are available by fitting a mathematical model which describes binding kinetics according 
to scheme 1. However, the PET signal arises from the sum of free, specifically and non-specifically bound 
radiotracer, and free concentrations cannot be measured at the binding site. Instead of the free drug 
pharmacokinetics at the binding site, a reference tissue which is similar to the binding site but has no 
specific binding is commonly used [50,51]. PET/SPECT can be regarded as an in vivo version of 
autoradiography (discussed in the ex vivo section), with inferior spatial resolution but with the advantage 
that the pharmacokinetics of the tracer can be measured in a single experiment, or even in repeated studies 
on the same subject [52]. This also provides the possibility to obtain target occupancy values at different 
time points within the same subject. Over the past decade, there are considerable developments of both 
PET and SPECT systems with improved spatial resolution designed specifically for small-animal imaging (i.e. 
microPET and microSPECT). 
A limiting factor in longitudinal PET/SPECT measurements is the half-life of the radioactive decay of the 
tracer (depending on the applied radiolabel), which can limit the duration of the experiment after tracer 
administration. This limited duration of the imaging decreases the suitability of PET/SPECT for measuring 
drugs with slow binding kinetics 
One of the main concerns in PET/SPECT is that the anesthesia, applied to immobilize the animals before and 
during imaging, could hamper the accuracy of target occupancy assessment by, for example, altering the 
level of neurotransmitters [53]. Moreover, the use of anesthesia might also impose additional experimental 
variability (e.g. due to variable susceptibility to the anesthetic effect [54]).  
Since both the tracer and the drug of interest interact with the same receptor, the observed effect cannot 
be completely attributed to the drug. Therefore, drug effect measurements are considered less useful, 
except for studies which are focused on the binding and effect of only the tracer. Depending on the target of 
interest, the required anesthesia can also interact with drug effects and make their measurement 
impossible or less useful. 
3.1.5 Beta-microprobe 
Another method of measuring a radiotracer in a living animal’s brain is the use of a beta-microprobe. The 
microprobe captures beta/positron emission (similar to the PET detector) and is surgically implanted in the 
brain structures of interest, allowing in vivo measurement of local radioactivity concentrations within 1-2 
14 
millimeters from the probe. Reports on the application of beta-microprobe on target occupancy assessment 
are limited. Good correlations have been reported between in vivo beta-microprobe measurements and ex 
vivo brain homogenate and in vivo microPET measurements of respectively D2 and 5HT1A target occupancy 
in rat brain [55,56].  
The potential advantages of beta-microprobe are that the target occupancy could be measured in awake, 
non-anesthetized animals and simultaneous assessment of drug-induced changes in behavior is allowed, 
which are critical for drugs that act on CNS receptors. Nevertheless, the surgical implantation procedures 
might interfere with the neurochemistry and the pharmacokinetics and pharmacodynamics of the drug and 
tracer. Implantation of the electrode into the brain would cause mechanical trauma and trigger both acute 
and chronic tissue responses, and the final outcome depends on factors such as the size, geometry and 
material of the probe, the insertion method, and the period after insertion [57]. Device implantation could 
also alter the release of neurotransmitters and neural activity [58]. While the previously developed beta-
microprobes were based on a single pixel scheme that did not provide any spatial information on the 
radiotracer distribution [55], a new wireless probe was recently published, which contains 10 submillimeter 
pixels which allows the analysis of the spatial distribution of the radiotracer within the region of interest in 
freely moving rats [59]. 
3.2 Ex vivo approaches of target occupancy measurements 
3.2.1 Tissue homogenate method with radiolabeled tracer 
While for in vivo methods both the drug and the tracer are administered to the living animals, for ex vivo 
methods the tracer is added to the collected tissue from the drug-treated animal, and the amount of 
radiotracer bound to the target in the homogenate is measured by liquid scintillation counting. In this way 
tracers with unfavorable in vivo characteristics (e.g. slow equilibrium at target tissue, pharmacokinetic 
variability etc.) can be used and the costs of developing suitable tracers are reduced and the amount of 
tracer can be precisely controlled. However, the values of target occupancy obtained by this method are 
highly dependent on the binding conditions (particularly the time and temperature of tracer incubation) and 
tend to give an underestimation of drug-induced target occupancy [60]. This is mainly due to the 
dissociation of the drug from the receptor during the ex vivo tracer incubation and the tissue 
homogenization step, particularly for those drugs with a fast dissociation rate from the receptor. Therefore, 
a short incubation time and a radiotracer with a fast association rate is recommended [60]. 
 
3.2.2 Tissue slice autoradiography imaging 
The procedures of this method are the same as that with tissue homogenate method described above, 
except that the animal tissue is sectioned into slices and the amount of radiotracer bound to the target is 
quantified by autoradiography. Unlike tissue homogenate, the tissue slice preparation maintains structural 
integrity. It offers higher spatial resolution than PET/SPECT imaging and thus allows the investigation of 
anatomical regions that are small in size. Traditionally, the radioactivity on the slice is captured by 
autoradiographic film, which requires a long exposure period (weeks) and thus is not considered as an 
efficient screening method for determining the target occupancy of compounds [61]. The introduction of 
storage phosphor imaging is a major improvement in ex vivo receptor autoradiography, which shortens the 
exposure time from weeks to days or even one day [62]. An alternative method is to use a beta-imager 
which uses a highly sensitive gaseous detector of beta particles. This allows the exposure time to be 
shortened to a few hours [63].  
4. Comparison of in vitro and in/ex vivo measurements of binding kinetics 
To investigate whether the current in vitro and in vivo measurements of binding kinetics deliver similar or 
translatable values, we performed a literature survey to identify compounds for which both in vitro and in 
vivo estimates of target association or dissociation rates were available. Since in vivo estimates are the least 
available, we started our search with in vivo estimates and continued to search for in vitro estimates of the 
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same compounds. Since the number of compounds for which we could find in vitro and in vivo estimates of 
their target binding kinetics was very low, we decided to list all estimates we could find and discuss the 
reliability and comparability of the estimates below. The results of this search are listed in table 3.   
Based on table 3, we can start to answer our first question: 
• What is the relation between in vitro measured binding kinetics and in vivo measured binding 
kinetics? 
From the results in table 3, it can be directly seen that the difference between in vitro and in vivo estimates 
of target dissociation rates can be quite substantial (up to 30 fold) and inconsistent (the ratio varies from 0.2 
to 31). This clearly indicates that the use of in vitro measured target binding kinetics to predict in vivo 
binding profiles is not straightforward. Apart from the studies in table 3, another study was published in 
which no in vivo values for kon and koff were included, but in vitro values were used to predict target 
occupancy profiles of the CRF1 receptor in rats for several antagonists [23]. Although the in vivo results 
were not highly informative for the identification of the binding kinetics for some compounds in this study, 
the target occupancy profiles could be predicted reasonably well.  
To investigate the origin of the observed difference between in vitro and in vivo binding studies, the 
experimental details need to be taken into account to identify which results are less reliable or comparable. 
4.1 Temperature 
Firstly, all in vitro estimates of association and dissociation rates which are not obtained at 37 °C cannot be 
compared directly to in vivo estimates, since these rates are temperature dependent in a compound specific 
manner [85–87]. Therefore entry 3, 9, 12, 13, 17, 18 and 19 from table 3 cannot be used to compare in vitro 
and in vivo dissociation rates.  
4.2 Influence of in vivo displacer/competitor dose 
Another important factor in the comparison between in vitro and in vivo estimates of target dissociation 
rates is the method by which the dissociation is induced. Drug-target dissociation can be induced in in vitro 
studies either by continuous washing, the so-called “infinite dilution” method, or by displacement of the 
drug by adding an excess of a competing ligand. These methods can give quite different results since 
washing cannot displace all free ligand molecules and diffusion-limited binding (or “rebinding”) can occur. 
Thus, comparisons between in vitro and in vivo estimates should use the same method of dissociation 
measurement [19]. However, in the in vivo setting, continuous washing cannot be applied and the amount 
of competing compound which can be added is limited by its toxicological effects. In the analysis of in vivo 
drug-target binding studies, computational models can be used to correct for remaining drug concentrations 
or partial displacement. However, this is often not done and assumptions have to be made about the effect 
of a displacer dose or of a remaining drug concentration. For entry 1, 3, 4, 8 and 10 from table 3, the 
rationale for the displacer dose was not clear, and model-based analysis was not used. These entries should 
therefore not be used to compare in vitro and in vivo dissociation rates. For entry 1, the in vitro experiment 
did not use either a displacer or continuous washing, which makes it even less appropriate for comparison 
with the in vivo experiment.  
For entries 14-19 in table 3, the in vivo drug-target binding kinetic parameters are estimated from PK and PD 
data without target occupancy measurements. This makes these estimates indirect and subject to 
influences of signal transduction kinetics and other factors between PK and PD. Therefore, entry 14-19 
cannot be used for a direct comparison of in vitro and in vivo binding kinetic parameters. 
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a t1/2 assoc.: concentration-dependent association half-life in min•nM (at a constant concentration of free 
ligand or free target and with absence of dissociation), t1/2 dissoc.: dissociation half-life in min (with absence 
of association). Values are obtained by calculating 0.693/kon and 0.693/koff, respectively. 
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b I = transfected CHO cells, II = rat striatal membranes, III = rat striatal homogenate, IV = rat brain 
homogenate, V = guinea pig brain homogenate, VI = baboon occipital homogenate, VII = rat brain P2 
fraction, VIII = rat cardiac membranes.  
c this value was obtained at 25 °C. 
d displayed value is the average from all brain regions as reported in the reference.  
e displayed value is the average from all experiments as reported in the reference.  
f displayed value is the average from all brain regions as reported in the reference, except for the pons, 
which had an insufficient significance. 
g this value was obtained at 4 °C. 
h this value was obtained at 22 °C. 
i displayed value is the average from the three-compartment estimation from all brain regions as reported in 
the reference. 
j this value was obtained at room temperature. 
k The published kon values in this reference seem to be erroneously calculated. The value in this table is 
obtained by dividing the measured koff over Ki.  
l This value was based on a model fit on drug effect data of heart rate. The same model was also fitted on 
blood pressure which resulted in a similar but dose dependent estimate, which was ignored. 
PET: Postiron Emission Tomography, SPECT: Single Photon Emission Computed Tomography, NA: Not 
Available. 
 
4.3 Most valid comparisons 
To evaluate the difference between in vitro and in vivo estimates of association and dissociation rates, we 
should only use the most valid comparisons, restricting table 3 to entries 2,5,6,7 and 11. Now the ratio 
between in vitro and in vivo estimates varies between 0.9 and 4 which is considerably better, but based only 
on four compounds and two targets. Moreover, it should be noted that these entries include only one entry 
for which the comparison is made with human binding data. Also, all observations from table 3 originate 
from GPCRs and therefore, none of the studies used isolated receptors. One could speculate that the 
correlation between in vitro and in vivo estimates is better for membrane-bound targets than for soluble 
targets since the membrane-bound receptors are mostly measured in membrane fractions and therefore 
retain some of their natural environment, whereas soluble targets can be completely purified. However, the 
natural exposure of membrane-bound receptors to the differential composition of extracellular and 
intracellular fluids cannot be reproduced in homogenized in vitro experiments, while the homogeneous 
environment of soluble targets can be replicated in vitro. 
4.4 Summary 
The amount of available literature data to compare in vitro and in vivo estimates for drug-target dissociation 
rates in a valid manner is too low to draw general conclusions about the predictive value of the in vitro drug-
target dissociation estimates. This is even more so for drug-target association rates. Moreover, differences 
in experimental approach and conditions, and differences in data analysis hamper the comparison of in vitro 
and in vivo binding kinetics data. These differences include most frequently a difference in temperature (i.e. 
in vitro experiment not at 37 °C), difference in dissociation method (washout vs. displacement) and analysis 
method (model-based parameter estimation vs. graphical methods). Therefore, the current in vitro 
estimates of drug-target binding kinetics cannot be translated reliably into in vivo binding kinetics due to a 
lack of available information on comparability and due to methodological differences between in vitro and 
in vivo experiments.  
 
5. Missing links in the translation between in vitro and in vivo binding kinetics 
The differential results that have been observed from in vitro and in vivo studies can be explained by a 
multitude of differences between the extremely complex in vivo situation and the much more simplified in 
vitro environment. Possible explanations include factors that are poorly understood, such as the in vivo 
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occurrence of complicated ligand interactions with multiple targets, allosteric binding sites, exosites and 
subcellular compartments or organelles, but also complex target interactions with other proteins (homo- 
and heterodimerisation), and other cell membrane and intra- and extracellular fluid constituents, such as 
ions. Moreover, the in vivo three-dimensional structure of multiple cell types is rarely replicated in vitro and 
unknown contributors to the observed in vivo target binding kinetics cannot be excluded.  
However, the following section is focused on the better understood contributors to in vivo target binding 
kinetics and how these can be accounted for in the design and analysis of both in vitro and in vivo 
experiments 
5.1 Experimental conditions in in vitro and in vivo studies of binding kinetics 
As described in the previous section, the comparison of in vitro and in vivo binding kinetic parameters is 
often hampered by differential experimental conditions between in in vitro and in vivo studies. We will 
discuss here the most relevant experimental conditions which can hamper the translation between in vitro 
and in vivo measured binding kinetics. These are: in vitro temperature, in vivo displacement method and the 
presence of endogenous ligand. 
5.1.1 Temperature 
One very important in vitro and ex vivo experimental condition is the temperature. Since both drug-target 
association and dissociation rate are temperature dependent in a compound-specific manner [85–87], 
translation of binding kinetics from one temperature to another temperature cannot be done unless the 
temperature dependency has been determined for that specific compound. Moreover, since the target 
conformation might be temperature dependent as well, the Arrhenius plots of kon and koff are not 
necessarily linear. A few literature examples are available of linear Arrhenius plots for kon and koff [87–89]. 
Therefore, it is highly relevant to obtain in vitro binding parameters at 37 °C, or to obtain a linear Arrhenius 
plot at lower temperatures.  
5.1.2 Displacer/competitor 
Another condition that may affect translational success is the presence or absence of a 
displacer/competitor. To account for this, it is necessary to obtain both in vitro and in vivo estimates for koff 
in the presence of a displacer. If both experiments are done in the absence of a displacer, translation can 
still be hampered because of differential diffusion rates and target clustering in the two experiments, 
leading to different diffusion-limited binding (“rebinding”). 
5.1.3 Endogenous ligand 
The presence of an endogenous ligand is also influencing the rate of drug-target association and 
dissociation. An endogenous ligand can be present both in vitro and in vivo. To enable an accurate in vivo 
and in vitro estimation of drug-target kon and koff in the presence of an endogenous ligand, the concentration 
profile over time during the experiment and the binding kinetics of the endogenous ligand need to be 
known. 
5.2 Integrated analysis of multiple determinants of in vivo target occupancy and drug effect 
In order to use in vitro binding kinetic data to predict in vivo target occupancy and effect kinetics, all kinetic 
processes which influence the in vivo kinetics of drug effect need to be taken into account (see also section 
7). These include pharmacokinetics, endogenous competition, diffusion-limited binding, non-specific 
binding, target turnover and signal transduction. Each of these processes will be discussed in the following 
section. 
5.2.1 Pharmacokinetics 
One of the clearest examples for the need to integrate all kinetic processes for the prediction of in vivo 
target occupancies is the role of pharmacokinetics: If the drug concentration in the human body has a 
constant profile, an equilibrium situation will be reached and a slow dissociation rate will not prolong the 
target occupancy anymore. On basis of a very simple relation between pharmacokinetics and binding 
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kinetics, one can expect a slow dissociation rate to be prolonging target occupancy only when its 
dissociation rate is slower than its elimination rate (figure 2, upper panels) [15,19]. However, this might be 
an oversimplification, and other processes need to be integrated as well [19].   
5.2.2 Endogenous competition 
Another process which is important for the role of binding kinetics is endogenous competition. The 
presence of a varying concentration of endogenous ligand can make a drug’s binding kinetics more 
important, also when its dissociation half-life does not exceed its plasma elimination half-life (figure 1) 
[14,18,90–92]. Since endogenous ligands usually have a varying concentration, endogenous competition 
might be relevant for the binding kinetics of most agonists and antagonists. A hypothesis in this direction 
was already published by Kapur and Seeman before the recent interest in binding kinetics [92]. In their 
publication, fast dissociating dopamine antagonists were suggested to be less resistant to dopamine 
signaling, thereby preventing side effects from over-suppression of dopamine signaling. 
 
Figure 1. The influence of drug-target binding kinetics on drug (dashed lines) and dopamine (solid lines) target occupancy 
(TO) is influenced by endogenous competition, as simulated by Vauquelin et al [18]. A constant drug concentration and 
pulsatile dopamine concentration are used, and the system is allowed to reach equilibrium before t = 0. The dopamine 
concentrations rise after 4 seconds to represent a high activity period. The drug target dissociation rate (koff) changes from 
181 min-1 (light grey) to 6.03 min-1 (dark grey), and 0.181 min-1 (black).  
5.2.3 Diffusion-limited binding  
A kinetic process which has got only limited attention for its effect on target occupancy profiles is diffusion-
limited binding. If the effective diffusion of a drug around its target is limited, the chance that it will re-
associate to its target before diffusing into the tissue (often called ‘rebinding’) will increase and thus the 
target occupancy will decrease slower than expected from its binding kinetics and tissue concentration. 
Although the possible significance of diffusion and diffusion-limited binding (or ‘rebinding’) has already been 
indicated in studies with rats, humans and in vitro over three decades ago [9,10,93], there is no general 
practice of taking this into account in either in vitro or in vivo studies. As reported several times by 
Vauquelin and his colleagues, based on literature, experimental and theoretical findings, “rebinding” can 
have a significant impact on the estimated koff value in in vitro and in vivo studies, and therefore needs to be 




Figure 2. The influence of drug-target binding kinetics on target occupancy (TO) depends on both pharmacokinetics and 
diffusion-limited binding, as simulated by Vauquelin et al [19]. The drug target dissociation rate (koff) changes from 83 hr-1 
(black) to 2.1 hr-1 (dark grey), 0.35 hr-1 (grey), and 0.087 hr-1 (light grey). The drug elimination rate constant is 0.35 hr-1 for 
the left panel and 0.087 hr-1 for the right panel. 
5.2.4 Non-specific binding 
Another kinetic process which can influence the profile of target occupancy is non-specific binding. Non-
specifically bound drug can act as a reservoir which releases drug upon decreasing free drug concentrations, 
thereby decreasing the effective elimination rate. Moreover, if the release of non-specifically bound drug is 
slow, this can become the rate determining factor for the rate of drug elimination from either the plasma or 
the target tissue (figure 3) [97,98].  
 
5.2.5 Target turnover 
The rate of target synthesis and degradation can also influence the profile of target occupancy, since the 
breakdown of occupied target and synthesis of new (unoccupied) target decreases the occupied fraction. 
Thus, target turnover provides a suitable explanation for the limited duration of the antiplatelet effect of 
the irreversible binder aspirin [1]. Moreover, target synthesis and degradation can be regulated and 
function as feedback mechanisms [99–103]. A high rate of target turnover can limit the impact of a 
decreasing dissociation rate constant and can increase the impact of the association rate constant (figure 4). 
5.2.6 Signal transduction 
Apart from these multiple factors which influence the target occupancy profiles, another step is required to 
predict effect kinetics from target occupancy profiles. To do this, the kinetics of all signal transduction steps 
need to be taken into account. The significance of signal transduction kinetics with respect to binding 
kinetics has been indicated by a simulation study of binding kinetics, enzyme inhibition and several signal 
transduction pathways [17]. However, since signal transduction can have various mechanisms and includes 
feedback mechanisms, the influence of signal transduction on the role of drug-target binding kinetics can 
differ greatly between targets.  
Although the kinetics of signal transduction can be important, direct relationships between target 
occupancy and drug effect have been characterized for a few targets. However, in vivo target occupancy and 
drug effect are rarely measured simultaneously, and mathematical models are often required to estimate 
the relationship between target occupancy and effect from pharmacokinetic and pharmacodynamic data. 
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One example where in vivo target occupancy and drug effect were measured simultaneously for the 
dopamine D2 receptor demonstrated the typical hyperbolical relationship [104]. However, linear 
relationships between target occupancy and effect have been used by mathematical models as well, for 
example to describe drug effect for calcium channel blockers and DPP-4 inhibitors [20, 26]. 
 
Figure 3. The target occupancy (TO) profile can be influenced by non-specific binding of the drug, as simulated for lipid and 
protein binding in the brain by Peletier et al [97]. The drug target dissociation rate constant (koff) is 36 hr-1for all lines. For 
the left panel, the drug-protein dissociation rate constant changes from 1000 sec-1 (black) to 100 sec-1 (red), 10 sec-1 
(green), and 1 sec-1 (orange). For the right panel, the drug-lipid dissociation rate constant changes from 500 sec-1 (black) to 
100 sec-1 (red) and 20 sec-1 (green). The drug-protein and the drug-lipid affinity change in the same way as the dissociation 
rate constants, since both drug-protein and drug-lipid association rate constants remain unchanged. 
 
Figure 4. The influence of drug-target binding kinetics on target occupancy (TO) can be influenced by target turnover, as 
described by the model of Hong et al. for the antiplatelet effect of aspirin and ibuprofen [1]. The drug target dissociation 
rate (koff) changes from 0 (black line representing aspirin) to 0.001 hr-1 (red), 0.01 hr-1 (green), 0.1 hr-1 (orange) and 1 
hr-1(blue). The target degradation rate constant (kdeg) is 0.02 hr-1(as identified for aspirin and ibuprofen) for the left panel 
and 0.2 hr-1 for the right panel (note the different time scale). The target synthesis rate constant (ksyn) was adjusted 




5.2.7 Integrated mathematical modeling 
To incorporate all the processes as described above for the prediction of target occupancy and drug effect 
and to use these predictions for the selection of the best drug candidates, quantitative mathematical 
description and integration of all these processes is essential. 
Mathematical models have made use of drug-target binding kinetics in the previous decades to describe and 
predict the time course of drug effect [20–26]. These mathematical models most often use differential 
equations to describe the rate with which concentrations change, rather than describing the absolute value 
of a concentration for any time point. The use of differential equations requires solving of the differential 
equations for each time profile and each initial value, but it also allows the integration of numerous 
processes in a relatively simple way. As an example, the decrease in drug concentration due to elimination is 
often described by an equation like equation 2, where dC/dt is the change in drug concentration per time 
unit, C is the drug concentration and kel is the elimination rate constant.  
𝑑𝐶
𝑑𝑡
=  −𝑘𝑒𝑙 ∗ 𝐶                                                                (2) 
Equation 2 means that if kel = 0.1/min, for example, the drug concentration decreases with 10% every 
minute (if you solve the equation by taking time steps of 1 minute). For compartmental models, differential 
equations are used to describe the concentration in each compartment, and each compartment is 
considered to be homogeneous. For example, if the distribution of a drug over the body is fast or limited, 
the concentration profile of a drug in plasma can often be described by a one-compartment model with 
absorption and elimination. Such a compartmental approach can be used to describe drug-target binding by 
adding one or more compartments which represent the drug-target complex and assuming homogeneous 
distribution of the target in one of the pharmacokinetic compartments. This approach has been used for the 
simulations of figure 1-4, where binding was simulated from a single compartment for figure 2 and 4, from a 
brain compartment for figure 3 while a constant concentration was used for figure 1. Although these 
simulations are based on simplifying assumptions such as homogeneity, they provide a conceptual insight in 
the impact of the described processes on the relation between drug-target binding kinetics and target 
occupancy. 
A special field where drug-target binding kinetics are taken into account as standard practice is the field of 
target mediated drug disposition (TMDD). TMDD describes the pharmacokinetics of drugs (mostly 
biologicals) which are distributed and eliminated predominantly when bound to their target. In this 
situation, binding kinetics are required to describe the drugs pharmacokinetics, since the pharmacokinetics 
depend on the binding and the dissociation is often relatively slow [105–108]. Mathematical analysis of a 
TMDD model revealed that kon had a more pronounced impact on the maximal target occupancy than koff 
[109]. Another field where drug-target binding kinetics are commonly incorporated in mathematical models 
is in the analysis of positron emission tomography (PET) data (see table 3). In all these examples and in the 
simulations shown in figure 1-4, mathematical models have demonstrated their potential to further our 
understanding of the role of drug-target binding kinetics in their complex physiological context. 
6. Conclusion 
On basis of the sparse amount of available literature estimates for drug-target binding kinetics, no 
conclusions can be made on how well in vivo binding kinetics are reflected in in vitro experiments. 
Moreover, differences in conditions, methodology and analysis avoid the comparison of available in vitro 
and in vivo estimates in many cases.  
Next to the relation between in vitro and in vivo estimates of binding kinetics, the relation between in vivo 
binding kinetics and in vivo target occupancy and effect kinetics is also uncertain. This relation can be 
influenced by pharmacokinetics, endogenous competition, target tissue diffusion, non-specific binding, 
signal transduction and other factors. A quantitative integration by means of mathematical models can 
greatly enhance our understanding of the role of drug-target binding kinetics in this context. 
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This implies that more scientific support is required for the rational selection and development of drug-
candidates on basis of in vitro estimates of drug-target binding kinetics.  
 
7. Expert opinion: Towards an integrated approach for translational binding kinetics analysis in 
drug discovery and development.  
The aforementioned determinants of target occupancy are related to each other, and need to be taken into 
account in an integrated manner. The use of compartmental modeling, as applied commonly in PK/PD 
modeling, is an important tool to facilitate the integration of all kinetic processes which are involved in the 
generation of drug effect (figure 5). The value of such models for all stages of drug discovery and 
development is increasingly recognized [110–112].  
 
Figure 5. Schematic representation of the interconnected kinetic processes which determine target occupancy and effect 
kinetics. The central compartment represents the blood, the target site compartment represents the direct environment 
around the target, from where binding occurs.  
The feasibility of such an integrative approach in (the early phases of) drug discovery and development may 
seem limited by its complex and time-consuming nature. However, it is important to note that some of 
these kinetic processes are system-specific processes (e.g. endogenous competition, target turnover and 
signal transduction). These system-specific processes are equal for all new compounds and will not decrease 
the screening throughput in drug discovery. The integrated analysis of these system-specific processes can 
thus be used to define which drug specific kinetic parameters (e.g. drug-target association and dissociation 
rate, non-specific binding rates and pharmacokinetic parameters) are most relevant per target/drug class to 
screen for. During the drug discovery process, the screening can start with only the most important 
parameter and be gradually extended to the other relevant parameters to refine the compound selection. 
The integrated analysis of all contributors to drug effect will not only improve compound selection, but it 
will also enable drug-candidate optimization on the most relevant parameters and optimization of drug 
dosing and sampling times in (pre)clinical investigations.  
7.2 Context-dependency of binding kinetics values 
To enable the integrated analysis of the kinetic processes which determine a drug’s effect kinetics, specific 
information on all of these separate processes is required. This urges the performance of both in vitro and in 
vivo experiments which deliver drug- and system specific parameters for all kinetic processes. This is 
necessary to avoid experiments which inform only on the combined effect of multiple processes and thus 
deliver context-dependent information. For example, if an in vivo binding study is analyzed to determine 
only the rate with which the target occupancy inclines and declines after a certain dose, process-specific 
information is lacking because no specific information is collected about the pharmacokinetics or binding 
kinetics. This applies also to in vitro experiments. If a washout experiment is used to estimate the 
dissociation rate without a competing ligand, the obtained estimate can be a combined parameter for both 
dissociation and diffusion, because ‘rebinding’ can occur [96]. The occurrence of multiple kinetic processes 
during one experiment is not necessarily problematic, as long as the results can be analyzed in a process-
specific manner to enable optimal translation to different experimental or clinical conditions. This type of 
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process-specific analysis can be obtained by using physiologically based PK/PD models with process-specific 
parameters. 
 
7.3 Need for an integrated approach 
Although experiments are available and in use to estimate the rate constants of the above mentioned 
kinetic processes, there is hardly any information available about what the relative contribution of each of 
those processes is in the determination of target occupancy profiles during the various scenarios of drug 
treatment. To enable the prediction of in vivo target occupancy and effect profiles, integrated analysis of 
experimental data and increased theoretical insight in the role of all contributors to target occupancy and 
effect are required. Mathematical models which describe the mechanisms of all relevant processes can be 
of great value to both analyze experimental data and simulate various cases of drug treatment in a 
comprehensive and integrated fashion. Increasing knowledge of the drivers of drug effect is of critical 
importance to select the best drug candidates in drug discovery, to optimize drug therapy in drug 
development and improve the health of those in need of medicines.   
8. Acknowledgements 
The K4DD project is supported by the Innovative Medicines Initiative Joint Undertaking (IMI JU) under grant 
agreement no 115366, resources of which are composed of financial contribution from the European 





1.  Hong Y, Gengo FM, Rainka MM, et al. Population pharmacodynamic modelling of aspirin- and ibuprofen-
induced inhibition of platelet aggregation in healthy subjects. Clin Pharmacokinet 2008;47(2):129–37  
2.  Katashima M, Yamamoto K, Tokuma Y, et al. Comparative pharmacokinetic/pharmacodynamic analysis of 
proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans. Eur J Drug Metab 
Pharmacokinet 1998;23(1):19–26  
3.  Äbelö A, Holstein B, Eriksson UG, et al. Gastric acid secretion in the dog: A mechanism-based pharmacodynamic 
model for histamine stimulation and irreversible inhibition by omeprazole. J Pharmacokinet Pharmacodyn 
2002;29(4):365–82  
4.  Copeland RA. The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy 
and safety. Expert Opin Drug Discov 2010;5(4):305–10  
5.  Tummino PJ, Copeland RA. Residence Time of Receptor-Ligand Complexes and Its Effect on Biological Function. 
Biochemistry 2008;47(20):5481–92  
6.  Swinney DC. The role of binding kinetics in therapeutically useful drug action. Curr Opin Drug Discov Devel 
2009;12(1):31–9  
7.  Kinzer-Ursem TL, Linderman JJ. Both ligand- and cell-specific parameters control ligand agonism in a kinetic 
model of g protein-coupled receptor signaling. PLoS Comput Biol 2007;3(1):84–94   
8.  Leysen JE, Gomeren W. Different kinetic properties of neuroleptic receptor binding in the rat striatum and 
frontal cortex. Life Sci 1978;23(5):447–52  
9.  Perry DC, Mullis KB, Oie S, et al. Opiate antagonist receptor binding in vivo: evidence for a new receptor binding 
model. Brain Res 1980;199(1):49–61  
10.  Syrota A, Paillotin G, Davy JM, et al. Kinetics of in vivo binding of antagonist to muscarinic cholinergic receptor in 
the human heart studied by positron emission tomography. Life Sci 1984;35(9):937–45  
11.  Guo D, Xia L, van Veldhoven JPD, et al. Binding Kinetics of ZM241385 Derivatives at the Human Adenosine A2A 
Receptor. ChemMedChem 2014;9(4):752–61  
12.  Schneider E V, Böttcher J, Huber R, et al. Structure-kinetic relationship study of CDK8/CycC specific compounds. 
Proc Natl Acad Sci U S A 2013;110(20):8081–6  
13.  Copeland RA, Pompliano DL, Meek TD. Drug-target residence time and its implications for lead optimization. 
Nat Rev Drug Discov 2006;5(9):730–9  
14.  Vauquelin G, Van Liefde I. Slow antagonist dissociation and long-lasting in vivo receptor protection. Trends 
Pharmacol Sci 2006;27(7):356–9  
15.  Dahl G, Akerud T. Pharmacokinetics and the drug-target residence time concept. Drug Discov Today 2013;18(15-
16):697–707   
16.  Guo D, Hillger JM, IJzerman AP, et al. Drug-target residence time - a case for G protein-coupled receptors. Med 
Res Rev 2014;34(4):856–92  
17.  Yin N, Pei J, Lai L. A comprehensive analysis of the influence of drug binding kinetics on drug action at molecular 
and systems levels. Mol Biosyst 2013;9(6):1381–9  
18.  Vauquelin G, Bostoen S, Vanderheyden P, et al. Clozapine, atypical antipsychotics, and the benefits of fast-off 
D2 dopamine receptor antagonism. Naunyn Schmiedebergs Arch Pharmacol 2012;385(4):337–72  
19.  Vauquelin G. Rebinding : or why drugs may act longer in vivo than expected from their in vitro target residence 
time. Expert Opin Drug Discov 2010;5(10):927–41  
20.  Shimada S, Nakajima Y, Yamamoto K, et al. Comparative Pharmacodynamics of Eight Calcium Channel Blocking 
Agents in Japanese Essential Hypertensive Patients. Biol Pharm Bull 1996;19(3):430–7  
21.  Yun H-Y, Yun M-H, Kang W, et al. Pharmacokinetics and pharmacodynamics of benidipine using a slow receptor-
binding model. J Clin Pharm Ther 2005;30(6):541–7  
22.  Steagall PVM, Pelligand L, Giordano T, et al. Pharmacokinetic and pharmacodynamic modelling of intravenous, 
intramuscular and subcutaneous buprenorphine in conscious cats. Vet Anaesth Analg 2013;40(1):83–95  
23.  Ramsey SJ, Attkins NJ, Fish R, et al. Quantitative pharmacological analysis of antagonist binding kinetics at CRF1 
receptors in vitro and in vivo. Br J Pharmacol 2011;164(3):992–1007  
24.  Yassen A, Olofsen E, Dahan A, et al. Pharmacokinetic-Pharmacodynamic Modeling of the Antinociceptive Effect 
of Buprenorphine and Fentanyl in Rats : Role of Receptor Equilibration Kinetics. J Pharmacol Exp Ther 
2005;313(3):1136–49  
25.  Äbelö A, Andersson M, Holmberg AA, et al. Application of a combined effect compartment and binding model 
for gastric acid inhibition of AR-HO47108: A potassium competitive acid blocker, and its active metabolite AR-
HO47116 in the dog. Eur J Pharm Sci 2006;29(2):91–101  
26.  Landersdorfer CB, He YL, Jusko WJ. Mechanism-based population pharmacokinetic modelling in diabetes: 
Vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV. Br J Clin Pharmacol 
2012;73(3):391–401  
27.  Guo D, Mulder-Krieger T, IJzerman AP, et al. Functional efficacy of adenosine A₂A receptor agonists is positively 
correlated to their receptor residence time. Br J Pharmacol 2012;166(6):1846–59  
26 
28.  Motulsky HJ, Mahan LC. The Kinetics of Competitive Radioligand Binding Predicted Mass Action by the Law of 
Mass Action. Mol Pharmacol 1984;25(1):1–9  
29.  Zweemer AJM, Nederpelt I, Vrieling H, et al. Multiple binding sites for small-molecule antagonists at the CC 
chemokine receptor 2. Mol Pharmacol 2013;84(4):551–61  
30.  Guo D, van Dorp EJH, Mulder-Krieger T, et al. Dual-point competition association assay: a fast and high-
throughput kinetic screening method for assessing ligand-receptor binding kinetics. J Biomol Screen 
2013;18(3):309–20  
31.  Mathis G, Pierre N, Tardieu J. Determination of association(kon) and dissociation(koff) rate constants of 
Spiperone on the Dopamine D2 receptor using the Tag-lite® platform. 2011. p. SBS 17th Annual Conference. 
Orlando, USA  
32.  Schiele F, Ayaz P, Fernández-Montalván A. A universal, homogenous assay for high throughput determination of 
binding kinetics. Anal Biochem 2014;468:42–9  
33.  Patching SG. Surface plasmon resonance spectroscopy for characterisation of membrane protein-ligand 
interactions and its potential for drug discovery. Biochim Biophys Acta 2014;1838(1A):43–55  
34.  Rich RL, Myszka DG. Higher-throughput, label-free, real-time molecular interaction analysis. Anal Biochem 
2007;361(1):1–6  
35.  Shiau AK, Massari ME, Ozbal CC. Back to basics: label-free technologies for small molecule screening. Comb 
Chem High Throughput Screen 2008;11(3):231–7  
36.  Gronewold TMA, Baumgartner A, Hierer J, et al. Kinetic Binding Analysis of Aptamers Targeting HIV-1 Proteins 
by a Combination of a Microbalance Array and Mass Spectrometry (MAMS). J Proteome Res 2009;8(7):3568–77  
37.  Gronewold TMA. Surface acoustic wave sensors in the bioanalytical field: recent trends and challenges. Anal 
Chim Acta 2007;603(2):119–28  
38.  Kenakin T, Jenkinson S, Watson C. Determining the potency and molecular mechanism of action of 
insurmountable antagonists. J Pharmacol Exp Ther 2006;319(2):710–23  
39.  Vauquelin G, Fierens F, Verheijen I, et al. Insurmountable AT 1 receptor antagonism : the need for different 
antagonist binding states of the receptor Glutamate signalling in the lung. Trends Pharmacol Sci 
2001;22(7):343–4  
40.  Szczuka A, Wennerberg M, Packeu A, et al. Molecular mechanisms for the persistent bronchodilatory effect of 
the beta 2-adrenoceptor agonist salmeterol. Br J Pharmacol 2009;158(1):183–94  
41.  Lindström E, von Mentzer B, Påhlman I, et al. Neurokinin 1 receptor antagonists: correlation between in vitro 
receptor interaction and in vivo efficacy. J Pharmacol Exp Ther 2007;322(3):1286–93  
42.  Le MT, Pugsley MK, Vauquelin G, et al. Molecular characterisation of the interactions between olmesartan and 
telmisartan and the human angiotensin II AT1 receptor. Br J Pharmacol 2007;151(7):952–62  
43.  Atack JR, Wong DF, Fryer TD, et al. Benzodiazepine binding site occupancy by the novel GABAA receptor 
subtype-selective drug 7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-
triazolo[4,3-b]pyridazine (TPA023) in rats, primates, and humans. J Pharmacol Exp Ther 2010;332(1):17–25  
44.  Laruelle M. Measuring Dopamine Synaptic Transmission with Molecular Imaging and Pharmacological 
Challenges : The State of the Art. Neuromethods 2012;71:163–203  
45.  Chernet E, Martin LJ, Li D, et al. Use of LC/MS to assess brain tracer distribution in preclinical, in vivo receptor 
occupancy studies: dopamine D2, serotonin 2A and NK-1 receptors as examples. Life Sci 2005;78(4):340–6  
46.  Barth VN. Typical and atypical antipsychotics: Relationships between rat in vivo dopamine D(2) receptor 
occupancy assessed using LC/MS and changes in neurochemistry and catalepsy. Section Title: Mammalian 
Hormones. 2006.  
47.  Need AB, McKinzie JH, Mitch CH, et al. In vivo rat brain opioid receptor binding of LY255582 assessed with a 
novel method using LC/MS/MS and the administration of three tracers simultaneously. Life Sci 2007;81(17-
18):1389–96  
48.  Hume SP, Gunn RN, Jones T. Pharmacological constraints associated with positron emission tomographic 
scanning of small laboratory animals. Eur J Nucl Med 1998;25(2):173–6  
49.  Kung M-P, Kung HF. Mass effect of injected dose in small rodent imaging by SPECT and PET. Nucl Med Biol 
2005;32(7):673–8  
50.  Hume SP, Myers R, Bloomfield PM, et al. Quantitation of carbon-11-labeled raclopride in rat striatum using 
positron emission tomography. Synapse 1992;12(1):47–54  
51.  Tantawy MN, Jones CK, Baldwin RM, et al. [(18)F]Fallypride dopamine D2 receptor studies using delayed 
microPET scans and a modified Logan plot. Nucl Med Biol 2009;36(8):931–40  
52.  Lancelot S, Zimmer L. Small-animal positron emission tomography as a tool for neuropharmacology. Trends 
Pharmacol Sci 2010;31(9):411–7  
53.  Müller CP, Pum ME, Amato D, et al. The in vivo neurochemistry of the brain during general anesthesia. J 
Neurochem 2011;119(3):419–46  
54.  Schiffer WK, Mirrione MM, Biegon A, et al. Serial microPET measures of the metabolic reaction to a 
microdialysis probe implant. J Neurosci Methods 2006;155(2):272–84  
27 
55.  Ginovart N, Sun W, Wilson AA, et al. Quantitative Validation of an Intracerebral beta-Sensitive Microprobe 
System to Determine in Vivo Drug-Induced Receptor Occupancy Using [11C]Raclopride in Rats. Synapse 
2004;52(2):89–99  
56.  Balasse L, Maerk J, Pain F, et al. PIXSIC, a Pixelated β(+)-Sensitive Probe for Radiopharmacological Investigations 
in Rat Brain: Binding Studies with [(18)F]MPPF. Mol imaging Biol 2014;  
57.  Polikov VS, Tresco PA, Reichert WM. Response of brain tissue to chronically implanted neural electrodes. J 
Neurosci Methods 2005;148(1):1–18  
58.  Wang Y, Michael AC. Microdialysis probes alter presynaptic regulation of dopamine terminals in rat striatum. J 
Neurosci Methods 2012;208(1):34–9  
59.  Märk J, Benoit D, Balasse L, et al. A wireless beta-microprobe based on pixelated silicon for in vivo brain studies 
in freely moving rats. Phys Med Biol 2013;58(13):4483–500  
60.  Li J, Fish RL, Cook SM, et al. Comparison of in vivo and ex vivo [3H]flumazenil binding assays to determine 
occupancy at the benzodiazepine binding site of rat brain GABAA receptors. Neuropharmacology 
2006;51(1):168–72  
61.  Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: 
in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996;124(1-2):57–73  
62.  Lengyel K, Pieschl R, Strong T, et al. Ex vivo assessment of binding site occupancy of monoamine reuptake 
inhibitors: methodology and biological significance. Neuropharmacology 2008;55(1):63–70  
63.  Langlois X, te Riele P, Wintmolders C, et al. Use of the beta-imager for rapid ex vivo autoradiography 
exemplified with central nervous system penetrating neurokinin 3 antagonists. J Pharmacol Exp Ther 
2001;299(2):712–7  
64.  Baker JG, Hall IP, Hill SJ. Pharmacological characterization of CGP 12177 at the human beta(2)-adrenoceptor. Br 
J Pharmacol 2002;137(3):400–8  
65.  Delforge J, Syrota A, Lançon JP, et al. Cardiac beta-adrenergic receptor density measured in vivo using PET, CGP 
12177, and a new graphical method. J Nucl Med 1991;32(4):739–48  
66.  Kessler RM, Votaw JR, Schmidt DE, et al. High affinity dopamine D2 receptor radioligands. 3. [123I] and 
[125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat 
brain. Life Sci 1993;53(3):241–50  
67.  Mukherjee J, Yang ZY, Brown T, et al. 18F-desmethoxyfallypride: a fluorine-18 labeled radiotracer with 
properties similar to carbon-11 raclopride for PET imaging studies of dopamine D2 receptors. Life Sci 
1996;59(8):669–78  
68.  Mukherjee J, Yang Z-Y, Lew R, et al. Evaluation of d -Amphetamine Effects on the Binding of Dopamine D-2 
Receptor Radioligand , 18F-Fallypride in Nonhuman Primates Using Positron Emission Tomography. Synapse 
1997;27(1):1–13  
69.  Christian BT, Narayanan T, Shi B, et al. Measuring the in vivo binding parameters of [18F]-fallypride in monkeys 
using a PET multiple-injection protocol. J Cereb blood flow Metab 2004;24(3):309–22  
70.  Vandehey NT, Moirano JM, Converse AK, et al. High-affinity dopamine D2/D3 PET radioligands 18F-fallypride 
and 11C-FLB457: a comparison of kinetics in extrastriatal regions using a multiple-injection protocol. J Cereb 
blood flow Metab 2010;30(5):994–1007  
71.  Leysen JE, Gommeren W. Drug-Receptor Dissociation Time , New Tool for Drug Research : Receptor Binding 
Affinity and Drug-Receptor Dissociation Profiles of Serotonin-S2 , Dopamine-D2 , Histamine-HI Antagonists , and 
Opiates. Drug Dev Res 1986;131:119–31  
72.  Perlmutter JS, Kilbourn MR, Welch MJ, et al. Non-Steady-State Measurement of in vivo Receptor Binding with 
Positron Emission Tomography :“Dose Response” Analysis. J Neurosci 1989;9(7):2344–52  
73.  Leslie CA, Bennett JP. [3H]spiperone binds selectively to rat striatal D2 dopamine receptors in vivo: a kinetic and 
pharmacological analysis. Brain Res 1987;407(2):253–62  
74.  Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. 
Implications for atypical antipsychotic action. J Psychiatry Neurosci 2000;25(2):161–6  
75.  Johnson M, Kozielska M, Pilla Reddy V, et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling of 
the dopamine D2 receptor occupancy of olanzapine in rats. Pharm Res 2011;28(10):2490–504  
76.  Laruelle M, Abi-Dargham A, Ai-Tikriti MS, et al. SPECT Quantification of [123I] lomazenil Binding to 
Benzodiazepine Receptors in Nonhuman Primates : II . Equilibrium Analysis of Constant Infusion Experiments 
and Correlation with In Vitro Parameters. J Cereb blood flow Metab 1994;14(3):453–65  
77.  Millet P, Graf C, Moulin M, et al. SPECT quantification of benzodiazepine receptor concentration using a dual-
ligand approach. J Nucl Med 2006;47(5):783–92  
78.  Sakiyama Y, Saito M, Inoue O. Acute treatment with pentobarbital alters the kinetics of in vivo receptor binding 
in the mouse brain. Nucl Med Biol 2006;33(4):535–41  
79.  Sihver W, Sihver S, Bergström M, et al. Aspects for In Vitro Characterization of Receptor Ligands : Receptor 
Binding Using 11C-Labeled A Detailed Study with the Benzodiazepine Receptor Antagonist [11C] Ro 15-1788. 
Nucl Med Biol 1997;24(8):723–31  
28 
80.  Koeppe RA, Holthoff VA, Frey KA, et al. Compartmental analysis of [11C]flumazenil kinetics for the estimation of 
ligand transport rate and receptor distribution using positron emission tomography. J Cereb blood flow Metab 
1991;11(5):735–44  
81.  Ishii A, Toyama J. Binding Properties of (+/-)[3H] Benidipine Hydrochloride to Rat Heart Membranes. J 
Cardiovasc Pharmacol 1993;21(2):191–6  
82.  Cassel JA, Daubert JD, DeHaven RN. [(3)H]Alvimopan binding to the mu opioid receptor: comparative binding 
kinetics of opioid antagonists. Eur J Pharmacol 2005;520(1-3):29–36  
83.  Yassen A, Olofsen E, Romberg R, et al. Mechanism-based PK/PD modeling of the respiratory depressant effect of 
buprenorphine and fentanyl in healthy volunteers. Clin Pharmacol Ther 2007;81(1):50–8  
84.  Yassen A, Kan J, Olofsen E, et al. Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of the 
Respiratory-Depressant Effect of Buprenorphine and Fentanyl in Rats. 2006;319(2):682–92  
85.  Casadó V, Allende G, Mallol J, et al. Thermodynamic analysis of agonist and antagonist binding to membrane-
bound and solubilized A1 adenosine receptors. J Pharmacol Exp Ther 1993;266(3):1463–74  
86.  Langlois X, Megens A, Lavreysen H, et al. Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 
antagonist for the treatment of schizophrenia. J Pharmacol Exp Ther 2012;342(1):91–105  
87.  Treherne JM, Young JM. Temperature-dependence of the kinetics of the binding the histamine H 1 -receptor : 
comparison with the kinetics of [ 3H ] -mepyramine. Br J Pharmacol 1988;94(3):811–22  
88.  Wallace RM, Young JM. Temperature Dependence Related Compounds of the Binding of [3H]Mepyramine to 
the Histamine H1 Receptor. Mol Pharmacol 1983;23(1):60–6  
89.  Sakai S. Effect of hormones on dissociation of prolactin from the rabbit mammary gland prolactin receptor. 
Biochem J 1991;279:461–5  
90.  Endres CJ, Kolachana BS, Saunders RC, et al. Kinetic modeling of [11C]raclopride: combined PET-microdialysis 
studies. J Cereb blood flow Metab 1997;17(9):932–42  
91.  Morris ED, Yoder KK. Positron emission tomography displacement sensitivity: predicting binding potential 
change for positron emission tomography tracers based on their kinetic characteristics. J Cereb blood flow 
Metab 2007;27(3):606–17  
92.  Kapur S, Seeman P. Does Fast Dissociation From the Dopamine D 2 Receptor Explain the Action of Atypical 
Antipsychotics ?: A New Hypothesis. Am J Psychiatry 2001;158(3):360–9  
93.  Wiley HS. Anomalous Binding of Epidermal Growth Factor to A431 Cells Is Due to the Effect of High Receptor 
Densities and a Saturable Endocytic System. J Cell Biol 1988;107(2):801–10  
94.  Packeu A, Wennerberg M, Balendran A, et al. Estimation of the dissociation rate of unlabelled ligand-receptor 
complexes by a “two-step” competition binding approach. Br J Pharmacol 2010;161(6):1311–28  
95.  Vauquelin G, Van Liefde I. Radioligand dissociation measurements: potential interference of rebinding and 
allosteric mechanisms and physiological relevance of the biological model systems. Expert Opin Drug Discov 
2012;7(7):583–95  
96.  Vauquelin G, Charlton SJ. Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug 
action. Br J Pharmacol 2010;161(3):488–508  
97.  Peletier LA, Benson N, van der Graaf PH. Impact of protein binding on receptor occupancy: a two-compartment 
model. J Theor Biol 2010;265(4):657–71  
98.  Proost JH, Wierda JM, Meijer DK. An extended pharmacokinetic/pharmacodynamic model describing 
quantitatively the influence of plasma protein binding, tissue binding, and receptor binding on the potency and 
time course of action of drugs. J Pharmacokinet Biopharm 1996;24(1):45–77  
99.  Kim KM, Valenzano KJ, Robinson SR, et al. Differential regulation of the dopamine D2 and D3 receptors by G 
protein-coupled receptor kinases and beta-arrestins. J Biol Chem 2001;276(40):37409–14  
100.  Macey TA, Gurevich V V, Neve KA. Preferential Interaction between the Dopamine D2 Receptor and Arrestin2 in 
Neostriatal Neurons. Mol Pharmacol 2004;66(6):1635–42  
101.  Paspalas CD, Rakic P, Goldman-Rakic PS. Internalization of D2 dopamine receptors is clathrin-dependent and 
select to dendro-axonic appositions in primate prefrontal cortex. Eur J Neurosci 2006;24(5):1395–403  
102.  Dang VC, Christie MJ. Mechanisms of rapid opioid receptor desensitization, resensitization and tolerance in 
brain neurons. Br J Pharmacol 2012;165(6):1704–16  
103.  Skinbjerg M, Liow J-S, Seneca N, et al. D2 dopamine receptor internalization prolongs the decrease of 
radioligand binding after amphetamine: a PET study in a receptor internalization-deficient mouse model. 
Neuroimage 2010;50(4):1402–7 
104.      Haraguchi K, Ito K, Kotaki H, et al. Prediction of drug-induced catalepsy based on dopamine D1, D2, and 
muscarinic acetylcholine receptor occupancies. Drug Metab Dispos 1997;25(6):675–84 
105.  Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J 
Pharmacokinet Pharmacodyn 2001;28(6):507–32  
106.  Eppler SM, Combs DL, Henry TD, et al. A target-mediated model to describe the pharmacokinetics and 
hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin Pharmacol Ther 
2002;72(1):20–32  
29 
107.  Jin F, Krzyzanski W. Pharmacokinetic model of target-mediated disposition of thrombopoietin. AAPS J 
2004;6(1):86–93  
108.  Retlich S, Duval V, Graefe-Mody U, et al. Impact of target-mediated drug disposition on Linagliptin 
pharmacokinetics and DPP-4 inhibition in type 2 diabetic patients. J Clin Pharmacol 2010;50(8):873–85  
109. Aston PJ, Derks G, Raji A, et al. Mathematical analysis of the pharmacokinetic-pharmacodynamic (PKPD) 
behaviour of monoclonal antibodies: Predicting in vivo potency. J Theor Biol 2011;281(1):113–21 
110.  Zhang L, Sinha V, Forgue ST, et al. Model-based drug development: the road to quantitative pharmacology. J 
Pharmacokinet Pharmacodyn 2006;33(3):369–93  
111.  Stone JA, Banfield C, Pfister M, et al. Model-Based Drug Development Survey Finds Pharmacometrics Impacting 
Decision Making in the Pharmaceutical Industry. J Clin Pharmacol 2010;50(S9):20S – 30S  
112.  Van der Graaf PH, Gabrielsson J. Pharmacokinetic – pharmacodynamic reasoning in drug discovery and early 
























Chapter 2. The long residing negligence of target saturation 
 
Wilhelmus E.A. de Witte1*, Meindert Danhof1, Piet H. van der Graaf1,2, Elizabeth C.M. de Lange1 
1 Division of Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, 2333 CC Leiden, 
The Netherlands 
2 Certara Quantitative Systems Pharmacology, Canterbury Innovation Centre, Canterbury CT2 7FG, United 
Kingdom 
* correspondence: wilbertdew@gmail.com 
 
 






The interaction between a drug and its biological target molecule is a key step in the causal chain between 
drug dosing and drug effect in the human body. The strength of this interaction may be represented by the 
drug-target dissociation constant (KD), which describes the drug concentration that results in 50% target 
occupancy (i.e. the percentage of target molecules that is bound to a drug molecule) in equilibrium. 
However, the KD does not inform on the rate at which target binding equilibrium is reached after a change in 
the drug concentration. The kinetics of target binding is described by two rate constants: the second order 
association rate constant kon and the first order dissociation rate constant koff. From the value of koff, the 
average time that each drug molecule spends bound at the target after drug-target association (the drug-
target residence time or RT) can be calculated as 1/koff. 
The significance of drug-target residence time has received increasing attention in drug discovery following 
the publication of an Opinion article in 2006, which discussed the beneficial effect of a long dissociation half-
life on (selective) prolongation of target occupancy (Nat. Rev. Drug Discov. 5, 730–9 (2006))[1]. However, 
the role of target saturation (i.e. target occupancy close to 100%) on prolongation of target occupancy was 
not fully considered in this, as well as other  subsequent publications.[2–5] 
By using simulations, we demonstrate the impact of target saturation on prolongation of target occupancy 
and show that lack of consideration of this role may contribute to  inaccurate conclusions about the 
influence of drug-target binding kinetics.[1,2,4,5] Moreover, we demonstrate that stating that a drug-target 
dissociation rate constant lower than the pharmacokinetic elimination rate constant prolongs the duration 
of target occupancy[3,6,7], does not incorporate the role of target saturation and therefore does not always 
hold, especially if target occupancy values are higher than 50%. However, it should be noted that not all 
simulations demonstrating the influence of koff on the duration of target occupancy are misleading because 
of target saturation. Most notably, when differential equation models are used and the koff is changed 
simultaneously with the kon to keep the KD constant, the target saturation is not obscuring the influence of 
koff on the duration of target occupancy.[6,8]  
The fact that a higher drug concentration leads to an increased duration of drug effects has been described 
in quantitative terms in the early days of PKPD modelling.[9,10] More recently, the relationship between 
target saturation and the duration of target occupancy has also been explained quantitatively with respect 
to drug-target binding kinetics.[11,12]The role of target saturation that we describe here should be taken 
into account for the decision whether or not to select drug candidates with low koff values in drug discovery 
and for understanding the role of drug-target binding kinetics in pharmacotherapy. 
In the initial opinion article of Copeland et al.[1], the influence of target saturation has been attributed to a 
low dissociation rate constant for the calculated target occupancy.[13] However, in fact, the high 
dissociation rate constants (0.009 – 1.0 s-1) compared to the low elimination rate constant of the unbound 
drug (0.0002 s-1) indicate that the observed long duration of target occupancy cannot be influenced by the 
dissociation rate constant.[6,11] Later publications from these authors[2,4] showed that the target 
occupancy was calculated according to the equilibrium equation[4], which challenges the conclusions about 
the role of binding kinetics, since this assumes binding equilibrium has been reached.[14]  
To demonstrate that the duration of target occupancy in the simulations of Copeland et al.[1] is  influenced 
by target saturation, we have performed similar simulations with a simple single-step drug-target binding 
model (Figure 1). Changing the value of the association rate constant (kon) instead of the dissociation rate 
constant (koff), resulted in similar target occupancy profiles as observed in the simulations of Copeland et 
al[1]. This means that the duration of target occupancy is mostly influenced by the affinity and not by the 
binding kinetics. To exclude the influence of the drug target affinity, we performed additional simulations 
with a constant affinity. In these simulations, koff had to be lower than 2 h-1 to prolong the occupancy 






Figure 1. Simulations of plasma drug concentrations (left panel) and the resulting target occupancy profiles (right panel) 
for different values of kon. All plasma concentration profiles overlap.  The model structure is provided at the top. Here, ka 
and kel represent the first-order absorption constant (3.0 hr-1) and elimination rate constant (0.69 h-1), respectively. The 
value of koff was fixed at 50 h-1 and the target concentration at 1 pM. For the associated differential equations, see 
supplementary information S1, and for the R simulation script see supplementary information S2.  Note: similar 
simulations can be performed online at: wilbertdewitte.shinyapps.io/absorption_binding_elimination. 
As shown in figure 2, a koff value of 2 h-1 results in almost the same duration of target occupancy as a koff 
value of 36 h-1. To find the koff value that gives a significant prolongation of target occupancy, we identified 
for what values of target occupancy the elimination rate constant (kel) of the drug from plasma would have 
less influence on the duration of target occupancy than the koff. The horizontal lines in figure 2 demonstrate 
that slow drug-target dissociation is the main determinant of the duration of target occupancy if both the 
dissociation rate constant and the target occupancy have values such that  
 BF < 1 - koff / kel     
in which BF is the target fraction bound.[11,15] It should be noted that this equation is an approximation of 
the simple drug-target binding model and only holds for this model if the target concentration is lower than 
the ratio kel/kon, as described previously (which provides this equation in a slightly modified form as 
Equation 2).[11] However, the target occupancy versus time curves in figure 1 and figure 2 are independent 
from this approximation, as they are simulated with the full differential equation model. From this equation, 
it follows that when the clinical situation requires a target occupancy that, for example, should continuously 
be above 90%, the koff needs to be more than tenfold smaller than the kel for it to become the main 
determinant of the duration of target occupancy.[15] This equation also indicates that if koff > kel, the 
required target occupancy would be negative, which means that the koff cannot be the main determinant of 
the duration of target occupancy for this condition.  
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Figure 2. Simulations of plasma drug concentrations (left panel) and the resulting target occupancy profiles (right panel) 
for different values of koff. All plasma concentration profiles overlap. The KD was set at 10 nM for all simulations, resulting 
in kon values of 3.6 (solid), 0.2 (dashed), 0.025 (dotted) and 0.0075 nM-1 h-1 (dash-dotted). The absorption and elimination 
rate constants ka and kel were 3.0 and 0.69 h-1, respectively, and the concentration of the target was set at 1 pM. The grey 
lines denote the situation where the target fraction bound equals 1 - koff / kel for the corresponding line type (see text). 
Below that line, the condition is met for which koff is the main determinant of the decline rate of target occupancy. 
Our findings demonstrate the importance of target saturation on the duration of drug effects in vivo. These 
findings can directly be applied to the selection of drug candidates. A clear example where our insights 
should have been applied is the study of Lindström et al.[5] In this study, the in vivo drug effects of three 
NK1 antagonists are compared with their pharmacokinetics. Aprepitant demonstrated a much longer 
duration of drug effect, which can clearly be attributed to target saturation, considering the equation 
described above and the shape of the drug effect versus time curve (i.e. first a flat section close to the 
maximal effect and a subsequent rapid decline of the drug effect). In contrast, the authors conclude that the 
duration of the effect of Aprepitant cannot be explained by its pharmacokinetics. The other two compounds 
in this study did not show this target saturation and the authors conclude that this is likely explained by 
their faster binding kinetics. Aprepitant was therefore concluded to be the preferable drug of the three 
drugs due to its duration of effect. However, our findings above indicate that the other drugs may also 
exhibit this duration of effect at higher drug concentrations. 
Our insights can also be applied to the decision as to whether to include target binding kinetics in hit or lead 
selection. For CCR2 antagonists, an occupancy of above 90% is considered to be required for a sufficient 
drug effect. This means that the dissociation half-life needs to be 10 times larger than the plasma 
elimination half-life. Together with an average plasma half-life of 5 hours[6], this means that the 
dissociation half-life needs to be 50 hours or longer before it becomes the main determinant of the duration 
of drug effect. In combination with the knowledge that such long dissociation half-lives are rarely 
observed[11], this suggests that inclusion of drug target binding kinetics for CCR2 antagonist screening 
should not be prioritized. In conclusion, target saturation is an important factor that should be included in 
the analysis of the influence of drug-target binding kinetics on target occupancy. By doing so, drug discovery 
scientists would be better equipped to decide on the relevance of drug-target binding kinetics for each 
specific project, depending on the required level of target occupancy and the (predicted) pharmacokinetics. 
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Supplementary information S1. Differential equations for Figure 1 and Figure 2. 
 
 
The concentrations in the depot and the plasma compartment were modeled according to equation S.1 - 
S.3. In these equations, [DEP] is the drug concentration in the depot compartment, [C] is the unbound drug 
concentration in the plasma compartment, [R] is the unbound target concentration in the plasma 
compartment, [Rtot] is the total target concentration and [LR] is the bound drug concentration. ka is the first 
order absorption rate constant, kel is the first order elimination rate constant, kon is the second order drug-
target association rate constant and koff is the first order drug-target dissociation rate constant. For this 
model, the total target concentration is assumed to be constant, which allows the calculation of the free 
target concentration according to equation S.4. All initial concentrations were equal to zero and the dose 
was administered in the depot compartment. 
𝑑[𝐷𝐸𝑃]
𝑑𝑡
=  − 𝑘𝑎  ∙ [𝐷𝐸𝑃]                                                                   (S.1) 
𝑑[𝐶]
𝑑𝑡
=  𝑘𝑎  ∙ [𝐷𝐸𝑃] − 𝑘𝑒𝑙  ∙ [𝐶] − 𝑘𝑜𝑛 ∙ [𝐶] ∙ [𝑅] + 𝑘𝑜𝑓𝑓 ∙ [𝐿𝑅]                           (S.2) 
𝑑[𝐿𝑅]
𝑑𝑡
=  𝑘𝑜𝑛 ∙ [𝐶] ∙ [𝑅] − 𝑘𝑜𝑓𝑓 ∙ [𝐿𝑅]                                                         (S.3) 




Supplementary information S2. R script for the simulations for Figure 1 and Figure 2. 
 
# The following packages are required for the script below.  
# Please install those by removing the hashtag and running the install commands below 
# install.packages("deSolve") 












parameters = c( 
  ka = 3, 
  kel = 0.693,        #h-1 
  kon = 1,     #nM-1 h-1        
  koff = 50,        #h-1 
  Kd = expression(koff/kon), 
  Rtot = 0.001, #nM 
 dose =  800, 
  dosetime = 0  )  
#---------------------------------------------------------- 
# ODE solving function 
#---------------------------------------------------------- 
solveivro<-function(allparams2){ 
    allparams2<-lapply(allparams2,FUN=eval,envir=allparams2) 
    #---------------------------------------------------------- 
  # initial states 
  #---------------------------------------------------------- 
   state<-  c( 
    D = 0, 
    C = 0,                                       
    RL = 0    ) 
  #---------------------------------------------------------- 
  # ODE system plus dosing function 
  #---------------------------------------------------------- 
    ivro <<- function(t, state, allparams2) { 
    with(as.list(c(state, allparams2)),{ 
      dD = -ka*D 
      dC =  - kon*C*(Rtot-RL)  + koff*RL - kel*C  +ka*D                   
      dRL=     kon*C*(Rtot-RL)  - koff*RL          
       
            list(c(dD,dC,dRL))    })  } 
  eventdat<-data.frame(var = "D",  
                       time = with(allparams2,{dosetime}),  
                       value = with(allparams2,{dose}),  
                       method = "add" 
                       )#dosing regiments 
   time<-  seq(0,  24, by = 0.01)  
  out <-  lsoda(y = state, times = time, func = ivro, parms = allparams2, 
                events = list(data = eventdat)) 
   #---------------------------------------------------------- 
  # derived output 
  #---------------------------------------------------------- 
  dout <- as.data.frame(out) 
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  outpar<-c(as.list(dout),as.list(allparams2)) 
  outderpar <- within(outpar, { 
      TO = RL/Rtot      })  
    outder<-outderpar[names(outderpar)[!(names(outderpar)%in%names(allparams2))]] 
  doutder<-as.data.frame(outder) 
  return(doutder) 
} #end function solveivro 
######################################################### 
# changing parameters for additional simulations 
######################################################### 
params<-as.list(parameters) 
changedpars1<-within(params, {  kon=16 }) 
changedpars2<-within(params, {  kon=125 }) 
changedpars3<-within(params, {  kon=500 }) 
######################################################### 











# plots over time 
#---------------------------------------------------------- 
# plot pharmacokinetics over time ----------------------------------------------------------------------- 
plotpk<-ggplot()+ 
  geom_line(data=(data=doutder1),aes(y=C,x=time),lty=1,size=1.5)+ 
  geom_line(data=(data=doutder2),aes(y=C,x=time),lty=1,size=1.5, col = 1)+ 
  geom_line(data=(data=doutder3),aes(y=C,x=time),lty=1,size=1.5, col = 1)+ 
  geom_line(data=(data=doutder4),aes(y=C,x=time),lty=1,size=1.5, col = 1)+ 
  ylab("Concentration (nM)")+ xlab("Time (hours)")+ 
  theme_bw()+theme(text=element_text(size=15))+ 
  coord_cartesian(xlim = c(0,15)    )   
plotpk 
# plot target occupancy over time ----------------------------------------------------------------------- 
cbbPalette <- c("#000000", "#E69F00", "#56B4E9", "#009E73", "#F0E442", "#0072B2", "#D55E00", "#CC79A7") 
plotTO<-ggplot()+ 
    geom_line(data=data.frame(doutder1,col=factor(1,levels = c(1,2,3,4))),aes(y=TO*100,x=time, col=col),lty=1,size=1.5)+ 
    geom_line(data=data.frame(doutder2,col=factor(2,levels = c(1,2,3,4))),aes(y=TO*100,x=time, col=col),lty=1,size=1.5)+ 
   geom_line(data=data.frame(doutder3,col=factor(3,levels = c(1,2,3,4))),aes(y=TO*100,x=time, col=col),lty=1,size=1.5)+ 
  geom_line(data=data.frame(doutder4,col=factor(4,levels = c(1,2,3,4))),aes(y=TO*100,x=time, col=col),lty=1,size=1.5)+ 
  ylab(" Target occupancy (%)")+ xlab("Time (hours)")+ 
  theme_bw()+theme(text=element_text(size=15),plot.margin = unit(c(5,5,5,5),"mm"))+ 
  scale_color_manual(name= expression(k[on]~(nM^-1~h^-1)),values = cbbPalette, breaks=c(4,3,2,1), labels = 
c(500,125,16,1))+ 
  coord_cartesian(ylim = c(0,100),xlim = c(0,15) 
  )   
plotTO 
######################################################### 
# changing parameters for additional simulations 
######################################################### 
changedpars8<-within(params, {  kon = 3.6 
koff = 36.00 
dose = 1600}) 
changedpars9<-within(params, {  kon = 0.2 
koff = 2.00 
dose = 1600}) 
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changedpars10<-within(params, {  kon = 0.025 
koff = 0.25 
dose = 1600}) 
changedpars11<-within(params, {  kon = 0.0075 
koff = 0.075 
dose = 1600}) 
 
######################################################### 










# plot pharmacokinetics over time ----------------------------------------------------------------------- 
plotpk3<-ggplot()+ 
  geom_line(data=(data=doutder9),aes(y=C,x=time),lty=1,size=1.5)+ 
  geom_line(data=(data=doutder10),aes(y=C,x=time),lty=1,size=1.5, col = 1)+ 
  geom_line(data=(data=doutder11),aes(y=C,x=time),lty=1,size=1.5, col = 1)+ 
  geom_line(data=(data=doutder12),aes(y=C,x=time),lty=1,size=1.5, col = 1)+ 
  ylab("Concentration (nM)")+ xlab("Time (hours)")+ 
  theme_bw()+theme(text=element_text(size=15))+ 
  coord_cartesian(xlim = c(0,15)  )   
plotpk3 
# plot target occupancy over time ----------------------------------------------------------------------- 
plotTO3<-ggplot()+ 
  geom_line(data=(data=data.frame(doutder9,col=factor(1))),aes(y=TO*100,x=time,col=col),lty=1,size=1.5)+ 
  geom_line(data=(data=data.frame(doutder10,col=factor(2))),aes(y=TO*100,x=time,col=col),lty=1,size=1.5)+ 
  geom_line(data=(data=data.frame(doutder11,col=factor(3))),aes(y=TO*100,x=time,col=col),lty=1,size=1.5)+ 
  geom_line(data=(data=data.frame(doutder12,col=factor(4))),aes(y=TO*100,x=time,col=col),lty=1,size=1.5)+ 
  geom_line(aes(y=rep((1-0.075/0.693)*100,2),x=c(0,15)),lty=2, col = cbbPalette[4],size=1.5)+ 
  geom_line(aes(y=rep((1-0.25/0.693)*100,2),x=c(0,15)),lty=2, col = cbbPalette[3],size=1.5)+ 
  ylab(" Target occupancy (%)")+ xlab("Time (hours)")+ 
  theme_bw()+theme(text=element_text(size=15))+ 
  scale_color_manual(name= expression(k[off]~(h^-1)),values = cbbPalette, breaks=c(4,3,2,1),  
                     labels = c(0.075,0.25,2,36))+ 
  coord_cartesian(ylim = c(0,100),xlim = c(0,15) 




















Chapter 3. Mechanistic modelling of drug target binding kinetics as determinant of the time 
course of drug action in vivo 




Drug-target binding kinetics refers to the kinetics of the central event in pharmacology: target engagement. 
The kinetics of this event can be described in its simplest form according to equation 1, in which kon is the 
second order association rate constant, koff is the first order dissociation rate constant, L is the 
concentration of the ligand (i.e. a drug or an endogenous ligand), R is the concentration of the target and LR 
is the concentration of the bound ligand-target complex. The equilibrium dissociation constant (KD) is given 
by the ratio koff/kon. 





 𝐿𝑅                                                                     Eq. 1  
The mathematical description of drug target binding according to equation 1 is regularly incorporated in the 
models that describe the pharmacokinetic profile of monoclonal antibodies and their associated 
pharmacodynamic profiles in so-called target mediated drug disposition (TMDD) models.[1–3] For small 
molecules however, the role of drug-target binding kinetics has also been incorporated [4–7] but this effect 
is most often assumed to be negligible in both PKPD modelling practices and in the design and development 
of new molecules. 
With the publication of Copeland et al. in 2006 [8], a new interest was initiated to utilize drug-target binding 
kinetics and especially the drug-target dissociation rate constant (koff) or its reciprocal value that expresses 
the mean target residence time (RT) of each drug molecule on the target after drug-target association. In 
this regard, especially a low koff value was proposed to be a desirable property for new drug candidates. 
The reasons why a low koff value is considered as a desirable drug property are diverse: 
• A lower koff can lead to a slower decline of target occupancy and as a result, a prolongation of the 
drug effect, compared to a drug with rapid target equilibration kinetics.[9,10]  
• Differences in target equilibration kinetics at different targets may result in an improved 
selectivity of action over time, a phenomenon which is often referred to as kinetic 
selectivity.[8,11]  
• The value of koff may affect fluctuations in target occupancy upon repeated dosing  and/or in the 
situation of fluctuating endogenous ligands concentration, with potentially a more favourable 
efficacy/safety balance.[12]  
• A low koff gives rise to longer binding of each drug molecule to the target molecule, which could 
improve the efficacy of signal transduction.[13,14] 
In this thesis, we focus on the first three points, which are all focused on the duration of target occupancy as 
determinant of the duration of drug effect. As outlined in chapter 1, the duration of target occupancy is not 
only influenced by the drug-target binding kinetics but also by all other kinetic factors that connect drug 
dosing to drug effect [15]: 
First of all, after a drug enters the body and is absorbed into the blood circulation, the elimination and 
distribution of a drug are the main determinants for how quickly the drug concentrations decline. If the drug 
concentration is declining slowly compared to the koff, the duration of target occupancy is hardly influenced 
by the value of koff. 
Secondly, the distribution into and out of the tissue where the target resides can also affect the time course 
of target occupancy and, similar to a slow elimination from plasma, slow distribution out of the target tissue 
compared to drug-target dissociation reduces the influence of the koff value on the duration target 
occupancy.  
Thirdly, the concentration profile and target binding kinetics of endogenous ligands can also influence the 
time course of drug-target occupancy. If a drug is bound to the target, a steep increase in the endogenous 
ligand concentration would lead to faster displacement of the drug by endogenous ligand binding for drugs 
with a higher koff value compared to drugs with a lower koff value.  
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Fourthly, the target synthesis and degradation rate constants can influence the time course of target 
occupancy, especially when the target turnover is fast, compared to drug target dissociation. In essence, 
target turnover functions as an additional dissociation mechanism (since drug-bound target is degraded and 
unbound target is synthesized) and determines the duration of target occupancy if it is much faster than the 
drug-target dissociation. On top of this influence of target turnover on the effective drug-target dissociation, 
the degradation of target-bound drug also functions as additional elimination mechanism of the drug, which 
is described in Target-Mediated Drug Disposition models.[2] 
Finally, signal transduction and homeostatic feedback kinetics can influence the time course of drug action, 
as well as the factors that affect the time course of target occupancy described above. Especially a slow 
turnover of one of the signalling molecules in a signalling cascade, compared to the fluctuations in target 
occupancy, will decrease the fluctuations of the drug effect compared to a fast turnover of all signalling 
molecules.  
In this respect, it is important to emphasize that prolonged target occupancy compared to the plasma 
pharmacokinetics is not defined by a lower log-linear tangent of the target occupancy versus time curve at a 
given time point, compared to the log-linear slope of plasma concentrations. As explained in chapter 2, if 
the target occupancy is close to 100 %, the log-linear tangent of target occupancy versus time profile is 
lower than the log-linear slope of the plasma concentration versus time profile, even if target binding is fast 
and results in an immediate binding equilibrium. This is a result of the non-linear drug concentration versus 
equilibrium target occupancy relationship. 
The aim of our studies was to investigate how the influences of drug-target binding kinetics on the time 
course of the target occupancy (Section II) and the drug effect (Section III) depend on the other kinetic 
processes that constitute the PKPD context of drug-target binding kinetics. 
 
Section II. Simulations, model analysis and experimental validation of the influence of binding 
kinetics on the time course of target occupancy 
 
In Section II, we first investigate how, upon single dose administration, the time course of the target 
occupancy depends on one hand on the drug-target binding kinetics and on the other hand also on the 
pharmacokinetics, in particular the elimination rate constant and the tissue distribution kinetics. Secondly, 
we apply this insight and study how this affects the selectivity of action of a drug and the ability to 
discriminate between a drug-target binding model and a biophase distribution model to account for 
hysteresis in PKPD modeling. 
 
Kinetics of in vivo target occupancy: impact of drug distribution and elimination versus target binding 
kinetics 
To understand the influence of the drug-target dissociation rate constant (koff) on the time course of target 
occupancy and its dependence on the plasma elimination rate constant (kel), one cannot just compare the 
koff with the kel and conclude that the lowest rate constant determines the decline rate of target occupancy, 
as suggested previously [10]. The problem with this approach is that it does not take into account that the 
decline of drug concentrations over time are influenced by drug target binding, as is well documented for 
biologics [1,2] and has been described as rebinding for small molecules on a local scale [9].  In chapter 4, we 
therefore investigate when, on the one hand the elimination rate constant and the tissue distribution 
kinetics and on the other hand, the drug-target dissociation become the rate-limiting step in the decline of 
target occupancy, taking into account the important role of the total target concentration. This rate-limiting 
step refers to the slowest step in a chain of reactions that determines the overall rate of the whole chain of 
reactions, which is a concept often applied in chemistry.[16] 
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To explore the interrelationships between the pharmacokinetics and the target association and dissociation 
kinetics as determinants of the time course of target occupancy, we approximate two minimal 
pharmacokinetic target binding models, with first order elimination from the central compartment, in which 
the target binding either takes place in the only pharmacokinetic (plasma) compartment or in a peripheral 
tissue compartment connected to the plasma by linear distribution kinetics. These approximations are 
obtained by formalizing the rate-limiting step concept as described in the previous paragraph to obtain 
algebraic equations for the tangent of the target occupancy versus time curve for a given value of target 
occupancy.  
The obtained approximations are subsequently used to visualise the influence of the values of kon and koff, 
relative to the elimination rate constant, on the time course of target occupancy for a wide range of kon and 
koff values and to calculate the influence of the elimination rate constant, the tissue distribution rate 
constants and the target concentration on the duration of target occupancy. With this analysis, we show 
that at concentrations of a drug target which largely exceed the KD value, the values of koff and the kon have 
an equal effect on the duration of target occupancy, which is thus driven by the KD and in equilibrium under 
these conditions. 
Chapter 5 focuses on the role of rebinding as determinant of the duration of target occupancy and the 
mathematical approximation of this phenomenon. More specifically, we compared the rate-limiting step 
approximation, with the steady-state approximation. The rate-limiting step approximation assumes that the 
slowest step in the chain from drug-target dissociation, drug distribution and drug elimination determines 
the duration of target occupancy, as described in chapter 4, whereas the steady-state approximation is 
based on the assumption that the target site concentrations are in steady-state and dependent on the 
target-bound concentration.[17–19]. In chapter 5, we investigate how the rate limiting step approximation 
differs from the steady-state equation. To do so, we rewrite our rate-limiting step approximation equations 
in the same format as the steady-state approximation equations, compare these equations and perform 
simulations to investigate which approximation provides the most similar results to the full 
pharmacokinetic-target binding model. We demonstrate that the rate-limiting step approximation performs 
best in most situations and performs much better if the steady state assumption does not hold: if the drug-
target dissociation is fast compared to the distribution out of the target site and the drug-target association. 
Based on these findings, we propose that either the rate-limiting step approximation or the full differential 
equation model is used, rather than the steady-state approximation. 
Selectivity of action: target selectivity vs tissue selectivity 
As explained before, one of the proposed benefits of a low koff value for a small molecule drug is that it 
could dissociate slower from the therapeutic target compared to the secondary-target (kinetic selectivity). 
However, the results in chapter 4 indicate that for drugs with a high target concentration compared to the 
KD value, a low koff value would still lead to equilibrium target binding. This implies that kinetic selectivity 
would be decreased or absent for drugs with a high target concentration and low KD value. On the other 
hand, if a high target concentration compared to the KD value leads to an increased target site concentration 
compared to the plasma concentration, this could lead to increased tissue selectivity for tissues with high 
target concentrations. The aim of chapter 6 is therefore to explore the influence of tissue distribution 
kinetics, drug-target binding kinetics, and target concentrations on the time course of target and tissue 
selectivity. To that end, we perform simulations in three minimal physiologically-based pharmacokinetic 
models and combine those with target binding kinetics models. The first model is designed to investigate 
target selectivity, where we lump all tissues without drug-target binding except the eliminating organ and 
the plasma, and incorporate one tissue with drug-target binding to two different targets. The second model 
is designed to investigate tissue selectivity and differs from the first model in that it has two tissues with 
drug-target binding and that only one target type is incorporated in both tissues. The third model is a more 
specific case study that combines drug-target binding to 4 different targets in 3 different brain areas.  
With these simulations, we describe that the characteristics that determine the decline of target occupancy, 
as identified in chapter 4, could similarly be identified in the more complex models for target and tissue 
selectivity. We describe the influence of target expression levels and the affinity constant KD on target and 
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tissue selectivity. The identification of a context-dependent optimal KD value rather than aiming to minimize 
the KD increases the value of KD predictions in early drug discovery. Therefore, we developed a Quantitative 
Structure Activity Relationship (QSAR) with a random forest model based on public affinity values for the 
CB1, 5-HT1a, mGlu5 and TRPV1 targets. Combined with the target concentrations for these targets in 3 
different brain areas, we simulate the target occupancy profiles for Rimonabant, CP-55490 and Δ8 THC, CB1 
ligands which have approximately tenfold different KD values for the CB1 receptor. In these studies, the dose 
was adjusted to obtain similar equilibrium CB1 occupancy for all three compounds. When steady state 
occupancy was reached, all compounds showed selectivity for the different targets according to the 
difference in their KD values for the different targets. We also describe that the higher affinity compounds 
Rimonabant and CP-55490 showed a much slower approach to steady-state occupancy in the brain regions 
with the highest target expression compared to Δ8 THC, which led to a change in target selectivity across 
tissues in the first week of treatment. We thus show the advantage and propose the application of 
combined computational methods to predict target and tissue selectivity in the earliest phase of drug 
discovery and generate understanding of multiple target binding in multiple target tissues. 
 
SECTION III.   Simulations, model analysis and experimental validation of the influence of 
binding kinetics on the time course of drug action 
 
In chapter 4, 5 and 6, we show how the influence of drug-target binding kinetics on the time course of 
target occupancy is dependent on the pharmacokinetics and target concentrations. This invokes the 
question when a drug-target binding model can be discriminated from linear target site distribution models 
and when these models provide similar drug effect profiles. To investigate this, in chapter 7 we fit an effect 
compartment model, a target binding model and a combined effect compartment-target binding model to a 
historical morphine PKPD dataset in rats. This dataset contained plasma and brain extracellular fluid (ECF) 
morphine concentrations and EEG amplitudes as pharmacodynamic endpoint. In addition, we perform 
simulations with a one compartment PK model with drug-target binding to identify for what parameter 
values the time to the maximal target occupancy (TmaxTO) changed significantly with a tenfold increase in 
the dose. We describe that the differentiation between the target binding and effect compartment model is 
difficult, both if the plasma concentrations or the brain concentrations are assumed to be directly linked to 
the target binding/effect compartment. Moreover, our simulations show that the shift in TmaxTO with 
increasing dose is only observed for intermediate koff values around the elimination rate constant and for 
low KD values relative to the target concentrations. We conclude that successful target binding or effect 
compartment model fits are not supportive for the relevance of target binding or target site distribution, 
respectively. The target binding model should be considered more often as alternative to the effect 
compartment model to obtain the best model and to generate the possibility to inform the in vivo model 
with in vitro parameters. 
 
So far, we have focused on the role of target binding kinetics as a determinant of the time course of the 
target occupancy and the selectivity of action in a stationary system without homeostatic feedback, where a 
constant drug concentration leads to a constant drug effect. In reality, fluctuations of the drug effect may 
occur, also with constant drug concentration. Such fluctuations may result from fluctuations in the release 
of neurotransmitters or from homeostatic feedback mechanisms. In Section III, we study how the influence 
of drug-target binding kinetics depends on the concentration profile and target binding kinetics of 
endogenous ligands, on the signal transduction and on homeostatic feedback. We investigate this question 
in chapter 8 based on the in vitro binding kinetics and cAMP response data for 17 dopamine D2 antagonists. 
The relation between drug-target binding kinetics, endogenous competition and signal transduction is 
especially relevant for D2 antagonists since it has been postulated in the “fast-off” hypothesis that a high 
antagonist koff value would reduce their side effects by partially allowing the endogenous dopamine binding 
to the D2 receptor.[20] This hypothesis has been investigated with a more detailed simulation study for 
fluctuating dopamine concentrations, but the signal transduction and feedback kinetics were not taken into 
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account in that study.[12] Therefore, we firstly develop a minimal mechanistic model that included 
antagonist and dopamine binding kinetics to the D2 receptor, the synthesis and degradation of cyclic 
adenosine monophosphate (cAMP) and the synthesis and degradation of phosphodiesterase (PDE), which 
provides negative feedback on cAMP concentrations. This model is fitted to the in vitro cAMP response data 
of all 17 D2 antagonists and subsequently used to simulate the response to fluctuating dopamine 
concentrations with a wide variety of fluctuation frequencies, as observed in vivo.[21] We find that the 
influence of the antagonist koff on the amplitude of the induced cAMP fluctuations is restricted by both the 
cAMP degradation rate constant and the dopamine koff which also means that an antagonist koff higher than 
one of these values does not influence the cAMP fluctuations. This means that to study the relevance of the 
koff value, the signal transduction kinetics, endogenous ligand binding kinetics and the homeostatic feedback 
kinetics need to be taken into account, especially for fluctuating endogenous ligand concentrations. 
In chapter 9, we discuss how the findings in this thesis affect our understanding of the influence of drug-
target binding kinetics on the time course of target occupancy and drug effect. We conclude that this is 
dependent on the pharmacokinetic and pharmacodynamic context and that modeling and simulation can be 
a valuable tool to increase the understanding of the complex biological system that determines the 
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It is generally accepted that, in conjunction with pharmacokinetics, the first-order rate constant of target 
dissociation is a major determinant of the time course and duration of in vivo target occupancy. Here we 
show that the second-order rate constant of target association can be equally important. On the basis of the 
commonly used mathematical models for drug-target binding, it is shown that a high target association rate 
constant can increase the (local) concentration of the drug, which decreases the rate of decline of target 
occupancy. The increased drug concentration can also lead to increased off-target binding and decreased 
selectivity. Therefore, both the kinetics of target association and dissociation need to be taken into account 
in the selection of drug candidates with optimal pharmacodynamic properties. 
Glossary 
Endogenous ligand; A compound that is naturally present in the body and functions by binding to a certain 
receptor. 
Endogenous competition; Binding of an endogenous ligand to the same binding site as a drug.  
Kinetic selectivity; Differential kinetics of a compound for binding to intended and unintended targets. Most 
often considered beneficial if the residence time on the intended target is longer than the residence time on 
the unintended targets 
Non-specific binding; Drug binding to proteins, lipids or other materials that do not initiate signaling. Often 
unsaturated. 
Pharmacokinetics; The combination of all processes that influence the concentration of a drug over time, 
including absorption, distribution, metabolism and excretion in all body compartments. 
Pharmacodynamics; The combination of all processes that influence the relation between drug 
concentrations and drug effects. 
Residence time; The average time each drug molecule remains bound to the target after the binding event, 
calculated as 1/koff. 
Rebinding; The occurrence of multiple binding events during the dissociation phase, as a consequence of 
increasing unbound drug and target concentrations due to dissociation. Mostly used to describe the 
increased local drug concentration due to dissociation and limited diffusion near the drug target, for 
example in a synapse. 
Signal transduction; The cascade of (cellular) reactions that is initiated by receptor activation and leads to 
the eventual effect. 
Target-Mediated Drug Disposition; Extensive drug-target binding that influences the pharmacokinetic 
characteristics of a drug. 
Target occupancy; The fraction of target that is bound to a drug or ligand molecule. 




Optimisation of in vivo drug-target binding kinetics for drug discovery 
To optimise the duration of drug action for its therapeutic use, developers have primarily focused on 
modification of pharmacokinetic parameters. However, an alternative approach is to optimise the duration 
of drug action by the modification of drug-target binding kinetics. 
The target association and dissociation rate constants are important determinants of both the time course 
and the extent of drug effects, and their values can be measured in high-throughput in vitro systems. This 
has led to the inclusion of drug-target binding kinetics as a selection criterion in the evaluation of drug 
candidates in drug discovery [1,2].  
Although drug-target binding kinetics can be optimised for different purposes regarding the magnitude and 
the kinetics of both wanted and unwanted drug effects [3–7], the most frequently proposed application is to 
prolong the duration of action by prolonging the target occupancy (see Glossary). Generally, the emphasis 
has been put on an increase of the target residence time through a reduction of the rate of target 
dissociation [8–10]. 
However, as drugs act in the human body, which is a complex and dynamic biological system, the duration 
of drug action is also influenced by other factors. These factors include the time course of the drug 
concentration (pharmacokinetics), the rates of synthesis and breakdown of the target molecule (target 
turnover), the concentrations of endogenous ligands competing for the same target, and the kinetics of the 
signal transduction [11]. 
Of these factors, the pharmacokinetics of the drug and the drug-target binding kinetics are the most 
frequently considered determinants of the time course of target occupancy. It is generally believed that the 
drug-target dissociation will only prolong target occupancy if it is slower than the rate of elimination of the 
drug [10]. 
While this rule of thumb offers a valuable approach to evaluate the role of drug-target binding kinetics, it 
does not account for all aspects of the complex interaction between the drug and its target. An important 
factor in this respect is that binding to the target can modify the local pharmacokinetics of the drug. In this 
way, binding of the drug to the target may lead to a decrease in the free drug concentration, while 
dissociation from the target may lead to an increase of the free drug concentration. This process is 
commonly referred to as “target-mediated drug disposition” or TMDD. The quantitative significance of this 
effect depends on the ratio of target-bound and unbound drug concentrations, which in turn depends on 
the target affinity of the drug and the concentration of the target in the biological system. Particularly for 
drugs with a high affinity for the target, target binding may reduce the elimination of the drug, as reflected 
in a long terminal phase in the decrease of the unbound plasma concentration, as has been demonstrated 
for warfarin and other drugs (Box 2) [12–19]. 
The influence of drug-target binding kinetics has not only been described for unbound drug concentrations 
in plasma, but also for unbound drug concentrations in the local environment of the target, such as a 
synapse or a cell membrane. In the local context, this interaction is commonly referred to as “diffusion-
limited binding”, “rebinding” or drug-target binding from a “micro compartment” [20–24].  
To understand the role of drug-target binding kinetics, others have analysed when binding equilibrium can 
be assumed in a TMDD model with target binding in plasma [17] and what the role of binding kinetics is 
when rebinding occurs [22]. Most recently, Vauquelin et al. demonstrated in a simulation study that both 
the drug-target association and dissociation rate constant have a similar impact on the duration of target 
occupancy if rebinding occurs [25]. However, an integrated analysis that indicates when binding kinetics are 
most relevant in a pharmacokinetic context, including tissue distribution, is currently missing.  
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Our aim here is to obtain such an integrated analysis. We firstly present an approximation to understand 
and visualize the role of drug-target binding kinetics if binding occurs in plasma. Subsequently, we expand 
this approximation to binding in a tissue. We obtain simple algebraic expressions to calculate when the 
drug-target dissociation rate is determining the duration of target occupancy for both binding in plasma and 
in tissues. Thus, we provide a connection of model-based insights from TMDD and rebinding models to 
predict the role of drug-target binding kinetics for drugs that bind to targets in the blood or in more 
peripheral tissues. 
Drug-target binding in vivo: where does it happen? 
The commonly used mathematical models for drug-target binding were analysed in this study to yield a 
quantitative insight in the relative impact of drug-target binding kinetics and pharmacokinetics on the time 
course of target occupancy in vivo. The simplest model considers the situation where drug-target binding 
and elimination of the unbound drug occur simultaneously from the blood or from a tissue that is in fast 
equilibrium with the blood. This is schematically represented by Model 1 (Figure 1). The central 
compartment represents the blood and all organs that equilibrate quickly with the blood (see Box 1 for 
more information). Similar models have been used to describe binding to enzymes and binding to centrally 
expressed targets [26,27]. Note that absorption is not incorporated in this model and the dose is 
administered directly in the central compartment to represent intravenous dosing or very fast absorption. 
Although drug-target binding from the blood is commonly seen for circulating enzymes or receptors on 
circulating cells, many drug targets are only expressed in specific tissues, such as the brain. For such targets, 
Model 2 (see Figure 1) might be more relevant. Model 2 is a common model for distribution into a specific 
tissue and binding to a drug target which is localised only in this tissue. This model has been used for a long 
time, for example to describe dopamine D2 receptor binding in the human brain and β-Adrenergic receptor 
binding in the human heart [28,29]. The central compartment represents the blood and all organs that 
equilibrate quickly with the blood. Absorption is not incorporated in this model and the dose is given 
directly in the central compartment to represent intravenous dosing or very fast absorption. 
Simultaneous elimination and drug-target binding: what’s the difference? 
The influence of pharmacokinetics on the role of drug-target binding kinetics has been acknowledged 
previously. This influence has been summarized in the general paradigm that the rate of drug-target 
dissociation has to be slower than the rate of elimination of the unbound drug to prolong the duration of 
target occupancy. However, this general rule does not take into account the possible influence of drug-
target binding on unbound drug concentration profiles. The influence of drug-target binding on the 
unbound drug concentration is known to be most pronounced for drugs with high affinities or high target 
concentrations (i.e. if the ratio of the target concentration and the affinity exceeds 1, see Box 2) [12]. As the 
interaction between pharmacokinetics and drug-target binding depends on the dissociation constant (KD), 
decreasing the drug-target dissociation rate constant (koff) or increasing the drug-target association rate 
constant (kon) will both have a similar impact on the unbound drug concentrations (Box 1 and Box 2). As a 
consequence, changing the kon of a drug can have the same impact on the duration of target occupancy as 
changing the koff. However, the impact of kon and koff on the initial increase of target occupancy might be 
different. The comparable impact on the duration of target occupancy of changing only koff (left panels) or 
only kon (right panels) is illustrated in Figure 2. The different rows in Figure 2 demonstrate that the impact of 
kon and koff on the duration of target occupancy depends on the target concentration and the elimination 
rate constant kel: In the first row, where the target concentration is 10 nM, the impact of kon and koff is very 
similar, but in the second row, where the target concentration has changed to 1 nM, the impact of kon and 
koff is different, as can be seen most clearly for the yellow and the blue line. In the bottom row, where the 
target concentration stays 1 nM and the elimination rate constant changes from 1 to 0.1 h-1, the impact of 
kon and koff on the duration of target occupancy is again similar. 
  
50 
Box 1. Drug-target binding in compartmental models. 
Compartmental models are the most common form of mathematical models in pharmacology. In these models, the 
different locations and states in which the drug can occur are lumped into one or more compartments. Differential 
equations are used to describe the time profile in each compartment (see Supplemental Information S1 for the differential 
equations of Model 1 and Model 2). The underlying assumptions of a compartmental description of drug-target binding 
are the following: 
1. Homogeneity within each compartment: Although the represented biological systems are clearly non-
homogeneous, the assumption of homogeneity can be used if equilibration within each compartment is 
sufficiently fast. 
 
2. Drug-target binding occurs in the unbound drug compartment: As the drug target has to reside in the same 
location as the unbound drug to enable drug-target binding, the volume of the ligand-receptor compartment 
and the volume of the unbound drug compartment that drives the drug-target binding (i.e. the tissue 
compartment for Model 2) are assumed to be the same. 
Model 1 connects the drug concentration to the target binding according to the law of mass action. The law of mass 
action states that the rate of elementary (single-step) chemical reactions is proportional to the product of the 
concentrations of the reactants. This results in the familiar equations that describe the drug-target association rate as the 
product of the drug-target association rate constant kon, the unbound target concentration [R] and the unbound ligand 
concentration [L], while the drug-target dissociation rate is the product of the dissociation rate constant koff and the bound 
ligand concentration [RL]. As the drug-target association and dissociation rates are equal in equilibrium, this leads to the 
common equilibrium equation for the dissociation constant KD: 







In a closed system (without drug or target elimination) with a low target concentration (as in most in vitro binding 
experiments) [L] can be assumed to be constant and much larger than [R]. This has led to analytical expressions that 
describe the drug-target binding profile in vitro, such as published by Motulsky and Mahan [39]. For the in vivo situation, 
[L] is not constant, because high target concentrations can lead to depletion of the ligand upon binding, and because of 




Figure 1. Schematic representation of the two models that are used in this study. Model 1 describes drug-target binding in 
the central compartment (representing blood and quickly equilibrating tissues) with the second-order association rate 
constant kon and the first order dissociation rate constant koff. Elimination of the drug from the body (by excretion or 
metabolism) is described by the first order rate constant kel. Model 2 describes drug-target binding from a tissue, and 
distribution into and out of the tissue is described by the first-order rate constants kin and kout, respectively. The differential 
equations of Model 1 and 2 can be found in Supplemental Information S1. 
 
Box 2. Target-Mediated Drug Disposition. 
To describe the influence of extensive drug-target binding on the pharmacokinetic profile of the drug, the term “Target-
Mediated Drug Disposition” (TMDD) was introduced by Levy et al. in 1994[35]. Extensive target binding occurs mainly 
when the ratio of total target concentration/dissociation constant KD is larger than 1, as a consequence of the law of mass 
action. For example, if the unbound concentration of a drug in binding equilibrium is 5 nM, the total target concentration 
is 50 nM and the KD is 5 nM, 50 % of the target will be occupied, which corresponds to 25 nM. This means that the 
concentration of the bound drug is five times larger than the concentration of the unbound drug. As most drugs can only 
be eliminated if they are unbound, this extensive target binding leads to a slower elimination of drug from the body, 
compared to the situation without extensive target binding. This extensive target binding decreases if the target becomes 
saturated. If the drug concentration is increased from 5 to 500 nM for the example of a target concentration of 50 nM and 
a KD of 5 nM, the equilibrium occupancy becomes 99%, corresponding to a target-bound drug concentration of 50 nM. This 
means that the concentration of bound drug is now ten times smaller than the concentration of the unbound drug. The 
impact of extensive target binding on free drug concentrations in plasma is most apparent if the average target 
concentration is high in the whole body. This has led to the frequent application of TMDD models to describe the plasma 
concentration profile of antibodies, as they often bind with high affinity to centrally expressed targets [14]. Since the 
degradation/internalization of target-bound antibodies often contributes significantly to the elimination of the total 
amount of antibody, TMDD models often incorporate these processes [16]. If extensive target binding only occurs locally 





Figure 2. Simulation of the target fraction bound for drug-target binding in the blood (Model 1). The simulated affinities 
are increased by changing either the dissociation rate constant koff (left panels) or the association rate constant kon (right 
panels). The kon was 0.36 nM-1h-1 for all lines in the left panels and the koff was 36 h-1 for all lines in the right panels. The 
initial concentration is 25*KD for the top and middle row and 2.5*KD for the bottom row, to achieve similar maximal 
occupancies in all panels. KD is the drug-target dissociation equilibrium constant and kel is the drug elimination rate 
constant. [Rtot] = total target concentration. Top row: [Rtot] = 10 nM, kel 1 h-1, middle row: [Rtot] = 1 nM, kel 1 h-1, bottom 
row: [Rtot] = 1 nM, kel 0.1 h-1. 
The influence of pharmacokinetics, target concentration, and affinity on drug-target binding kinetics 
requires simultaneous analysis of the influence of all parameters. To focus on the duration of target 
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occupancy, we derived an approximation of the decrease of target occupancy after it maximal value. This 
decrease of target occupancy is described here as the derivative of the target fraction bound (BF) vs. time 
curve. As the decrease of target occupancy often follows an exponential decline, the derivative is calculated 
for the semi logarithmic target fraction bound (BF) vs. time curve, where the target fraction bound is on the 
logarithmic axis. The derivative of the semi logarithmic target fraction bound (BF) vs. time curve, called λTO 
here, is not always constant over time as it depends on the saturation of drug-target binding: If the drug 
concentration is much higher than the affinity and all target molecules are bound to the drug, a relatively 
small proportion of the drug is bound to the target and the elimination of the drug is not limited by target 
binding. Also, if target binding is saturated and the unbound drug concentration decreases with a certain 
percentage, the target fraction bound decreases much less than that percentage. However, a fractional 
decrease in the unbound drug concentration will result in a similar decrease in the target fraction bound if 
the target fraction bound is low and binding is not saturated. As an example, if the unbound drug 
concentration decreases 90% from 500 to 50 nM for a drug with a KD of 5.0 nM, the corresponding 
equilibrium bound fraction decreases 7%: from 0.99 to 0.91. If the unbound drug concentration decreases 
90% from 50 to 0.50 nM for a drug with a KD of 5.0 nM, the corresponding equilibrium bound fraction 
decreases 82%: from 0.50 to 0.091, (see also box 2 and Supplemental Information S2). As the derivative of 
the semi logarithmic target fraction bound (BF) vs. time curve, λTO, depends on the saturation of drug-target 
binding, it can be expressed as a function of the target fraction bound: λTO(BF). 
Our approximation is based on the assumption that the process that results in the slowest decrease of 
target occupancy (elimination or dissociation) will determine the decrease of target occupancy as rate-
limiting step. To predict which of these processes is the rate-limiting step in the decrease of target 
occupancy, one needs to take into account that only elimination of the unbound drug occurs, and 
elimination is thus limited by drug-target binding. Moreover, incorporation of the influence of drug-target 
target saturation on the relationship between the decline of unbound and target-bound drug 
concentrations is required. As demonstrated in Supplemental Information S2, the derivative of the semi 
logarithmic target fraction bound (BF) vs. time curve, as function of BF, λTO(BF), can be approximated on this 
basis. The resulting approximation of λTO(BF) for the physiological range of parameter values for Model 1 
reveals 3 different situations for the influence of drug-target binding kinetics on the duration of target 
occupancy:  
1) Only the koff determines the duration of target occupancy. This is the case if drug-target 
dissociation is the rate-limiting step for the decrease of the target occupancy. 
 
2) Both koff and kon influence the duration of target occupancy equally. The duration of target 
occupancy is determined by the dissociation constant KD, the elimination rate constant kel, and 
the total target concentration[Rtot].  
 
3) Only the elimination rate constant kel determines the duration of target occupancy. 
Which of these situations applies for a specific drug depends on the value of kon and koff, but also on the 
target concentration and the pharmacokinetic parameters. The situation where drug-target dissociation is 
rate limiting and koff the only determinant for the decrease of target occupancy requires both a low value 
for kon and koff. On basis of our approximation, we could identify a constant for the value of koff and kon that 
results in drug elimination as the rate-limiting step in the decrease of target occupancy. The constants that 
approximate the threshold value of kon and koff for the rate-limiting step, KRLon and KRLoff(BF), are given by 
Equation 1 and 2 (which are derived as equation S25 and S26). It should be noted that the KRLon is 
independent of target saturation while KRLoff(BF) is dependent on target saturation and thus given as 









𝒌𝒆𝒍 ∙ (𝟏 − 𝑩𝑭)
𝒌𝒐𝒇𝒇
 
If KRLon and KRLoff(BF) are both greater than 1, dissociation is the rate-limiting step in the decrease of target 
occupancy, which is than determined by koff. If either of these constants is smaller than 1, elimination is the 
rate-limiting step in the decrease of target occupancy.  
If elimination is the rate-limiting step in the decrease of target occupancy, the decrease rate can be either 
determined by the kel alone, or by kel, kon and koff. The maximal value of koff that leads to an elimination rate 
that is significantly influenced by kel, koff and kon is given in Equation 3 (derived as equation S28). 
Equation 3 
𝒌𝒐𝒇𝒇 = 𝒌𝒐𝒏 ∙ [𝑹𝒕𝒐𝒕] ∙ (𝟏 − 𝑩𝑭) 
Equations 1-3 provide the basis to identify which of the situations regarding the influence of drug-target 
binding kinetics on the duration of target occupancy applies, as visualised in Figure 3. 
The analysis of Model 1 as presented in Figure 3 provides several general insights for drug discovery: 
1) Increasing the kon can increase the duration of target occupancy (indicated by the changing color 
in the horizontal direction), even if the koff is higher than the kel. 
 
2) If the kon or the koff is sufficiently high to result in a KRLon or KRLoff(BF) > 1, decreasing the koff has 
the same impact on the duration of target occupancy as increasing the kon (indicated by the 
diagonal color bands in the lower right corner). 
 
3) If both the koff and the kon value are sufficiently low to make both KRLon and KRLoff(BF) < 1, drug-
target dissociation is rate-limiting and koff determines the duration of target occupancy (as 
indicated by the horizontal color bands in the lower left corner). A rate-limiting drug-target 
dissociation is required to obtain a slower decline of target occupancy than expected on basis of 
the unbound drug concentration and the drug-target affinity. This means that only a combination 
of a low koff and a low kon could lead to longer binding to the intended than to the unintended 
target (which also requires a lower dissociation rate from the intended compared to the 
dissociation rate from the unintended target, i.e. kinetic selectivity) [1,30]. 
 
Model 1 applies to drugs which have their target in the blood or in a tissue that equilibrates rapidly with 
blood. Mainly targets that are expressed in the blood, such as circulating enzymes (HSP90, Factor X) have 





Figure 3. Approximation of the decline in target occupancy using Model 1. The total target concentration is 1 nM (left 
panel) and 20 nM (right panel), the elimination rate constant is 0.1/h and the target fraction bound is 0.75, to represent a 
clinically relevant degree of target occupancy. Colors represent the decrease of target occupancy (λTO(BF)) as calculated 
according to Supplemental Information S2 (Equation S19). The vertical line is given for KRLon = 1 (see Equation 1), the 
horizontal line is given by KRLoff(BF) = 1 (see Equation 2) and the diagonal line is given by Equation 3. In these equations, kel 
is the elimination rate constant, [Rtot] is total target concentration and BF is the bound fraction of the target. The 
annotations indicate which parameters influence the decrease in target occupancy in the corresponding segment of the 
plot. This figure is an approximation of Model 1 (insert) (Supplemental Information S2). 
 
Is the impact of drug-target binding kinetics different for target binding in a tissue? 
To expand our understanding of drug-target binding, a similar analysis was performed for drugs that bind 
only in a specific tissue, similarly as was done for drug-target binding from the blood. The results of this 
analysis can be found in Supplemental Information S3. One of the main differences with the analysis for 
Model 1 is that the drug distribution from the tissue to the central compartment can be rate limiting for 
Model 2. A high value of kon still leads to an equal impact of kon and koff on the decline of target occupancy in 
the same way as for Model 1 if drug distribution out of the tissue is rate-limiting, but this is not necessarily 
reflected in the unbound plasma concentration versus time profile. Moreover, rate-limiting elimination can 
similarly influence the duration of target occupancy due to extensive target binding, but this occurs only at 
high target concentrations in the tissue, as the fraction of the total amount of drug in the body that is bound 
to the target decreases for decreasing volumes of the drug-target binding tissue.  
To understand what our analysis means for drug discovery, our equations have been applied to a 
combination of common pharmacokinetic parameters (Figure 4, key figure). A small literature survey was 
performed to find a common value for the total tissue target concentration. The target concentration for 
common targets such as µ-opioid [23], adenosine [32], dopamine D2 [28], GABA [33], 5-HT [34], and Vitamin 
K epoxide reductase [35] varied between 2 [34] and 2000 [35] nM, with most values in the range between 
56 
10 and 100 nM. As can be seen in Figure 4, our analysis reveals a very similar influence of the drug-target 
binding kinetics for drug-target binding in tissue compared to drug-target binding in the blood (Figure 4).  
To investigate how the combination of kon and koff values of drug discovery compounds relate to the 
expected determinants of the duration of target occupancy, all compounds from the K4DD (kinetics for drug 
discovery http://www.k4dd.eu) consortium database were included in Figure 4. This K4DD database is 
brought together by both industry and academia and consists of in vitro binding kinetics measurements of 
small molecule drug discovery compounds on different targets, including kinases and GPCRs. We will refer 
to this data set as the “discovery dataset”. 
Moreover, a literature dataset of compounds with known drug-target binding kinetics which were 
developed into drugs or drug candidates, as published by Dahl and Akerud [10], was also included in Figure 
4. Below, we will refer to this dataset as the “candidate dataset”. The data in Figure 4 show that the 
majority of compounds from both datasets have high kon values for the common pharmacokinetic 
parameters and target concentration and would be expected to have an equal influence of both kon and koff 
on the duration of target occupancy. Moreover, as the drug distribution is rate limiting for the decline of 
target occupancy for a high value of kon and the given pharmacokinetic parameters and target concentration 
in Figure 4, binding equilibrium will be reached and no kinetic selectivity is expected over unintended 
targets that are located in the same tissue as the intended target. Interestingly, comparison of the discovery 
and the candidate dataset shows a similar distribution of kon values in both datasets, but a distribution of koff 
values which is approximately one order of magnitude lower for the candidate dataset. The differential 
distribution for koff but not for kon in these datasets can have multiple explanations. As indicated by others, 
kon is often less sensitive to chemical modifications of similar compounds or for biological modifications of 
the target compared to koff [36]. Also, the selection of drug (candidates) was based on the availability of 
drug-target binding kinetics, which could lead to a biased dataset for compounds where the drug-target 
binding kinetics plays a more significant role. Moreover, achieving a high affinity in drug discovery and 
development by changing the kon is limited by the diffusion-limited maximal value of kon, whereas the koff 
has no theoretical minimum until  irreversible binding is reached [37]. 
The similar values for kon in both datasets correspond with our finding that an increasing kon can increase the 
duration of target occupancy but at the cost of increasing the (local) drug concentrations, which can result 
in increased side effects. Moreover, the observation of lower koff values in the candidate dataset indicates 
that a low koff value might contribute to successful drug development. Dahl and Akerud observed that the 
drug-target dissociation for most compounds in the candidate dataset is slower than the plasma 
elimination, which means in their analysis that the elimination rate determines the duration of target 
occupancy (assuming there is no rebinding). In our analysis, the high kon values in the candidate and in the 
discovery dataset result in a decline of target occupancy that is influenced by the elimination rate constant 
and the binding affinity and that the resultant decline of target occupancy can be slower than the 
elimination and the dissociation rates. 
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Figure 4. Calculated duration of target occupancy for drug-target binding in a tissue (Model 2). Top panel: Relation 
between drug-target binding kinetics and the duration of target occupancy for binding in tissue. The points and their linear 
regressions provide an overview of the distribution of binding kinetics measurements of all compounds in the drug 
discovery compound database of the K4DD consortium (white) or the drug (candidate) dataset from the review published 
by Dahl and Akerud (purple). The colors and black lines depend on the pharmacokinetic parameters according to equation 
S35 in Supplemental Information S3 and are based on Model 2 (insert) with the following parameter values: [Rtot] = 50 nM, 
kel = 0.5/hr, kin = 0.2/hr, VC = 40 L, VT = 1 L, BF = 0.5. [Rtot] is the total target concentration, kel is the elimination rate 
constant, kin is the brain to plasma distribution rate constant, VC is the volume of the central compartment, VT is the 
volume of the tissue and BF is the bound fraction of the target. Bottom panels: distribution of the dissociation (left) and 
association (right) rate constants of both datasets with the corresponding colors in the top panel. The distribution of the 
parameter values of each dataset is plotted as the estimated probability density function. 
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Optimising drug-target binding kinetics: to what end? 
Both for drug-target binding in plasma and in tissue, our analysis indicates that high kon values can decrease 
the target occupancy decline below the elimination and dissociation rates. However, this increased duration 
of target occupancy is caused by increased (local) drug concentrations unless both koff and kon are low. This 
means that the optimal value for kon depends on the target, the drug class and the drug-specific 
pharmacokinetic, pharmacodynamic and toxicity processes.  
If an increased duration of target occupancy is desired, this can be achieved by both increasing the kon or by 
decreasing the koff. If the kon is high enough, kon and koff have the same impact on the duration of target 
occupancy (Figure 2, top and bottom row), but not on the initial increase rate of target occupancy after 
dosing (Figure 2, bottom row). Moreover, a high value of kon will lead to increased local drug concentrations 
and a rate-limiting role for the pharmacokinetics, which can result in increased off-target binding and 
decreased selectivity. How drug target binding can influence only local drug concentrations is illustrated by 
our simulations for diprenorphine (Supplemental Information S4 and S5). 
Our analysis is based on a simplification of the complex biological system that determines the duration of 
target occupancy, see Outstanding Questions. Three important factors that can play a role in the kinetics of 
target occupancy are non-specific binding, endogenous competition and target turnover. Non-specific 
binding could influence the relevance of our analysis as a high percentage of non-specific binding could 
mean that the impact of specific binding on drug concentrations decreases for drugs with extensive non-
specific binding. Also, the presence of an endogenous ligand that competes for binding to the drug target 
will reduce the number of available target molecules and thus decrease the impact of drug-target binding. 
Moreover, the synthesis and degradation of the target and drug-target complex can increase the decline of 
target occupancy and thus decrease the impact of drug-target binding. However, our analysis provides a 
quantitative improvement of the commonly used consideration that only a drug-target dissociation rate 
lower than the plasma elimination rate can influence the duration of target occupancy [10,36]. 
Apart from these complications, the validity of our findings depends on the validity of our assumptions and 
mathematical method. However, mathematical and experimental findings that explored the interaction 
between local concentrations in the target vicinity and drug-target binding(“rebinding”) also pointed 
towards the importance of kon in similar equations [20–22,38]. Moreover, published [3H] diprenorphine 
plasma and brain concentrations were fitted with Model 2 for this study, and subsequent simulations with 
varying drug-target binding kinetics revealed an equal impact of kon and koff on the target occupancy profile 
over time, as expected from our analysis (Supplemental Information S4 and S5). Supplemental Information 
S4 supports the relevance of the analysed model, Model 2, as it is able to describe the experimental data of 
diprenorphine plasma and brain concentration. Supplemental Information S5 supports the necessary 
assumptions that were made to analyse Model 2, as the role of binding kinetics in the full model 
corresponds with the predicted role of binding kinetics from our approximation. Finally, comparison of 
approximated and simulated target occupancy vs. time derivatives indicated a high accuracy of our 
approximation and a high relevance of our assumptions, except for the combination of low association, 
dissociation and elimination rate constants with low target concentrations (Supplemental Information S6). 
Altogether, this supports the relevance and validity of our analysis. 
To enable the rational use of drug-target binding kinetics in drug discovery, the whole kinetic context 
between drug dosing and effect should be taken into account. The algebraic equations as presented in this 
study provide a first step to integrate and understand both pharmacokinetics and drug-target binding 
kinetics. If the pharmacokinetic parameters are unknown, commonly observed values can be used, as 
demonstrated in Figure 4. If more detailed information is required on both the duration and the extent of 




Comprehensive analysis of the commonly used models for drug-target binding reveals that high drug-target 
association rate constants result in longer target occupancy than expected on basis of the drug-target 
dissociation and the drug elimination rate constants. The kon value that separates high and low values of kon 
increases with increasing target concentration and with decreasing drug elimination and distribution rate 
constants and can be calculated algebraically. High values of kon, for common pharmacokinetic parameter 
values, are observed frequently for both drug discovery and drug (candidate) compounds and result in an 
equal impact of both kon and koff on the duration of target occupancy. However, these high kon values can 
lead to more off-target toxicity. Comparison of drug discovery and drug (candidate) compounds shows 
similar distributions of kon while koff is approximately one order of magnitude smaller for the drug 
(candidate) compounds. 
The target occupancy versus time profile can only be predicted if the target concentration and the rate 
constants of drug binding, elimination and distribution are taken into account, which often results in an 
equal impact of kon and koff on the duration of target occupancy. 
Our findings demonstrate that optimizing the drug discovery requires mechanistic knowledge of the 
intended mechanism of action, including the in vivo concentration of the drug target. Moreover, the role of 
the drug-target association rate constant (kon) should be taken into account in the optimization of the 
duration of drug effects. Although this study does not include all relevant processes that can influence the 
duration of drug effects following administration of a drug (see Outstanding Questions box), the presented 
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Appendix S1. Differential equations of models 1 and 2, related to Box 1 and Figure 1. 
Used parameters 
kel = first order drug elimination rate constant 
kin = first order drug distribution rate constant into the tissue 
kout = first order drug elimination rate constant out of the tissue 
koff = first order drug-target dissociation rate constant 
kon = second order drug-target association rate constant 
C = unbound drug in the central compartment 
T = unbound drug in the tissue compartment 
LR = drug-target complex 
Ltot = total drug in de body = C + T + LR 
Rfree = unbound target 
Rtot = total target = Rfree + LR 
[] = concentration 
A = amount 
 
Model 1 
The rate of change in the amount of drug in the central compartment of model 1, AC, is given by Equation 
S1, where kel and koff are the first order rate constants describing elimination and drug-target dissociation, 
respectively, where kon is the second order drug-target association rate constant, [Rfree] is the unbound 
target concentration and ALR is the amount of drug-target complex. Drug absorption and non-specific 




= −𝑘𝑒𝑙 ∙ 𝐴𝐶 −  𝑘𝑜𝑛 ∙ 𝐴𝐶 ∙ [𝑅𝑓𝑟𝑒𝑒] +  𝑘𝑜𝑓𝑓 ∙ 𝐴𝐿𝑅 
 
The rate of change of the unbound receptor concentration [Rfree], is given by Equation S2 and the rate of 








=  𝑘𝑜𝑛 ∙ 𝐴𝐶 ∙ [𝑅𝑓𝑟𝑒𝑒] −  𝑘𝑜𝑓𝑓 ∙ 𝐴𝐿𝑅 
 
As the total target concentration is constant in this model, [Rfree] can be calculated from the total target 
concentration [Rtot] and the bound target concentration [LR] as in Equation S4: 
Equation S4 
[𝑅𝑓𝑟𝑒𝑒] = [𝑅𝑡𝑜𝑡] − [LR] 
 
Model 2 
For model 2, the rate of change in the amount of drug in the central compartment,  
AC, is described by Equation S5, where kout and kin are the first order rate constants describing distribution 
into and distribution out of the tissue, respectively, and AT is the amount of drug in the tissue. Drug 





= −𝑘𝑒𝑙 ∙ 𝐴𝐶 −  𝑘𝑖𝑛 ∙ 𝐴𝐶 +  𝑘𝑜𝑢𝑡 ∙ 𝐴𝑇 
 




= 𝑘𝑖𝑛 ∙ 𝐴𝐶 −  𝑘𝑜𝑢𝑡 ∙ 𝐴𝑇 −  𝑘𝑜𝑛 ∙ 𝐴𝑇 ∙ [𝑅𝑓𝑟𝑒𝑒] +  𝑘𝑜𝑓𝑓 ∙ 𝐴𝐿𝑅 
 





=  − 𝑘𝑜𝑛 ∙ [𝑇] ∙ [𝑅𝑓𝑟𝑒𝑒] +  𝑘𝑜𝑓𝑓 ∙ [𝐿𝑅] 
 




=  𝑘𝑜𝑛 ∙ 𝐴𝑇 ∙ [𝑅𝑓𝑟𝑒𝑒] −  𝑘𝑜𝑓𝑓 ∙ 𝐴𝐿𝑅 
 
The total target concentration is constant in this model, so [Rfree] can be calculated from the total target 
concentration [Rtot] and the bound target concentration [LR] as in Equation S9: 
 
Equation S9 
[𝑅𝑓𝑟𝑒𝑒] = [𝑅𝑡𝑜𝑡] − [LR] 
 
All simulations were performed in Berkeley Madonna, version 8.3.18, while visualisations were performed in 
R, version 3.1.1[1].  
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Appendix S2. Approximation and analysis of model 1, related to Figure 1. 
As known since the study of Wagner et al[2], the terminal log-linear slope of a PK curve with fast binding 
equilibrium (λz) is given by Equation S10. 
Equation S10 






As explained in box 2, the extensive target binding that leads to a decreased terminal slope of the plasma 
concentration depends on the ratio of [Rtot] and KD. Equation S10 can be derived as in Equation S12 by 
assuming that the free target concentration equals the total target concentration, since the slope of only 
the last part of the PK curve is derived. For earlier phases of the PK curve, the target binding might be 
saturated, leading to a decreased extent of target binding and a steeper PK curve. This saturated part of the 
PK curve is of interest, as most drugs require a substantial target saturation to be efficacious, especially if 
the drug is an antagonist. 
To make Equation S10 valid for the whole part of the PK curve where equilibrium between bound and 
unbound drug concentration can be assumed, the value of the target fraction bound (BF) needs to be 
incorporated as in Equation S13. Here, λel(BF) describes the derivative of the drug concentration profile over 
time on semi-log scale (i.e. ln(drug concentration) vs. time), as a function of the target fraction bound. This 
can be derived by recognizing that the total amount of drug decreases with the same rate as the free 











= −𝒌𝒆𝒍 ∙ 𝑨𝑳𝒕𝒐𝒕 ∙
𝑨𝑪
𝑨𝑳𝒕𝒐𝒕
 =  −𝑨𝑳𝒕𝒐𝒕 ∙
𝒌𝒆𝒍





𝝀𝒆𝒍(𝑩𝑭) =   
𝒌𝒆𝒍




The derivative of the semi-logarithmic drug concentration-time curve, λel(BF), is important for the duration 
of target occupancy, as the rate-limiting (i.e. the slowest) step in the decline of target occupancy can be 
either the drug-target dissociation or the decline of the free drug concentration. 
To calculate the derivative for the semi logarithmic target fraction bound vs. time curve as function of the 
target fraction bound, λTO(BF), it is important to realise that λel(BF) and λTO(BF) are equal to each other if 
elimination is rate limiting in the decline of target occupancy and if the target fraction bound is low. If target 
binding is saturated (i.e. BF is high), the decline of the unbound target concentration is higher, as explained 
above and in box 2, but the decline of the bound target fraction is lower. As an example, if the unbound 
drug concentration decreases 90% from 500 to 50 nM for a drug with a KD of 5.0 nM, the corresponding 
equilibrium bound fraction decreases 7%: from 0.99 to 0.91. If the unbound drug concentration decreases 
90% from 50 to 0.50 nM for a drug with a KD of 5.0 nM, the corresponding equilibrium bound fraction 
decreases 82%: from 0.50 to 0.091. To calculate the derivative for the semi-loarithmic target fraction bound 
vs. time curve if elimination is rate-limiting λelTO(BF) from λel(BF), the relationship between unbound 
concentration needs to be taken into account. This relationship can be derived from the law of mass action 










As we intend to calculate λelTO(BF) from λel(BF), which are both derivatives on a semi-log scale, we need to 
obtain the derivative of the logarithm of the BF-unbound concentration relationship, as a function of BF. 
Thus, we first convert Equation S14 to Equation S15 to obtain the logarithm of BF as function of the 
logartithm of L/KD, which results in Equation S16 after taking the derivative with respect to ln(L/KD). 
Equation S15 








































= 𝟏 − 𝑩𝑭 
Thus, Equation S18 can be used to obtain λelTO(BF) from λel(BF): 
Equation S18 
𝝀𝒆𝒍𝑻𝑶(𝑩𝑭) =  (𝟏 − 𝑩𝑭) ∙ 𝝀𝒆𝒍(𝑩𝑭) =  
(𝟏 − 𝑩𝑭) ∙ 𝒌𝒆𝒍




As said before, the decline of the target fraction bound over time can be determined by two processes: 
dissociation and elimination. Thus, λelTO(BF) can be compared directly to koff, which is the slope of the target 
fraction bound vs. time plot on semi-log scale if drug-target dissociation is rate-limiting in the decline of the 
target fraction bound. 
By selecting the smallest of λelTO(BF) and koff, Equation S19 can be used to calculate λTO(BF), the slope of the 
target fraction bound vs. time plot on semi-log scale. In other words, Equation S19 represents our 
assumption that the decline of target occupancy is determined by the process that gives rise to the slowest 










To find for what parameter values elimination is the rate-limiting step in the decline of the target fraction 
bound, Equation S20 can be solved for the parameter of interest.  
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Equation S20 
𝒌𝒆𝒍 ∙ (𝟏 − 𝑩𝑭)
𝟏 +  [𝑹𝒕𝒐𝒕] ∙  
𝟏 − 𝑩𝑭
𝑲𝑫
 < 𝒌𝒐𝒇𝒇 
Equation S20 can be solved for kon (by rewriting KD as koff/ kon, deviding both sides by koff and rewriting the 
resultant fraction) to find the required value of kon to make elimination the rate-limiting step in the decline 
of the target fraction bound as in Equation S21. 
Equation S21 
𝒌𝒐𝒏 >
𝒌𝒆𝒍 ∙ (𝟏 − 𝑩𝑭) − 𝒌𝒐𝒇𝒇
[𝑹𝒕𝒐𝒕] ∙ (𝟏 − 𝑩𝑭)
 
To obtain from Equation S21 the value of kon for which elimination is rate-limiting in the decline of BF for all 
possible values of koff, it can be reduced to Equation S22 by substituting koff = 0 into Equation S21. Equation 
S22 equals Equation S23. 
Equation S22 
𝒌𝒐𝒏 >
𝒌𝒆𝒍 ∙ (𝟏 − 𝑩𝑭)







Equation S20 can also be used to find the value of koff for which elimination becomes the rate-limiting step, 
for all values of kon, as it can be reduced to Equation S24 by substituting kon = 0 into Equation S20. 
Equation S24 
𝒌𝒐𝒇𝒇 < 𝒌𝒆𝒍 ∙ (𝟏 − 𝑩𝑭) 
Equations 23 and 24 can be rewritten to obtain KRLon and KRLoff(BF), which are the corresponding constants 















The koff value that marks the transition where the slope of target occupancy for a rate-limiting elimination 
(λelTO(BF)) starts to be strongly influenced by the affinity can be derived from Equation S18 and is given by 
Equation S27, which can be rewritten as Equation S28. 
Equation S27 




𝒌𝒐𝒇𝒇 = [𝑹𝒕𝒐𝒕] ∙ (𝟏 − 𝑩𝑭) ∙ 𝒌𝒐𝒏 
 
 
The threshold values as obtained in equations 25, 26 and 28 provide the relation of Figure 3 with all the 
parameters of model 1 that are not explicitly incorporated in Figure 3: [Rtot], BF and kel.  
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Appendix S3. Approximation and analysis of model 2, related to Figure 4. 
Since model 2 is similar to model 1, the prediction of the derivative of the target fraction bound (λTO(BF)) 
over time as function of the target fraction bound (BF) for model 2 has similar components as for model 1. 
Since model 2 has three compartments, three processes can be rate-limiting for the decrease of the target 
fraction bound; drug-target dissociation, unbound drug distribution and unbound drug elimination. If drug-
target dissociation is rate limiting, λTO(BF) is equal to koff. If the unbound drug distribution from tissue to 
plasma is rate limiting, the distribution is influenced by drug-target binding in a similar way as the 
elimination is influenced by drug-target binding (see Equation S13) for model 1. The resultant derivative for 
the unbound concentration in tissue vs time curve on semi logarithmic scale, as function of the target 
fraction bound, λout(BF), is thus given by Equation S29. 
Equation S29 
𝝀𝒐𝒖𝒕(𝑩𝑭) =   
𝒌𝒐𝒖𝒕




If the unbound drug elimination is rate limiting, the derivative for the unbound concentration in the blood 
vs time curve on semi logarithmic scale, as function of the target fraction bound, λel(BF)is influenced again 
by the fraction of the drug that resides in the central compartment. This fraction is for model 2 not only 
determined by the drug target binding, but also by the tissue distribution. If passive diffusion is assumed to 
be the only mechanism of drug distribution, leading to equal equilibrium concentrations in both tissue and 
plasma, the ratio of the amount of drug in the central compartment (AC) and the total amount of drug in 




















With the ratio of amounts of drug in the central compartment and in the total body as in Equation S31, 
λel(BF) is given by Equation S32. 
Equation S32 
𝝀𝒆𝒍(𝑩𝑭) =  𝒌𝒆𝒍 ∙
𝑽𝑪





As λout(BF) and λel(BF) represent the derivatives of the unbound drug concentration vs time profile on semi 
logarithmic scale, Equation S17 can be used to get the corresponding derivatives of the bound drug 
concentration vs time profile on semi logarithmic scale, as in equations 33 and 34. 
With the values of koff, λoutTO(BF) and λelTO(BF), the derivative of the target fraction bound vs. time on semi 
logarithmic scale can be approximated according to Equation S35. 
Equation S33 
𝝀𝒐𝒖𝒕𝑻𝑶(𝑩𝑭) =  ∙
𝒌𝒐𝒖𝒕 ∙ (𝟏 − 𝑩𝑭)







𝝀𝒆𝒍𝑻𝑶(𝑩𝑭) =  𝒌𝒆𝒍 ∙ (𝟏 − 𝑩𝑭) ∙
𝑽𝑪











 +  
𝟏
𝝀𝒐𝒖𝒕𝑻𝑶(𝑩𝑭)




Equation S35 can be used to identify the rate-limiting step in the decline of the target fraction bound 
similarly as Equation S19, but the dependency on the parameters is more complex as there are three 
possible rate-limiting steps. To find the maximal kon value for which drug-target dissociation is the rate 
limiting step in the decline of the target fraction bound, either λoutTO(BF) or λelTO(BF) needs to be smaller 
than koff, as described by Equation S36.  
Equation S36 
𝒌𝒆𝒍 ∙ (𝟏 − 𝑩𝑭) ∙ 𝑽𝑪




< 𝒌𝒐𝒇𝒇 𝒐𝒓 
𝒌𝒐𝒖𝒕 ∙ (𝟏 − 𝑩𝑭)
𝟏 +  [𝑹𝒕𝒐𝒕] ∙  
𝟏 − 𝑩𝑭
𝑲𝑫
 < 𝒌𝒐𝒇𝒇 
This equation is solved in the same way as Equation S20 to obtain the minimal value of kon for which no 
value of koff results in dissociation as the rate-limiting step in the decrease of the target fraction bound, 
which gives Equation S37. Equation S37 comprises two components as well, which can be rewritten to two 
more simple equations as in Equation S38 and Equation S39 where min{} is an operation that selects the 
























Equation S36 can also be used to find the minimal value of koff for which no values of kon result in 
dissociation as the rate-limiting step in the decline of the target fraction bound in a similar way as Equation 
S20 by substituting kon = 0 into Equation S36. As a result, Equation S40 is obtained. The value of koff for 
which dissociation is not rate-limiting for all values of kon is given by Equation S41 and S42. 
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Equation S40 
𝒌𝒐𝒇𝒇 >  𝒌𝒆𝒍 ∙ (𝟏 − 𝑩𝑭) ∙
𝑽𝑪
𝑽𝑪 + 𝑽𝑻
 𝒐𝒓 𝒌𝒐𝒇𝒇 >  𝒌𝒐𝒖𝒕 ∙ (𝟏 − 𝑩𝑭) 
 
Equation S41 
𝒌𝒐𝒇𝒇 = 𝒌𝒎𝒊𝒏𝒐𝒇𝒇 
Equation S42 
𝒌𝒎𝒊𝒏𝒐𝒇𝒇 = 𝒎𝒊𝒏 {𝒌𝒆𝒍 ∙ (𝟏 − 𝑩𝑭) ∙
𝑽𝑪
𝑽𝑪 + 𝑽𝑻
, 𝒌𝒐𝒖𝒕 ∙ (𝟏 − 𝑩𝑭)} 
The koff value that marks the transition where the decline of occupancy for a rate-limiting elimination 
(λelTO(BF)) or rate-limiting distribution (λoutTO(BF)) starts to be strongly influenced by the affinity can be 
derived from Equation S33 and S34 and is given by Equation S43 for λelTO(BF) and Equation S44 for λoutTO(BF). 
Equation S43 
𝑽𝑻 ∙ [𝑹𝒕𝒐𝒕] ∙ (𝟏 − 𝑩𝑭)
𝑲𝑫
= 𝑽𝑪 + 𝑽𝑻 
Equation S44 
[𝑹𝒕𝒐𝒕] ∙ (𝟏 − 𝑩𝑭)
𝑲𝑫
= 𝟏 





∙ 𝒌𝒐𝒏 ∙ [𝑹𝒕𝒐𝒕] ∙ (𝟏 − 𝑩𝑭) 
Equation S46 
𝒌𝒐𝒇𝒇 = 𝒌𝒐𝒏 ∙ [𝑹𝒕𝒐𝒕] ∙ (𝟏 − 𝑩𝑭) 





∙ 𝒌𝒐𝒏 ∙ [𝑹𝒕𝒐𝒕] 
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Appendix S4. Experimental validation of model 2, related to Figure 4. 
Model 2 was fitted to describe digitised literature summary data of [3H]diprenorphine brain and serum 
concentrations[3] with NONMEM version 7.3, ADVAN6 [4]. The results of our model fit and the obtained 
literature data are plotted in Figure S1, and the estimated parameter values are given in table S1. 
 
Figure S1. NONMEM fits of model 2 (lines) of [3H] diprenorphine brain radioactivity data after administration of a tracer 
and unlabeled dose of diprenorphine as obtained from Perry et al. (points) [3]. Unlabeled diprenorphine was administered 
at t=60 min (left panel) or at t=0 (right panel) at different doses: 0 (red), 24 (green), 50 (blue), 500 (purple) nmol/kg. The 
tracer dose was 0.10 nmol Top: model structure of model 2, which was used to fit these data. 
Table S1. Parameter estimates for [3H]diprenorphine.  Proportional errors were 0.6% and 9% with 
uncertainties of 29% and 19% in plasma and brain, respectively. 
Parameter Estimate (% CV) 
kel (h-1) 0.96 (0.6) 
kin (h-1) 0.29 (4.1) 
kout (h-1) 17 (5.5) 
kon (nM-1h-1) 5.6 (4.7) 
koff (h-1)  4.0 (3.8) 
[Rtot] (nM) 20 (4.0) 
VC (L) 2.9 (0.6) 




Appendix S5. Simulation example of local concentrations determining target occupancy, related to Figure 
4. 
To simulate the relative impact of kon and koff in a relevant set of parameters, obtained from in vivo 
measurements, we used the parameter values as obtained from fitting model 2 to literature diprenorphine 
data (see appendix S5). In these simulations, either kon or koff were changed which means that the KD 
changed accordingly. To compensate the effect of a changing KD on the extent of target binding in 
equilibrium and to obtain relevant target occupancies, the dose was normalized for the KD. On basis of our 
approximations, we would expect a similar impact of kon and koff on the duration of target occupancy for 
these parameter values, which was confirmed by our simulations, see Figure S2. These simulations also 
demonstrate clearly that only the local (i.e. brain) free drug concentrations are affected by drug-target 
binding, while the plasma free drug concentrations remain mainly unaffected (Figure S2). 
 
Figure S2. Simulated target binding of diprenorphine (black lines) and 2 hypothetical drugs (red and green lines) with a 10-
fold decrease and increase in koff (left-hand panels) or kon (right-hand panels). The other parameter values remain 
constant: kel = 0.96, kin = 0.29, kout = 17, VC = 2.9 L, VT = 0.022 L. The dose was normalised for the affinity: dose = KD*5.9 
nmol.   
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Appendix S6. Accuracy of the approximation of model 1, related to Figure 3. 
To identify the accuracy of our approximation of the derivative of the semi logarithmic target occupancy 
curve, simulation studies (“observed slope”) were compared with the results of the approximation, the 
“approximated slope” for different target concentrations, dissociation and elimination rate constants. To 
obtain a normalized measure for the accuracy of our approximation, we used the ratio of the approximated 
and simulated slope, which equals 1 for a perfect approximation. First, we analysed the accuracy over time 
for a regular set of pharmacokinetic and binding kinetic parameters, with a low target concentration, see 
Figure S3. The initial phase of the target occupancy is not predicted accurately for the simulation with a low 
koff value as the time to reach maximum target occupancy is increased by a low koff, and our approximation 
is only meant for the decreasing phase of the target occupancy profile. This initial phase is longer for 
combinations of low koff, kon*[Rtot] and kel. This can be seen in Figure S4, where a low elimination rate 
(0.1/hr) constant leads to inaccurate predictions at 24 hours post dosing for low target concentrations, 
compared to a high elimination rate constant(1/hr). This inaccuracy is still only present for the low target 
concentrations if the elimination rate constant is further decreased to an extremely low value (0.001/hr), 
see Figure S5. Furthermore, our approximation can introduce a underestimation of the derivative of the 
semi logarithmic target fraction bound vs time curve of up to two fold. This underestimation is especially 













Figure S3. Simulations with model 1 for the time-dependent accuracy of Equation S19 for various values of koff after 
repeated dosing. kel = 1/hr, kon = 0.36/(nM*hr), [Rtot]= 1nM
 
Figure S4. The accuracy of equation S19 for model 1 at 24 hours post dosing depends on the value of koff, [Rtot]and kel. kel = 
0.1/hr (left panel) and 1/hr (right panel), kon = 0.36/(nM*hr). 
 
Figure S5. The accuracy of Equation S19 for model 1 at 24 hours post dosing depends on the value of koff, [Rtot] and kel. kel = 
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The influence of drug-target binding kinetics on target occupancy can be influenced by drug distribution and 
diffusion around the target, often referred to as “rebinding” or “diffusion-limited binding”.  This gives rise to 
a decreased decline of the drug-target complex concentration as a result of a locally higher drug 
concentration that arises around the target, which leads to prolonged target exposure to the drug. This 
phenomenon has been approximated by the steady-state approximation, assuming a steady-state 
concentration around the target. Recently, a rate-limiting step approximation of drug distribution and drug-
target binding has been published. However, a comparison between both approaches has not been made so 
far. 
In this study, the rate-limiting step approximation has been rewritten into the same mathematical format as 
the steady-state approximation in order to compare the performance of both approaches for the 
investigation of the influence of drug-target binding kinetics on target occupancy.   
While both approximations clearly indicated the importance of kon and high target concentrations, it was 
shown that the rate-limiting step approximation is more accurate than the steady-state approximation, 
especially when dissociation is fast compared to association and distribution out of the binding 
compartment. 
It is therefore concluded that the new rate-limiting step approximation is to be preferred for assessing the 






Although drug-target binding kinetics (the association and dissociation rate constants) are important 
determinants of the kinetics of drug action [1–4], their role can be influenced by rebinding or diffusion-
limited binding. [5–7] The term rebinding has been introduced to describe the result of a (micro-
)environment around the target site which is not in instantaneous equilibrium with the plasma or target 
tissue, and where a concentration difference between target site and  plasma or target tissue 
concentrations can be enhanced by drug-target binding. This local target site concentration can thus induce 
a delay in both drug-target association and dissociation and should therefore be considered in the analysis 
and prediction of the relationship between drug-target binding kinetics and target occupancy. This is 
especially important when in vitro values for drug-target binding are used to explain or predict in vivo target 
occupancy and effect.  
The local concentration that drives rebinding has been approached historically from different perspectives. 
The biophysical approach started by describing diffusion around clustered receptors on a spherical or planar 
surface, which was subsequently discretized by dividing the space surrounding the receptor into the target 
vicinity and the bulk solution [8,9]. The pharmacological approach started from in vitro/in vivo observations 
of target binding that could not be explained by drug-target binding from bulk/tissue concentrations, which 
was solved by assuming the existence of a micro-compartment surrounding the target [10–12]. The effect 
compartment model is a less mechanistic and more general approach that is often used in PKPD modelling 
to explain a delay between drug concentrations and drug effect. In this approach, the drug concentrations in 
a hypothetical compartment drives the drug effect. The effect compartment model is most often combined 
with the assumption of fast target binding in the effect compartment (resulting in a “Emax model”) [13–16], 
although binding kinetics have also been incorporated in the effect compartment model [17,18].  
The mathematical models that have been proposed from the different approaches as listed above share a 
similar compartmental structure and give rise to similar equations. In these models, the compartment in 
which binding takes place (in this paper referred to as the binding compartment) represents the target site, 
which is the (micro-) environment that surrounds the target.[5,9,11,17,19,20] An approximation of these 
compartmental models  has been derived previously by assuming quasi steady-state in the binding 
compartment [19] and has been used since for simulation studies.[5,6] We will refer to this approximation 
as the steady-state approximation. A recent comparison between the steady-state approximation of 
rebinding and the effect compartment model (which has the same mathematical structure as the full two-
compartment model from which the steady-state approximation is derived) indicated that the steady-state 
approximation is not capturing the behavior of the effect compartment model for fast dissociating 
ligands.[6] 
A recently published approximation for describing target binding from a local (tissue) compartment, 
assumed that the overall decline of target occupancy is most influenced by the slowest process (the rate-
limiting step).[7] We will refer to this approximation as the rate-limiting step approximation. 
The rate-limiting step approximation has not yet been compared with the steady-state approximation as 
described by deLisi (deLisi, 1980). In this study, we use the rate limiting step approximation and the steady-
state approximation of drug distribution and drug-target binding and compare their ability to capture the 
behavior of the original compartmental model, from which both models are derived. 
 
Methods 
To allow comparison of the steady-state approximation and the rate-limiting step approximation of drug-
target binding and drug distribution as proposed here, both approximations should be written in the same 
mathematical format. In appendix A, the steady-state rebinding formula is rewritten in our format of choice, 
resulting in equation 1.  
 
In equation 1, df1 is the delay factor for Model 3 that is multiplied with koff and kon to account for the 
influence of the local concentration, kout is the first-order distribution or diffusion rate constant from the 
micro compartment into plasma, kon is the second-order association rate constant and N is the unbound 
target concentration. In appendix B, our rate-limiting step formula for rebinding is derived from our 
                                                                      df1 =
𝑘𝑜𝑢𝑡
𝑘𝑜𝑢𝑡 + 𝑘𝑜𝑛 ∙ 𝑁
                                                                   (1) 
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previously published approximation of target binding, tissue distribution and plasma elimination, resulting 
in equation 2.  
 
 
In Equation 2, df2 is the delay factor for Model 4, the additional parameter BF is the fraction of target that is 
bound to the drug and koff is the first-order dissociation rate constant. It should be noted that kout is used to 
replace the drug distribution rate constant that has been called k- or just k in the biophysical approach, kout 
in the mechanistic pharmacological approach and keo in the non-mechanistic PKPD modelling approach. 
Our rate-limiting step approximation of target binding was intended to approximate the duration of target 
occupancy after its maximal value and is thus applicable to calculate the delay factor for koff. However, both 
koff and kon need to be multiplied with the same delay factor to ensure that rebinding does not affect 
equilibrium target occupancy. Multiplying kon and koff with the same factor is also common practice in 
previous rebinding studies.[6,9] 
To assess the performance of the rate-limiting step approximation and to compare this with the recently 




Figure 1. Schematic representation of all model structures that are used for simulations. Model 1 and Model 2 share a 
similar model structure, as depicted in the left panels. Model 3 and Model 4 share the model structure as depicted in the 
right panels. Dashed arrows indicate the absence of mass transfer between compartments. The binding compartment in 
Model 1 and Model 2 is assumed to be very small and the mass transfer between the Central and Binding compartment is 
ignored. This allows the direct modelling of the concentrations in the Binding compartment and the assumption that kout 
equals kin. 
Model 1 (fig 1) is the full compartmental model that consists of a depot compartment from which 
absorption into plasma occurs, a central compartment representing the blood, a binding compartment in 
which binding occurs and a ligand-receptor compartment that represents ligand in the target-bound state. 
Since rebinding is often hypothesized to occur from a small “micro-compartment”, the mass transfer from 
plasma to this compartment was assumed to be negligible and was excluded from the model equations. 
However, since rebinding can result in accumulation or depletion of ligand in the binding compartment, 
mass transfer was incorporated in the model equations describing the concentration in the binding 
                                                     df2 =
𝑘𝑜𝑢𝑡 ∙ (1 − 𝐵𝐹)
𝑘𝑜𝑓𝑓 + 𝑘𝑜𝑢𝑡 ∙ (1 − 𝐵𝐹) + 𝑘𝑜𝑛 ∙ 𝑁




Model 2 (fig 1) is equal to Model 1, except that it does not take into account mass transfer between the 
binding compartment and the target-bound compartment. This model was required for comparison with 
the previous publication on the performance of the steady-state rebinding formula in which Model 2 was 
compared to Model 3 [6]. 
Model 3 (fig 1) encompasses an absorption and central compartment in the same way as Model 1, but drug-
target binding is now driven by the plasma concentrations. Both kon and koff are multiplied by the delay 
factor, according to the steady-state approximation (equation 1). 
Model 4 (fig 1) is the same as model 3, but kon and koff are now multiplied by the delay factor according to 
the newly derived rate-limiting step approximation (equation 2).  
As Model 1 is the original compartmental model that is approximated by Model 3 and Model 4, we can 
assess the performance of Model 3 and Model 4 by comparing the simulation outcomes of these models to 
the outcome of Model 1. More similarity to Model 1 means a more accurate approximation. Model 2 is 
included for comparison with the recent publication of Vauquelin [6], in which Model 2 was compared to 
Model 3. Also, the parameter values for kon, koff, kout, kel and ka were set to the same values as for the 
simulations in the study of Vauquelin [6]. In contrast to the publication of Vauquelin, the delay factor is 
calculated from equation 1 and 2, where kout is used both for simulation of distribution to the binding 
compartment and for calculation of the delay factor. The total target concentration was chosen to yield 
similar results as in the recent publication of Vauquelin.[6]  
The differential equations for all models are given in appendix C. The initial concentration in the absorption 
compartment was 15·KD in all simulations. The differential equations were solved by using the lsoda solving 
method in the deSolve package in R, version 3.3.1[21,22]. 
Results  
The only differences between equation 1 and 2 are the addition of koff in the denominator and the 
correction for the influence of target saturation in the factor (1-BF). Since koff + kout · (1-BF) + kon · N reduces 
to kout · (1-BF) + kon · N if koff << kout · (1-BF) + kon ·N, equation 1 and 2 only give similar results for the delay 
factor df if koff is relatively small compared to kout · (1-BF) or kon · N. This corresponds to the steady-state 
approximation that is used to derive equation 1, which assumes that the concentration in the binding 
compartment adapts quickly to the surrounding concentrations. This requires that the rate at which the 
drug is distributed out of the binding compartment (determined by kout · (1-BF) and kon · N) is relatively large 
compared to the rate at which drug is distributed into the binding compartment (determined by koff). It 
should be noted that the influence of the saturation factor (1-BF) only has a major influence for high values 
of target occupancy. 
The performance of our rate-limiting step approximation has been visualized in figure 2 and 3. Figure 2A 
demonstrates that both approximations (steady-state: Model 3 and rate-limiting step: Model 4) produce 
similar results as Model 1, although Model 4 seems to approximate Model 1 a bit better than Model 3 does. 
In figure 2B, the difference between Model 3 and Model 4 is clearly demonstrated for the simulations with 
the lowest values of kout and Model 4 performs much better for the parameter values that were used for 
figure 2B (i.e. high koff, low affinity and average receptor concentration). The mismatch between Model 3 
and Model 1 in figure 2B is not only the result of the high dissociation rate constant: if the target 
concentration is set to 1 pM instead of 1 nM, a similar mismatch as in figure 2B is observed, as 
demonstrated in figure 2C. As can be derived from equation 1 and 2, the same effect is observed when the 
kon value is lowered instead of the target concentration (data not shown). Similarly, the mismatch between 
Model 3 and Model 1 in figure 2B can be almost completely reversed by a thousand-fold increase in the 
target concentration or the kon (figure 2D). 
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Figure 2. Comparative simulations of target occupancy (TO) over time for the models 1-4. Unless otherwise indicated 
above the panels, the parameter values remain the same as for panel A: kout = 10 (solid line), 0.0047 (dashed line), 0.0005 
(dotted line) or 0.000087 (dash-dotted line) min-1. koff = 0.0069 min-1, kon = 1·107 M-1 ·min-1, [Rtot] = 1 nM, ka = 0.0115 min-1 




The performance of our rate-limiting step approximation of rebinding was also investigated in the context in 
which rebinding formulas are frequently applied: in simulations of the influence of koff on target occupancy. 
Figure 3A demonstrates that the influence of koff is much better approximated by Model 4 than by Model 3. 
Although Model 4 also shows a mismatch in the increase rate of target occupancy for the lowest koff values, 
the duration of target occupancy and the influence of koff thereon resembles Model 1 closely (note the 
increase in the simulation duration).  
For a more typical drug treatment situation, with nanomolar drug-target affinity and target concentration 
and a moderate delay in distribution from plasma to the binding site, both Model 3 and Model 4 produce 
comparable results with Model 1, as illustrated in figure 3B. The result of incorporating a correction for 
target saturation in our rate-limiting step approximation is illustrated in figure 3C and 3D: While for figure 
3C Model 3 and Model 4 result in similar simulations, an increased dose results in a mismatch between 
Model 3 and Model 1, which is not observed for Model 4. 
 
 
Figure 3. Comparative simulations of target occupancy (TO) over time for the different models. Unless otherwise indicated 
above the panels, the parameter values remain the same as for panel A: koff = 0.1 (solid line), 0.01 (dashed line), 0.001 
(dotted line) or 0.0001 (dash-dotted line) min-1. kout = 0.00006 min-1, KD = 1·10-7 M, [Rtot] = 10 nM, ka = 0.0115 min-1, kel = 
0.00575 min-1 and C0 (the initial concentration) = 15·KD. The different grey tones are used for visual distinction of the lines. 
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Discussion 
The rate-limiting step approximation for drug distribution and drug-target binding that we propose here on 
basis of our previous publication differs significantly from the steady-state approximation when the 
dissociation rate constant (koff) is high, compared to the distribution rate constant (kout) and the product of 
the association rate constant and the unbound target concentration (kon · N). This difference results in an 
improved approximation of the original compartmental model (Model 1), from which both approximations 
are derived. 
The improved robustness of the rate-limiting step approximation compared to the steady-state 
approximation that we demonstrated here, yields a mathematically reliable simulation of the influence of 
kon and koff for a wider range of pharmacological situations. Moreover, our new approximation can help to 
understand the role of the relevant parameters and to interpret the observed influence of rebinding from in 
vivo, in vitro or in silico data. For example, the steady-state approximation results in a decline of target 
occupancy that is linearly related to koff as long as the drug elimination from plasma is not rate-limiting 
(equation 1). This is not in line with the intuitive thinking that the distribution/diffusion out of the target 
vicinity could also be determining the decrease of target occupancy, which would make koff less influential. 
With our rate-limiting step approximation, this intuitive thought is confirmed and the influence of koff on the 
decline rate of target occupancy decreases when koff becomes relatively large. Also, a correct approximation 
of binding and distribution is essential if this approximation is used to discriminate between various 
mechanisms that can explain the duration of drug action or target occupancy. 
While the rate-limiting step approximation as presented here is a more robust approximation than the 
steady-state approximation, the difference between these two approximations is most significant when the 
extent of influence of drug distribution is low (since the product of target concentration and kon has to be 
relatively small). We do not provide a rigorous mathematical proof here that the rate-limiting step 
approximation is better than the steady-state approximation. However, the determining equations and the 
simulations make clear that the rate-limiting step approximation can be significantly different and more 
accurate for conditions with limited rebinding, slow distribution out of the binding compartment and 
relatively fast dissociation. An approximation of the full rebinding model, such as the two approximations 
discussed here, is not required for simulations or model fitting of drug distribution and drug-target binding, 
since the full compartmental model (Model 1) can be used. However, the previous use of the steady-state 
approximation demonstrates the value of the rate-limiting step approximation for investigations in the role 
of drug-target binding kinetics and rebinding. 
In conclusion, the rate-limiting step approximation provides an improved approximation of drug-target 
binding and drug distribution which can be used as an alternative for the existing steady-state 
approximation. Using the rate-limiting step approximation as presented here is especially important when 
dissociation is fast compared to association and distribution out of the binding compartment. 
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Appendix A: Rewriting the steady-state approximation of rebinding 
In the steady-state approximation of rebinding, both kon and koff are multiplied with the delay factor df1 that 
is defined in equation A.1, where all parameters are defined as explained in methods[6]: 
 




Appendix B: Derivation of the rate-limiting step approximation of target binding and drug distribution. 
For the rate-limiting step approximation, our previously published approximation of pharmacokinetics and 
target binding was used as the starting point [7]. From this publication, equation S35 is the most relevant 
which is given as equation B.1 here. In equation B.1, λTO(BF) is the fractional decrease in target occupancy, 
as a function of the target fraction bound (BF). λelTO(BF) is the value that λTO(BF) would have if the 
elimination would be rate limiting and thus determining the decrease of target occupancy. λoutTO(BF) is the 
value that λTO(BF) would have if drug distribution from the binding compartment to plasma would be rate 
limiting. λTO(BF) equals the reverse rate constant koff ·df from equation 1 and 2 if there would be no drug in 
plasma, i.e. if the elimination rate would be extremely high. Such a high elimination rate can be assumed for 
equation 1 and 2, since these equations are meant for models that simulate plasma concentrations 
separately. Assuming an extremely high elimination rate constant leads to an extremely high value of 
λelTO(BF), which reduces equation B.1 to equation B.2. 




















                                                               (B.2) 
Since λoutTO(BF) is given by equation B.3 according to our previous publication (equation S33), equation B.2 
equals equation B.4, which can be rewritten as equation B.5. 




























                                                         (B.5) 
Equation B.5 can be rewritten as equation B.6 by realizing that KD equals the ratio of koff to kon and by 
multiplying each fraction by unity in such a way that the denominators become equal and the two fractions 
can be summed as in equation B.7. Equation B.7 equals equation B.8 and since [Rtot]·(1-BF) is equal to the 
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                                                                   (A. 1) 
                                                                       𝑑𝑓1 =
               1                 
𝑘𝑜𝑢𝑡 + 𝑘𝑜𝑛 ∙ 𝑁
𝑘𝑜𝑢𝑡
                                                            (A. 2) 
                                                                       𝑑𝑓1 =
𝑘𝑜𝑢𝑡
𝑘𝑜𝑢𝑡 + 𝑘𝑜𝑛 ∙ 𝑁












 𝑘𝑜𝑓𝑓+ [𝑅𝑡𝑜𝑡]∙(1−𝐵𝐹)∙𝑘𝑜𝑛+𝑘𝑜𝑢𝑡 ∙(1−𝐵𝐹) 
                                                (B.8) 
 
Appendix C: Differential equations of the four different models as used for the simulations. 
The concentrations in the depot and the central compartment were modeled in the same way for all four 
models according to equation C.1 and C.2, respectively. In these equations, [DEP] is the drug concentration 
in the depot compartment, [C] is the drug concentration in the central compartment, ka is the first-order 
absorption rate constant and kel is the first-order elimination rate constant.  
𝑑[𝐷𝐸𝑃]
𝑑𝑡
=  −𝑘𝑎  ∙ [𝐷𝐸𝑃]                                                             (C.1) 
𝑑[𝐶]
𝑑𝑡
=  𝑘𝑎  ∙ [𝐷𝐸𝑃] − 𝑘𝑒𝑙  ∙ [𝐶]                                                       (C.2) 
The concentration in the binding compartment is only explicitly simulated in Model 1 and Model 2 according 
to equations C.3 and C.4, respectively. Here, [B] denotes the drug concentration in the binding 
compartment, [N] denotes the unbound target concentration (which is calculated by assuming the total 
target concentration is constant), [LR] denotes the drug that is bound to the target, kout is the first-order 
distribution constant between the binding compartment and plasma, kon is the second-order association 
rate constant and koff is the first-order dissociation rate constant. 
Model 1:                                        
𝑑[𝐵]
𝑑𝑡
=  𝑘𝑜𝑢𝑡  ∙ ([𝐶] − [𝐵]) − 𝑘𝑜𝑛 ∙ [𝐵] ∙ [𝑁] + 𝑘𝑜𝑓𝑓 ∙ [𝐿𝑅]                            (C.3) 
Model 2:                                                             
𝑑[𝐵]
𝑑𝑡
=  𝑘𝑜𝑢𝑡  ∙ ([𝐶] − [𝐵])                                                                 (C.4) 
The concentration of the target-bound drug is calculated identically for Model 1 and Model 2 according to 
equation C.5: 
Model 1, Model 2:                                     
𝑑[𝐿𝑅]
𝑑𝑡
=  𝑘𝑜𝑛 ∙ [𝐵] ∙ [𝑁] − 𝑘𝑜𝑓𝑓 ∙ [𝐿𝑅]                                                    (C.5) 
For Model 3 and Model 4 the target bound drug is calculated according to equation C.6 and C.7, where BF 
denotes the fraction of the target that is bound to the drug. 
Model 3:                                  
𝑑[𝐿𝑅]
𝑑𝑡
=  (𝑘𝑜𝑛 ∙ [𝐶] ∙ [𝑁] − 𝑘𝑜𝑓𝑓 ∙ [𝐿𝑅])  ∙
𝑘𝑜𝑢𝑡
𝑘𝑜𝑢𝑡+𝑘𝑜𝑛∙𝑁
                                              (C.6) 
 
Model 4:                      
𝑑[𝐿𝑅]
𝑑𝑡
=  (𝑘𝑜𝑛 ∙ [𝐶] ∙ [𝑁] − 𝑘𝑜𝑓𝑓 ∙ [𝐿𝑅])  ∙
𝑘𝑜𝑢𝑡∙(1−𝐵𝐹)
𝑘𝑜𝑓𝑓+𝑘𝑜𝑢𝑡∙(1−𝐵𝐹)+𝑘𝑜𝑛∙𝑁
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Selectivity is an important attribute of effective and safe drugs, and prediction of in vivo target and tissue 
selectivity would likely improve drug development success rates. However, a lack of understanding of the 
underlying (pharmacological) mechanisms and availability of directly applicable predictive methods 
complicates the prediction of selectivity. We explore the value of combining physiologically based 
pharmacokinetic (PBPK) modelling with quantitative structure-activity relationship (QSAR) modelling to 
predict the influence of the target dissociation constant (KD) and the target dissociation rate constant on 
target and tissue selectivity. The KD values of CB1 ligands in the ChEMBL database are predicted by QSAR 
random forest (RF) modelling for the CB1 receptor and known off-targets (TRPV1, mGlu5, 5-HT1a). Of these 
CB1 ligands, Rimonabant, an inverse agonist at the CB1 receptor, CP-55940, a selective agonist for the CB1 
and CB2 receptor and Δ8-tetrahydrocanabinol, one of the active ingredients of cannabis, were selected for 
simulations of target occupancy for CB1, TRPV1, mGlu5 and 5-HT1a in three brain regions, to illustrate the 
principles of the combined PBPK-QSAR modelling. Our combined PBPK and target binding modelling 
demonstrated that the optimal values of the KD and koff for target and tissue selectivity were dependent on 
target concentration and tissue distribution kinetics. Interestingly, in many cases the optimal KD value is not 
the lowest KD value, suggesting that optimisation towards high drug-target affinity can decrease the benefit-
risk ratio. The presented integrative structure-pharmacokinetic-pharmacodynamic modelling provides an 







Selectivity is an important attribute of successful drugs since highly selective compounds are less likely to 
mediate side-effects.[1] On the other hand, targeting multiple targets simultaneously is increasingly 
considered as a valuable option to exert sufficient effect on a complex biological system.[2,3] Regardless the 
desired degree of selectivity, understanding and prediction of the target binding to multiple targets in 
multiple tissues is essential for the optimisation of pharmacotherapy. In this article, we differentiate 
between two types of selectivity: target selectivity and tissue selectivity. Target selectivity is defined as a 
difference in target binding to different receptors and tissue selectivity is defined as a difference in target 
binding to the same target in different tissues. Additionally, a distinction is made between equilibrium 
selectivity and kinetic selectivity. Equilibrium selectivity refers to differential target binding while target 
binding is in equilibrium with the free drug concentration around the target. This equilibrium binding is 
described for single step target binding without target turnover according to Equation 1, in which KD is the 
dissociation constant, [L] is the unbound drug concentration, [R] is the unbound target concentration, [LR] is 
the bound drug-target complex concentration, koff is the first order target dissociation rate constant and kon 
is the second order target association rate constant. 
 
(1)                                                                 𝐾𝐷  =  
[𝐿]∙[𝑅]
[𝐿𝑅]





Equilibrium target selectivity is thus driven by differential KD values for the different targets. Kinetic 
selectivity, however,  refers to a difference of the duration of target occupancy, which can be achieved by 
differential koff values.[4] Differential koff values do not always result in a differential duration of target 
occupancy in vivo since the plasma and local pharmacokinetics can also be rate-limiting for the duration of 
target occupancy.[5,6] As kinetic selectivity has previously been equated with differential koff values[7], we 
will refer to differential koff values as in vitro kinetic selectivity, while we will refer to an in vivo difference in 
the duration of target occupancy due to slow dissociation as in vivo kinetic selectivity. 
 
A previous study that analysed a minimal mechanistic model for drug elimination, tissue distribution and 
target binding showed that an increase in drug-target affinity decreases the chance of observing in vivo 
kinetic selectivity, especially for slow tissue distribution and a high target concentration.[6] On that basis, it 
is expected that the optimal KD for target and tissue selectivity is dependent on the target concentration, 
tissue distribution kinetics and binding kinetics. This contrasts with the current practice of drug discovery 
and development which often aims at a minimal value for the KD and koff and a maximal ratio to the off-
target KD and koff value if selectivity is concerned. 
 
The minimal mechanistic model that was analysed in the study of de Witte et al.[6] did not consider i) the 
effects of  slow distribution of a drug into tissues where no target binding takes place nor ii) the limiting role 
that blood flow can have on tissue distribution. In order to capture the influence of these pharmacokinetic 
mechanisms, physiologically based pharmacokinetic (PBPK) models can be used. In these models, a 
distinction is made between system-specific properties and drug-specific properties. In this type of analysis, 
the values of system-specific parameters such as blood flows and volumes for each organ are based on the 
physiological literature data, while the values of drug-specific parameters, such as partition coefficients and 
protein binding are often based on in vitro data or on Quantitative Structure Activity Relationships (QSARs). 
[8] As such, these models allow the prediction of plasma and tissue unbound drug concentrations. The 
influence of drug-target binding on free drug concentrations has been described frequently with target-
mediated drug disposition (TMDD) models. [9] The combination of  PBPK and TMDD modelling has been 
reported in the literature previously but is not generally used in selectivity optimisation. [10–13] To obtain 
the drug-specific properties that determine the values of the partitioning parameters in PBPK models either 
experimental data for each individual drug or quantitative structure-activity relationships (QSAR) are 
required. These QSARs enable the prediction of partitioning parameters from the molecular structure. While 
these QSARs are often used in PBPK modelling to predict non-specific tissue distribution parameters, the 
prediction of specific target binding parameters is currently not incorporated in PBPK modelling, based on 
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the assumption that the amount of drug bound to its biological target is negligible relative to the total 
amount of drug in the body. [14–17] 
 
QSAR models may be either regression or classification models which predict a response variable from a set 
of predictor values. In regression models, these predictor values are related to a continuous response 
variable (e.g. a KD value), while in classification models the predictor values relate to a categorical variable 
(e.g. labelled “active” or “inactive”). The predictor values represent the molecular structure and molecular 
properties, and the response variable is an activity value, such as the KD in the case of affinity. Machine 
learning methods such as support vector machines (SVMs), decision trees such as random forests (RFs) and 
deep neural networks (DNNs) are generally used to obtain a predictive learning model.[18–20] The training 
of these models is based on prior data, which means that their performance is greatly dependent on data 
quality and availability. A suitable database for  bioactivity data is available in the ChEMBL, which can be 
used to obtain predictive QSAR models. [21,22] 
 
Integration of drug-target binding prediction and pharmacokinetic modelling allows for the prediction of the 
selectivity profile for a given ligand directly from its molecular structure. As such, this modelling approach 
may provide information on a ligand’s efficacy and safety in vivo during the very early stage of drug 
development. This is especially relevant in systems that contain off-targets or targets that are also 
expressed in organs were no drug effect is desired. An example of the latter system is the cannabinoid 
system, of which the cannabinoid receptor CB1 is a major component. The CB1 receptor is widely expressed 
throughout the body but mainly found in the brain where it mediates a broad range of effects in health and 
disease. [23,24] Many off-targets have been identified for CB1 ligands, including the vanilloid receptor 
TRPV1, the metabotropic glutamate receptor mGlu5, and the serotonin receptor 5-HT1a. [25,26] Activity at 
these receptors, predominantly in the brain, may amplify or counteract effects at the CB1 receptor. TRPV1, 
for example, has been suggested to have an effect opposite of that of CB1 in anxiety and depression, which 
are common side effects observed for CB1 antagonists, and mGlu5 is a major player in the GABA-system, 
which is the target system for CB1 mediated therapies in Parkinson’s disease. [27–29] The mechanisms 
underlying functional in vivo selectivity are diverse and complex, but computational elucidation of off-target 
affinities and their integration in combined PBPK-TMDD modelling could help to identify safety concerns 
early in drug discovery and development, which would improve decision making in (pre)clinical drug 
development. 
 
This article describes an approach towards the development of an integrative predictive modelling for drug 
selectivity. Firstly, the main determinants of in vivo equilibrium and kinetic selectivity, are identified by 
minimal PBPK-TMDD modelling and simulation. Secondly, the development and validation of a Random 
Forest based QSAR (QSAR-RF) model for the prediction of KD values is described. Lastly, an example of the 
use of predicted KD values in PBPK-TMDD modelling is provided for the combined in vivo target and tissue 
selectivity of Rimonabant, a prototype antagonist at the CB1 receptor.  
 
Materials and Methods 
 
1 Software 
All simulations were performed in RStudio Version 1.0.136 coupled to R version 3.4.0. [30,31] 
Physicochemical property prediction and QSAR modelling were performed in Pipeline Pilot version 2016. [32] 
2 Pharmacological Models 
Three PBPK-TMDD models were developed: a minimal PBPK-TMDD model for simulation of target 
selectivity (Model I, Figure 1), a minimal PBPK-TMDD model for simulation of tissue selectivity (Model II, 
Figure 2) , and an integrated brain PBPK-TMDD model for simulation of selectivity across brain regions and 




Figure 1. Schematic overview of the minimal target selectivity model (Model I). ka = rate of absorption (h-1), kin = inwards 
distribution rate (h-1), kout = outwards distribution rate, kon = association rate (nM-1h-1), koff = dissociation rate (h-1), kF = 
forward rate of elimination constant (h-1), LR = ligand-receptor complex, V = tissue volume (L), nbt = non-binding tissue, c = 
central compartment, bt = binding tissue, el = eliminating tissue. 
 
Figure 2. Schematic overview of the minimal tissue selectivity model (Model II). ka = rate of absorption (h-1), kin = inwards 
distribution rate (h-1), kout = outwards distribution rate, kon = association rate (nM-1h-1), koff = dissociation rate (h-1), kF = 
forward rate of elimination constant (h-1), LR = ligand-receptor complex, V = tissue volume (L), nbt = non-binding tissue, c = 
central compartment, bt = binding tissue, el = elimination tissue. 
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Figure 3. Schematic model of the brain PBPK-TMDD model. ka = rate of absorption (h-1), Q = blood flow (L/h), kon = 
association rate (nM-1h-1), koff = dissociation rate (h-1), kF = forward rate of elimination constant (h-1), LR (with R = CB1, 
mGlu5, TRPV1 or 5-HT1a) = ligand-receptor complex, V = tissue volume (L), nbt = non-binding tissue, c = central 






2.1.1 Model I and II 
All physiological values of the system-specific parameters were obtained from literature.[33–38] 
The heart was used as a reference organ for the determination of distribution into and out of the binding 
tissue. An overview of all model parameters is supplied in Supplemental 1. 
2.1.2 Model III 
All physiological values of the system-specific parameters were obtained from literature.[33–38] Target site 
distribution in the brain was characterized by the average effective flow through the target site as obtained 
from literature values from brain extra-cellular fluid flow to the cerebrospinal fluid as estimated for 9 
drugs.[39] The conversion of these values as well as an overview of all parameters are supplied in 
Supplemental 1. 
Receptor densities of CB1, mGlu5, TRPV1, and 5-HT1a in the cerebellum, hypothalamus, and 
frontal cortex were obtained from the literature for all four receptors, except the receptor concentration of 
mGlu5 in hypothalamus and 5-HT1a in cerebellum, which were not reported in the literature. [40–44] The 
mGlu5 receptor concentration in the hypothalamus was filled in with the averages of the other brain regions 
since differences between brain regions for the other receptors did not differ drastically. The 5-HT1a 
receptor concentration in cerebellum was set to the low value of 0.01 nM as it was reported to be 
unidentifiable.[43] Receptor concentrations in rats and humans  were used interchangeably since no 
complete set of receptor densities could be obtained for either rats or humans. Values found in literature 
have shown to differ no more than ten-fold. [41,45] TRPV1 concentrations were given in ng/mg lysate and 
converted to pmol/mg protein by linear conversion. For this, the receptor concentration in ng/mg lysate and 
fmol/mg protein in the hypothalamus as reported in the literature was used. [42,46] The receptor density in 
the hypothalamus in fmol/mg was divided by the receptor density in ng/mg lysate and the resulting 
coefficient was used to transform the receptor density in ng/mg lysate of the cerebellum, hypothalamus and 
frontal cortex to the corresponding receptor density in fmol/mg. CB1 and TRPV1 concentrations in pmol/mg, 
were then converted to nM using a conservative (i.e. the lowest published) estimate of protein 
concentration in wet tissue of 100 mg/mL from literature. [47–49] An overview of the target concentrations 




Table 1. An overview of the conversions and all target concentrations can be found in Supplemental 2. 
Table 1. Receptor concentrations for the brain PBPK-TMDD model 
 Rtot,cer (nM) Rtot,hyp (nM) Rtot,fc (nM) 
CB1 527 248 529 
mGlu5 5.1 16 25 
TRPV1 19 13 12 
5-HT1a 0.01 2.37 1.7 
* cer = cerebellum, hyp = hypothalamus, fc = frontal cortex 
 
 Tissue-blood partition coefficients were calculated according to Poulin & Theil 2000 (Equation (2)). 
[50]  The required physicochemical parameters (logP, logSo) [51] were determined in Pipeline Pilot.  An 
overview of all parameters is supplied in Supplemental 3. 
 






Pt:b = predicted value of the tissue-blood partition coefficient 
So = the solubility of the ligand in n-octanol (mol*m-3) 
Sw = the solubility of the ligand in water (mol*m-3) 
Nb = the neutral lipid content of blood (as fraction of blood volume) 
Nt = the neutral lipid content of the tissue (as fraction of tissue volume) 
Pb = the phospholipid content of blood (as fraction of blood volume) 
Pt = the phospholipid content of the tissue (as fraction of tissue volume) 
Wb = the water content of blood (as fraction of blood volume) 





 Model I was used to investigate the influence of KD, target concentration (Rtot) and koff on in vivo 
target selectivity.  To this end, four different simulations (a,b,c,d) were performed. In all four simulations, 
the koff at the first target (R1) was set to 0.01 h-1 and the koff at the second target (R2) was set to 10 h-1 while 
both the KD and Rtot were the same for both targets. An overview of the parameter values that were varied 
in these simulations can be found in Table 2. An overview of all other parameters can be found in 
Supplemental 1. 
Table 2. Parameter values for in vivo target selectivity simulations with Model I.  
 Model I Model II 
 KD  Rtot  koff R1  koff R2  KD  Rtot1  Rtot2  koff  
a 10 25 0.01 10 10 25 0.025 10 
b 0.01 25 0.01 10 1 25 0.025 10 
c 10 0.25 0.01 10 0.1 25 0.025 10 
d 0.01 0.25 0.01 10 0.01 25 0.025 10 
* R1 is target 1, R2 is target 2, KD and Rtot are given in nM, koff is given in h-1 
Model II 
This model was used to perform simulations to investigate the influence of KD, target 
concentration (Rtot) and tissue distribution (kin) on in vivo tissue selectivity.  To this end, four different 
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simulations were performed for a kin value of 8.6 h-1 (fast tissue distribution) and for a kin value of 0.86 h-1 
(slow tissue distribution). An overview of the variable parameter values can be found in Table 2. An 
overview of all other parameters can be found in Supplemental 1. 
Model III 
Simulations were performed for Rimonabant, ∆8 tetrahydrocannabinol (∆8 THC) and CP-55940 in a 
minimal-PBPK-TMDD model (Figure 3). The KD at the selected targets (CB1, mGlu5, TRPV1, and 5-HT1a) was 
predicted by a QSAR per target model trained on the complete pChEMBL dataset per target. A fast 
dissociation from the receptor was assumed for all compounds by setting the koff value to 10 h-1 at all 
receptors. Simulations were performed for a time span of 7 days during which a dose was administered 
every 24 hours. 
 
In order to investigate the influence of increasing drug-target affinity without a change in 
equilibrium selectivity, additional simulations were performed in which the ratio between the different KD 
values for the different receptors was kept the same while adjusting the absolute KD values by a factor 10 
and 100. Simulations were performed for a time span of 7 days with dosing once every 24 hours. The dose 
was scaled for the KD to obtain similar equilibrium occupancies in all simulations.  
 
3 QSAR 
 A Random Forest QSAR per target model was developed using the Random Forest package from 
CRAN. [52]  
 
3.1 Data selection 
 
Bio-activity data from ChEMBL22 was used for the development of the QSAR model.[53] High 
quality data was selected by setting assay confidence at 9 and requiring an assigned pChEMBL value for all 
data points.[22] This means that a direct single protein target is assigned to the ligand. PubChem database 
data and potential duplicates were excluded from the dataset. Bioactivity data from ChEMBL was limited to 
four different constants: KD, Ki, IC50 and EC50. It has been shown previously that Ki and IC50 can be combined 
for modelling.[54] In order to check if these constants could be used interchangeably, a statistical analysis of 
their pChEMBL values was performed. In this analysis, the mean, standard deviation (SD), median and 
median absolute deviation (MAD) were analysed within and between all four constants. An overview of all 
results is provided in Supplemental 4. Since from this analysis it could be concluded that the deviation 
between pChEMBL values between KD and Ki do not differ significantly from the deviation within the KD 
dataset, both KD and Ki values were used in the model development. 
 
The molecular structure of the ligands was extracted from the molfile and physicochemical 
properties and FCFP_6 circular fingerprints were calculated in Pipeline Pilot.[55] The FCFP_6 fingerprints 
were then converted to 768 feature properties for use in model training. Selection was performed based on 
the relative frequency of substructures per target, where the optimal frequency was close to being present 
in 50% of the ligands. 
 
The complete dataset was split into a training set (70%) and validation set (30%). This split was 
performed seven times, each time with a different seed (111, 222, …, 777) in order to create seven different 
datasets. In this way, the model training and validation could be performed 7 times, allowing for 




For each target, a Random Forest model consisting of 500 trees was trained using the seven 
different training sets. The models were trained on a predefined set of properties consisting of log(P), 
molecular weight, number of proton donors, number of proton acceptors, number of rotatable bonds, 
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number of atoms, number of rings, number of aromatic rings, molecular solubility, molecular surface area, 
molecular polar surface area and the 768 FCFP_6 fingerprint properties that describe the molecular 




The model performance was validated internally and externally using the corresponding validation 
dataset per seed, as described above. Internal validation was performed by an out-of-bag (OOB) estimate 
and presented as the average R2 regression coefficient and the root-mean-squared error (RMSE). [56] The 
OOB estimate method uses subsamples from the training dataset to determine the mean prediction error of 
the RF model. The RMSE is a value that measures the average magnitude of the error and is presented by 
the same unit as the dependent variable, which in this case is the pChEMBL value (-log KD/Ki in M). External 
validation was performed by a regression validation of the validation dataset against the predicted 
pChEMBL values. These results are also presented as the average R2 regression coefficient and the RMSE. 
Results 
1. Model I 
 
The simulations in Figure 4 show in vivo kinetic target selectivity in all simulations, due to a 
difference in the koff value for target 1 and target 2. However, the extent of the observed selectivity is 
dependent on the KD value and target concentration. Given that optimisation is often performed towards 
lower koff values, the target at which koff is 0.01 h-1 is considered as the desired therapeutic target.  Initially, 
target selectivity for the off-target is observed, but this selectivity reverses to selectivity for the therapeutic 
target over time in all simulations, except in Figure 4b, where the KD is low and the target concentration is 
high. As it would be unlikely in drug development to develop two drugs with a 1000-fold different binding 
kinetics but the same KD value, we also performed these simulations with 100-fold different binding kinetics 
and 10-fold different KD values as presented in supplemental 5. In these figures, the same trend is observed, 
although the residual selectivity is higher due to the difference in KD values. 
 
In summary, we observed that both a high target concentration and a low KD value decrease the in 




Figure 4. Target concentration and KD determine the extent of in vivo kinetic target selectivity in Model I. Target selectivity 
is characterised by a difference in target occupancy between target 1 (solid) and target 2 (dashed). The parameter values 
for these simulations can be found in Supplemental 1. 
2. Model II 
 
 
Figure 5. Tissue selectivity reverses to off-target selectivity as KD decreases in Model II. kin is 8.6 h-1. Tissue selectivity is 
characterised by a difference in target occupancy between target 1 (solid) and target 2 (dashed). The parameter values for 
these simulations can be found in Supplemental 1. 
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For the simulations presented in Figure 5, no difference in koff or KD values between the two target 
sites could be included, since the ligand binds to the same target and the differences in target occupancy 
arise due to a difference in the target concentration. No selectivity is observed for the higher KD values (10 
and 1 nM), and only marginal selectivity is observed for lower KD-values (0.1 nM and 0.01 nM). Assuming 
that the target concentration in the target tissue is higher than the target concentration in the off-target 
tissue, the lowest simulated KD-values showed selectivity in the first 12 hours to the off-target tissue after 
which selectivity for the target tissue is observed (Figure 5d). Marginal selectivity for the target tissue is 
observed for a KD value of 0.1 nM (Figure 5c). Taken together, this means that the KD and receptor 
concentrations influence the extent of in vivo tissue selectivity. 
The simulations in Figure 5 were performed for fast tissue distribution based on the reported 
blood flow of well-perfused organs in the human body.[37]  
Figure 6 shows the simulation results for slower tissue distribution, representing limited perfusion 
of the target site (e.g. in a synaptic cleft) or the presence of diffusion barriers (e.g. for intracellular or CNS 
targets). In these figures, the same patterns are observed as for fast tissue distribution, but the observed 
selectivity is greater and the affinity for maximal selectivity for the target-rich tissue is lower. 
 
Figure 6. Slower tissue distribution amplifies the influence of KD on tissue selectivity in Model II. kin is 0.86 h-1. Tissue 
selectivity is characterised by a difference in target occupancy between target 1 (solid) and target 2 (dashed). The 
parameter values can be found in Supplemental 1. 
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3 QSAR-RF 
From the simulations described above, it follows that there is an optimal KD for both tissue selectivity and 
target selectivity. To facilitate the optimisation of the KD, we aimed to predict the KD value from the 
molecular structure with predictive QSAR modelling. In this study, a QSAR-RF model was developed. The 
results of the internal and external validation are given in Figure 7. For the OOB validation, R2 values range 
from 0.57 to 0.70, with an average of 0.63 (SD 0.04) and RMSE values range between 0.64 and 0.83 with an 
average of 0.69 (SD 0.05). For external regression validation, the R2 values range from 0.50 to 0.73 with an 
average of 0.62 (SD 0.05) and RMSE values ranging between 0.9 and 0.64 with an average of 0.71 (SD 0.06). 
These values indicate good model performance, since the error in public data is around 0.44 for pKi data. 
Moreover, based on this error it has been shown that the theoretical maximal achievable R2 value then 
becomes 0.81 for the perfect model. [57–59] A full overview of the results is supplied in Supplemental 4. 
 
Figure 7. QSAR RF model performance regression validation. Internal out-of-bag validation resulted in an average R2 value 
of 0.63 ± 0.06 (SD 0.04), with an RMSE of 0.69 ± 0.1 (SD 0.05). External regression validation gave an average R2 value of 
0.62 ± 0.12 (SD 0.05) with an RMSE of 0.71 ± 0.13 (SD 0.06). 
4 Model III 
To reflect a drug discovery/candidate selection scenario, the developed QSAR model was used to predict the 
affinity of the molecules Rimonabant, ∆8 tetrahydrocannabinol (∆8 THC) and CP-55940 for the four selected 
receptors (CB1, TRPV1, mGlu5, 5-HT1a, Figure 8). These KD values were then used to predict the selectivity 
over different brain regions (cerebellum, hypothalamus and the frontal cortex). The results of these 
simulations are given in Figure 8. For the target occupancy of ∆8 THC, the compound with the lowest CB1 
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affinity, no selectivity is observed between brain regions. The target occupancy for the higher affinity 
compounds Rimonabant and CP-55490 show a slower increase of target occupancy in the brain regions with 
the highest target concentrations, the cerebellum and frontal cortex compared to the hypothalamus. The 
difference in target occupancy between the brain regions is similar for all targets, which results in a change 
in target selectivity across brain regions. Two days after the start of Rimonabant dosing, for example, the 
simulated target occupancy at TRPV1 in the hypothalamus is similar to the CB1 target occupancy in 
cerebellum and frontal cortex.  
 
Figure 8. Simulated PK-profile for Rimonabant in cerebellum, frontal cortex and hypothalamus. Predicted KD values of Δ8-
THC, Rimonabant and CP-55940 at the CB1, 5-HT1a, mGlu5 and TRPV1 receptor were used in these simulations. koff values 
were assumed to be 10 h-1. A dose of 104 nM was administered every 24 hours. Rtot,cer,CB1 = 527 nM, Rtot,cer,mGlu5 = 5.1 nM, 
Rtot,cer,TRPV1 = 19 nM, Rtot,cer,5-HT1a = 0.01, Rtot,hyp,CB1 = 248 nM, Rtot,hyp,mGlu5 = 16 nM, Rtot,hyp,TRPV1 = 13 nM, Rtot,hyp,5-HT1a = 2.37, 
Rtot,fc,CB1 = 529 nM, Rtot,fc,mGlu5 = 25 nM, Rtot,fc,TRPV1 = 12 nM, Rtot,fc,5-HT1a = 1.7. 
 For CP-55940, it takes more than 7 days to reach the maximal occupancies in the cerebellum and frontal 
cortex, while this delay would be even more extensive for lower doses. It should be noted that equilibrium 
selectivity (i.e. the difference in KD values for the different receptors) is different for the compounds in 
Figure 8. To obtain a better view of the role of the value of the KD as such, rather than the KD ratio between 
targets, the simulations for Rimonabant were repeated with the same KD ratio between targets and tenfold 
increased and decreased KD values, as shown in Supplemental 6, Figure I. Additionally, to explore the 
influence of error propagation from the QSAR model into model III, simulations were performed for the 
lowest and highest KD value within the RMSE based KD(±) prediction range as shown in Supplemental 6, 
Figure II. Summarizing the results, it is consistently found that the selectivity profile changes drastically over 
time while this would not be expected based on plasma concentrations and KD values alone. 
Discussion  
In this study, we have shown that the integration of target binding and PBPK modelling demonstrates the 
importance of target concentrations, target site distribution kinetics, the KD and koff for both in vivo target 
selectivity and tissue selectivity. We observe that a low KD, in combination with a high target concentration, 
decreased the kinetic target selectivity. Moreover, we find that an increasing KD can both increase and 
decrease tissue selectivity, dependent on the target concentration and tissue distribution. The 
demonstrated mechanistic modelling can thus be instrumental to find an optimal KD value for a specific 
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target/therapeutic area. To utlize this approach most effectively, our QSAR model to predict CB1 and off-
target KD values can be used to predict tissue and target selectivity directly from the molecular structure. 
Using this combination of models, our simulations for the CB1 ligands confirm that lower KD values for all 
targets can decrease the CB1 and brain region selectivity significantly during the first days of treatment. 
Our results suggest that optimisation towards high drug-target affinity and slow drug-target dissociation, as 
is commonly performed within the current drug development paradigm, may not result in the most 
selective compounds. While this study demonstrates the influence of target concentrations on the target 
occupancy in different tissues, the influence of target concentrations on the occupancy-response 
relationship has previously been described as driving factor for tissue selectivity of partial agonists.[60–62] 
For the development of more selective drugs, target concentrations of both the intended target and off-
targets as well as distribution to the target tissue/target site should be taken into consideration. In this 
respect, it is important to consider that distribution to the target site is not only dependent on distribution 
into the target tissue, but also on the localisation of the target within this tissue (e.g. in the blood stream or 
intracellularly). Moreover, factors such as target concentrations and tissue distribution may be altered in a 
disease state, which is important for the translation from healthy volunteers to patients.[24,63–65] Finally, 
it should be considered that there is an increased interest towards allosteric modulation in CNS drug 
discovery due to the potential benefits with regard to selectivity and side effects.[66] However, it has also 
been shown that allosteric modulators display different physicochemical and efficacy (Ki versus ligand 
efficacy) profiles compared to orthosteric ligands.[67] These parameters can be included in the modelling 
approach for future studies. 
The methods described in this study provide valuable insights for drugs in later stages of the drug 
development process. The selectivity profiles in Figure 8, for example, would result in underestimation of 
CB1 selectivity in (pre)clinical studies, if only the first 7 days were studied. This might lead to the 
unnecessary discontinuation of the development of valuable drug candidates. Moreover, the slowly 
increasing target occupancy for high affinity drugs such as CP-55940 might lead to a clinically undesired 
delay and unfavourable selectivity between the initiation of treatment and the onset of the therapeutic 
effect. This can potentially be mitigated by a higher dose (i.e. a loading dose), which can be lowered as soon 
as steady state occupancy is reached. Since monitoring of occupancy levels in the clinic is hardly feasible, 
this would required in-depth knowledge of the mechanisms and predicted occupancy profile as described in 
this study. Moreover, it should be noted that the target occupancy will decline only slowly after 
discontinuation of treatment and that it might take several days or even weeks for these high affinity drugs 
before the target occupancy is back to insignificant levels. This could be counteracted in the clinic by 
administration of a competitive antagonist or agonist to displace the drug from the receptor and enhance 
the clearance out of the target binding tissue. 
The simulations in this study were all based on physiological parameter values as obtained from PBPK 
models and target concentration literature. However, additional assumptions were sometimes necessary. 
For the simulations in Figure 6, the tissue distribution of the drug was not based on the blood flow trough 
well-perfused organs, as for the other figures, but we assumed a delayed distribution due to, for example, 
limited diffusion into a synaptic cleft or the cytosol. The magnitude of this delay is compound and target 
specific and this assumption will thus only hold for a limited number of compounds. Secondly, the 
simulation in Figure 8 assumed fast binding kinetics as the actual binding kinetics of Rimonabant have been 
reported to be complex and therefore hard to accurately determine in in vitro studies.[68,69] The 
assumption of fast binding kinetics is supported by the the short dissociation half-life as reported by Packeu 
et al.[70] Additionally, this assumption will be valid for any drug for which the binding kinetics are not rate-
limiting compared to the pharmacokinetics, but slower binding kinetics could change the outcome of the 
simulations, as shown in Figure 4 and in previous studies. [5,6] Thirdly, a number of assumptions concerning 
(interspecies) translatability of target densities were made in order to obtain useful target densities for the 
simulations in Figure 8. In general, the quality of absolute tissue-specific target concentration data, rather 
than relative expression values, might be limited. This is illustrated by the large deviations between 
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experimental tissue density results found in the literature between PET-studies and tissue ‘no wash’ assay 
experiments. [41,71] Furthermore, the limited amount of information on target-site distribution for the 
simulations in Figure 8 limits the predictive value of these simulations. These simulations should therefore 
be considered as a prediction of the relevant parameters for combined target and tissue selectivity for a 
realistic set of traget concentrations and KD values, rather than a precise prediction of target occupancy 
values for the simulated CB1 ligands. One of the most striking findings in our study is that increasing the KD 
in drug development can both increase and decrease the target and tissue selectivity. This demonstrates the 
relevance of target concentrations and tissue distribution, and the valuable role of mechanistic modeling.  
The prediction error that is observed for the KD predictions of the developed QSAR model introduces an 
extra level of uncertainty into the overall reliability of the selectivity predictions. The largest RMSE value in 
this study was found for the mGlu5 QSAR, with an average value of 0.8. This value relates to the deviation of 
the predictions from the actual pChEMBL value, and has the same unit as the dependent variable, which in 
this case is the -log KD. This uncertainty is therefore carried on into the pharmacological simulations. From 
the simulations performed with the highest and lowest value within the KD prediction range of Rimonabant, 
it can be concluded that this propagation of error does influence the observed selectivity profile. This error 
is limited to the extent of selectivity and the distribution across brain regions during the first one to four 
days. However, part of this error is already present in the public data that was used to train our QSAR model, 
in which a larger standard deviation is found compared to the Rimonabant predictions at the CB1 receptor 
from the QSAR model (Supplemental 4, Figure I). Additionally, having the ability to predict the selectivity 
profile in the earliest stages of drug disovery justifies the use of predictions with significant uncertainty. 
Moreover, both the overrepresentation and underrepresentation of structural features or scaffolds in the 
ChEMBL database might decrease the predictive power for new compounds that do not share these 
structural features.  
Although the predictive value of the presented models is limited by the assumptions we made, the 
presented insight into the influence of the target concentration and tissue distribution kinetics is in line with 
the previous analysis of more simple models with only one target and one tissue.[6] Moreover, the 
relevance of incorporating target binding in PBPK models for the accurate prediction of tissue 
concentrations has been demonstrated before.[13] The basic principle behind the role of the KD and target 
concentration on the duration of occupancy is the high concentration of target-bound drug concentrations 
compared to unbound drug concentrations at the target site. This is mainly relevant for for drugs with a high 
KD and target concentration and at a target occupancy that is not completely saturated. If this target 
occupancy is increasing, drug-target association will deplete the unbound target site concentration, and if 
the occupancy is decreasing, drug-target dissociation will increase the unbound target site concentration 
compared to plasma concentrations.  
In summary, the information presented in this study provides new insights into the mechanisms underlying 
in vivo target and tissue selectivity, specifically in relation to drug-target affinity, target concentration, tissue 
and target-site distribution, as well as binding kinetics. The study provides situations in which selectivity is 
expected to occur, which may aid as a lead towards creating ligands with the desired selectivity profile. 
Additionally, the demonstrated integration of mechanistic modelling and machine learning could enable the 
incorporation of these insights in the earliest phases of drug discovery. The need for this model-based 
selectivity optimisation is especially valuable for therapeutic areas in which an optimal target or tissue 
selectivity profile is difficult to obtain (e.g. in oncology) and might be less valuable for therapeutic areas 
were selectivity is less challenging and the traditional minimisation of the KD is desired (e.g. for 
antibiotic/antiviral targets that are not expressed in human cells). 
Conclusions 
Simulations performed in semi-physiological pharmacological models with target binding revealed an 
important role for the target concentration and tissue distribution, next to the KD and koff values, in 
determining the extent of selectivity. Interestingly, it was observed that the optimal selectivity is not 
observed for the drug that displays the highest drug-target affinity when assuming that the desired target 
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concentrations are high and the desired binding kinetics are slow. Additionally, it was observed that kinetic 
selectivity is unlikely when the target concentrations and the drug-target affinity are high, while tissue 
selectivity is first increased and then decreased for increasing target concentrations and drug-target 
affinities. The context-dependent optimum of drug-target affinity in determining the extent of selectivity 
demonstrates the value of KD prediction for drug development. Taken together, this study demonstrates the 
potential of integrative predictive modelling in providing improved strategies to optimize drug candidates 
for maximal in vivo selectivity. 
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A. Model I 
𝑑𝑎𝑐
𝑑𝑡
=  −𝑎𝑐𝑘𝑎   
𝑑𝑏𝑙
𝑑𝑡
=  𝑎𝑐𝑘𝑎 +  𝑘𝑜𝑢𝑡𝑏𝑡𝑏𝑡 + 𝑘𝑜𝑢𝑡𝑛𝑏𝑡𝑛𝑏𝑡 + 𝑘𝑜𝑢𝑡𝑙𝑖𝑙𝑖 − 𝑏𝑙(𝑘𝑖𝑛𝑏𝑡 + 𝑘𝑖𝑛𝑛𝑏𝑡 + 𝑘𝑖𝑛𝑙𝑖) 
𝑑𝑏𝑡
𝑑𝑡
=  𝑘𝑖𝑛𝑏𝑡𝑏𝑙 −  𝑘𝑜𝑢𝑡𝑏𝑡𝑏𝑡 − 𝑘𝑜𝑛1𝑏𝑡 (𝑅𝑡𝑜𝑡1 −
𝑅𝐿1
𝑉𝑏𝑡
) + 𝑘𝑜𝑓𝑓1𝑅𝐿1 − 𝑘𝑜𝑛2𝑏𝑡 (𝑅𝑡𝑜𝑡2 −
𝑅𝐿2
𝑉𝑏𝑡
) + 𝑘𝑜𝑓𝑓2  
𝑑𝑛𝑏𝑡
𝑑𝑡
= 𝑘𝑖𝑛𝑛𝑏𝑡𝑏𝑙 − 𝑘𝑜𝑢𝑡𝑛𝑏𝑡𝑛𝑏𝑡  
𝑑𝑙𝑖
𝑑𝑡
= 𝑘𝑖𝑛𝑙𝑖𝑏𝑙 − 𝑘𝑜𝑢𝑡𝑙𝑖𝑙𝑖 − 𝑘𝐹𝑙𝑖  
𝑑𝑅𝐿1
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=  𝑘𝑜𝑛1𝑏𝑡 (𝑅𝑡𝑜𝑡1 −
𝑅𝐿1
𝑉𝑏𝑡
) −  𝑘𝑜𝑓𝑓1𝑅𝐿1  
𝑑𝑅𝐿2
𝑑𝑡
=  𝑘𝑜𝑛2𝑏𝑡 (𝑅𝑡𝑜𝑡2 −
𝑅𝐿2
𝑉𝑏𝑡
) −  𝑘𝑜𝑓𝑓2𝑅𝐿2        
Table S1. Input paramters for model I. kin is the inwards distribution rate constant, V is volume, kF is the 
forward rate of elimination constant, ka is the absorption rate constant, bt is binding tissue, nbt is 
nonbinding tissue, li is liver, bl is blood.  
Parameter Value Unit 
kinbt 8.6 h-1 
kinnbt 25 h-1 
kinli 27 h-1 
Vbl 5.5 L 
Vbt 1.4 L 
Vnbt 61 L 
Vli 1.8 L 
kF 100 h-1 
ka 0.25 h-1 
 
 
B. Model II 
𝑑𝑎𝑐
𝑑𝑡
=  −𝑎𝑐𝑘𝑎    
𝑑𝑏𝑙
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= 𝑘𝑖𝑛𝑛𝑏𝑡𝑏𝑙 − 𝑘𝑜𝑢𝑡𝑛𝑏𝑡𝑛𝑏𝑡  
𝑑𝑙𝑖
𝑑𝑡
= 𝑘𝑖𝑛𝑙𝑖𝑙𝑖 −  𝑘𝑜𝑢𝑡𝑙𝑖𝑙𝑖 − 𝑘𝐹𝑙𝑖  
𝑑𝑅𝐿1
𝑑𝑡
=  𝑘𝑜𝑛𝑏𝑡1 (𝑅𝑡𝑜𝑡1 −
𝑅𝐿1
𝑉𝑏𝑡1
) −  𝑘𝑜𝑓𝑓𝑅𝐿1  
𝑑𝑅𝐿2
𝑑𝑡
=  𝑘𝑜𝑛𝑏𝑡2 (𝑅𝑡𝑜𝑡2 −
𝑅𝐿2
𝑉𝑏𝑡2
) − 𝑘𝑜𝑓𝑓𝑅𝐿2  
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i. Fast distribution 
Table S2. Input parameters for the fast distribution simulations in model II. kin is the inwards distribution 
rate constant, V is volume, kF is the forward rate of elimination constant, ka is the absorption rate constant, 
bt is binding tissue, nbt is nonbinding tissue, li is liver, bl is blood, Rtot is receptor concentration, kon is the 
ligand-target association rate constant. 
Parameter Value Unit 
kinbt1 8.6 h-1 
kinbt2 8.6 h-1 
kinnbt 17 h-1 
kinli 27 h-1 
Vbl 5.5 L 
Vbt1 1.4 L 
Vbt2 1.4 L 
Vnbt 60 L 
Vli 1.8 L 
kF 100 h-1 
Rtot1  25 nM 
Rtot2 0.25 nM 
koff 10 nM-1h-1 
 
ii. Slow distribution 
Table S3. Input parameters for the slow distribution simulations in model II. kin is the inwards distribution 
rate constant, V is volume, kF is the forward rate of elimination constant, ka is the absorption rate constant, 
bt is binding tissue, nbt is nonbinding tissue, li is liver, bl is blood, Rtot is receptor concentration, kon is the 
ligand-target association rate constant. 
Parameter Value Unit 
kinbt1 8.6 h-1 
kinbt2 8.6 h-1 
kinnbt 17 h-1 
kinli 27 h-1 
Vbl 5.5 L 
Vbt1 1.4 L 
Vbt2 1.4 L 
Vnbt 60 L 
Vli 1.8 L 
kF 100 h-1 
Rtot1  25 nM 
Rtot2 0.25 nM 





C. Model III 
𝑑𝑎𝑐
𝑑𝑡
=  −𝑎𝑐𝑘𝑎   
𝑑𝑏𝑙
𝑑𝑡
















































) −  𝑘𝑜𝑛𝐶𝐵1𝑐𝑒𝑟 (𝐶𝐵1𝑐𝑒𝑟 −
𝐶𝐵1𝑅𝐿𝑐𝑒𝑟
𝑉𝑐𝑒𝑟
) + 𝑘𝑜𝑓𝑓𝐶𝐵1𝐶𝐵1𝑅𝐿𝑐𝑒𝑟 − 𝑘𝑜𝑛𝑚𝐺𝑙𝑢5𝑐𝑒𝑟 (𝑚𝐺𝑙𝑢5𝑐𝑒𝑟 −
𝑚𝐺𝑙𝑢5𝑅𝐿𝑐𝑒𝑟
𝑉𝑐𝑒𝑟
) + 𝑘𝑜𝑓𝑓𝑚𝐺𝑙𝑢5𝑚𝐺𝑙𝑢5𝑅𝐿𝑐𝑒𝑟 − 𝑘𝑜𝑛𝑇𝑅𝑃𝑉1𝑐𝑒𝑟 (𝑇𝑅𝑃𝑉1𝑐𝑒𝑟 −
𝑇𝑅𝑃𝑉1𝑅𝐿𝑐𝑒𝑟
𝑉𝑐𝑒𝑟
) +  𝑘𝑜𝑓𝑓𝑇𝑅𝑃𝑉1𝑇𝑅𝑃𝑉1𝑅𝐿𝑐𝑒𝑟 −
 𝑘𝑜𝑛𝐻𝑇1𝑎𝑐𝑒𝑟 (𝐻𝑇1𝑎𝑐𝑒𝑟 −
𝐻𝑇1𝑎𝑅𝐿𝑐𝑒𝑟
𝑉𝑐𝑒𝑟













) −  𝑘𝑜𝑛𝐶𝐵1ℎ𝑦𝑝 (𝐶𝐵1ℎ𝑦𝑝 −
𝐶𝐵1𝑅𝐿ℎ𝑦𝑝
𝑉ℎ𝑦𝑝
) +  𝑘𝑜𝑓𝑓𝐶𝐵1𝑅𝐿ℎ𝑦𝑝 − 𝑘𝑜𝑛𝑚𝐺𝑙𝑢5ℎ𝑦𝑝 (𝑚𝐺𝑙𝑢5ℎ𝑦𝑝 −
𝑚𝐺𝑙𝑢5𝑅𝐿ℎ𝑦𝑝
𝑉ℎ𝑦𝑝
) + 𝑘𝑜𝑓𝑓𝑚𝐺𝑙𝑢5𝑚𝐺𝑙𝑢5𝑅𝐿ℎ𝑦𝑝 − 𝑘𝑜𝑛𝑇𝑅𝑃𝑉1ℎ𝑦𝑝 (𝑇𝑅𝑃𝑉1ℎ𝑦𝑝 −
𝑇𝑅𝑃𝑉1𝑅𝐿ℎ𝑦𝑝
𝑉ℎ𝑦𝑝
) + 𝑘𝑜𝑓𝑓𝑇𝑅𝑃𝑉1𝑇𝑅𝑃𝑉1𝑅𝐿ℎ𝑦𝑝 −
 𝑘𝑜𝑛𝐻𝑇1𝑎ℎ𝑦𝑝 (𝐻𝑇1𝑎ℎ𝑦𝑝 −
𝐻𝑇1𝑎𝑅𝐿ℎ𝑦𝑝
𝑉ℎ𝑦𝑝













) −  𝑘𝑜𝑛𝐶𝐵1𝑓𝑐 (𝐶𝐵1𝑓𝑐 −
𝐶𝐵1𝑅𝐿𝑓𝑐
𝑉𝑓𝑐




 𝑘𝑜𝑓𝑓𝑚𝐺𝑙𝑢5𝑚𝐺𝑙𝑢5𝑅𝐿𝑓𝑐 −  𝑘𝑜𝑛𝑇𝑅𝑃𝑉1𝑓𝑐 (𝑇𝑅𝑃𝑉1𝑓𝑐 −
𝑇𝑅𝑃𝑉1𝑅𝐿𝑓𝑐
𝑉𝑓𝑐
) + 𝑘𝑜𝑓𝑓𝑇𝑅𝑃𝑉1𝑇𝑅𝑃𝑉1𝑅𝐿𝑓𝑐 − 𝑘𝑜𝑛𝐻𝑇1𝑎𝑓𝑐 (𝐻𝑇1𝑎𝑓𝑐 −
𝐻𝑇1𝑎𝑅𝐿𝑓𝑐
𝑉𝑓𝑐





= 𝑘𝑖𝑛𝑙𝑖𝑙𝑖 −  𝑘𝑜𝑢𝑡𝑙𝑖𝑙𝑖 − 𝑘𝐹𝑙𝑖  
𝑑𝐶𝐵1𝑅𝐿𝑐𝑒𝑟
𝑑𝑡
=  𝑘𝑜𝑛𝐶𝐵1𝑐𝑒𝑟 (𝐶𝐵1𝑐𝑒𝑟 −
𝐶𝐵1𝑅𝐿𝑐𝑒𝑟
𝑉𝑐𝑒𝑟
) − 𝑘𝑜𝑓𝑓𝐶𝐵1𝐶𝐵1𝑅𝐿𝑐𝑒𝑟  
𝑑𝑚𝐺𝑙𝑢5𝑅𝐿𝑐𝑒𝑟
𝑑𝑡
=  𝑘𝑜𝑛𝑚𝐺𝑙𝑢5𝑐𝑒𝑟 (𝑚𝐺𝑙𝑢5𝑐𝑒𝑟 −
𝑚𝐺𝑙𝑢5𝑅𝐿𝑐𝑒𝑟
𝑉𝑐𝑒𝑟
) − 𝑘𝑜𝑓𝑓𝑚𝐺𝑙𝑢5𝑚𝐺𝑙𝑢5𝑅𝐿𝑐𝑒𝑟  
𝑑𝑇𝑅𝑃𝑉1𝑅𝐿𝑐𝑒𝑟
𝑑𝑡
=  𝑘𝑜𝑛𝑇𝑅𝑃𝑉1𝑐𝑒𝑟 (𝑇𝑅𝑃𝑉1𝑐𝑒𝑟 −
𝑇𝑅𝑃𝑉1𝑅𝐿𝑐𝑒𝑟
𝑉𝑐𝑒𝑟
) − 𝑘𝑜𝑓𝑓𝑇𝑅𝑃𝑉1𝑇𝑅𝑃𝑉1𝑅𝐿𝑐𝑒𝑟  
𝑑𝐻𝑇1𝑎𝑅𝐿𝑐𝑒𝑟
𝑑𝑡
=  𝑘𝑜𝑛𝐻𝑇1𝑎𝑐𝑒𝑟 (𝐻𝑇1𝑎𝑐𝑒𝑟 −
𝐻𝑇1𝑎𝑅𝐿𝑐𝑒𝑟
𝑉𝑐𝑒𝑟
) − 𝑘𝑜𝑓𝑓𝐻𝑇1𝑎𝐻𝑇1𝑎𝑅𝐿𝑐𝑒𝑟  
𝑑𝐶𝐵1𝑅𝐿ℎ𝑦𝑝
𝑑𝑡
=  𝑘𝑜𝑛𝐶𝐵1ℎ𝑦𝑝 (𝐶𝐵1ℎ𝑦𝑝 −
𝐶𝐵1𝑅𝐿ℎ𝑦𝑝
𝑉ℎ𝑦𝑝
) − 𝑘𝑜𝑓𝑓𝐶𝐵1𝐶𝐵1𝑅𝐿ℎ𝑦𝑝  
𝑑𝑚𝐺𝑙𝑢5𝑅𝐿ℎ𝑦𝑝
𝑑𝑡
=  𝑘𝑜𝑛𝑚𝐺𝑙𝑢5ℎ𝑦𝑝 (𝑚𝐺𝑙𝑢5ℎ𝑦𝑝 −
𝑚𝐺𝑙𝑢5𝑅𝐿ℎ𝑦𝑝
𝑉ℎ𝑦𝑝
) −  𝑘𝑜𝑓𝑓𝑚𝐺𝑙𝑢5𝑚𝐺𝑙𝑢5𝑅𝐿ℎ𝑦𝑝  
𝑑𝑇𝑅𝑃𝑉1𝑅𝐿ℎ𝑦𝑝
𝑑𝑡
=  𝑘𝑜𝑛𝑇𝑅𝑃𝑉1ℎ𝑦𝑝 (𝑇𝑅𝑃𝑉1ℎ𝑦𝑝 −
𝑇𝑅𝑃𝑉1𝑅𝐿ℎ𝑦𝑝
𝑉ℎ𝑦𝑝
) − 𝑘𝑜𝑓𝑓𝑇𝑅𝑃𝑉1𝑇𝑅𝑃𝑉1𝑅𝐿ℎ𝑦𝑝  
𝑑𝐻𝑇1𝑎𝑅𝐿ℎ𝑦𝑝
𝑑𝑡
=  𝑘𝑜𝑛𝐻𝑇1𝑎ℎ𝑦𝑝 (𝐻𝑇1𝑎ℎ𝑦𝑝 −
𝐻𝑇1𝑎𝑅𝐿ℎ𝑦𝑝
𝑉ℎ𝑦𝑝
) − 𝑘𝑜𝑓𝑓𝐻𝑇1𝑎𝐻𝑇1𝑎𝑅𝐿ℎ𝑦𝑝  
𝑑𝐶𝐵1𝑅𝐿𝑓𝑐
𝑑𝑡
=  𝑘𝑜𝑛𝐶𝐵1𝑓𝑐 (𝐶𝐵1𝑓𝑐 −
𝐶𝐵1𝑅𝐿𝑓𝑐
𝑉𝑓𝑐
) − 𝑘𝑜𝑓𝑓𝐶𝐵1𝐶𝐵1𝑅𝐿𝑓𝑐  
𝑑𝑚𝐺𝑙𝑢5𝑅𝐿𝑓𝑐
𝑑𝑡
=  𝑘𝑜𝑛𝑚𝐺𝑙𝑢5𝑓𝑐 (𝑚𝐺𝑙𝑢5𝑓𝑐 −
𝑚𝐺𝑙𝑢5𝑅𝐿𝑓𝑐
𝑉𝑓𝑐
) − 𝑘𝑜𝑓𝑓𝑚𝐺𝑙𝑢5𝑚𝐺𝑙𝑢5𝑅𝐿𝑓𝑐  
𝑑𝑇𝑅𝑃𝑉1𝑅𝐿𝑓𝑐
𝑑𝑡
=  𝑘𝑜𝑛𝑇𝑅𝑃𝑉1𝑓𝑐 (𝑇𝑅𝑃𝑉1𝑓𝑐 −
𝑇𝑅𝑃𝑉1𝑅𝐿𝑓𝑐
𝑉𝑓𝑐
) − 𝑘𝑜𝑓𝑓𝑇𝑅𝑃𝑉1𝑇𝑅𝑃𝑉1𝑅𝐿𝑓𝑐  
𝑑𝐻𝑇1𝑎𝑅𝐿𝑓𝑐
𝑑𝑡
=  𝑘𝑜𝑛𝐻𝑇1𝑎𝑓𝑐 (𝐻𝑇1𝑎𝑓𝑐 −
𝐻𝑇1𝑎𝑅𝐿𝑓𝑐
𝑉𝑓𝑐
) − 𝑘𝑜𝑓𝑓𝐻𝑇1𝑎𝐻𝑇1𝑎𝑅𝐿𝑓𝑐  
 
The clearances from brain extra-cellular fluid to the cerebrospinal fluid presented by Yamamoto et al are 
0.0556, 0.0250, 0.0598, 0.0200,0.0248, 0.0133, 0.0237, 0.0176 and 0.0254 ml/min, resulting in a mean value 
of 0.0295 ml/min. These values were allometrically scaled to humans by multiplying this value by 
(70/0.25)0.75, resulting in a value of 2.02 ml/min, which equals to 0.121 L/h. In this study, the ECF volume in 
humans was reported as 0.240 L. Given that the equation for clearance is 𝐶𝐿 =  𝑉 ∗ 𝑘𝑜𝑢𝑡, kout can be 
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calculated as 0.121 (L/h)/0.240 (L), resulting in a value of 0.504 h-1. By multiplying this value by the tissue 
volume, the effective flow through the target site (cerebellum, hypothalamus, frontal cortex) is obtained. 
Table S4. Model parameters for model III. Q is blood flow, P is the partition coefficient, V is volume, koff is 
the ligand-target dissociation rate constant, kF is the forward rate of elimination constant, ka is the 
absorption rate constant, bl is blood, nbt is nonbinding tissue, cer is cerebellum, hyp is hypothalamus, fc is 
frontal cortex, li is liver. 
Parameter Value Unit References 




Qcer Vcer*0.504 L/h [39] 
Qhip Vhyp*0.504 L/h [39] 
Qfc Vfc*0.504 L/h [39] 
Qli 27 L/h [37] 
Pnbt 46   
Pcer 13   
Phyp 13   
Pfc 13   
Pli 9.4   
Vbl 5.5 L [37]  
Vnbt 62 L [37]  
Vcer 0.15 L [35]  
Vhyp 1.4*10-2 L [38]  
Vfc 0.27 L [72]  
Vli 1.8 L [37]  
koff 10 h-1   
kF 100 h-1   
ka 0.25 h-1   





Table S5. Receptor density values obtained from literature. CB1 is cannabinoid 1 receptor, TRPV1 is vanilloid 
1 receptor, 5-HT1a is serotonin 1a receptor, mGlu5 is metabotropic glutamate receptor 5. All these values 




























cerebellum 5.27 527 5.1  
 
4.03 19 0.01d 
(frontal) cortex 5.29 529 25 2.53 12 1.70 
hypothalamus 2.48 248 16e 2.76 13 2.37f 
References [40]  [41] [42]  [43] 
a Conversion from pmol/mg protein to nM was obtained by multiplying with an assumed protein concentration of 100 
mg/ml tissue.[48] 
b Values from humans. 
c These values were obtained by multiplying the protein level in ng/mg lysate with the ratio of protein level in pmol/mg 
protein[46] and in ng/mg lysate[42] and subsequent multiplication with an assumed protein concentration of 100 mg/ml 
tissue.[48] 
d This value was too low to be identified in the reference and was therefore set to a low concentration. 
e The Bmax value was calculated as the average of the cortex, caudate-putamen and cerebellum. 
f  The reported value for the limbic average was used for the hypothalamus.  
 
Supplemental 3 
A. Physicochemical Properties 
Table S6. Physicochemical properties for the partition coefficient calculations in the Integrated QSAR-RF 
PBPK-TMDD model. P is the octanol-water partition coefficient, Sw is the solubility in water, So is the 
solubility in octanol. 
Ligand logP logSw P Sw So 
Δ8-THC 6.109 -6,152 12*105 7.05*10-7 0.91 
Rimonabant 6.613 -8,112 41*105 7.73*10-9 0.03 





B. Volume Fractions 
Table S7. Volume fractions of water, neutral lipids and phospholipids in human tissues. Nbt is nonbinding 
tissue. 
 
Water Neutral lipid Phospholipid 
Blood 0.8 0.0044 0.0021 
Liver 0.72 0.039 0.028 
Nbt  0.56 0.21 0.071 
Brain 0.79 0.0462 0.0638 
 
Supplemental 4 
A. Compare Binding 
i. Within 
Table S8. Statistical analysis of the pChEMBL value deviations within measurements of the same bioactivity 
value and all bioactivity values together. Mean Δ is the mean difference between measurements of the 
same ligand at the same target. KD is the dissociation rate constant, Ki is the inhibitory constant, IC50 is the 
half-maximal inhibitory constant ions, and EC50 is the half-maximal effective concentration. 
 
KD - KD Ki - Ki IC50 - IC50 EC50 - EC50 Any - Any 
Mean Δ 0.32 0.44 0.61 0.50 0.61 





Table S9. Statistical analysis of the pChEMBL value deviations between measurements of different 
bioactivity values. Mean Δ is the mean difference between measurements of the same ligand at the same 
target. KD is the dissociation rate constant, Ki is the inhibitory constant, IC50 is the half-maximal inhibitory 
constant ions, and EC50 is the half-maximal effective concentration 
 
KD - Ki Ki - IC50 Ki - EC50 IC50 - EC50 
Mean Δ 0.16 0.50 0.52 0.21 
Mean pChEMBL value 7.16 ± 0.19  6.93 ± 0.28 7.21 ± 0.23 6.83  0.29 
 
B. Out-of-bag validation 
i. R2 
Table S10. The R2 values of the out-of-bag validation of the QSAR-RF model trained on seven different 
datasets. The R2 values are reported per training of the model on a data set obtained using a different split 
seed. 
Seed CB1 TRPV1 ADORA2a mGlu5 5-HT1a 
111 0.62 0.61 0.67 0.59 0.62 
222 0.64 0.59 0.67 0.67 0.57 
333 0.65 0.61 0.68 0.70 0.59 
444 0.66 0.63 0.66 0.63 0.58 
555 0.64 0.64 0.68 0.68 0.58 
666 0.62 0.62 0.67 0.67 0.59 
777 0.63 0.61 0.68 0.64 0.59 
STDEV 0.016 0.015 0.0076 0.038 0.015 





Table S11. The RMSE values of the out-of-bag validation of the QSAR-RF model trained on seven different 
datasets. The root-mean squared error (RMSE) values are reported per training of the model on a dataset 
obtained using a different split seed. 
Seed CB1 TRPV1 ADORA2a mGlu5 5-HT1a 
111 0.67 0.66 0.67 0.83 0.68 
222 0.66 0.68 0.67 0.69 0.70 
333 0.65 0.67 0.67 0.73 0.70 
444 0.64 0.66 0.68 0.81 0.70 
555 0.65 0.65 0.66 0.76 0.70 
666 0.67 0.64 0.67 0.77 0.69 
777 0.66 0.67 0.66 0.75 0.69 
STDEV 0.013 0.013 0.0076 0.047 0.0085 




Table S12. The R2 values of external validation of the QSAR-RF model trained on seven different datasets. 
The R2 values are reported per training of the model on a dataset obtained using a different split seed. The 
external validation was performed as a regression validation, using a validation dataset, containing only data 
which was not exposed to the model before validation. 
 
CB1 TRPV1 ADORA2a mGlu5 5-HT1a 
111 0.65 0.66 0.70 0.73 0.57 
222 0.59 0.60 0.72 0.62 0.62 
333 0.57 0.63 0.64 0.52 0.61 
444 0.59 0.50 0.68 0.68 0.60 
555 0.60 0.52 0.63 0.58 0.61 
666 0.63 0.56 0.67 0.62 0.57 
777 0.62 0.5 0.69 0.65 0.58 
STDEV 0.028 0.056 0.031 0.070 0.020 





Table S13. The RMSE values of the out-of-bag validation of the QSAR-RF model trained on seven different 
datasets. The root-mean squared error (RMSE) values are reported per training of the model on a dataset 
obtained using a different split seed. The external validation was performed as a regression validation, using 
a validation dataset, containing only data which was not exposed to the model before validation. 
 
CB1 TRPV1 ADORA2a mGlu5 5-HT1a 
111 0.66 0.64 0.65 0.72 0.68 
222 0.68 0.70 0.64 0.75 0.66 
333 0.7 0.66 0.69 0.90 0.67 
444 0.71 0.74 0.64 0.74 0.69 
555 0.70 0.73 0.70 0.85 0.69 
666 0.67 0.76 0.67 0.79 0.69 
777 0.67 0.68 0.66 0.87 0.7 
STDEV 0.019 0.045 0.021 0.071 0.015 
AVG 0.68 0.70 0.66 0.80 0.68 
 
C. Prediction errors for Rimonabant at the CB1 receptor 
In Figure S1, it can be seen that all predicted pChEMBL values for Rimonabant at the CB1 receptor fall within 
the confidence interval of pChEMBL values which are reported in the ChEMBL database. Although the 
structure of Rimonabant was present in the training set, this is indicative of a reliable prediction of the KD 
values (at the CB1 receptor) used in this study. 
 
Figure S1. All model predictions for the binding affinity of Rimonabant at the CB1 receptor fall within measured range. The 
average pChEMBL value and the standard deviation are reported. Measured pChEMBL values include all the reported 
pChEMBL values for Rimonabant at the CB1 receptor in the ChEMBL database after filtering to obtain a high-quality 
dataset. Measured: average pChEMBL value is 8.3 with a standard deviation of 0.52. The full model predicted a pChEMBL 
value of 8.28 for Rimonabant at the CB1 receptor. The average pChEMBL value as predicted by the externally validated 





Figure S2. Target concentration and KD determine the extent of in vivo kinetic target selectivity in Model I. Target 
selectivity is characterised by a difference in target occupancy between target 1 (solid) and target 2 (dashed). The 









Figure S3. The simulated influence of KD on the Rimonabant selectivity profile in Model III. Predicted KD values of 
Rimonabant at the CB1, 5-HT1a, mGlu5 and TRPV1 receptor were used in these simulations, and multiplied by 10 or 0.1. 
koff values were assumed to be 10 h-1. A dose of 104 nmol was administered every 24 hours. Rtot,cer,CB1 = 527 nM, Rtot,cer,mGlu5 = 
5.1 nM, Rtot,cer,TRPV1 = 19 nM, Rtot,cer,5-HT1a = 0.01, Rtot,hyp,CB1 = 248 nM, Rtot,hyp,mGlu5 = 16 nM, Rtot,hyp,TRPV1 = 13 nM, Rtot,hyp,5-HT1a = 
2.37, Rtot,fc,CB1 = 529 nM, Rtot,fc,mGlu5 = 25 nM, Rtot,fc,TRPV1 = 12 nM, Rtot,fc,5-HT1a = 1.7. 
 
Figure S4. The influence of prediction errors on the simulated Rimonabant selectivity profile in Model III. Predicted KD 
values of Rimonabant at the CB1, 5-HT1a, mGlu5 and TRPV1 receptor were used in these simulations. The RMSE values 
obtained from the external model validation of the QSAR were added or substracted from the predicted pChEMBL value 
and then converted to the KD value in nM (10-pChEMBL value*109). koff values were assumed to be 10 h-1. A dose of 104 nmol was 
administered every 24 hours. Rtot,cer,CB1 = 527 nM, Rtot,cer,mGlu5 = 5.1 nM, Rtot,cer,TRPV1 = 19 nM, Rtot,cer,5-HT1a = 0.01, Rtot,hyp,CB1 = 248 
nM, Rtot,hyp,mGlu5 = 16 nM, Rtot,hyp,TRPV1 = 13 nM, Rtot,hyp,5-HT1a = 2.37, Rtot,fc,CB1 = 529 nM, Rtot,fc,mGlu5 = 25 nM, Rtot,fc,TRPV1 = 12 nM, 
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Introduction. Drug-target binding kinetics (as determined by association and dissociation rate constants, kon 
and koff) can be an important determinant of the kinetics of drug action. However, the effect compartment 
model is used most frequently instead of a target binding model to describe hysteresis. Here we investigate 
when the drug-target binding model should be used in lieu of the effect compartment model.  
Methods. We tested the utility of the effect compartment (EC), the target binding kinetics (TB) and the 
combined effect compartment-target binding kinetics (EC-TB) model on either plasma (ECPL, TBPL and EC-
TPPL) or brain extracellular fluid (ECECF, TBECF and EC-TPECF) morphine concentrations and EEG amplitude in 
rats. We also analyzed when a significant shift in the time to maximal target occupancy (TmaxTO) with 
increasing dose, the discriminating feature between the TB and EC model, occurs in the TB model. All TB 
models assumed a linear relationship between target occupancy and drug effect on the EEG amplitude. 
Results. We found that all three model types performed similarly in describing the morphine PD data, 
although the EC model provided the best statistical result. Our analysis of the shift in TmaxTO (∆TmaxTO) as a 
result of increasing dose revealed that ∆TmaxTO is decreasing towards zero if the koff is much smaller than 
the elimination rate constant or if the target concentration is larger than the initial morphine concentration. 
Discussion and Conclusion. Our results for the morphine PKPD modelling and the analysis of ∆TmaxTO 
indicate that the EC and TB models do not necessarily lead to different drug effect versus time curves for 
different doses if a delay between drug concentrations and drug effect (hysteresis) is described. Drawing 
mechanistic conclusions from successfully fitting one of these two models should therefore be avoided. 
Since the TB model can be informed by in vitro measurements of kon, either plasma (a target binding model 










Abbreviations: AIC: Akaike Information Criterion, CNS: Central Nervous System, DE: Direct Effect, ECF: 
Extracellular Fluid, EC: Effect Compartment, IE: Indirect Effect, GOF: Goodness Of Fits, IIV: Inter-Individual 
Variability, OFV: Objective Function Value, PD: Pharmacodynamics, Pgp: P-glycoprotein, PK: 
Pharmacokinetics, PD: Pharmacodynamics, TB: Target binding, TmaxPD: Time between dosing and maximal 
drug effect, TmaxTO: Time between dosing and maximal target occupancy, ∆TmaxTO: TmaxTO of the lower 





Drug-target binding kinetics is an important criterion in the selection of drug candidates, as it can be a 
determinant of the time course and the selectivity of drug effect.[1–4] 
However, the in vivo time course of drug action is influenced by multiple factors including plasma 
pharmacokinetics, target site distribution, target binding kinetics, competition with endogenous ligands, 
turnover of the target, signal transduction kinetics and the kinetics of homeostatic feedback. As a 
consequence, the influence of binding kinetics on drug action can only be understood in conjunction with 
these kinetic processes and its relevance is still not fully understood and subject to an ongoing debate.[3,5–
8] 
One of the arguments against an important role of binding kinetics for in vivo drug action is that binding 
kinetics are most often not required to get a good fitting PKPD model for small molecules. However, 
numerous examples are available were binding kinetic models have been successfully applied, and binding 
kinetics are routinely incorporated in models for biologics and PET data.[9–17] The sparsity of target binding 
PKPD models for small molecules can be explained by the relatively fast binding kinetics of many drugs 
currently on the market, compared to their pharmacokinetics.[3] In addition, when a delay between drug 
concentrations and effect is observed, this delay is often described by an effect compartment or indirect 
response model.[18,19]  
Here we study the difference between the effect compartment (EC) model, the target binding (TB) model 
the direct effect (DE) and the indirect effect (IE) model which are described below. The EC model describes 
the delay between pharmacokinetics (PK) and pharmacodynamics (PD) by including first order distribution 
of the drug into and out of a hypothetical target-site (biophase) compartment, which drives the PD mostly in 
a nonlinear fashion.[20] The indirect effect (IE) model describes the delay between PK and PD by the zero 
order synthesis and first order degradation of an effector molecule which represents the PD, mostly in a 
linear fashion.[21] The target binding (TB) model describes the delay between PK and PD by the second 
order drug-target association and first order dissociation of the drug-target complex, which drives the effect 
in a linear or nonlinear fashion, depending on the efficacy and receptor reserve.[22–24] The DE model 
describes no delay between the PK and PD and links the drug concentration directly to the effect 
measurements in a linear or nonlinear fashion. 
These models thus result in a zero, first and second order formation of the compounds that drives the PD, 
being the drug concentration in the effect compartment, the target-bound drug concentrations and the 
endogenous effector molecule in the EC, TB and IE model, respectively. This results in different dose 
dependencies of the time to the maximal effect TmaxPD. As a current paradigm, the shift in TmaxPD 
(∆TmaxPD) in a PKPD dataset as a consequence of a change in the dose,  identifies the appropriate PKPD 
model to describe the data: with increasing dose, the TmaxPD can increase for the indirect response model, 
decrease for the TB model and is constant for the EC model.[25–27]  
However, in contrast to common belief, the indirect response model does not always result in an increasing 
TmaxPD with increasing doses but can also give rise to a decreasing TmaxPD with increasing doses, as shown 
by Peletier et al.[28] A comprehensive analysis of the conditions for which a shift in TmaxTO for changing 
doses occurs in a TB model is currently not available. It might be that EC models have been used while TB 
models could have been applied equally well to describe the data in previous PKPD studies.  
One example in which performance of TB and EC models has been investigated  indicates comparable 
performance in describing the data of eight calcium channel blockers, but this study used only one dose 
level for all drugs[14] and therefore cannot be used to validate the relationship between dose and ∆TmaxPD. 
An additional complexity in choosing the most appropriate PKPD model to describe PKPD data is that, for 
most drugs, factors as target site distribution, drug-target binding and turnover of signaling molecules occur 
in parallel. It is not always needed to incorporate all these factors in the PKPD model, as only the rate 
limiting mechanism is required for a proper model fit that describes the observed data. However, leaving 
out such factors will never lead to understanding of the individual contributions and the interplay between 
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these factors.  Combined EC-TB models[13,29,30] as well as combined IE-TB models[10] have been applied 
successfully to discriminate between the contributions of separate factors. However, this discrimination is 
not always possible if one of the factors is relatively fast and does not contribute significantly to the delay 
between PK and PD.[31–33]. In short, the relevance of drug-target binding kinetics cannot be excluded if 
one of the other models is successfully fitted to a dataset, and there is a need to generate more insight into 
the difference between the TB model and the EC model. 
The aim of the current study is to investigate if the TB and EC model can give similar drug effect versus time 
curves and under what conditions this will occur. In this study, we used a historical PKPD dataset for 
morphine [34] to compare the goodness of fit for the TB model with the EC model  and the combined EC-TB 
model in describing the time course of the EEG effect following administration of 3 different doses of 
morphine (4, 10 and 40 mg/kg). Both plasma and brain ECF drug concentrations were measured and tested 
in this study to be connected to the PD via an EC, TB or EC-TB model. Subsequently, a more general insight 
in the shift of TmaxTO for different dose levels in the drug-target binding model is obtained to identify for 
what parameter values the TB model can be discriminated from the EC model based on the ∆Tmax TO. To 
that end, we performed comprehensive simulations and mathematical model analysis for a wide range of 
drug-target association and dissociation rate constants, for various plasma elimination rate constants, target 




Pharmacokinetic and pharmacodynamic (PKPD) data of morphine in rats 
All PK and PD data used in this study were obtained from the experiments described earlier.[35] In short: 
Morphine was intravenously administered to Male Wistar rats, during a 10-minute infusion, in 4 different 
dose groups: 0, 4, 10 or 40 mg/kg with 5, 29, 11 and 14 animals, respectively.  The P-glycoprotein (Pgp) 
inhibitor GF120918 or vehicle was given as a continuous infusion. In the group of 29 animals that received 4 
mg/kg morphine, 9 animals received GF120918, the other 20 animals received the vehicle. Furthermore, 
while plasma concentrations were measured in all animals, brain ECF concentrations were measured with 
microdialysis in 29 animals, of which 15 received 4 mg/kg, 0 received 10 mg/kg, 9 received 40 mg/kg and 5 
received 0 mg/kg morphine.  
For the modelling data set, all data entries without time recordings, without concentration data or with 
concentration data equal to 0 were removed from the dataset. The lower limit of quantification for 
morphine in plasma samples was 88 nM and 1.75 nM for morphine in ECF samples. The PD of morphine was 
measured as the amplitude in the δ frequency range (0.5-4.5 Hz) of the EEG, and recorded every minute. 
The EEG data were further averaged for every 3-minute interval to reduce the noise and decrease the model 
fitting time. 
General model fitting methods 
Data fitting was based on minimization of the Objective Function Value (OFV =  – 2*log likelihood) as 
implemented in NONMEM 7.3.[36] To account for the number of parameters for the comparison of non-
nested models, the Akaike Information Criterion (AIC) was calculated by adding two times the number of 
estimated parameters to the OFV.[37] Variability in the data was described by IIV (Inter Individual 
Variability: variability in parameter values between animals) and a residual error term. IIV was implemented 
assuming a log-normal distribution according to equation 1: 
𝑃𝑖 =  𝑃𝑝𝑜𝑝 ∗  𝑒
𝜂𝑖                                                                        (1) 
In which Pi is the individual parameter value, Ppop is the typical parameter value in the population and ηi is 
normally distributed around a mean of zero with variance ω2 according to equation 2: 
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𝜂𝑖  ~ 𝑁(0, 𝜔
2)                                                                           (2) 
The remaining variation between the data and the model predictions are incorporated as residual error for 
which both a proportional (equation 3) and a combined proportional and additive (equation 4) error model 
were tested. 
𝑜𝑏𝑠𝑖𝑗 =  𝑝𝑟𝑒𝑑𝑖𝑗 ∗ (1 + 𝜀𝑝𝑟𝑜𝑝,𝑖𝑗)                                                          (3) 
𝑜𝑏𝑠𝑖𝑗 =  𝑝𝑟𝑒𝑑𝑖𝑗 ∗ (1 + 𝜀𝑝𝑟𝑜𝑝,𝑖𝑗) + 𝜀𝑎𝑑𝑑,𝑖𝑗                                                   (4) 
In these equations, obsij is the observation, predij is the model prediction, εprop,ij is the proportional error and 
εadd,ij is the additive error  for individual i at time point j. Both εprop,ij and εadd,ij are normally distributed 
around a mean of zero with variance σ2 according to equation 5 and 6: 
𝜀𝑝𝑟𝑜𝑝,𝑖𝑗  ~ 𝑁(0, 𝜎
2)                                                                           (5) 
𝜀𝑎𝑑𝑑,𝑖𝑗 ~ 𝑁(0, 𝜎
2)                                                                           (6) 
Morphine plasma PK modelling 
One-compartment, two-compartment and three-compartment models were fitted to the plasma PK data, 
with both proportional and additive plus proportional error models, and with IIV on the various parameters. 
The best fits (based on AICs) of each structural model were compared for their GOFs (Goodness Of Fits) and 
AICs. Since the purpose of the plasma PK modelling was to get the best possible input for the PD modelling, 
GOF was assessed by the AIC and by individual fits. Over- or underestimation of IIV and population 
parameter estimates and high uncertainties in population parameter estimates were not regarded as 
problematic, since only the right individual parameter estimates were required for PD modeling. 
Morphine brain ECF PK Modelling 
The individual parameter estimates that were estimated to describe the plasma PK were used as fixed 
parameters to describe the plasma PK profile as input for the brain ECF concentrations. To describe the ECF 
concentrations, we thus assumed that the distribution of the drug into and out of the ECF did not lead to a 
change in plasma concentrations. The best fits, based on the AICs, of each structural model were compared 
for their GOFs (Goodness Of Fits) and AICs. Since the purpose of the brain ECF PK modelling was to get the 
best possible input for the PD modelling, GOF was assessed by the AIC and by individual fits. Over- or 
underestimation of IIV and population parameter estimates and high uncertainties in population parameter 
estimates were not regarded as problematic, since only the right individual parameter estimates were 
required for PD modeling. 
EEG PD modelling 
To maximize the identifiability of the PD model parameters, all pharmacokinetic parameters were used as 
fixed parameters to describe the plasma and brain ECF concentrations as input for all the described PD 
models to describe EEG effects.[38] The different type of models that were tested are outlined in Table 1. 
For each model, the most informative variations on the model structure are given in the results section.  
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Table 1. Overview of the different model types, the data that were used and the model numbers as used in 
this manuscript. EC = Effect compartment, TB = target binding, EC-TB = effect compartment – target binding. 
IE = indirect effect, DE = direct effect and ECF = brain extracellular fluid. 
Model type Concentrations linked to 
effect 
Model number 
EC PLasma ECPL1 – ECPL4 
EC ECF ECECF1 
TB PLasma TBPL1 – TBPL5 
TB ECF TBECF1 
EC-TB PLasma ECTBPL1 – ECTBPL5 
IE ECF IEECF1 
DE ECF DEECF1 
 
To compare structural models that linked plasma or brain ECF concentrations directly to the PD, the models 
that used plasma PK were fitted to the reduced dataset that only contained animals with plasma PK, brain 
ECF and EEG measurements.  Model comparison was based on the AIC, visual inspection of the GOF and a 
VPC (Visual Predictive Check) to check if the IIV was captured appropriately. 
Drug-target binding model simulations 
Simulations with a one-compartment binding model with IV administration were performed for a wide 
range of kon and koff values and for a variety of elimination rate constants, target concentrations and drug 
dose levels. The TmaxTO was compared for 2 different doses to determine the influence of the drug dose on 
the TmaxTO. The ∆TmaxTO values were calculated by subtracting the TmaxTO of the highest dose from the 
TmaxTO of the lowest dose and ∆TmaxTO was plotted against kon and koff. 
 
Results 
Morphine PK modelling 
Modelling of morphine pharmacokinetic data in plasma and brain ECF as described in Supplement S 1 
identified very similar model structures as previously described for pharmacokinetic modelling of the same 
dataset by Groenendaal and coworkers.[35]  In short, the plasma concentrations were described by a 3-
compartment model and the ECF concentrations were described by passive distribution into and out of the 
brain combined with saturable active influx and first-order efflux. 
EEG PD modelling 
ECPL model fitting 
EC and TB models have been applied to the morphine data to describe the relationship between the 
observed plasma concentrations and EEG amplitude and direct effect (DE) indirect effect (IE), EC and TB 
models have been applied to brain ECF and EEG amplitude data. The differential equations for these models 
are given in Supplement S 1. Firstly, the originally published ECPL model structure was optimized by adding a 
slope parameter which describes the linear decline of EEG amplitude over time during the experiment 
independent of the drug effect, and including IIV on the baseline EEG amplitude only. For this model, a 
transit compartment was required between the plasma and the effect compartment.[34] An overview of the 
different variations on this basic model structure is given in Table 2. The structure of all ECPL is identical and 
is depicted in Figure 1. Based on the AIC, the parameter estimates and the GOF, model ECPL1 was chosen as 
the best parameterization for the effect compartment model in Figure 1. 
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Figure 1. Schematic representation of the ECPL model structure that was used to describe the morphine EEG amplitudes 
over time. kie  = first-order in- and outward distribution rate constant for the transit compartment. keo first-order outward 
distribution rate constant from the effect compartment. The effect compartment concentrations were linked to the EEG 
amplitude by a sigmoidal Emax model. The distribution from plasma to the tissue compartments and the brain ECF 
compartment is described in Supplement S 1. The arrows indicate morphine flows, the dotted line indicates a direct 
relationship. 
Table 2. Parameter values and objective function values of the tested EC models describing the EEG data 
based on plasma concentrations. CV denotes the coefficient of variation as percentage. OFV denotes the 
Objective Function Value, AIC denotes the Akaike Information Criterion. ω2 and σ2 denote the variances of 






no slope  
ECPL3 
k1e = keo 
ECPL4 
no Pgp effect 
OFV 44748.0 45084.2 44853.3 44868.4 
AIC 44770.0 45104.2 44871.3 44886.4 
parameter Value (%CV) Value (%CV) Value (%CV) Value (%CV) 
k1e(/min) 0.0393 (18) 0.0432 (10) 0.0403 (10) 0.0375 (8) 
keo(/min) 0.0382 (14) 0.0458 (9) - 0.0375 (8) 
k1e -Pgp (/min) 0.0565 (44) 0.0661 (38) 0.0295 (18) - 
keo -Pgp (/min) 0.016 (46) 0.0203 (20) - - 
E0 (µV) 45.1 (4) 42.2 (4) 45.8 (4) 45.9 (4) 
Emax (µV) 27.9 (23) 25.3 (16) 26.1 (18) 27.0 (18) 
EC50 (nM) 1270 (52) 1220 (31) 912 (37) 1000 (37) 
NH 1.44 (43) 2.02 (27) 1.46 (36) 1.37 (33) 
slope (µV/min) -0.024 (22) 0 FIX -0.0263 (15) -0.0267 (15) 
     
ω2 E0 (µV) 0.111 (20) 0.125 (19) 0.115 (20) 0.116 (20) 
     
σ2 proportional 0.0554 (7) 0.0584 (7) 0.0562 (6) 0.0564 (6) 
 
TBPL model fitting 
The TBPL model was applied to describe target binding from plasma, all TBPL models in  
Table 3 shared the same structure as represented in Figure 2. The parameter estimation results are given in  
Table 3. Since the target concentration is of influence only if it is similar to the drug concentration (which is 
mostly above 100 nM in plasma and in brain ECF, as shown in Supplement S 1), the target concentration 
could not be estimated in this model and was fixed to an arbitrary low value of 1 nM in the model 
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estimations. This low target concentration prevents the influence of the target concentration on the EEG 
amplitude in the model. The influence of blocking Pgp has been incorporated by estimating separate 
parameter values with and without the presence of Pgp blocker. While the influence of blocking Pgp on the 
koff or KD is mechanistically not plausible, the improved model fits for the models which incorporate these 
influences might indicate that the estimated koff and KD values refer to apparent values which include not 
only the molecular properties. The target occupancy is linearly related to the EEG amplitude in model TBPL1 - 
TBPL5, as nonlinear relationships could not be identified accurately in this study. On basis of the objective 
function values, model TBPL4 was selected as the best drug-target binding model. It should be noted that the 
AIC of model TBPL4 is 338 points higher than model ECPL1, which means that model ECPL1 performs better in 
fitting the data. All TBPL models have one compartment less than the transit-EC models ECPL1 - ECPL4. 
Therefore, the combined EC-TBPL models EC-TBPL1 - EC-TBPL5 were developed. 
 
Figure 2. Schematic representation of the TBPL model structure that was used to describe the morphine EEG amplitudes 
over time. kon is the second-order drug-target association rate constant. koff is the first-order drug-target dissociation rate 
constant. Target occupancy is linearly related to the EEG amplitude. The distribution from plasma to the tissue 
compartments and the brain ECF compartment is described in Supplement S 1. The arrows indicate morphine flows, the 
dotted line indicates a direct relationship. 
 
Table 3. Parameter values and objective function values of the tested TBPL models describing the EEG data 
based on plasma concentrations. CV denotes the coefficient of variation as percentage. OFV denotes the 
Objective Function Value, AIC denotes the Akaike Information Criterion. ω2 and σ2 denote the variances of 




no Pgp effect 
slope = 0 
TBPL2 
no Pgp effect 
TBPL3 




slope = 0 
OFV 45677.7 45170.1 45166.6 45092.1 45536.9 
AIC 45689.7 45184.1 45182.6 45108.1 45550.9 
parameter Value (%CV) Value (%CV) Value (%CV) Value (%CV) Value (%CV) 
koff (/min) 0.017 (8) 0.0103 (13) 0.0109 (17) 0.009 (26) 0.0149 (15) 
koff -Pgp (/min) - - 0.0087 (26) - - 
KD (nM) 1980 (37) 995 (36) 935 (37) 1570 (59) 3610 
KD -Pgp (nM)    381 (88) 715 
E0 (µV) 42.4 (4) 45.9 (4) 45.8 (4) 45.4 (4) 42.2 
Emax (µV) 32.2 (14) 29.3 (13) 28.9 (13) 32.9 (20) 38.9 
Rtot (nM) 1 FIX 1 FIX 1 FIX 1 FIX 1 FIX 
slope (µV/min) 0 FIX -0.0313 (13) -0.0315 (12) -0.0299 (12) 0 FIX 
      
ω2 E0 (µV) 0.135 (18) 0.117 (20) 0.117 (20) 0.113 (19) 0.13 (17) 
      
σ2 proportional 0.0639 (6) 0.059 (6) 0.059 (6) 0.0584 (6) 0.0626 (6) 
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EC-TBPL model fitting 
 
The EC-TBPL model structure that was tested to describe the EEG data is shown in Figure 3. The parameter 
values, OFVs and AICs are given in Table 4. Model EC-TBPL1 was selected as best model on basis of the AIC, 
but this AIC is still 39 points higher than Model ECPL1. The uncertainty in the parameter estimate of the KD in 
the presence of the Pgp blocker (KD –Pgp) is rather high with 93%, but this was allowed to test the 
conclusion that none of the binding models (TBPL1 - TBPL5 and EC-TBPL1 - EC-TBPL5) yielded lower AICs than 
the best effect compartment model (ECPL1) in a conservative manner. 
 
Figure 3. Schematic representation of the EC-TBPL model structure that was used to describe the morphine EEG amplitudes 
over time. kon is the second-order drug-target association rate constant. koff is the first-order drug-target dissociation rate 
constant. keo is the first-order distribution rate constant into and out of the effect compartment. Target occupancy is 
linearly related to the EEG amplitude. The distribution from plasma to the tissue compartments and the brain ECF 
compartment is described in Supplement S 1. The arrows indicate morphine flows, the dotted line indicates a direct 
relationship. 
 
Table 4. Parameter values and objective function values of the tested EC-TBPL models describing the EEG 
data based on plasma concentrations. CV denotes the coefficient of variation as percentage. OFV denotes 
the Objective Function Value, AIC denotes the Akaike Information Criterion. ω2 and σ2 denote the variances 






no Pgp effect 
EC-TBPL3 
Pgp on keo 
EC-TBPL4 
koff = 1 
EC-TBPL5 
slope = 0 
OFV 44790.9 44880.3 44873.8 45008.2 45235.3 
AIC 44808.9 44896.3 44891.8 45024.2 45251.3 
parameter Value (%CV) Value (%CV) Value (%CV) Value (%CV) Value (%CV) 
koff (/min) 0.0275 (14) 0.0243 (14) 0.0247 (14) 1 FIX 0.0400 (9) 
keo (/min) 0.0327 (17) 0.0365 (12) 0.0389 (14) 0.0162 (28) 0.036 (13) 
keo -Pgp (/min) - - 0.0265 (31) - - 
KD (nM) 1520 (34) 1150 (30) 1110 (30) 2110 (50) 3150 (36) 
KD -Pgp (nM) 296 (93) - - 385 (78) 594 (47) 
E0 (µV) 45.0 (4) 45.7 (4) 45.6 (4) 45.2 (4) 41.9 (4) 
Emax (µV) 31.8 (11) 30.7 (11) 30.5 (11) 34.4 (18) 37.3 (12) 
Rtot (nM) 1 FIX 1 FIX 1 FIX 1 FIX 1 FIX 
slope (µV/min) -0.0276 (15) -0.0296 (13) -0.0296 (13) -0.0273 (14) 0 FIX 
      
ω2 E0 (µV) 0.111 (20) 0.116 (20) 0.116 (20) 0.111 (19) 0.129 (18) 
      
σ2 proportional 0.057 (7) 0.0565 (7) 0.0565 (7) 0.0576 (7) 0.0597 (7) 
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ECECF, TBECF, IEECF and DEECF model fitting 
The last models that were fitted to the EEG data were based on the ECF concentrations instead of the 
plasma concentrations. Various model structures were tested, as shown in Figure 4. To compare the model 
fits based on ECF concentrations (ECECF1, TBECF1, IEECF1 and DEECF1) with the model fits that were based on 
plasma concentrations (ECPL, TBPL and EC-TBPL), the best plasma model (ECPL1) was fitted to the limited 
dataset that included only animals with ECF data. This model fit was compared to the ECF-based model fits 
on basis of their AICs, as shown in Table 5. 
 
Figure 4. Schematic representation of the ECECF, TBECF, IEECF and DEECF model structures that were used to describe the EEG 
data based on brain ECF concentrations. The different structures represent A) the DEECF model, B) the ECECF model, C) the 
TBECF model and D) the IEECF model, with ksyn being the zero-order effect generation rate constant, and kdeg being the first-
order effect degradation rate constant. The distribution from plasma to the tissue compartments and the brain ECF 






Table 5. Parameter values and objective function values of the tested models describing the EEG data based 
on ECF concentrations. CV denotes the coefficient of variation as percentage. OFV denotes the Objective 
Function Value, AIC denotes the Akaike Information Criterion. ω2 and σ2 denote the variances of the 
exponential IIV distribution and the proportional error distribution, respectively. 
 a This value was estimated as the maximal ksyn minus baseline ksyn (calculated from E0 and kdeg) and 
calculated by dividing the estimated value by the kdeg.                             
Of all the models that are described above, model ECPL1 has the lowest AIC. To evaluate its performance in 
more detail, the most relevant diagnostic plots are given in Figure S 6 to Figure S 10. These diagnostic plots 
indicate that the main trend of the data is captured, although the obtained fit is not optimal (which is 
especially clear from Figure S 10). The small difference in AIC between the best combined EC-TB model (EC-
TBPL1) and the best EC model (ECPL1) is also reflected by very similar VPC results, as shown in Figure S 11. 
Moreover, the best model with only binding from plasma(TBPL4) also provided a similar VPC result (see 
Figure S 12). 
Dose-dependency of TmaxTO in a TBPL model 
Our simulations of drug-target binding in a TBPL model for the range of the most relevant binding kinetics 
demonstrated that the observable influence of dose on TmaxTO, which discriminates the TB model from the 
EC model, is limited to a confined range of kon and koff combinations. As visualized in Figure 5, if the koff has a 
value around the elimination rate constant of 0.03/hr ∆TmaxTO is maximal. Also, the initial drug 
concentration C0 should not be above a specific threshold value which is approximately equal to the target 
concentration. The absolute ∆TmaxTO for different doses (as shown in Figure 5) will be most relevant for the 
identification of the dose-dependent ∆TmaxTO in a PKPD modelling study. However, for the understanding of 
the underlying determinants of this shift in ∆TmaxTO, the ratio of the ∆TmaxTO values belonging to the 2 
doses should also be considered, as shown in Figure 6. For example, if the two different TmaxTO values 
obtained from the two doses are 1 and 3 minutes, their ratio is 3, but the absolute difference is 2 minutes. If 
the two TmaxTO values are 1 and 3 hours, their ratio is still 3, but the difference is now 2 hours. In this latter 
case, the influence of the dose on the TmaxTO will be more easily identified. Representative example 
















OFV 25996.1 26284.1 26284.0 26255.1 26240.3 
AIC 26118.1 26300.1 26300.0 26273.1 26258.3 
parameter Value (%CV) Value (%CV) Value (%CV) Value (%CV) Value (%CV) 
k1e(/min) 0.0457 (35) - - - - 
keo(/min) 0.0377 (41) - - 0.161 (40) - 
k1e -Pgp (/min) 0.0647 (36) - - - - 
keo -Pgp (/min) 0.0155 (77) - - - - 
E0 (µV) 47.6 (6) 48.9 (6) 48.9 (6) 49.1 (6) 49.1 (6) 
Emax (µV) 27.5 (20) 32.7 (17) 23.4 (18) 24.9 (19) 25.4a (36) 
Emax –Pgp (µV) -  41.6 (14) 43.2 (15) 43.3 (42) 
EC50 (nM) 1100 (87) - 173 (22) 182 (26) 182 (25) 
NH 2.05 (49)  2.3 (41) 2.02 (43) 2.07 (43) 
slope (µV/min) -0.0235 (34) -0.0400 (17) -0.0359 (17) -0.0373 (19) -0.0377 (19) 
koff (/min) - 0.0932 (37) - - - 
KD - 283 (40) - - - 
KD -Pgp - 55.9 (15) - - - 
kdeg (/min)     0.124 (34) 
      
ω2 E0 (µV) 0.0668 0.0668 (26) 0.072 (25) 0.0696 (26) 0.0961 (26) 
      
σ2 proportional 0.0550 (10) 0.0598 (10) 0.0598 (10) 0.0593 (10) 0.059 (10) 
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Figure 5. Overview of the shift in TmaxTO that was observed in the simulations with the TBPL model (see 
upper-right corner) as a result of the change in the affinity-normalized dose (leading to an initial 
concentration of 5 and 0.5 times the KD). The elimination rate constant kel was 0.03/hr and the target 
concentration was 0.1 nM for all simulations in this figure. 
 
Figure 6. Overview of the ratio of TmaxTO values that was observed in the simulations with the TBPL model 
(see inset) as a result of the change in the affinity-normalized dose (leading to an initial concentration of 5 
and 0.5 times the KD). The elimination rate constant kel was 0.03/hr and the target concentration was 0.1 nM 
for all simulations in this figure. 
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Interestingly, the relationship between the ∆TmaxTO, the elimination rate constant, the target concentration 
and the dose could be approximated mathematically for the upper region, the lower-left region and the 
lower-right region of Figure 5 as presented in Supplement S 3. From this analysis, it follows that for the 
upper half of Figure 5, where the koff is much larger than the kel, TmaxTO is always small, and a significant 
∆TmaxTO will thus not be observed. For the lower and the lower-right part of Figure 5, where the koff is much 
smaller than the kel, it is found that TmaxTO does not depend on the dose. More specifically, when the initial 
drug concentration is much lower than the target concentration (and koff is smaller than kel), the TmaxTO is 
merely determined by the kel. On the other hand, when the initial drug concentration is much larger than 
the target concentration (and koff is smaller than kel), the TmaxTO is given by a relation between koff and kel. 
This relationship between the ∆TmaxTO, the elimination rate constant, the target concentration and the 
dose is illustrated in Figure 7. 
 
 
Figure 7. Overview of the ∆TmaxTO that was observed in the simulations as a result of the change in the 
affinity-normalized dose for different combinations of parameter values as indicated above the panels. All 
panels vary only one parameter compared to the upper left panel. 
 
Discussion 
In this study, we compared TB and EC models to describe the delay between morphine plasma 
concentrations and EEG effects for 3 different dose levels. We found that model discrimination was difficult 
to obtain and that selection of the best model (the ECPL model in this study) was only possible on basis of 
the objective function value differences. Moreover, our simulation study with the TBPL model showed that a 
shift in TmaxTO with increasing doses, the distinctive future of the TB model compared to the EC model, only 
occurs for a limited range in parameter values. Both a koff value much smaller and much larger than the kel 
value and a target concentration larger than the initial drug concentration decrease this shift in TmaxTO 
towards zero. 
Since our model simulations show that the TmaxTO does not depend on the dose for koff values much lower 
than the kel and target concentrations much higher than the initial drug concentration, this means that the 
TBPL model for these parameter values behaves like an ECPL model, with a first order increase and decrease 
in the concentration that is linked to the effect. Together with the small differences in EC and TB model fits 
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to the morphine EEG data, this shows that for many parameter combinations, a TB model gives rise to 
similar drug effect profiles as an EC model. This means that neither a successful fit of a TB or EC model 
necessarily supports the relevance of target binding or target site distribution, respectively, while a single 
successful fit is often presented as such support[11,23,39]. To obtain support for one of the two 
mechanisms, both models should be fitted to the data and compared on basis of objective metrics such as 
the AIC. This approach demonstrated the added value of the combined EC-TBPL model compared to the ECPL 
and the TBPL model for buprenorphine and AR-HO47108.[13,29] However, this method also demonstrated 
that the TBPL model performed similarly as the ECPL model for eight calcium antagonists[14] and that the EC 
model performed similarly as the EC-TBPL model for fentanyl [13]. This demonstrates that even if objective 
metrics are used, discrimination between two models is not always possible. Moreover, obtained model 
discrimination strictly informs on the data fit of each model, not directly on the plausibility of the 
represented mechanism. The TB model should be considered and tested more often as alternative to the EC 
model, as its parameters can be measured in vitro/ex vivo, which enables a better in vitro-in vivo 
extrapolation (IVIVE). 
In this study, we also found that the models based on brain ECF concentrations did not perform better than 
the models based on plasma concentrations. One would expect that the brain ECF concentrations would 
reflect the target site concentration better than the plasma concentrations, especially if brain distribution is 
relatively slow and nonlinear, as it was in this study. The inferior performance of the brain ECF-based 
models might be explained by the extremely high variability in the brain ECF data of the 4 mg/kg dose 
group, as shown in Figure S 5. However, a direct effect model (DEECF1) could be identified from the brain ECF 
concentrations and showed an only 39 points higher AIC than the best model IEECF1, while such a model fit 
could not be obtained from the plasma concentrations, indicating that the ECF concentrations reflect the 
target site concentration more closely compared to the plasma concentrations. This is in line with the 
relevance of drug concentrations in the brain for CNS effects that has been demonstrated by several other 
studies[40–43] and the difference between plasma and brain concentrations that has been identified for 
several compounds[44]. In all our target binding models, a linear target occupancy-effect relationship had to 
be assumed to keep the model parameters identifiable. Such a linear relationship has been observed and 
can be expected unless for full agonists in tissues with relatively high target concentrations compared to the 
concentration of signal transduction molecules (i.e. for a high receptor reserve).[24] 
Only a one compartment pharmacokinetic model was used in this study in combination with the simplest 
TBPL model to investigate the ∆TmaxTO. We expect that the same principles apply if the TBPL model has a 
two-compartment or three compartment pharmacokinetic models or with target turnover or signal 
transduction models, but the parameter range for which TmaxTO shifts with a change in dose might be 
different compared to the model used in our simulations. In analogy to Figure 7, for the combined EC-TB 
model one would expect that to obtain a significant ∆TmaxTO and to identify the TB model in addition to the 
EC model, the ke0 should be in the same order of magnitude as the koff if the maximal drug concentration is 
around or below the KD. This is indeed the case for the two successful examples of a EC-TBPL fit: for 
buprenorphine, the ke0 was 0.0242 min-1 and the koff was 0.0731 min-1[13] and for AR-HO47108, the ke0 was 
0.0351 for the drug and 0.00749 for its metabolite and the koff was 0.00303 min-1 and 0.00827 min-1, 
respectively[29]. On the other hand, the combined EC-TB model EC-TBPL1 that was identified in this study 
for morphine also showed a similar value for ke0 and koff (0.0327 and 0.275, respectively), but this model was 
not better than the EC model ECPL1. In comparison with our one compartment PK model with intravenous 
dosing, especially the absorption or the distribution phase into the target site could pose additional limiting 
factors that prevent a shift in TmaxTO with increasing doses. 
One of the most important advantages of the EC model is that it only requires one parameter, ke0. However, 
the EC model most often needs to be combined with an Emax model, which also requires two or three 
parameters, Emax, EC50 and possibly the hill factor. The binding model has 3 parameters, kon, koff and Rtot, 
and needs at least 1 additional parameter, Emax, to convert occupancy predictions to effect predictions. 
One or two additional parameters might be required to describe a nonlinear target occupancy-effect 
relationship, which is required in case of a high efficacy and receptor reserve[24]. The discrimination 
between the two nonlinearities in such cases might be hard or impossible to obtain. However, kon and koff 
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can be obtained from in vitro experiments and Rtot from ex vivo experiments. Especially the identification of 
Rtot from ex vivo data can help to reduce the difficulties with parameter identifiability as often associated 
with the TB model [45].  
In summary, the limited difference between TB and EC models should be taken into account in the 
evaluation of historical and the design of new modelling studies. By informing the TB models with in vitro 
data, TB models can help to translate between in vitro and in vivo studies. The combination of parameter 
values for which the TmaxTO in the target binding model is dependent on the dose is limited to koff values 
around the elimination rate constant and to target concentrations lower than the initial drug concentration. 
Although the combination of multi-compartment PK models, TB models and target turnover models might 
affect the parameter range were the TmaxTO is dependent on the dose, our study is a first indication that 
such limitations should be taken into account for understanding TB models. 
Conclusion 
In this study, we have shown that successful fitting of a TB or EC model is not enough support to assume the 
relevance of target binding or target site distribution. Moreover, we have shown for a one-compartment 
pharmacokinetic model with target binding that the ∆TmaxTO for changing doses can only be identified if the 
koff has a value around the pharmacokinetic elimination rate constant and the target concentration is lower 
than the initial drug concentration. We have thus identified that the TmaxTO is determined by the rate of 
target binding relative to the decline rate of unbound drug and unbound target concentrations. Our findings 
indicate that the relatively sparse occurrence of target binding models in literature does not discredit the 
relevance of target binding kinetics. Our study also shows that a TB and EC model might be similar for the 
tested dose range and pharmacokinetic conditions, while extrapolation to different conditions might result 
in different effect versus time profiles for the TB and EC model. We conclude that identification of the 
appropriate model is important and that target binding models should be tested more often to increase the 
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Supplement S 1. Morphine PK and PD model fits, GOF plots and VPCs 
Plasma concentration modelling 
A three-compartment model (Figure S 1) was identified as the best model with respect to the AIC and the 
individual fits. The goodness of fit of this model is illustrated in Figure S 2 and Figure S 3. 
  
Figure S 1. Schematic representation of the three-compartment model structure that was used to describe the morphine 
plasma concentrations over time. 
The differential equations of the model in Figure S 1 are given in equations 1-3. In these equations, Ac, A2 
and A3 represent the amount of drug in the central, second and third compartment, respectively. kel k12, k21 
k13 and k31 represent the first order rate constants of elimination and distribution between the 
compartments. The relation between the parameters in equations 1-3 and the estimated parameters as 
given in Table S 1 is shown in equation 4-8. Vc, V2 and V3 represent the volumes of the respective 
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The goodness of fit of this model is illustrated in Figure S 2 and Figure S 3. Inter individual variability (IIV) 
was estimated for 4 of the estimated model parameters. Attempts to add IIV on more parameters resulted 
in a failing covariance step while the drop in OFV was limited (9 points). Comparison to the 2-compartment 
model with the lowest OFV value that was tested demonstrated better individual fits and a 109-points lower 
OFV for the 3-compartment model. 
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Figure S 2. Diagnostic plots of the plasma concentration fits. Left panel: Overview of observed (dots) and predicted (lines) 
concentrations. Upper panel labels indicate the dose in mg/kg and lower panel labels the presence (1) or absence (0) of 
Pgp inhibitor GF120918. Right panel: relation between observed and individual predicted plasma concentrations on a 
double logarithmic scale. 
 
Figure S 3. Individual profiles of observed (dots) and predicted (lines) concentrations on a semi-logarithmic scale. Panel 
labels indicate the animal ID number.  
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Table S 1. Parameter values and objective function values of the tested models for the plasma 
concentrations. CV denotes the coefficient of variation as percentage. OFV denotes the Objective Function 
Value. ω2 and σ2 denote the variances of the exponential IIV distribution and the error distribution, 
respectively. 
 2-cmp model 3-cmp model 
4 IIV parameters 
3-cmp model  
5 IIV parameters 
OFV 9314 9205 9194 
parameter Value (CV) Value (CV) Value (CV) 
CL (L/min) 0.0300 (8) 0.028 (22) 0.028 
V1 (L) 0.200 (11) 0.17 (49) 0.12 
Q12 (L/min) 0.0432 (10) 0.019 (66) 0.056 
V2 (L) 1.15 (10) 1.3 (48) 0.51* 
Q13 (L/min) - 0.031 (30) 0.020 
V3 (L) - 0.36 (32) 1.4* 
    
ω2 CL 0.34 (23) 0.33 (25) 0.35 
ω2 V1 0.55 (27) 0.63 (35) 0.15 
ω2 Q12 0.28 (39) 0.62 (33) 0.72 
ω2 V2 0.32 (31) 0.66 (28) 0 FIX 
ω2 Q13   0.79 
ω2 V3   0.57 
    
σ2 proportional 0.0766 (15) 0.79 (14) 0.071 
σ2 additive 1710 (28) 0 FIX 7.2 
* To get the best model fit, V2 and V3 were estimated here as the ratio of V2 and V1 and the ratio of V3 and 
V2, respectively. The displayed values in this table are derived from the estimated ratios. CV = coefficient of 
variation as percentage. 
ECF concentration modelling 
Various structural models were tested for the description of the ECF concentrations, including a two-
compartent model (ECF and “deep brain”) and a target binding model (ECF-unbound and ECF bound). The 
best combination of OFV, parameter estimate uncertainty and diagnostic plots was obtained with the 
original one compartment ECF model, with passive first-order in- and outward distribution, saturable influx 
and first-order efflux (Figure S 4). As the parameters for the plasma concentrations were fixed, the only 
additional equation is given in equation 9, in which AECF and VECF refer to the amount and volume of the ECF 
compartment, respectively, kdiff and keff represent first order influx and efflux rate constants, Nmax 
represents the maximal saturable influx rate and C50 is the plasma concentration at which the saturable 
























Figure S 4. Schematic representation of the model structure that was used to describe the morphine ECF concentrations 
over time. kdiff  = first-order in- and outward distribution rate constant. keff first-order efflux rate constant. Nmax = zero-
order maximal saturable influx rate constant. 
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Different versions of this model were tested in which the inter-individual variability was tested on different 
parameters and the influence of Pgp was estimated. Estimating the influence of Pgp did not reduce the OFV 
enough, so the final model did not include the influence of Pgp and had IIV estimated for kdiff and Nmax. The 
diagnostic plots for the evaluation of the fit of this model is given in Figure S 5. 
Table S 2. Parameter values and objective function values of the tested models for the ECF concentrations. 
CV denotes the coefficient of variation as percentage. OFV denotes the Objective Function Value. ω2 and σ2 
denote the variances of the exponential IIV distribution and the error distribution, respectively. 
 IIV on kdiff, Nmax IIV on kdiff, keff IIV on kdiff, keff 
Pgp on Nmax 
IIV on kdiff, Nmax 
Pgp on Nmax 
OFV -1126 -1096 -1104 -1128 
parameter Value (CV) Value (CV) Value (CV) Value (CV) 
kdiff(/min) 0.0025 (17) 0.0027 (19) 0.0027 (17) 0.0025 (16) 
keff(/min) 0.020 (11) 0.021 (20) 0.0213 (24) 0.019 (12) 
Nmax (nM/min) 2.6 (21) 3.0 (38) 2.2 (34) 2.2 (29) 
NmaxPgp (nM/min) - - 4.45 (52) 3.15 (28) 
     
ω2 kdiff 0.36 (39) 0.44 (47) 0.44 (45) 0.35 (39) 
ω2 keff 0 FIX 0.35 (108) 0.31 (71) 0 FIX 
ω2 Nmax 0.42 (55) 0 FIX 0 FIX 0.39 (52) 
     
σ2 proportional 0.11 (18) 0.11 (22) 0.11 (22) 0.11 (20) 
 
 
Figure S 5. Diagnostic plots of the ECF concentration fits. Left panel: Overview of observed (dots) and predicted (lines) 
concentrations. lower panel labels indicate the dose in mg/kg and upper panel labels the presence (1) or absence (0) of 
Pgp inhibitor GF120918. Right panel: relation between observed and individual predicted plasma concentrations on a 
double logarithmic scale. 
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EEG effect modelling 
Model equations, Goodness of fit and VPC for model ECPL1 
The model equations for the connection between plasma concentrations and EEG effect are given in 
equations 10-12, where ATRANS and VTRANS refer to the amount of drug and the volume of the transit 
compartment, AEFF and VEFF refer to the amount of drug and the volume of the effect compartment k1e and 
ke0 refer to the first order distribution rate constants into and out of the transit and effect compartment, E0 
is the baseline EEG amplitude, slope is the linear change of the EEG amplitude during the experiment 
without morphine treatment, Emax is the maximal increase in EEG amplitude due to morphine, NH is the hill 
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12. 𝐸𝑓𝑓𝑒𝑐𝑡 (𝐸𝐸𝐺 𝑎𝑚𝑝𝑙𝑖𝑡𝑢𝑑𝑒) =  𝐸0 + 𝑠𝑙𝑜𝑝𝑒 ∗ 𝑡 + 















Figure S 6. Population (right panels) and individual (left panels) observed versus predicted EEG data as obtained from the 
model fit of model ECPL1. The upper panels have a linear scale and the lower panels have a logarithmic scale. 
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Figure S 7. Conditional weighted residuals versus time for the different dose groups and dose group combinations in the 
model fit of ECPL1. The top labels indicate the morphine dose in mg/kg. The side labels indicate the absence (0) or presence 
(1) of Pgp inhibitor GF120918. The columns and rows indicated with (all) display the combination of all dose groups or all 
Pgp inhibitor groups, respectively. 
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Figure S 8. Conditional weighted residuals versus observed EEG amplitudes. for the different dose groups and dose group 
combinations in the model fit of ECPL1. The top labels indicate the morphine dose in mg/kg. The side labels indicate the 
absence (0) or presence (1) of Pgp inhibitor GF120918. The columns and row indicated with (all) display the combination of 
all dose groups or all Pgp inhibitor groups, respectively. 
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Figure S 9. Individual model fits of model ECPL1 to the EEG data. The colors represent the different dose groups. Dots 
represent the observations, lines the model predictions. 
 
Figure S 10. Visual predictive check of the model fit of model ECPL1. The upper labels indicate the absence (0) or presence 
(1) of Pgp inhibitor GF120918. The lower labels indicate the morphine dose in mg/kg. The solid lines represent the 
observed 5%, 50% and 95% quantiles of the data. The dashed lines represent the median of the 5%, 50% and 95% 
quantiles of the simulated datasets. The shaded areas represent the 5%-95% percent interval of the 5%, 50% and 95% 
quantiles of the simulated datasets. 
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Model equations and VPC for model EC-TBPL1  
The model equations for the EC-TBPL model are provided in equations 13-15. In these equations, AEFF and 
VEFF refer to the amount and volume of the effect compartment, respectively. ARL and VRL refer to the 
amount and volume of the drug-target complex compartment, respectively. ARtot and VRtot refer to the 
amount and volume of the bound plus unbound target compartment, respectively. The rate constants ke0 
and koff are first order rate constants of distribution and dissociation, respectively. kon is the second order 
association rate constant. E0 is the baseline EEG amplitude, slope is the linear decline of the EEG amplitude 
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15. 𝐸𝑓𝑓𝑒𝑐𝑡 (𝐸𝐸𝐺 𝑎𝑚𝑝𝑙𝑖𝑡𝑢𝑑𝑒) =  𝐸0 + 𝑠𝑙𝑜𝑝𝑒 ∗ 𝑡 + 








Figure S 11. Visual predictive check of the model fit of model EC-TBPL1. The upper labels indicate the absence (0) or 
presence (1) of Pgp inhibitor GF120918. The lower labels indicate the morphine dose in mg/kg. The solid lines represent 
the observed 5%, 50% and 95% quantiles of the data. The dashed lines represent the median of the 5%, 50% and 95% 
quantiles of the simulated datasets. 
Model equations and VPC for model TBPL4 
The model equations for the combined TBPL model are provided in equations 16 and 17. In these equations, 
ARL and VRL refer to the amount and volume of the drug-target complex compartment, respectively. ARtot and 
VRtot refer to the amount and volume of the bound plus unbound target compartment, respectively. The rate 
constants koff is the first order rate constants of drug-target dissociation. kon is the second order association 
rate constant. E0 is the baseline EEG amplitude, slope is the linear decline of the EEG amplitude per time 
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17. 𝐸𝑓𝑓𝑒𝑐𝑡 (𝐸𝐸𝐺 𝑎𝑚𝑝𝑙𝑖𝑡𝑢𝑑𝑒) =  𝐸0 + 𝑠𝑙𝑜𝑝𝑒 ∗ 𝑡 + 









Figure S 12. Visual predictive check of the model fit of model TBPL4. The upper labels indicate the absence (0) or presence 
(1) of Pgp inhibitor GF120918. The lower labels indicate the morphine dose in mg/kg. The solid lines represent the 
observed 5%, 50% and 95% quantiles of the data. The dashed lines represent the median of the 5%, 50% and 95% 
quantiles of the simulated datasets. 
Supplement S 2. Dose-dependency of TmaxTO in a TBPL. 
To obtain a better understanding of the influence of dose on the TmaxTO in a TBPL model, some of the 
underlying simulations for Figure 5 are shown in this section. In Figure S 13, the simulation with the lowest 
values of kon and koff is showing that in this situation, the TmaxTO has a high value, but also that there is no 
difference between the two doses. This can be understood by comparing the rate of equilibration in a 
situation with a constant ligand concentration with the rate of elimination. 
The rate of equilibration (kobs) for  a constant ligand concentration [L] can be calculated by equation 1 [46]: 
kobs = kon * [L] + koff              (1) 
Since the ligand concentration in our simulations is normalized for the value of KD, equation 1 can be 
rewritten as equation 2, in which c is the ratio [L]/KD: 
kobs = kon * c * koff/kon  + koff = koff*(c + 1)                                 (2) 
From equation 2, it can be observed that a low value of koff leads to slow equilibration, unless the ligand 
concentration is much higher than the affinity. If the equilibration rate is slow, the TmaxTO is mainly 
determined by the elimination rate constant, which is independent on the dose/ligand concentration. Thus, 




Figure S 13. Simulation of drug target binding for two different doses. The solid lines indicate plasma concentrations for 
the high (dark grey line) dose and the low (light grey line) dose. The dashed lines indicate target-bound drug 
concentrations. The vertical dotted lines indicate the time point of the maximal target-bound concentration for each dose. 
In this simulation, the elimination rate constant kel was 0.03/hr and the target concentration was 0.1 nM. The initial 
concentrations for the high and the low dose corresponded to 5 and 0.5 times the KD, respectively. The kon and koff values 
were 0.001 nM-1 h-1 and 0.001 h-1, respectively, representing the area of Figure 5 that is indicated with the square in the 
right panel. 
A high value of koff gives rise to fast equilibration and a significant influence of the dose on the equilibration 
time, because equilibration is now much faster than elimination, and thus determining the TmaxTO. 
However, because of the fast equilibration, the decrease in TmaxTO with increasing doses is difficult to 
detect because all TmaxTO values are low, and the absolute difference is low as well, as illustrated in Figure S 
14. 
 
Figure S 14. Simulation of drug target binding for two different doses. The solid lines indicate plasma concentrations for 
the high (dark grey line) dose and the low (light grey line) dose. The dashed lines indicate target-bound drug 
concentrations. The vertical dotted lines indicate the time point of the maximal target-bound concentration for each dose. 
In this simulation, the elimination rate constant kel was 0.03/hr and the target concentration was 0.1 nM. The initial 
concentrations for the high and the low dose corresponded to 5 and 0.5 times the KD, respectively. The kon and koff values 
were 0.0032 nM-1 h-1 and 10 h-1, respectively, representing the area of Figure 5 that is indicated with the square in the 
right panel. 
A low value of the KD (and therefore a low dose) will also lead to a difference in TmaxTO which is negligibly 
small or sometimes even negative (i.e. the highest dose leads to the highest TmaxTO value). In this area the 
assumption of a constant ligand concentration does not hold anymore, even when there is no elimination of 
the drug. This is caused by the depletion of ligand as a result of drug-target binding. When the ligand 
concentration is much lower than the target concentration, the equilibration rate can now be approximated 
by assuming the target concentration (Rtot) is constant, according to equation 3: 
kobs = kon * [Rtot] + koff                   (3) 
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From equation 3, it should be observed that there is no influence of the ligand concentration any more, and 
therefore the dose does not influence the TmaxTO anymore. The small band in Figure 5 where the difference 
in TmaxTO values is negative can be explained by the situation where the lowest dose has the same target 
concentration and drug concentration. In this case, both the target and the drug concentration decline upon 
drug-target binding and equilibration is twice as fast compared to the situation with a constant target or 
ligand concentration. This can make the equilibration of the lowest dose faster than that of the highest 
dose. An example of such a situation is shown Figure S 15.  
 
Figure S 15. Simulation of drug target binding for two different doses. The solid lines indicate plasma concentrations for 
the high (dark grey line) dose and the low (light grey line) dose. The dashed lines indicate target-bound drug 
concentrations. The vertical dotted lines indicate the time point of the maximal target-bound concentration for each dose. 
In this simulation, the elimination rate constant kel was 0.03/hr and the target concentration was 0.1 nM. The initial 
concentrations for the high and the low dose corresponded to 5 and 0.5 times the KD, respectively. The kon and koff values 
were 3.2 nM-1 h-1 and 0.032 h-1, respectively, representing the area of Figure 5 that is indicated with the yellow square in 
the right panel. 
To observe a change in TmaxTO, it follows from the previous examples that the value of koff should be low 
enough to make the change in TmaxTO observable, but it should not be so low that the elimination of the 
drug determines the TmaxTO. Moreover, the initial concentration of the drug should not be lower than the 
target concentration. An example of such a situation is given in Figure S 16. Additionally, the lines koff = 
kel/(c+1) and KD = Rtot/(c+1) align reasonably well with the middle and the diagonal end of the area where 
TmaxTO is most significant, where c represents the initial concentration/KD ratio for the lowest dose as 
shown in Figure S 17. 
 
Figure S 16. Simulation of drug target binding for two different doses. The solid lines indicate plasma concentrations for 
the high (dark grey) dose and the low (light grey) dose. The dashed lines indicate target-bound drug concentrations. The 
vertical dotted lines indicate the time point of the maximal target-bound concentration for each dose. In this simulation, 
the elimination rate constant kel was 0.03/hr and the target concentration was 0.1 nM. The initial concentrations for the 
high and the low dose corresponded to 5 and 0.5 times the KD, respectively. The kon and koff values were 0.001 nM-1 h-1 and 
0.032 h-1, respectively, representing the area of Figure 5 that is indicated with the yellow square in the right panel. 
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Figure S 17. Overview of the ∆TmaxTO that was observed in the simulations as a result of the change in the affinity-
normalized dose for different combinations of parameter values as indicated above the panels. All panels vary only one 
parameter compared to the upper left panel. The horizontal and diagonal lines represent the equations koff = kel/(c+1) and 






Supplement S 3. Asymptotic analysis of TOTmax  and its dependency on the dose. 
 
1 One compartment model with drug-target binding 
 








offon   
 where 
  
    • L  is the drug concentration,  
    • R  is the free receptor concentration,  
    • B  is the concentration of bound complex of L  and R : ][LR ,  
    • onk  is the rate constant at which L  binds to free receptors, 
    • offk  is the rate constant at which L  unbinds, 
    • elk  is the elimination rate constant.  
  
Now, we use that the total receptor concentration is described by totR  so that totRBR = , 








offtoton   









offontoton   (1.1) 
 






cL ==(0)  and 
0=(0)B . 
 The aim of this analysis is to determine the value of t  where B  attains a maximum for 
general c . We denote this maximum by )(cTmaxTO . Furthermore, the interest is to determine 
the difference in )(cTmaxTO  for two (different) values of c . More specifically for 1= cc  and 
2= cc  where 12 > cc , we want to determine )()( 12 cTmaxcTmax TOTO  . 
 
2.  Rescaling the system 
In order to be able to analyse system (1.1), we rescale it by using the fact that both L  and B  
can maximally reach certain concentrations. From the initial conditions it follows that the drug 






ccKL ==(0) . Also, the bound complex is limited by the 
total receptor concentration totR . This suggests to rescale L  with DcK  and B  with totR , and 

















off   (2.1) 
 
with 1=(0)u  and 0=(0)v . In this system u  corresponds to L  and v  to B . 
 Next, we study system (2.1) in different parameter regions and determine the value of 
t  for which v  attains a maximum.We use the different sets of coefficients present in system 
(2.1) to determine the various regions. In these regions, we use asymptotic analysis to determine 
an asymptotic expansion for v  from which we determine the leading order of )(cTmaxTO . 
To define the regions, we look at the groups of parameters present in system (2.1) and 
set them to be equal. This gives us the following lines   
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 eloff kck =  
 eloff kk =  




ck totonoff =  (2.2) 
 eltoton kRk =  
 .= eltoton ckRk  
 
In the following analysis, we assume that c  is of order 1, hence (1)= Oc , then we 
define various regions   
 Dtoteloff KRandkckI )(=. O  
 Dtotoffel KRandkkII .  
 Dtoteloff KRandkkIII .  
 Dtotoffel KRandkkIV .  
 .. Dtoteloff KRandkkV   
 
Note that since (1)= Oc , not all the lines in (2.2) are needed when defining these 






Figure S18: Sketch of the different regions in the ),( offon kk -plane and the lines eloff kk =  and 
Dtot KR =  for 1>c . 
  
  
In these regions, we can find an asymptotic expression for v  and determine the leading 
order expression for TOTmax . Here, we summarise the results. 
 
In region I , we find that TOTmax  must satisfy an implicit relation depending on the different 






























































































 Note that we denote with log  the natural logarithm, ln . 
Hence, we find that when eloff kk   (in regions III and V) that TOTmax   does not 
depend on c , and therefore, is independent of the dosis, to leading order. For eloff kk   (in 
regions II and IV), we find from the above expressions that  TOTmax  is small, and so the 
dependence on the dose does also not play a role. 
Note that the above results are not true for 1c . We briefly study that case in 
section 5. 
To show how we obtain the above results, we give the details of the asymptotic analysis 
in two of the regions in the next sections. 
 
3.  The analysis in region III 
We choose the parameters to lie in region III such that Dtot KR   and eloff kk  . Then, we 

































= . From the choice of the relation between the parameters, 
we find that 1  . Now, we assume the following asymptotic expansions for u  and v    
 ,= 01100 termsorderhigheruuuu    
 .= 01100 termsorderhighervvvv    
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 And, from the initial conditions for system (2.1), it follows that 0=(0)1,=(0)0 ijuu , 
0=(0)ijv  for all ji, . 
In the following we assume that   and 2  are not of the same order. Next, we 
substitute the above expansions into system (3.1), collect terms at different orders and solve the 
corresponding equations at each level. 














 This can be solved and, together with the initial conditions, this leads to 0=0v  and 
eu =0 . 





















Together with the initial conditions, this gives 0=10u  and 
ev 1=10 . Since this 10v  does 
not attain a maximum, we need to determine higher order terms in the expansion of v . 

















which yields 0=01v . It turns out we don’t need 01u  to determine TOTmax  so we refrain from 
giving that here. 
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 From this, we find  














Since we do not need 20u  for further analysis, we also do not give that here. 





















)(1=)( 22  
to leading order. Using this expression, we can obtain a leading order expression for TOTmax . 
Differentiating we find  




















Setting this expression to zero, we can find TOTmax  from a balance between the first and the 
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c

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Rescaling back to original variables and parameters, we obtain  










Tmax   
4.  The analysis in region V 
 
In this section, we choose the parameters to lie in region V such that eloff kk   and 
































= . From the choice of the relation between the parameters, 
we find that 1  . Now, we assume the following asymptotic expansions for u  and v   
  
 ,= 10010 termsorderhigheruuuu    
 .= 10010 termsorderhighervvvv    
 
From the initial conditions for system (2.1), it follows that 0=(0)1,=(0)0 ijuu , 0=(0)ijv  for 
all ji, . 
In the following we assume that 
2  and   are not of the same order. Next, we 
substitute the above expansions into system (4.1), collect terms at different orders and solve the 
corresponding equations at each level. 

















This can be solved and, together with the initial conditions, this leads to 0=0v  and 
eu =0 . 
















which yields 0=01v . Solving for 01u  leads to  
                    .=01
  eu  
 























Together with the initial conditions, this gives 
ev 1=10 . We do not give 10u  since we will 
not need it in the further analysis. Again, 10v  does not attain maximum, and therefore, we need 
higher order terms in the expansion of v . 












 .=   e  
Hence,  
                     1,1)(=11 
 ev  
and the expansion for v  reads  
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                        ,1)1)((1=     eev  
to leading order. Differentiating leads to  






which becomes zero when  





Rescaling back to original variables and parameters, we obtain  












5.  The case when 1c . 
 
Next, we briefly look at the case when 1c . Then, the results are different from before. One 
essential difference is that the regions now depend on c  where 1c . 
We will only give results for region I . Note that this region shifts down in the 
),( offon kk -plane compared to before. 
We do still find that TOTmax  must satisfy an implicit relation depending on the 
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Chapter 8. In vitro and in silico analysis of the influence of D2 antagonist target binding kinetics 
on the cellular response to fluctuating dopamine concentrations 
 
Wilhelmus E. A. de Witte1, Joost W. Versfelt1, Maria Kuzikov2, Solene Rolland3, Victoria Georgi3, Philip Gribbon2, Sheraz 
Gul2, Dymphy Huntjens4, Piet Hein van der Graaf1,5, Meindert Danhof1, Amaury Fernández-Montalván3, Gesa Witt2, 
Elizabeth C. M. de Lange1*. 
1 Division of Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, 2333 CC Leiden, The 
Netherlands 
2 Fraunhofer Institute for Molecular Biology and Applied Ecology, ScreeningPort, Hamburg, Germany 
3 Bayer Healthcare Pharmaceuticals, Global Drug Discovery, Berlin, Germany 
4 Janssen R&D, Janssen Pharmaceutica, Beerse, Belgium 
5 Certara Quantitative Systems Pharmacology, Canterbury Innovation Centre, Canterbury CT2 7FG, United Kingdom 
* Correspondence: ecmdelange@lacdr.leidenuniv.nl  
 





Target binding kinetics can influence the time course of the drug effect (pharmacodynamics) both I) directly, 
by affecting the time course of target occupancy, driven by the pharmacokinetics of the drug, competition 
with endogenous ligands and target turnover, and II) indirectly, by affecting signal transduction and 
homeostatic feedback at the cellular and systems level. For dopamine D2 antagonists, it has been 
hypothesized that fast receptor binding kinetics cause fewer side effects, because part of the dynamics of 
the dopaminergic system is preserved by displacement of these antagonists.  
Methods 
Target binding kinetics of D2 antagonists and agonists and signal transduction after dopamine and D2 
antagonist exposure were measured in vitro. These data were integrated by mechanistic modeling, taking 
into account competitive binding of endogenous dopamine and the antagonist, the turnover of the second 
messenger cyclic adenosine monophosphate (cAMP), and negative feedback by phosphodiesterase 
turnover. 
Results 
The proposed signal transduction model successfully described the cellular cAMP response for 17 D2 
antagonists with widely different binding kinetics. Simulation of the response to fluctuating dopamine 
concentrations revealed that a significant effect of the target binding kinetics on the dynamics of the 
signaling only occurs at endogenous dopamine concentration fluctuations with frequencies below 1/min.  
Conclusion 
Signal transduction and feedback are important determinants of the time course of drug effects. The 
influence of the D2 antagonist dissociation rate constant (koff) is limited to the maximal rate of fluctuations in 












Abbreviations: cAMP: cyclic adenosine monophosphate, DMR: Dynamic Mass Redistribution, 




The potential influence of drug-target association and dissociation kinetics on the time course of drug 
effects (pharmacodynamics) has led to an increasing interest in the use of binding kinetic parameters as a 
criterion in the selection of drug candidates.[1–6] Although the influence of binding kinetics on the time 
course of target occupancy has been studied, its exact role in the complex relation between drug dosing and 
drug effect is potentially complex and not completely understood.[7,8]  
Under distinct circumstances, target binding kinetics can influence the pharmacodynamics directly by 
affecting the time course of the target occupancy.  To what extent this occurs depends on values of the rate 
constants of target association(kon) and dissociation(koff), relative to the pharmacokinetic rate constants 
characterizing the rates of tissue distribution and elimination. In this regard, additional factors to be taken 
into consideration are the rate constants characterizing the turnover of the target and the competition with 
endogenous target ligands. In addition to these direct effects of target binding on the pharmacodynamics, 
variation in kon and koff can also indirectly influence the pharmacodynamics via signal transduction and 
homeostatic feedback mechanisms, both at the cellular and the systems level.[7–11]  The possible influence 
of the drug-target dissociation rate constant (koff) on signal transduction has been suggested previously, 
based on observed in vitro efficacy measurements that correlated with koff, but not with the equilibrium 
dissociation constant KD.[12,13]  
One target for which the influence of drug-target binding kinetics on in vivo drug effects is thought to be 
relevant is the dopamine D2 receptor. Almost two decades ago, the influence of drug-target binding kinetics 
on the safety of dopamine D2 antagonists has been suggested, based on the correlation between low values 
of koff and the lack of typical side effects, such as extrapyramidal symptoms (i.e. atypicality).[14] This 
observation led to the hypothesis that quickly dissociating antagonists induce less side effects by allowing 
displacement from the receptor by  fluctuating dopamine concentrations and thus preserving part of the 
dopamine dynamics, which we will refer to as the “fast-off hypothesis” in this study.[15–18] To understand 
the influence of dopamine D2 antagonist binding kinetics on their efficacy and safety, it should be noted that 
the fluctuations in dopamine concentrations occur at various time scales, ranging from hours to 
microseconds.[16,19,20] The influence of these target binding kinetics needs to be studied in comparison to 
dopamine fluctuations at all these time scales. 
The dopamine D2 receptor belongs to the class of inhibitory G-protein coupled receptors (GPCRs). Thus, 
receptor activation is known to inhibit cAMP production and cAMP in turn is known to stimulate active PDE 
production, while active PDE stimulates degradation of cAMP. Moreover, GPCR receptor activation can lead 
to receptor phosphorylation and desensitization as described quantitatively for the β2-Adrenergic 
receptor.[21] The production of cAMP is thus regulated by a negative feedback loop, which is a common 
feature in signal transduction pathways[22]. 
In this respect, it should be noted that the distinction between agonists and antagonist is often based on 
historical data and does not always take into account the classification of partial agonists and inverse 
agonists. One example of this is the study in which Remoxipride was introduced as D2 antagonist based on 
its in vivo antidopaminergic action and the lack of in vitro adenylyl cyclase inhibition in rat striatum 
homogenate. [23] This study does not report the possibility of adenylyl cyclase stimulation, and inverse 
agonism is thus not excluded. Moreover, the occurrence of inverse agonism and partial agonism can be 
influenced by the experimental system and cannot directly be translated across systems. Many D2 binding 
drugs that have initially been classified as antagonist have been reported to function as inverse 
agonists.[24,25] For convenience, we only apply the terms agonist and antagonist in this study, but we 
assume that the antagonists can have inverse agonistic activities. 
In this study, in vitro and in silico methods were combined to elucidate the influence of D2 antagonist target 
binding kinetics on the cellular response to fluctuating dopamine concentrations and to investigate the fast-
off hypothesis. Firstly, experimental methods were developed to quantify the binding kinetics of D2 agonists 
and antagonists to investigate if the binding kinetics were different for these two types of D2 ligands. 
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Secondly, to investigate the fast-off hypothesis with respect to the competition between antagonists and 
dopamine, the cellular response kinetics after subsequent exposure to dopamine and D2 receptor 
antagonists with varying binding kinetics at different levels of the signaling pathway were measured. A 
minimal mechanistic model combining D2 receptor binding kinetics, D2 receptor turnover, cAMP and active 
PDE turnover was established to describe cAMP concentration versus time curves in response to D2 
antagonist exposure. Thirdly, the model was used to identify the role of binding kinetics on drug effect for 
fluctuating dopamine concentrations. The physiological range of dopamine fluctuation time scales was 
taken into account by using a frequency response analysis [22,26]. For a more general insight in the 
influence of binding kinetics on signal transduction, this analysis was expanded to a range of hypothetical 
turnover rates of cAMP and active PDE. 
Methods 
This study consists of three parts:  
I) In vitro measurements of target binding and signal transduction kinetics: drug-target binding parameters 
of 17 dopamine D2 antagonists and 12 agonists were measured at room temperature (RT) and at 37°C. Only 
for the antagonists, the in vitro response after dopamine pre-incubation was measured for two different 
biomarkers: cAMP concentrations over time as second messenger and Dynamic Mass Redistribution (DMR) 
as a composite signaling marker.  
II) Model-based analysis of the in vitro cAMP antagonist response curves: A minimal mechanistic model 
was developed to describe the cAMP responses of the antagonists, based on the target binding kinetics as 
determined in part I).  
III) Frequency Response Analysis: Simulations of the predicted in vivo response to fluctuating dopamine 
concentrations: The mechanistic model was used to simulate the cAMP response to dopamine 
concentrations that fluctuate according to a sine-wave pattern with a range of physiologically relevant 
frequencies between 2 * 10-6 min-1 and 7 min-1. The fluctuation amplitude of cAMP, compared to dopamine, 
was used to summarize the cAMP response. 
I) In vitro measurements of target binding and signal transduction kinetics 
Equilibrium and Kinetic Probe Competition Assay (ePCA and kPCA) 
Affinity and kinetic binding parameters for the 17 studied antagonists and the additional 12 agonists (see 
Table 1) were measured with a homogeneous time-resolved fluorescence energy transfer (TR-FRET) method 
as previously described for the Histamine H1 and the GnRH receptors [27,28]. In this study, Tag-lite® 
Dopamine D2 labeled cells and a poly-3-phenylhydrazone thiophene (PPHT)-based Dopamine D2 receptor 
red antagonist Fluorescent Ligand (both from Cisbio, Codolet, France) were used as receptor-tracer pair to 
be competed with unlabeled test compounds (Tocris bioscience, TRC, Sigma-Aldrich, Biotrend Chemicals AG 
or provided by Janssen). Briefly, frozen cells containing the terbium (Tb2+) labeled D2 receptor, were thawed, 
spun down and re-suspended in Tag-lite® buffer (Cisbio, Codolet, France) to the concentration indicated by 
the manufacturer and dispensed into Greiner black small volume 384-well microtiter plates already 
containing the fluorescent tracer (10 nM end concentration) and the test compounds 
(antagonists/agonists). These compounds were diluted and transferred to the test plates following the 
procedures described previously [27].  
Starting concentrations of the D2 antagonist/agonist dilution series were adapted according to their 
expected affinity, in order to cover a meaningful dose range (see Figure S 1). The ePCA and kPCA 
experiments as described above were performed at RT and 37°C, for which steady state assay plates were 
kept in standard tissue culture incubators, whereas for kinetic assays the temperature control function of 
the PHERAstar FSTM microtiter plate reader was used. For ePCA, tracer and D2 labeled cells were dispensed 
to the ready-to-use compound plates to a final volume of 5 µL, and the mixture was incubated for 1-2 h 
prior to acquisition of the steady state TR-FRET ratiometric signals (665/620 nm) upon excitation at 337 nm. 
Normalized values were fitted to a logistic 4-parameter model using the Genedata ScreenerTM software, and 
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Ki values calculated using the Cheng-Prusoff relationship [29]. For kPCA, the tracer was dispensed to the 
ready-to-use compound plates prior to introducing them into the PHERAstar FSTM microtiter plate reader. 
Then the D2 labeled cells were added to wells to a final volume of 10 µL using the injector system of the 
instrument, and kinetic TR-FRET readings were made at time zero and every 21-sec or 100-seconds 
(depending on whether faster or slower compounds were being measured) for the times indicated in Figure 
S 1. Baseline-normalized kinetic traces were analyzed with a competitive binding kinetics model [30] 
adapted to deal with normalized- instead of blank-subtracted curves using the Genedata ScreenerTM 
software. Prior to D2 agonist/antagonist testing, binding saturation and kinetic association and dissociation 
curves for the Dopamine D2 receptor red antagonist Fluorescent Ligand were recorded as described 
previously [27,28]. Subsequently, these curves were fitted to the corresponding models using Graph Pad 
PrismTM in order to obtain the affinity and kinetic constants used as parameters in the Cheng-Prusoff and 
Motulsky and Mahan models.[29] 
cAMP assay 
CHO/hD2L and wt-CHO cells were grown in DMEM/F12 with Glutamine (without phenol red, Gibco), 1 % 
heat inactivated FCS, 1 x Penicillin/ Streptomycin, 400 µg/mL G418. Cells were cultured in humidified 
atmosphere at 37°C and 5 % CO2 in air.  
To gain insight in the activity of known antagonists after binding to the D2-receptor, changes in the cellular 
cAMP level were analyzed. To allow real time kinetic measurement, a cAMP-biosensor variant pGloSensor™-
22F (Promega Corporation) was used, which consists of a cAMP binding domain (cAMP binding domain B 
from human PKA regulatory subunit type II β) fused to mutant luciferase. Binding of cAMP results in a 
conformational change and an increase in luminescence signal. The use of the biosensor system provides a 
method for a real-time measurement of changes in the cAMP level in a non-lytic assay format. Cells from a 
Chinese Hamster Ovary (CHO) cell line stably transfected with the long isoform of the human Dopamine 2 
receptor, CHO/hD2L cells, were kindly provided by Janssen Pharmaceutica. 
CHO/hD2L cells (15,000/50 µL) were transiently transfected with the pGloSensor™-22F plasmid (2ng/µL i.a.) 
using FuGeneHD transfection reagent (3 µL FuGeneHD: 1 µg DNA plasmid, Promega, Madison, USA). By 
reaching 70-80% confluency, cells were harvested using Trypsin/EDTA and resuspended in DMEM/F-12/ 
HEPES medium supplemented with 1% fetal calf serum (FCS), Pen/Strep and 1 mg/ml G418. Prior to addition 
of the pGloSensor™-22F plasmid to cells, it was incubated for 20 min with the FuGeneHD transfection 
reagent at room temperature. By the end of incubation time, the cells and transfection solution were 
combined, mixed and plated in white, solid bottom 384 well assay plates (Greiner CELLSTAR® 384 well 
plates). After 24 h of incubation the transfection mixture was replaced by 20 µL/well DMEM/F-12/HEPES 
medium with 9% Glo-substrate followed by 2 h incubation at room temperature. To achieve a good signal 
window, CHO/hD2L cells were treated with 3 µM forskolin for 30 min. Forskolin was used as an activator of 
the adenylate cyclase and therefore for a receptor-independent increase of the cellular cAMP level. In order 
to monitor antagonist activity against the natural receptor ligand, cells were incubated with 15 nM 
dopamine for 20 min prior to addition of antagonists. D2 receptor antagonists were tested in a 10-point 
dose response (top concentration 10 µM, 1:4 dilutions). Signal kinetics was detected for a total period of 1h 
every 2min. All compounds were dissolved in dimethyl sulfoxide (Carl Roth GmbH + Co. K, Karlsruhe, 
Germany). 
Dynamic mass redistribution (DMR) Assay 
For DMR measurements[31], 10 µl/ well cell culture media(DMEM/ F12 without phenol red, Gibco) were 
transferred into an EnSpire-LFC 384– fibronectin coated plate (PerkinElmer, Waltham, USA) and incubated 
for 30 min. A suspension of CHO/hD2L cells in cell culture media  was prepared and cells were seeded into 
the label-free cellular (LFC) plate (1.5 x 104 cells/well), resulting in a final volume of 30 µl/ well. The LFC plate 
was incubated overnight in a humidified atmosphere at 37°C and 5 % CO2 in air. 
On the next day, label-free assay buffer (HBSS (Sigma Aldrich), 20 mM HEPES (Sigma Aldrich), 0.5 % (v/v) 
DMSO, 0.05 % v/v Pluronic (AnaSpec)) was prepared. Dopamine was diluted in label-free assay buffer (5 uM, 
final assay concentration) and dispensed into an intermediate plate (Polypropylen 384 well microplate 
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(Greiner Bio-One GmbH, Frickenhausen, Germany)). Of each antagonist, a dilution series in dimethyl 
sulfoxide was prepared and transferred into an intermediate plate. Label free assay buffer was added to the 
intermediate plate to dilute the antagonists further. 
The media was removed from the LFC plate by washing the wells four times with label-free assay buffer (25 
µl/ well). The total assay volume after the washing step was 30 µl/ well. The LFC plate was placed in an 
EnSpire multimode reader equipped with Corning® Epic® Label-free technology (PerkinElmer). After 2 h, a 
baseline was recorded (10 minutes) followed by the addition of Dopamine or vehicle control (10 µl/well) 
from the intermediate plate. Antagonist dispensing and mixing was automated using a Janus Workstation 
(PerkinElmer). A 20-min kinetic DMR measurement was recorded on the EnSpire multimode reader. Directly 
afterwards, the D2R antagonists were transferred from the intermediate plate to the LFC plate (10 µl/well) 
and a 90-min kinetic DMR measurement was initiated on the EnSpire multimode reader.  
II) Model-based analysis of the in vitro cAMP antagonist response curves 
Modeling procedure 
To obtain a detectable cAMP signal, adenylyl cyclase was activated first by forskolin. The dynamics of this 
activation was recorded in a separate experiment. Since the cAMP response to forskolin addition was 
measured separately from the cAMP response to the D2 receptor antagonists, the D2 antagonist response 
measurements were normalized to the average cAMP response before antagonist addition (baseline). A 
mechanistic model, based on previous models and mechanistic information from literature [21,24,25,32–
34], combining dopamine-receptor binding kinetics, antagonist-receptor binding kinetics, and cAMP as well 
as active PDE turnover to describe the generation of the cAMP response was used to simultaneously fit the 
cAMP data of all compounds. A diversity of models, with differences in mechanistic detail (Table 2), was 
tested for their utility to describe the cAMP responses. Model fitting was performed in NONMEM v7.3 using 
ADVAN9. All values of koff, including the koff of dopamine, were fixed to the values that were measured 
according to the methods described above, while the KD values were estimated. Models were selected 
based on the objective function value (OFV) and visual inspection of the individual fits of the experiments. A 
schematic overview of the final model structure that was fitted to the cAMP response data (model 1) is 
given in Figure 1. 
 
Figure 1. Schematic overview of the structure of the final model (Model 1). DA denotes dopamine, L denotes the 
antagonist, R denotes the D2 receptor RD the D2 receptor-dopamine complex, RL the receptor antagonist complex. RR 
indicates receptor recycling; the internalization (or degradation) of the dopamine-receptor complex and the resurfacing 
(or synthesis) of the unbound receptor and dopamine. Black arrows denote mass transfer, green arrows an activating 
interaction, red arrows an inhibiting interaction. The equations of Model 1 are given in Supplement S 3.   
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III) Frequency Response Analysis: Simulations of the predicted in vivo response to fluctuating dopamine 
concentrations 
Dopamine concentrations were varied over time according to a sine wave with various frequencies and an 
amplitude of 10 nM. This dopamine fluctuation induces fluctuations in the cAMP concentrations, but the 
amplitude of these fluctuations is dependent on the frequency of the dopamine fluctuations. To get a 
complete analysis of the cAMP response to fluctuating dopamine concentrations in the presence of an 
antagonist and to cover all physiologically relevant frequencies [16,19,20], a wide frequency range was 
tested between 2 * 10-6 min-1 and 7 min-1. After the cAMP concentration had reached constant fluctuation 
around the average steady state (i.e. the mean of the minimal and maximal concentration), the amplitudes 
of both the dopamine and the cAMP concentrations were converted amplitudes relative to their average 
steady state values and their ratio was defined as the “cAMP gain”, according to equation 1. This gain is a 
measure for the degree in which dopamine fluctuations results in cAMP fluctuations. All simulations were 
performed in Rstudio using the deSolve package and the lsoda differential equation solving method.[35,36]  
𝐺𝑎𝑖𝑛 𝑐𝐴𝑀𝑃 =  
𝑎𝑚𝑝𝑙𝑖𝑡𝑢𝑑𝑒 𝑐𝐴𝑀𝑃 
𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑠𝑡𝑒𝑎𝑑𝑦 𝑠𝑡𝑎𝑡𝑒 𝑐𝐴𝑀𝑃
𝑎𝑚𝑝𝑙𝑖𝑡𝑢𝑑𝑒 𝑑𝑜𝑝𝑎𝑚𝑖𝑛𝑒 
𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑠𝑡𝑒𝑎𝑑𝑦 𝑠𝑡𝑎𝑡𝑒 𝑑𝑜𝑝𝑎𝑚𝑖𝑛𝑒
       Eq. 1 
Results  
I) In vitro measurements of target binding and signal transduction kinetics  
We have used a novel TR-FRET based assay technology to measure the KD, kon and koff values of 17 dopamine 
D2 antagonists and 12 agonists at both room temperature and 37°C. The results (shown in Figure 2, Table 1, 
Table S 1 and Table S 2) are in good agreement with previous literature reports that used radioligand 
binding [17,18,37–46]. Figure 2 shows that both the D2 antagonists and agonists in this study had diverse 
combinations of kon and koff values, and that none of them had a combined low kon and low koff value. Figure 
2 also shows that the investigated agonists tend to have higher koff values and lower kon values compared to 
the investigated antagonists. For compounds with higher dissociation rates than the competing fluorescent 
ligand (koff ≥ 0.01 s-1) the precision of their koff estimates is limited, or only the lower limit could be 
identified. However, for the experiments and model fits in this study, the exact value of the koff has less 
influence on the cAMP concentration for fast compared to slow dissociating compounds and a low precision 





Figure 2. In vitro measurements of kon and koff for each of the measured D2 antagonists from the kPCA assay at room 
temperature. Red symbols/lines represent agonists, black symbols/lines antagonists. Upper panel: The numbers refer to 
the compound numbers in Table 1. Lower panel: distribution of kon and koff for agonists compared to antagonists, plotted 
as the estimated probability density function. 
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Table 1. In vitro measurement of kon, koff, their standard deviation (SD) and the calculated KD for each of the 
measured D2 antagonists from the kPCA assay at room temperature. NA: not available, NPA: N-n-Propyl 
Apomorphine  
Compound ID # KD [M] SD kon [1/(M*s)] SD koff [1/s] SD 
(-)-Nemonapride 1 9.58E-11 3.26E-12 5.66E+06 2.73E+05 5.43E-04 4.46E-05 
(-)-Quinpirole  2 7.80E-07 6.28E-07 1.07E+05 4.77E+04 9.82E-02 1.04E-01 
Aripiprazole 3 2.39E-10 4.40E-13 7.24E+05 3.17E+05 1.73E-04 7.52E-05 
Bromocriptine  45 2.19E-10 1.96E-10 8.09E+04 2.54E+04 2.02E-05 1.80E-05 
Bromperidol 5 1.89E-09 7.49E-10 2.26E+06 9.57E+05 3.91E-03 1.21E-04 
Cabergoline 6 4.26E-10 2.13E-10 8.80E+05 5.13E+05 3.21E-04 3.15E-05 
Clozapine 7 5.05E-08 1.28E-08 1.20E+06 1.44E+06 5.13E-02 5.74E-02 
Domperidone 8 3.04E-09 5.08E-10 1.81E+05 5.26E+04 5.37E-04 6.75E-05 
Dopamine 9 1.27E-06 5.56E-07 1.88E+04 2.16E+04 2.82E-02 3.01E-02 
JNJ-37822681 10 9.32E-09 2.71E-09 7.33E+05  NA  9.54E-03   NA 
JNJ-39269646 11 4.87E-08 8.35E-09 4.53E+06 4.51E+06 1.79E-01 1.64E-01 
Haloperidol 12 3.82E-10 4.98E-11 1.21E+07 5.18E+06 4.48E-03 1.37E-03 
Memantine  13 2.61E-05 9.91E-06 2.98E+02  NA  1.07E-02  NA  
NPA   14  NA  NA   NA  NA   NA  NA  
Olanzapine 15 8.58E-09 3.38E-09 > 7.30E+05   NA > 1.00E-02   NA 
Paliperidone 16 5.45E-09 2.07E-09 6.81E+05 1.83E+05 3.52E-03 4.14E-04 
Pergolide  17 2.44E-08 1.24E-08 9.81E+05   NA 2.59E-02  NA  
Pimozide 18 2.55E-10 6.74E-11 3.10E+05 2.45E+05 7.08E-05 4.17E-05 
Piribedil  19 2.23E-07 5.90E-08 4.43E+04 9.30E+03 1.21E-02 4.18E-03 
Quetiapine  20 1.50E-07 6.94E-08 1.03E+05 2.04E+04 1.69E-02 6.07E-03 
R-(-)-Apomorphine  21 1.70E-07 7.68E-08 > 8.85E+04   NA > 1.00E-02   NA 
Remoxipride  22 8.31E-08 3.47E-08 3.28E+05  NA  3.14E-02   NA 
Risperidone 23 7.56E-10 7.62E-11 4.43E+06 8.54E+05 3.31E-03 3.09E-04 
Rotigotine  24 7.82E-09 2.86E-09 3.84E+06 3.78E+06 2.65E-02 2.75E-02 
S-(+)-Apomorphine  25 3.33E-07 1.15E-07 2.94E+04   NA 1.36E-02   NA 
Sertindole 26 4.07E-09 2.23E-09 7.70E+05 7.00E+05 2.35E-03 1.13E-03 
Spiperone 27 1.79E-10 4.11E-12 5.44E+06 1.11E+06 9.70E-04 1.76E-04 
S-(+)-Raclopride  28 6.34E-10 1.15E-10 9.57E+05 1.81E+05 5.96E-04 4.62E-06 
Ziprasidone 29 1.31E-09 8.40E-11 1.29E+06 2.01E+05 1.67E-03 1.55E-04 
 
Our cAMP and DMR measurement provide a new and extensive set of signal transduction data for 17 D2 antagonists. 
Figure 3 shows the measured cAMP concentrations during the complete time course of a typical experiment with and a 
control experiment without dopamine D2 receptor transfection. For comparison, the DMR responses are given in 
Supplement S 2, Figure S 3. In Figure 4, the complete set of measured cAMP time courses for all 17 D2 antagonists at 10 
different concentrations is given, together with their model fits. The data in Figure 4 show that the antagonists with lower 
koff values (pimozide, domperidone, raclopride) induce cAMP concentration-time curves for the lower antagonist 
concentrations, with later and lower peak concentrations, compared to faster dissociating compounds (JNJ-39269646, 
Clozapine, Olanzapine). However, this trend was not observed in the DMR data (see Supplement S 2). 
II) Model-based analysis of the in vitro cAMP antagonist response curves 
Model selection 
A series of related model structures, which differed in mechanistic detail, was evaluated for their utility to 
describe the cAMP responses (Table 2). From these models, Model 1 was selected as the final model for 
further analyses. This model selection was based on the lowest Objective Function Value (OFV) and on the 
goodness of fit, as described in the methods. In Model 1, all antagonists also functioned as inverse agonists 
by stimulating cAMP production (see Figure 1), and the inverse agonism efficacy was estimated by the 
model for each antagonist. Model 1 was compared with alternative models to ensure that Model 1 was the 
optimal model:  
Model 2 incorporated more mechanistic detail compared to Model 1 by including the role of PKA in linking 
the cAMP concentrations to active PDE concentrations. The performance of Model 2 was identical to the 
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performance of the simpler Model 1. In addition, the estimated value of PKA turnover was high compared to 
cAMP and active PDE turnover, which means that the PKA addition to the model did not introduce any 
further delay in the response kinetics.  
Models 3 and 4 were simplified models compared to Model 1 that excluded inverse agonism and receptor 
recycling, respectively. Model 3 and 4 clearly performed worse than Model 1, as indicated by the much 
higher OFVs.  
Model 5 included dopamine elimination/degradation, but this did not improve the model fit.  
Model 6 used a fixed value for k5 which was set to 0. This model performed slightly better than Model 1. The 
value of k5 (0.0005 min-1) in the final model (Model 1) was chosen for a combination of physiological and 
numerical reasons: setting k5 to zero as in Model 6 would mean that active PDE is only synthesized and not 
degraded, which would result in a physiologically implausible infinite increase in active PDE concentrations. 
Moreover, all other parameter values than k5 differed maximally 5% between Model 6 and Model 1.  
Finally, Model 7 demonstrates the contribution of slow binding kinetics to the model fit of the final model, 
as the exclusion of slow binding kinetics (koff was set to 10 min-1 for all antagonists in Model 7) resulted in a 
large increase of the OFV, compared to Model 1. 
Table 2. Overview of the Objective Function Values (OFVs) of the final model and the tested alternative 
models. The changes compared to Model 1 are indicated by the mechanistic detail that was added (+) or 
removed (-) from Model 1. 
# Model OFV model fit 
1 Final model 62404 successful 
2  + PKA 62411 successful 
3  - inverse agonism (k0) 102215 terminated 
4  - receptor recycling (RR) 81594 terminated 
5  + degradation of dopamine 62404 successful 
6  - active PDE degradation (k5) 62307 successful 
7  + assumption of fast binding kinetics 67468 successful 
 
Model fitting 
The model fits of Model 1 in Figure 4 demonstrate that the general shape of the cAMP concentration-time 
curve and the concentration-dependency of the antagonist effect on the cAMP concentration are well 
captured by the model for all compounds. The equations of Model 1 are given in  Supplement S 3. For a few 
compounds (i.e. Clozapine, Bromperidol) the peak cAMP concentration or the cAMP concentrations in the 
terminal phase for the highest antagonist concentrations are underpredicted. The parameter estimates that 
were the same for all antagonists are given in Table 3 and all parameter estimates are given in Supplement S 




Table 3. Estimates for the system-specific parameters and their uncertainties from fitting Model 1 to the 
cAMP response data. Naming of the parameters corresponds to Figure 1. DAFR50 denotes the ratio of the 
total receptor concentration divided by the dopamine-bound receptor concentration that inhibits the 
maximal cAMP synthesis to 50%, Rtot denotes the total receptor concentration, k0max denotes the maximal 
value of k0. h denotes the hill factor of the non-linear relationship between D2 receptor occupancy and 
cAMP synthesis (k0). The dopamine koff was based on the in vitro measurements and the chosen values for 
k4 and k5 are described in the text. RSE: Relative Standard Error. 
Parameter Value (unit) RSE (%) 
KD dopamine 10.3 (nM) 4.0 
koff dopamine 1.69 (min-1) Input parameter 
DAFR50 2.25  2.4 
Rtot 1.74 (nM) 1.3 
RR 0.238 (min-1) 2.2 
k0max 20.5 (AU·min-1) 0.50 
k1 4.12 (AU·min-1) 0.80 
k2 (active PDE-independent) 0.0334 (min-1) 11 
k3 (active PDE-dependent) 0.00882 (nM-1·min-1) 0.20 
k4 0.00882 (min-1) defined as identical to k3 
k5 0.0005 (min-1) input parameter 




Figure 3. Measured cAMP response during a typical experiment of the cAMP assay (see Methods). The arrows indicate 
addition of Glo-substrate, Forskolin, Dopamine and the tested ligand. The light grey data points were measured in wild 







Figure 4. Model fits for all in vitro cAMP data as measured in transfected CHO cells. Both the observed (dots) and model-
predicted (lines) cAMP signals are included. The order of the lines and symbols correspond to the order of the 
concentrations in the legend. The top-left panel shows the cAMP measurements and model predictions for the first 60 
minutes in between forskolin addition and antagonist addition. The lower panels only show the time points after 
antagonist addition.  
III) Frequency Response Analysis: Simulations of the predicted in vivo response to fluctuating dopamine 
concentrations 
The simulations of the response to fluctuating dopamine concentrations resulted in a fluctuation pattern of 
cAMP over time for each dopamine fluctuation frequency that was tested. The cAMP fluctuation amplitude 
was dependent on the frequency, as illustrated in Figure 5. 
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Figure 5. Example simulations of fluctuations in dopamine concentration for a low frequency (left-hand plots) and a high 
frequency (right-hand plots). The dashed lines indicate the average steady state values of the fluctuations, which is 
calculated as the mean of the maximal and the minimal concentration. Note the different time scales on the left compared 
to the right plots. The antagonist koff was 2.5 min-1 for these simulations. 
From these dopamine and cAMP fluctuations, the relative amplitudes and the ratio of these relative 
amplitudes could be calculated to obtain the cAMP gain (Equation 1, see Methods) as illustrated in Figure 6. 
The two simulations in Figure 5 and Figure 6 thus provide two points on the line for an antagonist koff of 2.5 
min-1 in the graph of Figure 7; at a frequency of 2 x 10-5 min-1 and 2 min-1, the cAMP gain is 0.36 and 0.0080, 
respectively. 
 
Figure 6. Converted dopamine and cAMP concentrations into relative fluctuations compared to average steady state. The 
delta sign refers to the difference between the concentration and the average steady state concentration. From this data, 
the gain can be identified according to equation 1, which is approximately 0.36 for the left-hand plots and 0.0080 for the 
right-hand plots. The antagonist koff was 2.5 min-1 for these simulations. 
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From the Frequency Response Analysis as shown in Figure 7, the following was observed:  
If dopamine fluctuations occur slowly, the cAMP response has a steady gain (i.e. the cAMP fluctuations have 
a constant amplitude) for frequencies lower than 1*10-5 min-1 in Figure 7. This gain is increased for 
intermediate frequencies (between 1*10-4 and 0.1/min) and decreases steeply for higher frequencies. The 
influence of drug-target binding kinetics on the transduction of dopamine fluctuations into cAMP 
fluctuations is limited to intermediate frequencies between 1*10-4 and 0.1/min of dopamine fluctuations. 
 
 
Figure 7. Frequency response analysis of the relative amplitude of cAMP fluctuations normalized to the relative amplitude 
of dopamine fluctuations (gain). The frequency on the x-axes denotes the frequency of the dopamine concentration sine 
wave that has been used as input for the simulations. The different colors represent different dissociation rate constants 
(koff) for the antagonist. The applied antagonist concentration was 14 nM while the antagonist KD was 6.9 nM for all 
simulations in both plots. The applied dopamine concentrations had a median value of 20 nM and an amplitude of 10 nM. 
The value of kon changed simultaneously with koff such that the KD was constant. The dashed lines indicate characteristic 
frequencies for the line where koff = 0.004 min-1 at which the gain increases (cf1) and decreases (cf2) to new plateau values 
and decreases linearly with increasing frequencies (cf3). The order of the lines follows the order of the legend. 
The model-based frequency response analysis allowed characterization of the cAMP response to a wide 
range of dopamine fluctuation frequencies (as shown in Figure 7). This analysis identified the influence of 
each model parameter on the cAMP response. The cAMP gain versus dopamine fluctuation frequency 
graphs as shown in Figure 7 are dependent on the antagonist koff and can have up to three characteristic 
frequencies around which the gain changes. The positions of the characteristic frequencies are dependent 
on the parameter values, as discussed below, and have been derived empirically from the gain versus 
frequency plot as the frequencies at which the cAMP gain starts to change. These frequencies were 
numbered cf1, cf2, and cf3, as indicated in Figure 7. From the lowest dopamine fluctuation frequencies to cf1, 
the cAMP gain is independent of the antagonist koff and does not change with increasing frequency, until cf1 
is reached where the gain increases towards a new plateau value. The frequency at which the cAMP gain 
declines to a new plateau value, cf2, is dependent on the antagonist koff and cannot be observed for high-koff 
antagonists, which is the case for koff values between 0.5 and 2.5 min-1 (Figure 7). The third characteristic 
frequency, cf3, is independent of the antagonist koff and introduces a decline in the cAMP gain that is linear 
with the increasing frequency.  
The influence of the model parameters on the characteristic frequencies was identified by repeating the FRA 
for different values of each model parameter, as shown in Supplement S 5. As illustrated by Figure S 5, the 
value of cf1 depends on the value of the active PDE turnover rate constant k5. This can be understood by 
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considering that the increase in cAMP gain is caused by a reduced negative feedback if the turnover of 
active PDE is to slow, relative to the fast fluctuations of cAMP. The second characteristic frequency, cf2, is 
influenced by the antagonist koff and by the antagonist concentration, as illustrated in Figure S 8. The role of 
the antagonist koff can be explained by the slow displacement of antagonists with a low koff value and the 
consequently reduced fluctuation of dopamine receptor occupancy. The role of the antagonist 
concentration can be explained by the higher antagonist receptor occupancy and the relatively lower 
influence of fluctuating dopamine concentrations on the antagonist receptor occupancy for higher 
antagonist concentrations. The third characteristic frequency, cf3, is determined by both the cAMP turnover 
and the dopamine koff, as shown in Figure S 6 and Figure S 7, respectively. These parameters determine the 
turnover of cAMP and dopamine receptor occupancy, respectively, and the slowest turnover is thus rate-
limiting for the eventual turnover of cAMP and the maximal frequency of dopamine fluctuations that can be 
translated into cAMP fluctuations without a declining fluctuation amplitude. In summary, if k5 (active PDE 
turnover) increases, cf1 increases, if the antagonist concentration or koff increases, cf2 increases and if k3 
(cAMP turnover) increases, cf3 increases  
Overall, the translation of fluctuating dopamine concentrations into fluctuation of cAMP concentrations is 
inhibited to a larger extent by antagonists with a low koff value compared to antagonists with a high koff 
value. However, this role of the antagonist koff is only present if the dopamine fluctuation frequency is not 
too high (i.e. higher than cf3) to be translated and not too slow (i.e. lower than cf2) to be able to displace 
even a slow dissociating antagonist. 
Discussion  
In this study, we developed a minimal mechanistic model that describes the cellular effects of dopamine D2 
antagonism on cAMP turnover, including both dopamine and antagonist receptor binding kinetics as well as 
active PDE turnover. The model was able to describe successfully in vitro binding and cAMP concentration-
time profiles data obtained for 17 D2 antagonists. Compared to fast dissociating antagonists, slowly 
dissociating D2 antagonists lead to a reduced response to fluctuating dopamine concentrations as previously 
suggested in the fast-off hypothesis (see below) for dopamine antagonists. However, this influence of 
antagonist binding kinetics is only observed when the dopamine fluctuations have a frequency in the range 
of 1/min to 1/hour. This range is determined by the cAMP turnover, the dopamine koff and the antagonist 
koff. 
Insight into the influence of target binding kinetics on dopamine D2 antagonism 
According to the fast-off hypothesis for dopamine D2 antagonists, it is beneficial if dopamine can displace D2 
antagonists receptor binding, to avoid extrapyramidal side effects.[15] Since the dopamine fast-off 
hypothesis only applies to D2 antagonists, one would expect more antagonists with a high koff value, 
compared to agonists, for which a high koff value is not considered beneficial. However, our results in Figure 
2 show that the koff of agonists tends to be higher compared to antagonists. The koff values that would be 
necessary for the displacement of dopamine according to the fast-off hypothesis were analyzed previously, 
[16] but the kinetics of signal transduction were not taken into account in that study. Here we show that the 
displacement of D2 antagonists by dopamine is not generating a fluctuating response if the frequency of 
fluctuation in dopamine D2 occupancy is higher than what the endogenous signal transduction can translate 
into a cellular signal, such as cAMP fluctuation. In this study, it is indicated that the rate of endogenous 
signal transduction is limited both by the dopamine koff and by the cAMP turnover. It was found that D2 
antagonists that dissociate faster than haloperidol (a typical antipsychotic) will lead to a similar signal 
transduction of fluctuating dopamine concentrations as haloperidol. However, this is in conflict with the 
fast-off hypothesis.[15] Moreover, this fast-off hypothesis has been challenged recently by in vitro 
electrophysiology measurements that revealed only moderate differences (6.4-2.5 fold) in recovery rates of 
the electrophysiological response to dopamine in oocytes between atypical antagonists and the typical 
antagonist haloperidol [47].  
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Extrapolation of in vitro to in vivo antagonism and signal transduction 
Our analysis demonstrates that the fast-off hypothesis for D2 antagonists is only relevant for a limited range 
of antagonist koff values and not applicable to sub-second pulses of dopamine release in the synaptic cleft. 
Moreover, this study reveals how the relevance of the D2 antagonist koff depends on the kinetics of signal 
transduction and negative feedback. Although we provide a quantitative estimate of the maximal value of 
koff that could decrease the inhibited transduction of dopamine fluctuations, it should be noted that this 
value cannot be translated directly into the in vivo situation.  
Firstly, the temperature at which the signal transduction experiments were performed, room temperature, 
is not the physiological temperature, and most reactions (including drug-target binding kinetics) will be 
faster at 37°C. However, the difference in binding kinetics between these temperatures is moderate, 
although highly variable: the ratio of the koff values for the measured D2 antagonists in this study at 37°C 
divided by the koff at room temperature was 3.2 fold on average and between 0.10 and 7.4 in the whole 
dataset, while for kon this ratio was 2.5 on average and between 0.038 and 6.7 (see Supplement S 1). 
Therefore, we expect that the kinetics of signal transduction will be different at 37°C compared to our 
measurements at room temperature, but we do not expect differences of more than one order of 
magnitude. 
Secondly, the analysis of Model 1 in this study only incorporates signal transduction into cAMP and active 
PDE levels, while in the clinical in vivo situation, more transduction steps are involved before the 
antipsychotic effect of D2 antagonists is obtained. The differences between the time curves of cAMP and 
cellular optical density as measured by DMR (Supplement S 2), provide a first indication of possible 
differences between the cAMP response and downstream signaling, but the mechanistic interpretation of 
cellular optical density requires more advanced experimental designs.[48]  
Thirdly, the analysis of the cAMP response data with Model 1-7 is not sufficient to obtain a conclusive and 
comprehensive description of the mechanism(s) underlying the observed cAMP responses. Although various 
mechanisms were represented by Model 1-7 and fitted to the data, some of these models provide similar 
fits (e.g. Model 1 and Model 5) and the true mechanism cannot be identified based on these fits alone. Also, 
the transfected CHO cells used in the in vitro measurements of CAMP are not brain cells, and the system-
specific parameter values as obtained by the model fit in this study might therefore be different from the in 
vivo situation.  
All of these factors might explain why the receptor recycling rate constant as identified here (0.238 min-1) 
does not correspond to previous more direct estimates of the D2 receptor degradation rate constant from 
rat striatum (0.0001 min-1)[49,50]. However, the critical elements in the structure of Model 1 are well 
supported by previous studies: Inverse agonism has been reported for many of the D2 antagonists as 
described in the introduction [24,25]. The active PDE-independent degradation of cAMP has been described 
before in a more extensive GPCR signaling model [21] and is also supported by the different molecules that 
can hydrolyze cAMP [33,34]. The two cAMP production rate constants represent the constitutive receptor 
activity, which is inhibited by inverse agonism [32], and the remaining cAMP production. 
Finally, the frequency response analysis that was used here is based on a sine-wave function while the 
dopamine fluctuations in the brain occur with a more variable frequency and amplitude.[16,19].  
Although the absolute limit of the influence of binding kinetics on antagonist effects cannot be translated 
directly into the in vivo situation, our findings demonstrate that such a limitation likely exists in the in vivo 
situation as well, and may be expected to be in the order of minutes. These results make it highly unlikely 
that sub-second dopamine fluctuations can be translated into cAMP fluctuations and that sub-second koff 
values are required to minimize extrapyramidal side effects. This also indicated that it is highly unlikely that 
antagonists with sub-second dissociation half-lives yield different inhibition of dopamine signaling compared 
to antagonists with dissociation half-lives in the second-minute range, as suggested before.[16]  
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We have shown that for a common transduction system including an indirect effect and a negative feedback 
loop, the relevance of fast drug-target dissociation is limited by the target dissociation of the endogenous 
ligand and the turnover of the second messenger. The rate constants for dopamine dissociation from the D2 
receptor and cAMP turnover that we have obtained in this study challenge the fast-off hypothesis. Our 
study demonstrates that the influence of target binding kinetics on drug effects cannot be fully understood 
without taking into account signal transduction and feedback kinetics, especially if fluctuating endogenous 
ligand concentrations are present.  
 
Conclusion  
The cellular cAMP response to dopamine D2 antagonists could be described using a minimal mechanistic 
model including in vitro measured dopamine and antagonist D2 binding kinetics, in conjunction with 
synthesis and degradation of cAMP and active PDE. This model revealed that slowly dissociating D2 
antagonists show a reduced transduction of dopamine fluctuations into cAMP fluctuations, compared to 
fast dissociating antagonists. However, this influence of the dissociation rate constant is limited to 
dopamine fluctuations that are faster than the koff value of the drug but slower than the dopamine koff value 
and the cAMP turnover. In general, we conclude that the influence of drug-target binding kinetics on drug 
effect kinetics is dependent on the dynamics of signal transduction kinetics and that both the turnover of 
second messengers and the koff value of endogenous ligands limit the discrimination between fast and 
slowly dissociating antagonists. 
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Supplement S 1. Measurements of binding kinetics and equilibrium binding for antagonists and agonist at 
room temperature and at 37 °C. 
Table S 1. Binding equilibrium (ePCA) and binding kinetics (kPCA) measurements at 37°C. NA: not available, 
NPA: N-n-Propyl Apomorphine 
 ePCA kPCA 
Compound ID KI [M] SD KD [M] SD kon [1/(M*s)] SD koff [1/s] SD 
(-)-Nemonapride 2.11E-10 5.96E-11 4.96E-11 3.54E-11 1.79E+07 1.95E+06 8.54E-04 5.38E-04 
(-)-Quinpirole  > 8.71E-07 NA  3.83E-06 2.84E-06 5.35E+04 2.42E+04 1.45E-01 1.47E-01 
Aripiprazole 1.03E-09 4.29E-10 5.58E-10 4.90E-11 1.77E+06 6.03E+05 1.00E-03 4.23E-04 
Bromocriptine  1.75E-09 4.04E-10 5.86E-10 3.22E-12 2.40E+05 8.64E+04 1.41E-04 5.14E-05 
Bromperidol 3.24E-09 1.55E-09 2.52E-09 8.27E-10 2.67E+06 1.04E+06 7.42E-03 2.68E-03 
Cabergoline 8.22E-10 1.03E-10 7.38E-10 6.89E-11 2.11E+06 4.75E+05 1.54E-03 2.06E-04 
Clozapine 3.12E-08 1.96E-09 5.39E-08 1.33E-08 8.35E+05   2.88E-02   
Domperidone 5.06E-09 8.69E-10 3.15E-09 3.92E-10 6.87E+05 2.62E+05 2.12E-03 5.56E-04 
Dopamine > 8.71E-07   1.07E-06 4.99E-07 1.02E+04 6.02E+03 9.36E-03 1.32E-03 
JNJ-37822681 1.61E-08 1.89E-09 1.93E-08 3.99E-09 1.24E+06 9.63E+05 2.19E-02 1.36E-02 
JNJ-39269646 7.22E-08 1.18E-08 9.14E-08 1.37E-08 1.71E+05  NA 1.84E-02 NA  
Haloperidol 9.48E-10 2.96E-10 3.86E-10 9.95E-11 7.23E+07  NA 3.30E-02 NA  
Memantine  > 8.71E-07 NA  1.01E-05 2.59E-07 1.99E+03 1.37E+03 2.41E-02 9.94E-03 
NPA  3.40E-08 8.42E-09 1.77E-07 6.90E-08 NA  NA NA NA  
Olanzapine 1.39E-08 1.29E-09 2.17E-08 9.44E-09 1.61E+06 1.00E+06 3.61E-02 5.99E-03 
Paliperidone 8.18E-09 1.56E-09 9.25E-09 2.71E-09 1.92E+06 1.56E+06 1.36E-02 5.91E-03 
Pergolide  1.30E-08 6.53E-09 2.87E-08 1.11E-08 3.27E+06  NA 7.89E-02 NA  
Pimozide 6.62E-10 3.27E-10 5.82E-10 1.40E-10 9.38E+05 5.11E+05 5.10E-04 1.66E-04 
Piribedil  2.99E-07 4.02E-08 4.22E-07 5.13E-08 2.23E+04 NA  8.25E-03 NA  
Quetiapine  1.63E-07 3.84E-09 1.60E-07 9.72E-08 6.74E+05 4.03E+05 1.03E-01 5.98E-02 
R-(-)-Apomorphine  1.69E-07 7.42E-09 2.71E-07 2.11E-07 > 5.92E+04 NA  > 1.00E-02 NA  
Remoxipride  1.23E-07 2.81E-08 1.35E-07 2.86E-08 1.10E+06 4.54E+05 1.30E-01 7.94E-02 
Risperidone 1.67E-09 9.11E-10 1.30E-09 7.52E-10 8.41E+06 5.96E+06 1.07E-02 5.02E-03 
Rotigotine  1.67E-08 4.25E-09 5.69E-09 1.68E-09 3.18E+06 8.05E+05 1.74E-02 7.63E-04 
S-(+)-Apomorphine  5.16E-07 6.50E-08 5.47E-07 1.75E-07 2.13E+04 NA  9.94E-03  NA 
Sertindole 6.80E-09 1.86E-09 7.52E-09 5.87E-10 1.33E+06  NA 9.45E-03  NA 
Spiperone 5.09E-10 2.29E-10 6.58E-11 1.77E-11 2.03E+07 7.02E+06 1.45E-03 6.22E-04 
S-(+)-Raclopride  2.19E-09 1.85E-09 1.29E-09 1.18E-10 2.43E+06 8.68E+05 3.08E-03 8.32E-04 




Table S 2. Binding equilibrium (ePCA) and binding kinetics (kPCA) measurements at room temperature. NA: 
not available, NPA: N-n-Propyl Apomorphine 
 ePCA kPCA 
Compound ID KI [M] SD KD [M] SD kon [1/(M*s)] SD koff [1/s] SD 
(-)-Nemonapride 2.70E-10 5.96E-12 9.58E-11 3.26E-12 5.66E+06 2.73E+05 5.43E-04 4.46E-05 
(-)-Quinpirole  > 8.53E-07   NA 7.80E-07 6.28E-07 1.07E+05 4.77E+04 9.82E-02 1.04E-01 
Aripiprazole 1.01E-09 3.46E-10 2.39E-10 4.40E-13 7.24E+05 3.17E+05 1.73E-04 7.52E-05 
Bromocriptine  5.04E-09 1.98E-09 2.19E-10 1.96E-10 8.09E+04 2.54E+04 2.02E-05 1.80E-05 
Bromperidol 3.09E-09 3.22E-10 1.89E-09 7.49E-10 2.26E+06 9.57E+05 3.91E-03 1.21E-04 
Cabergoline 9.58E-10 2.89E-10 4.26E-10 2.13E-10 8.80E+05 5.13E+05 3.21E-04 3.15E-05 
Clozapine 3.42E-08 3.93E-09 5.05E-08 1.28E-08 1.20E+06 1.44E+06 5.13E-02 5.74E-02 
Domperidone 4.18E-09 1.08E-09 3.04E-09 5.08E-10 1.81E+05 5.26E+04 5.37E-04 6.75E-05 
Dopamine > 8.53E-07   1.27E-06 5.56E-07 1.88E+04 2.16E+04 2.82E-02 3.01E-02 
JNJ-37822681 1.24E-08 2.14E-09 9.32E-09 2.71E-09 7.33E+05  NA  9.54E-03   NA 
JNJ-39269646 3.96E-08 2.10E-09 4.87E-08 8.35E-09 4.53E+06 4.51E+06 1.79E-01 1.64E-01 
Haloperidol 9.88E-10 1.55E-10 3.82E-10 4.98E-11 1.21E+07 5.18E+06 4.48E-03 1.37E-03 
Memantine  > 8.53E-07  NA  2.61E-05 9.91E-06 2.98E+02  NA  1.07E-02  NA  
NPA  2.42E-08 3.80E-09  NA  NA   NA  NA   NA  NA  
Olanzapine 1.37E-08 9.41E-10 8.58E-09 3.38E-09 > 7.30E+05   NA > 1.00E-02   NA 
Paliperidone 7.39E-09 9.15E-10 5.45E-09 2.07E-09 6.81E+05 1.83E+05 3.52E-03 4.14E-04 
Pergolide  1.33E-08 6.02E-09 2.44E-08 1.24E-08 9.81E+05   NA 2.59E-02  NA  
Pimozide 1.22E-09 4.23E-10 2.55E-10 6.74E-11 3.10E+05 2.45E+05 7.08E-05 4.17E-05 
Piribedil  2.26E-07 2.77E-08 2.23E-07 5.90E-08 4.43E+04 9.30E+03 1.21E-02 4.18E-03 
Quetiapine  1.26E-07 3.48E-08 1.50E-07 6.94E-08 1.03E+05 2.04E+04 1.69E-02 6.07E-03 
R-(-)-Apomorphine  1.13E-07 1.88E-08 1.70E-07 7.68E-08 > 8.85E+04   NA > 1.00E-02   NA 
Remoxipride  7.01E-08 1.08E-08 8.31E-08 3.47E-08 3.28E+05  NA  3.14E-02   NA 
Risperidone 1.05E-09 4.07E-10 7.56E-10 7.62E-11 4.43E+06 8.54E+05 3.31E-03 3.09E-04 
Rotigotine  1.16E-08 3.55E-11 7.82E-09 2.86E-09 3.84E+06 3.78E+06 2.65E-02 2.75E-02 
S-(+)-Apomorphine  2.65E-07 8.49E-08 3.33E-07 1.15E-07 2.94E+04   NA 1.36E-02   NA 
Sertindole 6.15E-09 3.21E-09 4.07E-09 2.23E-09 7.70E+05 7.00E+05 2.35E-03 1.13E-03 
Spiperone 2.96E-10 1.43E-10 1.79E-10 4.11E-12 5.44E+06 1.11E+06 9.70E-04 1.76E-04 
S-(+)-Raclopride  1.35E-09 9.97E-10 6.34E-10 1.15E-10 9.57E+05 1.81E+05 5.96E-04 4.62E-06 














Figure S 1. Determination of affinity and kinetic parameters for the binding of Dopamine D2 receptor drugs using the 
TagLite® homogeneous time resolved fluorescence (HTRF) technology and the equilibrium and kinetic Probe Competition 
Assays (ePCA and kPCA). Symbols represent the measured data and lines the fits to the corresponding binding models. The 
compounds indicated with fastD2 and fastD2bu refer to JNJ-37822681 and JNJ-39269646, respectively. These figures are 
also available as separate supplemental files to allow better readability. 
a) Characterization of the PPHT tracer used in ePCA and kPCA at room temperature and at 37°C. The upper panel shows 
representative steady state titration curves, and the lower panel kinetic association- and dissociation curves at increasing 
tracer concentrations. HTRF signals were fit to the models specified in the methods section and the resulting binding 
parameters are indicated in the graphs. 
b-c) Representative kPCA traces of the compounds listed in Table S1 at room temperature (b) and 37°C (c). Compound 
names are indicated on top of the graphs and dosing on the right-hand side. 
d-e) Representative ePCA curves of the compounds listed in Table S1 at room temperature (d) and 37°C (e). Compound 
names are indicated on top of the graphs and dosing on the right-hand side. Grey crosses indicate data points excluded 







Supplement S 2. DMR experimental overview and results for all D2 antagonists. 
 
Figure S 2 Example of the complete DMR versus time curve for 10 µM haloperidol. The time points of addition of dopamine 
and the ligand (haloperidol in this case) are indicated with the red arrows.  
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Figure S 3. Normalized Dynamic Mass Redistribution (DMR) responses as change in DMR response in picometer compared 
to the dopamine response after addition of various concentrations of the indicated antagonists. Normalization was 
performed by subtracting the response per well/replicate at the latest time point after dopamine addition and before 
antagonist addition (t = 31 min) from the raw DMR traces. Normalization for the dopamine + buffer was performed for 




Supplement S 3. Model 1 equations and parameter estimates for all dopamine D2 antagonists. 
To describe dopamine and antagonist binding to the D2 receptor, a simple drug-target binding model with 
competition between antagonist and dopamine was developed. This model assumed a constant total 
receptor concentration. This was represented as a single conservation equation of total receptor (Rt), where 
the receptor can have 3 different states: free receptor (R), antagonist bound to receptor (RL) and dopamine 
bound to receptor (RDA). Receptor recycling (RR) was added to this model as well, which describes 
internalization of the receptor-agonist complex, dissociation of this complex return of the free receptor to 
the cell membrane. This model is given by the following equations (equation 1-5): 
𝑑[𝐿]
𝑑𝑡
=  −𝑘𝑜𝑛𝐿[𝑅][𝐿] + 𝑘𝑜𝑓𝑓𝐿[𝑅𝐿] 
      (Eq. 1) 
𝑑[𝐷𝐴]
𝑑𝑡
=  −𝑘𝑜𝑛𝐷𝐴[𝑅][𝐷𝐴] + 𝑘𝑜𝑓𝑓𝐷𝐴[𝑅𝐷𝐴] + 𝑅𝑅[𝑅𝐷𝐴] 
      (Eq. 2) 
d[RL]
dt
=  𝑘𝑜𝑛𝐿[𝑅][𝐿] − 𝑘𝑜𝑓𝑓𝐿[𝑅𝐿] 
      (Eq. 3) 
d[RDA]
dt
=  𝑘𝑜𝑛𝐷𝐴[𝑅][𝐷𝐴] − 𝑘𝑜𝑓𝑓𝐷𝐴[𝑅𝐷𝐴] − 𝑅𝑅[𝑅𝐷𝐴] 
      (Eq. 4) 
[𝑅] = [𝑅𝑡] − [𝑅𝐿] − [𝑅𝐷𝐴] 
      (Eq. 5) 
In these equations, [L] represents the free antagonist concentration, [DA] represents the free dopamine 
concentration, [Rt] represents the total receptor concentration, [R] represents the free receptor 
concentration, [RL] represents the concentration of the receptor—antagonist complex and [RDA] represents 
the concentration of the receptor—dopamine complex. konL and konDA represent the second-order 
association rate constants of receptor with the antagonist and with dopamine, respectively. koffL and koffDA 
represent the first order dissociation rate constants of the antagonist and dopamine from the receptor-
bound complex, respectively. The receptor binding part of the model as described above was connected to 
cAMP concentrations in a mechanistic manner according to the following equations (equation 6 and 7). 
𝑑[𝑐𝐴𝑀𝑃]
𝑑𝑡







) − 𝑘2[𝑐𝐴𝑀𝑃] − 𝑘3[𝑐𝐴𝑀𝑃][𝑃𝐷𝐸] 
      (Eq. 6) 
Here, k0,max represents the maximum rate constant for inverse agonism by the receptor-antagonist complex, 
where n is the hill coefficient.  Additionally, k1 represents the rate constant for baseline synthesis of cAMP 
by adenylyl cyclase. Furthermore, the total cAMP synthesis is inhibited by the receptor dopamine complex 
(RDA) in a nonlinear manner, where n is the hill coefficient as well. k2 is the rate constant for cAMP 
elimination independent of active PDE, and k3 is the rate constant of active PDE-mediated cAMP 
elimination. active PDE synthesis is dependent on the cAMP concentration, and active PDE degradation is 
determined by the first order rate constant k5 as in equation 7. 
𝑑[𝑃𝐷𝐸]
𝑑𝑡
= 𝑘4[𝑐𝐴𝑀𝑃] − 𝑘5[𝑃𝐷𝐸] 
      (Eq. 7) 
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Table S 3. Parameter estimates from fitting the final model to the cAMP response data. Asterisks indicate 
parameter values that were not estimated but used as input parameter values. DAFR50 denotes the ratio of 
the total receptor concentration divided by the dopamine-bound bound receptor concentration that inhibits 
the cAMP synthesis to 50%, LFR50 denotes the ratio of the total receptor concentration divided by the 
antagonist bound receptor concentration that generates the half-maximal antagonist-dependent cAMP 
synthesis (i.e. k0 equals 0.5 * k0max), Rtot denotes the total receptor concentration, k0max denotes the maximal 
value of k0. 
Parameter (unit) Value RSE 
koff Bromperidol (min-1) 0.235*  
koff Clozapine (min-1) 3.08*  
koff Domperidone (min-1) 0.0322*  
koff JNJ-39269646 (min-1) 10.7*  
koff JNJ-37822681 (min-1) 0.573*  
koff Haloperidol (min-1) 0.269*  
koff Nemonapride (min-1) 0.0326*  
koff Olazapine (min-1) 0.600*  
koff Paliperidone (min-1) 0.211*  
koff Pimozide (min-1) 0.0042*  
koff Quetiapine (min-1) 1.01*  
koff Raclopride (min-1) 0.0358*  
koff Remoxipride (min-1) 1.89*  
koff Risperidone (min-1) 0.199*  
koff Sertindole (min-1) 0.141*  
koff Spiperone (min-1) 0.0582*  
koff Ziprasidone (min-1) 0.1*  
KD Bromperidol (nM) 2.04 2.0% 
KD Clozapine (nM) 440 2.1% 
KD Domperidone (nM) 1.72 2.1% 
KD JNJ-39269646 (nM) 104 1.9% 
KD JNJ-37822681 (nM) 19.5 1.9% 
KD Haloperidol (nM) 1.72 2.4% 
KD Nemonapride (nM) 0.454 2.2% 
KD Olazapine (nM) 22.7 2.3% 
KD Paliperidone (nM) 1.61 2.4% 
KD Pimozide (nM) 291 2.8% 
KD Quetiapine (nM) 942 2.2% 
KD Raclopride (nM) 8.29 2.2% 
KD Remoxipride (nM) 118 2.7% 
KD Risperidone (nM) 10.5 4.6% 
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KD Sertindole (nM) 6.89 2.0% 
KD Spiperone (nM) 0.19 2.5% 
KD Ziprasidone (nM) 3.56 1.8% 
KD Dopamine (nM) 10.3 3.9% 
koff Dopamine (min-1) 1.69*  
Rtot [D2 Receptor concentration] (nM) 1.74 1.3% 
k0max: Maximum cAMP synthesis induced by inverse agonism (min-1) 20.5 0.5% 
k1: Baseline cAMP synthesis (min-1) 4.12 0.8% 
k2: cAMP degradation independent from active PDE (min-1) 0.0334 10.8% 
k3: cAMP degradation by active PDE (nM-1 min-1) 0.00882 0.2% 
k4: active PDE synthesis (min-1) 0.00882a   
k5: active PDE degradation (min-1) 0.0005*  
DAFR50 Dopamine  2.25 2.4% 
Hill coefficient 1.77 0.4% 
LFR50 Bromperidol  1.54 0.6% 
LFR50 Clozapine  0.504 0.7% 
LFR50 Domperidone  1.71 0.6% 
LFR50 JNJ-39269646 0.856 0.5% 
LFR50 JNJ-37822681  0.823 0.4% 
LFR50 Haloperidol  0.699 0.5% 
LFR50 Nemonapride  2.47 1.1% 
LFR50 Olazapine  0.628 0.6% 
LFR50 Paliperidone  0.657 0.5% 
LFR50 Pimozide  618 1.9% 
LFR50 Quetiapine  0.827 0.9% 
LFR50 Raclopride  2.68 1.2% 
LFR50 Remoxipride  1.95 1.4% 
LFR50 Risperidone  5.37 3.6% 
LFR50 Sertindole  1.02 0.5% 
LFR50 Spiperone  1.56 0.6% 
LFR50 Ziprasidone  0.959 0.4% 
Receptor Turnover (min-1) 0.238 2.2% 
Proportional error 0.01 0.3% 
a k4 was set to have the same value as k3.  
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Supplement S 4. explanation of frequency response analysis results (FRA) 
In a frequency response analysis, the dynamic behavior of a system is investigated by providing a harmonic 
oscillation as input signal, described by a sine wave with a variable frequency. Subsequently, the amplitude 
and the phase of the resulting sine wave are compared to that of the original sine wave. This frequency 
response analysis is often applied to a linear or linearized system and is derived analytically from the 
system’s differential equations, but can also be derived from experimental data or simulations [26]. 
Dopamine concentrations are released in a pulsatile manner with a frequency of around 1 s-1, but also show 
more slowly fluctuating levels caused by transient activity. Therefore, a frequency response analysis with 
fluctuating dopamine concentrations as input is reflective of the relevant context of drug action for 
dopamine antagonists. 
Here we show the intermediate steps that lead to the eventual calculation of gain in cAMP amplitude. 
Firstly, we show in the top row of Figure S 4 three examples of different input frequencies, for which the 
different line colors all have the same overlaying sine wave characteristics and are not influenced by the 
drug-target koff.  
The second row of Figure S 4 shows how the dopamine occupancy follows the dopamine concentrations (in 
a non-linear fashion) until the frequency gets too high, as visible for the highest frequency, and the 
amplitude of the dopamine occupancy fluctuation declines. The slight influence of the antagonist koff on 
dopamine occupancy for the intermediate occupancy can be explained by the competitive binding of the 
antagonist and dopamine and the influence of the koff on antagonist binding, as shown in the third row of 
Figure S 4. 
The third row of Figure S 4 shows how all antagonists can be displaced by dopamine binding for the slowest 
frequency (hence the fluctuating occupancy), while for the intermediate frequency only the fast dissociating 
drug can be displaced fast enough to keep the original amplitude. Finally, for the highest frequency, none of 
the antagonists can be displaced fast enough and the fluctuation in dopamine concentrations and dopamine 
occupancy is not reflected in the antagonist-receptor occupancy. 
The bottom row of Figure S 4 shows how the differences in dopamine and antagonist occupancy are 
translated into cAMP concentrations in a frequency-dependent manner (note the increased gain for the 




Figure S 4. Example of input frequencies for dopamine as used in the simulations (top panels) and the simulated responses 
(lower panels). The second row shows the dopamine receptor occupancy, the third row the antagonist receptor occupancy 
and the bottom row the cAMP response for each simulation with the fluctuating dopamine concentrations from the 
corresponding top row panels. The different line colors represent different simulations for which the dissociation rate 
constant of the antagonist-receptor complex is changed. The dopamine fluctuation frequencies are indicated above the 
panels and by the different time scales on the x-axis. 
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Figure S 5. Frequency response analysis for 3 different active PDE turnover rate constants and 5 different antagonist koff 
values. The upper plots show the influence of koff for two different active PDE turnover rate constants, and the lower plots 
show the influence of the active PDE turnover rate constants for two different koff values. The input signal was a sine 
wave of free dopamine with an amplitude of 10nM and baseline of 20 nM, at the frequencies indicated on the x-axis. At 
each active PDE turnover rate, 5 different antagonist koff values were simulated, which are represented by the different 
line colors. The kon values were changed simultaneously with koff, which means that the KD was constant at 6.93 nM. The 
antagonist concentration was 14 nM, the LFR50 was 1.03 and all system-specific parameters were identical to Table 3. The 






Figure S 6. Frequency response analysis for active PDE-dependent cAMP turnover rate constants (k3) of 0.883 min-1 (left) 
and 0.883*10-4 min-1 (right). The input signal was a sine wave of free dopamine with an amplitude of 10nM and baseline 
of 20 nM, at the frequencies indicated on the x-axis. At each cAMP turnover rate, 5 different antagonist koff values were 
simulated, which are represented by the different line colors. The kon values were changed simultaneously with koff, which 
means that the KD was constant at 6.93 nM. The antagonist concentration was 14 nM, the LFR50 was 1.03 and all system-









Figure S 7. Frequency response analysis for dopamine-receptor dissociation rate constants (koffDA) of 8.45 min-1 (left) and 
0.0845 min-1 (right). The input signal was a sine wave of free dopamine with an amplitude of 10nM and baseline of 20 nM, 
at the frequencies indicated on the x-axis. At each dopamine dissociation rate constant, 5 different antagonist koff values 
were simulated, which are represented by the different line colors. The kon values were changed simultaneously with koff, 
which means that the KD was constant at 6.93 nM. The antagonist concentration was 14 nM, the LFR50 was 1.03 the 
receptor recycling rate constant was switched to 0 and all other system-specific parameters were identical to Table 3. The 








Figure S 8. Frequency response analysis for antagonist concentrations of 14 nM (left) and 500 nM (right). The input signal 
was a sine wave of free dopamine with an amplitude of 10nM and baseline of 20 nM, at the frequencies indicated on the 
x-axis. At each antagonist concentration, 5 different antagonist koff values were simulated, which are represented by the 
different line colors. The kon values were changed simultaneously with koff, which means that the KD was constant at 6.93 
nM. The antagonist concentration was 14 nM, the LFR50 was 1.03 and all system-specific parameters were identical to 







Chapter 9. Mechanistic modelling of drug target binding kinetics as determinant of the time 
course of drug action in vivo 
Discussion, perspectives and conclusion 
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abbreviations: BF: Target fraction bound, koff: drug-target dissociation rate constant, kon: drug-target 
association rate constant, kel: drug-target elimination rate constant, t1/2z-pl: terminal plasma, elimination 
half-life, t1/2-diss: drug-target dissociation half-life 
 
 
For any drug that is administered to patients or that is being developed, is essential that the time course of 
its effects can be predicted to ensure rational drug therapy and drug development. After its administration, 
the time course of the effect of a drug can be influenced by all processes that constitute the complex system 
of the human body. The most common processes that determine the time course of drug action can be 
categorised as related to either target site exposure, target binding, signal transduction or homeostatic 
feedback mechanisms, as indicated in Figure 1. For the development of new drugs, it is critical to predict the 
time course of drug action as early as possible. To this end, the in vitro measurement and in silico prediction 




Figure 1. The causal chain from drug dosing to drug effect. The drug is indicated by the yellow shape and the 
drug target is indicated by the complimentary red shape. Adapted by E.C.M. de Lange from Danhof, 2016.[1] 
To use target binding as selection criterion in drug discovery, the measurement of target binding under 
equilibrium conditions has been traditionally used to determine a single drug-specific parameter for the 
drug-target affinity, being the drug target dissociation constant KD. However, the kinetics of this target 
binding (drug-target binding kinetics), has often been demonstrated to influence the time course of drug 
action.[2–10] More than half a century ago, it has even been postulated that the strength of a drug effect is 
proportional to the rate of drug-target dissociation (rate theory), rather than to the occupancy of the target 
(occupancy theory).[11] Together with new technologies to determine drug-target binding kinetics and new 
compound series with varying binding kinetics, this has sparked a new interest in the application of 
especially the drug target dissociation rate constant koff as selection criterion in drug discovery.[12] 
However, drug-target binding kinetics is only a single step in the long chain of events from drug dosing to 
drug effect and many other processes influence the kinetics of drug action in vivo as discussed above. To 
understand the role of drug-target binding kinetics, to predict its influence on the time course of drug 
action, and to use it to develop better drugs, one should study drug-target binding kinetics in relation to the 
other determinants of the time course of drug action.  
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In this thesis, we studied a wide range of pharmacokinetic-pharmacodynamic (PKPD) models that include 
expressions to describe target binding kinetics by simulation for a wide range of their parameter values and, 
where possible, application to in vitro and in vivo pharmacokinetic and pharmacodynamic data. The main 
question in these studies was how the drug-target binding kinetics, in conjunction with plasma 
pharmacokinetics, tissue distribution kinetics, endogenous ligand competition, signal transduction kinetics 
and homeostatic feedback determine the in vivo time course of drug action. In this chapter, we first discuss 
how our findings contribute to our understanding of the influence of drug-target binding kinetics on the 
time course of drug action. Next, we discuss how our findings can be applied in drug discovery, drug 
development and in clinical practice. Finally, we provide suggestions for future research and conclude this 
thesis. 
The added value of drug target binding kinetics as selection criterion in drug discovery is relatively new and 
subject to an ongoing debate.[13] As described in chapter 1 and 3, the considerations regarding the role of 
drug-target binding kinetics, especially the dissociation rate constant koff, on the time course of drug effect 
in vivo fall into four categories:  
I) a low koff value can result in prolongation of target occupancy [3,14,15],  
II) a low koff value for the therapeutic target compared to the secondary-targets can give rise to 
an increase in selectivity over time [3,16,17],  
III) a low koff value will lead to a more constant blocking of endogenous ligand binding and thus 
block the endogenous signalling more effectively [18,19] and  
IV) a low koff value can yield a more efficient coupling to signal transduction, leading to a higher 
efficacy.[20,21] 
In this thesis, we have investigated the validity and the limiting conditions of the first three of the 
considerations that support the relevance of drug-target binding kinetics. The fourth consideration is 
beyond the scope of this work. Below, we will shortly summarise and discuss our findings for each of these 
three arguments.  
 
I. Target dissociation kinetics as determinant of the time course of target occupancy.  
 
The first consideration on the influence of the koff value on the duration of target occupancy was 
investigated in relation to i) plasma pharmacokinetics, ii) tissue distribution kinetics and iii) the 
concentration of the target, in chapter 2, 4 and 5. Simulations on the basis of a one-compartment 
pharmacokinetic model with target binding showed that the time course of target occupancy is only 
affected by the value of koff if both the koff is lower than the product of the elimination rate constant (kel) 
and unbound target fraction (1-BF) and the kon is lower than the ratio of kel/Rtot as illustrated in Figure 2. If 
the koff is lower than the product of the elimination rate constant and unbound target fraction and the kon is 









Figure 2. Approximation of the decline in target occupancy as function of koff and kon using a simple one 
compartment model with target binding. A: schematic representation of the approximated model. B: 
Approximation results for a total target concentration 1 nM (left panel) and 20 nM (right panel) an 
elimination rate constant of 0.1/h and a target fraction bound of 0.75, to represent a clinically relevant 
degree of target occupancy. Colours represent the decrease of target occupancy. The vertical line is given by 
KRLon = kel / (Rtot * kon) = 1, the horizontal line is given by KRLoff (BF) = kel * (1-BF)/koff = 1 and the diagonal line is 
given by the equation koff = kon * Rtot * (1-BF). In these equations, kel is the elimination rate constant, Rtot is 
total target concentration and BF is the bound fraction of the target. The annotations indicate which 
parameters influence the decrease in target occupancy in the corresponding segment of the plot.  
 
Figure 3. Simulations with a one compartment pharmacokinetic model with drug target binding demonstrate 
the parallel terminal phase of the pharmacokinetic and target occupancy curves. A: schematic 
representation of the model that was used for these simulations. For these simulations, the first order 
absorption rate constant ka was 3 hr-1, the first order pharmacokinetic elimination rate kel was 0.693 hr-1, the 




When drug distribution out of the target site is slow compared to its elimination from plasma, the 
distribution can also become the rate-limiting step in the decline of target occupancy, which leads to an 
equal influence of kon and koff on the duration of target occupancy. These findings contrast with studies that 
suggested that the role of the koff value is independent of the KD and the concentration of the 
target[4,15,22], but are in line with studies on rebinding, in which also a clear influence of the target 
concentration on the duration of target occupancy has been observed.[14,23,24] In chapter 4, we have 
shown that koff values, even when these are much lower than the pharmacokinetic elimination rate 
constant, lead to equilibrium between free target site and target-bound drug concentrations for high target 
concentration/KD ratios. This finding is in line with the equilibrium binding and steady-state assumptions, 
which require free and bound drug concentration to be in equilibrium, which are often successfully 
incorporated in drug target binding models.[25–27] Moreover, our findings in chapter 4 showed that the 
decline of plasma concentrations eventually parallels the decline of target occupancy on semi-log scale, 
even if drug-target dissociation is the rate-limiting step for the decline of target occupancy. This parallel 
decline is illustrated in Figure 3 for an extremely low target concentration of 0.001 nM and a KD of 10 nM. 
This low target concentration/KD ratio causes this parallel decline to appear only at the late time points and 
at an extremely low plasma concentration, but these simulations show that even in this case both plasma 
pharmacokinetics and target occupancy curves are eventually parallel. 
This parallel decline in drug concentration and target occupancy makes that the comparison of the terminal 
plasma half-life (t1/2z-pl) and target dissociation half-life (t1/2-dis) is only informative if the t1/2-dis is much 
shorter than the t1/2z-pl. If both half-lives have similar values, this does not necessarily dispute the influence 
of koff on the decline rate of target occupancy. This influence of the drug-target dissociation rate on the t1/2z-
pl might not be observed, because of the lower limit of quantification of the assays for determining drug 
concentrations in plasma. However, Dahl et al. [15] calculated the ratio of the t1/2z-pl and the t1/2-dis for a 
series of marketed drugs and observed that the t1/2-dis is often shorter than the t1/2z-pl. While this 
observation supports the conclusion of the authors that the t1/2-dis does not determine the duration of 
target occupancy, it should be noted that several of the studied drugs had a t1/2-dis in the same order of 
magnitude as the t1/2z-pl. As described above, if the target occupancy duration is determined by the t1/2-dis, 
the t1/2z-pl will be identical to the t1/2-dis. Thus, the duration of target occupancy for the drugs with a t1/2-dis 
in the same order of magnitude as the t1/2z-pl in the study of Dahl et al. could have been determined as well 
by the t1/2-dis.  
So far, our description of the influence of plasma elimination, target site distribution and the target 
concentration on the duration of target occupancy did not take into account the role of target synthesis and 
degradation, distribution to non-target binding tissues, and protein binding. These latter factors need to be 
addressed as well, as they can influence the duration of target occupancy (chapter 1). While extensive 
distribution to non-target binding tissues and plasma protein binding can reduce the effective elimination 
rate of the drug from the plasma and thereby prolong drug-target binding, a fast target turnover can reduce 
the duration of target occupancy, even for a slow drug-target dissociation compared to the plasma drug 
elimination or target site distribution. Thus, whereas the pharmacokinetic rate of elimination of the drug 
functions as an upper limit for the values of koff that influence the duration of target occupancy, the 
degradation rate constant of the drug-target complex functions as a lower limit for the values of koff that 
influence the duration of target occupancy. 
In summary, a low koff value can prolong the duration of target occupancy, but this prolongation can only be 
predicted in conjunction with the pharmacokinetics, target concentration and target turnover. 
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II. The relation between the koff value for different targets, target selectivity and tissue 
selectivity 
 
The second consideration for the relevance of the koff value for the time course of drug action is based on 
the differential duration of target occupancy between the therapeutic target and the off-target(s), as can be 
caused by different koff values. In chapter 6, we distinguish between selective binding to the therapeutic 
target relative to off-targets caused by differential koff values, which is commonly referred to as “kinetic 
selectivity” [3,16,17], and selective binding to a target in the therapeutic tissue, relative to tissues that 
mediate side effects, which is commonly referred to as “tissue selectivity”[28,29]. Kinetic selectivity is closely 
related to the time course of target occupancy for each target. Therefore, the principles for single target 
binding in one tissue as identified in chapter 4 are likely to hold for kinetic selectivity as well. Our 
simulations in chapter 6 were in line with chapter 4: a high target concentration/KD ratio leads to a 
prolonged duration of target occupancy, which is caused by a slow decline of the drug concentration at the 
target site. As a consequence, all targets at the same target site will be exposed to drug concentrations that 
decline slowly and their duration of target occupancy will be equally long. On the other hand, any tissues 
with much lower target concentrations than the therapeutic tissue will be exposed to faster decline of drug 
concentrations and the target occupancy in those tissues will also decline faster. This results in tissue 
selectivity. This is illustrated in Figure 4, where target 2 has a much longer target occupancy duration in 
tissue 1 compared to tissue 2, while both tissues have the same distribution rate constants, the same 
concentration of target 2 and the same binding kinetics to target 2. The long duration of target occupancy in 
tissue 1 is caused by the high concentration of target 1, which causes retention of the drug in tissue 1, as 
reflected by the concentration profiles.  
However, tissue selectivity decreases when KD is extremely low and the concentration of the target is higher 
than the KD in both therapeutic and non-therapeutic tissues, as compared to tissues with reasonably high KD 
values. These results demonstrate that a high KD value may result in a decrease in both kinetic selectivity 
and tissue selectivity. Moreover, the combination of target and tissue selectivity may lead to a reversal of 
selectivity over time if one of the targets has a high target concentration. We have shown that the use of 
mechanistic modelling and simulation combined with statistical Quantitative Structure Activity Relationship 
(QSAR) modelling can help to predict both target and tissue selectivity in the earliest stage of drug 
discovery. However, we also found that these predictions are dependent on the effective distribution of the 
target site and the target concentration. These latter parameters might be difficult to obtain with high 
precision, especially in the earliest phase of drug discovery.  
In short, a low koff value can result in kinetic selectivity, but only when the target concentration/KD ratio is 
not high enough to induce a slow decline of local drug concentrations. Moreover, a high target 
concentration or low KD value can increase tissue selectivity. 
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Figure 4. Simulation of simultaneous target and tissue selectivity and the influence of the target 
concentration. A: schematic representation of the applied model structure for these simulations. ka = 
absorption rate constant, kin = inwards distribution rate constant, kout = outwards distribution rate constant, 
kon = association rate constant, koff = dissociation rate constant, kF = forward rate of elimination constant, LR 
= ligand-receptor complex, V = tissue volume (L), nbt = non-binding tissue, c = plasma compartment, bt = 
binding tissue, nbt = non-binding tissue, el = elimination tissue. The values for kon and koff were 10 nM-1 h-1 
and 10 h-1, respectively, for both targets. The values for kinbt and koutbt were 2.6 and 0.88 h-1, respectively, and 
Vbt was 2 L for both tissues, the target concentration for target 1 was 100 nM and was 1 nM for target 2 in 
both tissues. The values of the other parameters were: ka = 3 h-1, kinnbt = 60 h-1, koutnbt = 5.5 h-1, kinli = 17 h-1, 
koutli  = 54 h-1, kF = 100 h-1, Vc  = 6 L, Vnbt  = 66 L, Vli  = 1.9 L  B: Drug concentration and target occupancy of 
target 1 (solid line) and target 2 (dashed line) in tissue 1. Both target occupancy profiles are identical. C: 
Drug concentration and target occupancy of target 2 (dashed line) in tissue 1. 
 
III. The relation between the koff value, resilience to endogenous ligand binding, signal 
transduction and homeostatic feedback. 
 
The third consideration that supports the relevance of the koff value for the time course of drug action is 
related to the resilience to endogenous ligand competition. This idea has been raised in relation to 
dopamine D2 antagonists [18], but the principle also holds for any other target where endogenous 
competition is important. In short, an endogenous signal in the form of a steep increase and decrease in the 
endogenous ligand concentration would normally lead to endogenous ligand binding to the target and 
further signal transduction. In the presence of a drug with a high koff value that is bound to the target, this 
rise in endogenous ligand would still lead to binding of the endogenous ligand, albeit to a lesser degree 
depending on the concentration of the drug and its KD. For a drug with a low koff value, the endogenous 
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ligand would not have enough time to displace the drug from the receptor before its concentrations go 
down to the basal level. As a result, for a drug with a relatively high koff value, part of the physiological 
signalling is maintained, whereas for a compound with a relatively low koff value the signalling would be 
completely blocked. In the case of the dopamine D2 receptor, this extensive blocking of the dopaminergic 
signalling is considered to lead to side effects, and a low koff value is therefore considered to be a 
disadvantage of a D2 antagonist. In Chapter 8, we found that a low koff value can indeed prolong the drug-
target occupancy with fluctuating endogenous ligand concentrations. However, we also found that this 
influence of the drug koff only occurs when the endogenous ligand koff is high enough to result in rapid 
endogenous ligand binding. Moreover, if the turnover of the signal transduction molecules is not fast 
enough, the rapid increase and decrease of endogenous ligand target occupancy does not lead to rapid 
fluctuations in the concentrations of the signalling molecules. This limited influence of the koff value on the 
drug effect to frequently fluctuating endogenous ligand concentrations for high koff values was not identified 
in a previous study that did not take the endogenous ligand koff and the signal transduction kinetics into 
account.[19] The limited translation of fluctuating endogenous ligand concentrations into fluctuating second 
messengers is in line with the concept of frequency encoding, which explains that the strength of biological 
signals can be translate into the frequency of the fluctuations in signalling molecules and vice versa. These 
fluctuations are therefore only representing the strength of a signal and eventually not translated into a 
fluctuating effect, but into a stable effect, the extent of which is dependent on the fluctuation frequency of 
the signalling molecules.[30] 
In summary, the koff value of a drug (especially an antagonist) is only relevant for the resilience to 
endogenous signalling if both the endogenous ligand koff and the turnover of the signalling molecules are 
high enough to translate the endogenous ligand fluctuations into fluctuations in signalling strength. 
 
Modelling the delay between pharmacokinetics and pharmacodynamics and the relevance of 
drug-target binding. 
 
One of the considerations that disputes the relevance of the koff value for the time course of drug action is 
that, on one hand, the drug-target binding kinetics are not generally required in PKPD models that give a 
good description of the observed drug concentration and effect data. On the other hand, target binding 
models are often required to adequately describe antibody pharmacokinetics, in so called Target Mediated 
Drug Disposition (TMDD) models, which can and have been applied to small molecules as well.[25,31,32]  
The effect compartment model is typically used to explain hysteresis, rather than a target binding 
model.[33] However, this does not necessarily mean that drug-target binding kinetics does not influence the 
time course of drug action. In Chapter 7, we compared the target binding model and the more popular 
effect compartment model and found that these models do not lead to a different time course of the drug 
effect for all parameter values combinations that result in a delay between drug concentrations and drug 
effect. In other words, hysteresis between plasma drug concentrations and effect can be described equally 
well by an effect compartment and a target binding model for many of the parameter value combinations 
used in this study. Although this is not a finding that directly supports the relevance of drug target binding 
for the time course of drug action, it does suggest that the drug-target binding model should be tested more 
often to allow prediction of the time course of drug action, by the incorporation of in vitro data, and 
therewith to improve the in vitro-in vivo translation in drug discovery.  
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Perspectives for the development and application of pharmacotherapy 
 
The centrality of the drug-target binding event in drug treatment makes our findings applicable across the 
whole range of pharmacotherapy, from drug discovery to clinical practice. The most general application of 
our work is that we obtained a better understanding of drug-target binding kinetics and its role in the 
complex chain between drug dosing and drug effect. Below, we discuss more specifically how our insights 
can be applied in drug discovery, drug development and clinical practice. 
In drug discovery, the selection of the best drug candidates is essential because of the limited resources and 
the large number of molecules that enter the drug discovery phase, while only a limited number of tests can 
be performed. Therefore, these tests need to yield information on the most critical drug properties which 
can be easily translated into selection criteria for the best drug candidates. The current understanding of the 
value of drug-target binding kinetics as a selection criterion in drug discovery is limited and mostly focussed 
on obtaining drugs with low koff values. In this thesis, we have shown that a low koff value is only a beneficial 
drug property if the whole PKPD context favours the influence of the koff on the time course of drug action. 
Therefore, our findings suggest that for any new disease/therapeutic indication, detailed knowledge on the 
system-specific parameters is required before knowledge of drug-target binding kinetics can be applied 
meaningfully. Such parameters include the concentration of the target, its degradation and synthesis rate 
constants, the perfusion of the target site and the concentration and binding kinetics of endogenous 
ligands. Subsequently, mechanistic PKPD modelling should be applied to identify the optimal drug 
properties, including the drug target koff and KD.  
As a rule of thumb, targets that are expressed at a higher concentration than the KD value of the drug and 
targets with a faster degradation rate constant than the koff value of the drug are not expected to favour the 
relevance of the koff value. 
In drug development, the in vitro – in vivo translation of drug effects and the translation across animal 
species is essential to get the best drug candidates to the market. For this, the combination of in vitro-in vivo 
extrapolations (IVIVE) with physiologically based pharmacokinetic models can be used to predict drug 
effects across animal species and humans.[34,35] However, drug target binding kinetics are often not 
incorporated in these models. Our results suggest that the target concentrations, the perfusion of the target 
tissue and active processes in drug distribution to the target site are important and need to be included in 
these models to enable translation between species, especially for high affinity compounds. 
In clinical practice, the prediction and understanding of the time course of drug action can be critical for 
effective and safe drug treatment. Our findings in chapter 4 and 6 demonstrate that a delayed onset and 
offset of drug action can be caused by slow drug-target binding kinetics or binding to a target with a high 
target concentration. Importantly, if these mechanisms drive a delayed onset of the drug effect, this can be 
avoided by using higher drug doses. Thus, the combination of a high initial drug dose (loading dose) 
combined with lower subsequent doses (maintenance dose) can be used to achieve rapid drug action while 
still minimizing toxicity. Since our findings demonstrate the influence of the target concentration on the 
time course of drug action, these findings can also be used to individualize drug dosing based on target 
concentrations. This might be especially relevant for high target concentrations that are also highly variable 




Future research  
 
The findings described in this thesis present an improved understanding of the influence of drug-target 
binding kinetics on the time course of drug action in relation to the most important determinants of the 
time course of drug action. However, the complete biological system that determines drug action is too 
complex to understand completely or even to describe all elements and their relation with the role of drug-
target binding kinetics. The main questions that remain elusive after the studies in this thesis are described 
below. 
As mentioned in chapter 1 and in the discussion above, the turnover of the target can be an important 
factor that influences the role of drug-target binding kinetics. Although target turnover is often referred to 
as a single parameter, its relation with drug-target binding kinetics is complex since the turnover of the 
unbound target can be different than the turnover of drug-target complex. This is schematically represented 
in Figure 5. The analysis of target turnover can be simplified by assuming that the turnover of the unbound 
target (kdegT) and the drug-target complex (kdegC) are equal, but differences between these two parameters 
of more than tenfold have been estimated from in vivo data.[37–39] In these studies kdegT has been 
observed to be both more than tenfold larger and more than tenfold smaller than kdegC. A consequence of a 
difference in kdegT and kdegC is that the total target concentration is not constant and depends on the amount 
of target binding. This makes the level of target occupancy and the drug-target affinity constant KD less 
informative parameters [40] and makes mathematical analysis of the model less straightforward. Moreover, 
the pharmacological entity that drives the drug effect depends on the disease and the target: for an enzyme 
inhibitor, the concentration of the unbound target determines the drug effect, while for a receptor agonist, 
the concentration of the drug-target complex drives the drug effect. These complexities have not been 
investigated in this thesis and it would require further research to understand their relationship with drug-
target binding kinetics. 
 
Figure 5. schematic representation of target turnover in relation to drug-target binding kinetics and 
pharmacokinetics. kel, kdegT, kdegC and koff represent the first order rate constant of elimination of the drug 
from plasma, degradation of the unbound target, degradation of the drug-target complex and dissociation 
of the drug-target complex, respectively. kon represents the second order drug-target association rate 
constant, ksyn represents the zero-order target synthesis rate constant. 
In addition to the influence of drug-target turnover, the translation from target occupancy to drug effect 
also requires further exploration. First of all, several authors have observed a correlation between the koff 
and the efficacy of agonists.[21,41,42] Interestingly, these correlations all show a higher efficacy for agonists 
with lower koff values, which is opposite to what Paton postulated in his rate theory in 1961.[11] The higher 
efficacy of slowly dissociating drugs can be explained by a more efficient coupling of activated receptors to 
signal transduction if they are active for a longer continuous period of time, which reduces the fraction  of 
aborted signalling events.[21] This correlation between koff and efficacy should be supported with more 
compound series for various targets and with the analysis of mechanistic signal transduction models. 
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Secondly, the occurrence of a non-linear target occupancy versus effect relationship (transducer function) 
can reduce the impact of a change in target occupancy levels and its rate.[43] If the transducer function, for 
example, has the classical sigmoidal shape, this means that a fast declining target occupancy does not lead 
to a fast decline of the drug effect if the target occupancy is close to 100%. In a clinical setting of 
continuously high target occupancies, this would make the decline rate of target occupancy less relevant for 
the duration of drug effects. It should be noted that this nonlinearity can have a similar influence on the 
time course of drug action as the nonlinearity between drug concentrations and target occupancy, as 
described in chapter 2. In addition, the occupancy versus effect relationship can have various profiles, 
including a parabolic profile [44,45], which further complicates the translation from target occupancy 
kinetics to drug effect kinetics. The signal transduction system that was analysed in chapter 8 included the 
turnover of secondary messengers and regulation via a negative feedback loop. While we did observe the 
influence of the turnover of the feedback molecule on the transduction of fluctuating endogenous ligand 
concentration, we focused mainly on the fluctuation amplitude of the response in steady-state. The 
presence of homeostatic feedback mechanisms can also influence the initial response to a drug after its first 
administration and lead to a system with multiple steady-states.[46] Such a system can be sensitive to the 
rate of administration of a drug[47] which makes it more likely for the rate of drug-target association to 
influence which of the steady-states will be reached. Finally, signal transduction is often interlinked with an 
extensive signalling network with signalling cascades that are branched and result in simultaneous signal 
transduction at multiple levels, as identified for GnRH analogues.[48] Analysing the influence of drug-target 
binding kinetics on the drug effect in such complex networks would require additional research. The 
simulation-based frequency response analysis that was applied in chapter 8 could also be applied to such 
signalling networks to unravel their dynamic behaviour and its determinants. 
Conclusions 
The research in this thesis has improved our understanding of the influence of drug-target binding kinetics 
on the time course of drug action. We have especially elucidated and quantified how drug-target binding 
kinetics relate to the other determinants of the time course of drug action, including pharmacokinetics, 
target turnover, endogenous competition and signal transduction. This research does not provide a 
complete understanding of all these factors and further research is especially required on the interaction 
between target turnover, signal transduction and binding kinetics. Nonetheless, our insights can be applied 
to the selection of better drug candidates, to improve translational research and to optimize and 
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Samenvatting in het Nederlands 
Op mechanisme gebaseerde modellering van de binding van geneesmiddelmoleculen aan het doelwit als 
bepalende factor voor het beloop van het effect in vivo. 
 
Deel 1. Introductie 
Zowel lichaamseigen stoffen als lichaamsvreemde geneesmiddelen kunnen alleen een effect in het lichaam bewerkstelligen 
als gevolg van het binden aan hun “bindingsplaats”. Dit is meestal een eiwit zoals een receptor, een enzym of een ion 
kanaal. De snelheid van het binden van een geneesmiddel aan (associatie) en het weer loskomen van (dissociatie) het 
doelwit wordt bindingskinetiek genoemd. Deze bindingskinetiek kan een bepalende factor zijn voor het beloop van het 
effect na toediening van een geneesmiddel.  
Van kandidaat geneesmiddelen wordt om die reden in toenemende mate de bindingskinetiek bepaald. De meest 
eenvoudige beschrijving van bindingskinetiek is weergegeven in vergelijking 1, waar kon de tweede orde associatie 
snelheidsconstante, koff de eerste orde dissociatie snelheidsconstante, L de concentratie van de stof die bindt aan het 
doelwit (het ligand), R de concentratie van het doelwit en LR de concentratie van het gebonden geneesmiddel-doelwit 
complex is. De ratio koff/kon is gelijk aan de dissociatie constante KD. 
 





 𝐿𝑅                                                                                                1  
De beschrijving van de bindingskinetiek van een geneesmiddel aan het doelwit, zoals gegeven in vergelijking 1, wordt in de 
praktijk toegepast om het beloop van concentraties van monoclonale antilichamen te beschrijven in zogenaamde 
wiskundige “target mediated drug disposition” (TMDD) modellen. Echter, in de selectie van kleine moleculen (dat wil 
zeggen stoffen met een molecuulgewicht kleiner dan 1000 Dalton) wordt de bindingskinetiek meestal niet meegenomen in 
de beschrijving van het beloop van de concentratie (de farmacokinetiek) en de optimalisatie tot geneesmiddelen. 
Bovendien wordt bij de beschrijving van de farmacokinetiek en van het effect (de farmacodynamiek)  de snelheid van 
associatie en dissociatie meestal verwaarloosd, er van uit gaande dat deze snelheden zo hoog zijn in vergelijking met 
andere processen op het causale pad van toediening tot het effect, dat deze niet een snelheidsbepalende stap vormen. 
Echter, sinds 2006 is er een nieuwe interesse ontstaan in het gebruik van de bindingskinetiek als selectie criterium bij het 
ontwikkelen van nieuwe kleine moleculen tot geneesmiddelen. Hierbij is er vooral aandacht voor de waarde van koff, om de 
volgende vier redenen:  
• Een lage koff waarde kan resulteren in een langere bezetting van het doelwit en daarmee indirect een verlenging 
van de werkingsduur. 
• Een lage koff waarde kan resulteren in een meer selectieve bezetting van de gewenste bindingsplaats ten opzichte 
van ongewenste bindingsplaatsen, met als gevolg een gunstiger verhouding tussen de gewenste werking en 
mogelijke bijwerkingen. 
• Een lage koff waarde kan resulteren in een bezetting van het doelwit die minder gevoelig is voor competitie door 
wisselende concentraties van endogene stoffen die aan dezelfde bindingsplaats binden.  
• een lage koff waarde kan resulteren in efficiëntere koppeling tussen de binding en de verdere signaal overdracht. 
Het onderzoek dat is beschreven in dit proefschrift is gericht op de relatie tussen de koff en het beloop van de bezetting van 
het doelwit en het effect, zoals naar voren komt in de eerste drie van de bovengenoemde punten. Het vierde punt lag 
daarmee buiten het beoogde bereik van dit proefschrift. 
De kinetiek van de binding van een geneesmiddel aan het doelwit is slechts éen van de processen op het causale pad van 
toediening tot en met effect die het beloop van de werking in vivo bepalen.  Dit is één van de redenen waarom het lastig is 
om in vitro metingen van bindingskinetiek te vergelijken met in vivo metingen, zoals besproken is in hoofdstuk 1. Andere 
factoren met een grote invloed op het tijdsverloop van geneesmiddeleffecten in vivo zijn o.a. de snelheid waarmee het 
geneesmiddel in het lichaam wordt opgenomen, zich verdeelt over de weefsels en uiteindelijk weer wordt 
afgebroken/verwijderd en de snelheid waarmee het geneesmiddel de plaats van werking bereikt en weer verlaat. Deze 
factoren bepalen het beloop van de concentratie in het lichaam en daarmee indirect ook het beloop  van het effect.  
Een andere belangrijke factor is de aanwezigheid van endogene stoffen. Deze binden aan dezelfde bindingsplaats als het 
geneesmiddel en kunnen door deze competitie de binding van het geneesmiddel aan de bindingsplaats verhinderen. 
Verder is ook de afbraaksnelheid van het doelwit een belangrijke factor die de werkingsduur van geneesmiddelen kan 
beïnvloeden, aangezien een doelwit dat snel wordt afgebroken bij voorbaat al geen lange duur van bezetting kan hebben. 
Tenslotte is de snelheid waarmee na binding, en daarmee activatie of blokkering van de bindingsplaats, het signaal wordt 
overgedragen via signaalstoffen en de terugkoppelingsmechanismen die dit in gang zet ook van invloed op de tijdsduur van 
het effect.  
Het doel van dit proefschrift was om de samenhang tussen enerzijds de kinetiek van de binding aan het doelwit en 
anderzijds het beloop van de bezetting van het doelwit en uiteindelijk het effect in vivo te onderzoeken. Dat is vooral, maar 
niet uitsluitend, belangrijk als de kinetiek van de binding de snelheidsbepalende stap is. Dit concept is bekend van 
chemische reactievergelijkingen waarbij de langzaamste reactie vaak de snelheidsbepalende stap wordt genoemd. Voor de 
duur van de bindingsplaats bezetting door het geneesmiddel kan de invloed van de koff dan ook onderzocht worden door 
de afnamesnelheid van de doelwitbezetting te vergelijken met de snelheid van de andere processen, zoals de snelheid 
waarmee de geneesmiddelconcentraties afnemen. 
Bij het bepalen van de snelheidsbepalende stap is een belangrijke factor dat de snelheid waarmee de doelwitbezetting 
afneemt niet constant is ten opzichte van de geneesmiddelconcentratie vanwege de niet-lineaire relatie tussen de 
concentratie van het geneesmiddel en de bezettingsgraad van het doelwit, waarbij bij hogere concentraties verzadiging 
van de binding aan het doelwit optreedt. Dit betekent, zoals beschreven in hoofdstuk 2, dat een halvering van de 
geneesmiddelconcentratie slechts zorgt voor een kleine afname in de bezettingsgraad van het doelwit wanneer de 
geneesmiddelconcentraties hoog zijn, terwijl bij een lage geneesmiddelconcentratie dit ook zorgt voor een halvering van 
de bezettingsgraad. Dit betekent dat bij een hoge bezettingsgraad van het doelwit pas bij een veel lagere waarde van de 
koff de dissociatie van de bindingsplaats de snelheidsbepalende stap is. In hoofdstuk 2 hebben we deze relatie verder 
gekwantificeerd. 
Deel 2. Simulaties, modelanalyse en experimentele validatie van de invloed van bindingskinetiek op het 
beloop van de doelwit bezetting.  
 
De relaties tussen enerzijds de kinetiek van de binding aan het doelwit en anderzijds het beloop van het effect zijn 
complex, omdat de verschillende processen op het causale pad niet onafhankelijk van elkaar zijn. Dit is vooral duidelijk bij 
de afname van geneesmiddelconcentraties en de dissociatie van het doelwit-geneesmiddel complex. Wanneer dit complex 
uiteenvalt komt er namelijk weer ongebonden geneesmiddel vrij die de dalende plasmaconcentraties aanvult, wat ervoor 
zorgt dat de afname van de geneesmiddelconcentratie langzamer gaat dan wanneer er geen geneesmiddel dissocieert van 
het doelwit. Om in deze situatie te bepalen wat de snelheidsbepalende stap is voor de afname van bindingsplaats 
bezetting, beschrijven we in hoofdstuk 4 een integraal wiskundig model voor het beloop van de bezetting van het doelwit 
voor een systeem waarin het doelwit zich in het plasma compartiment of in een perifeer compartiment bevindt. Daarbij 
houden we zowel rekening met de verzadiging van de bindingsplaats als met de interactie tussen farmacokinetiek en 
doelwitbinding. Het resultaat van onze benadering is een algebraïsche formule voor de afname van de bezettingsgraad van 
het doelwit, als functie van de kel, de koff, de kon, de concentratie van de bindingsplaats, de snelheidsconstanten die de 
distributiesnelheid naar de plaats van binding bepalen en de gebonden fractie van het doelwit. Met deze formule hebben 
we kunnen onderzoeken voor welke waarden van kon en koff de dissociatie van het doelwit de snelheidsbepalende stap 
voor het beloop van de bezettingsgraad van het doelwit is.  
Onder de aanname van een relatief snelle distributie naar de bindingsplaats geldt volgens deze benadering dat dissociatie 
alleen de snelheidsbepalende stap is wanneer de koff kleiner is dan kel * (1-BF) en kon kleiner is dan kel/Rtot. Hierbij is BF de 
gebonden fractie van de bindingsplaats en Rtot de concentratie van de bindingsplaats. Hieruit volgt dat voor een waarde 
van kon groter dan kel/Rtot, de dissociatie van het doelwit nooit de snelheidsbepalende stap is voor de afname van de 
doelwitbezettingsgraad, ongeacht hoe laag de waarde van koff is. In dit geval heeft de kon een even grote invloed op de 
afnamesnelheid van de doelwitbezetting als de koff, aangezien de binding in evenwicht is en daarmee dus bepaald wordt 
door de KD. In deze formules is ook duidelijk de belangrijke rol van de concentratie van het doelwit zichtbaar, terwijl hier 
vaak geen rekening mee wordt gehouden in het onderzoek naar de rol van bindingskinetiek. Wij concluderen dan ook dat 
het begrip van de rol van bindingskinetiek verbeterd is door rekening te houden met de concentratie van het doelwit en de 
invloed van binding op de farmacokinetiek. 
In hoofdstuk 5 concentreren we ons met name op de invloed van binding op lokale geneesmiddelconcentraties rondom de 
bindingsplaats (de concentraties in de zgn. “biofase”). Hiervoor spelen dezelfde principes een rol als beschreven in 
hoofdstuk 4, maar de lokale geneesmiddelconcentratie rondom de bindingsplaats, als gevolg van de binding aan het 
doelwit, is altijd hoger in vergelijking met de vrije concentraties elders in het weefsel of in het lichaam In dit hoofdstuk 
vergelijken we twee benaderingsmethoden voor de invloed van bindingsplaatsbinding op lokale concentraties: de 
“snelheidsbepalende stap” benadering, zoals beschreven in hoofdstuk 4, en de zogenaamde “evenwichtsbenadering”, 
waarbij wordt aangenomen dat de lokale concentraties snel veranderen ten opzichte van de doelwitbinding. Deze twee 
methodes zijn beide algebraische benaderingen van hetzelfde volledige wiskundige model, dat bestaat uit 
differentiaalvergelijkingen. We hebben deze benaderingsmethoden dan ook vergeleken met het volledige model door met 
alle methoden de bezettingsgraad van het doelwit te simuleren. Uit deze simulaties bleek dat de “snelheidsbepalende 
stap” benadering de beste benadering geeft van de volledige set aan differentiaalvergelijkingen. De verschillen tussen 
beide benaderingen zijn vooral groot wanneer de dissociatie van het doelwit-geneesmiddel complex relatief snel gaat ten 
opzichte van de snelheid waarmee het geneesmiddel verdwijnt uit de omgeving van het doelwit (middels diffusie of actief 
transport) en de associatie aan het doelwit. Dit valt ook te begrijpen omdat deze evenwichtsaanname onder deze condities 
niet geldt. We concluderen dat de snelheidsbepalende stap benadering de voorkeur heeft voor het beschrijven van de 
invloed van binding op lokale geneesmiddel concentraties. 
In hoofdstuk 6 breiden we ons onderzoek uit naar de duur van bindingsplaats bezetting van zowel de gewenste 
bindingsplaats als van een ongewenste bindingsplaats. We bestuderen hier dus het verloop van selectiviteit over tijd en de 
beïnvloeding hiervan door de bindingskinetiek en de bindingsplaatsconcentratie. We onderzoeken twee soorten 
selectiviteit d.m.v. simulatiestudies: “bindingsplaatsselectiviteit” verwijst naar selectiviteit voor een bindingsplaats ten 
opzichte van andere bindingsplaatsen, en “weefselselectiviteit” verwijst naar selectiviteit voor een weefsel ten opzichte 
van andere weefsels. Uit deze simulatiestudies blijkt dat de invloed van de bindingskinetiek en de 
bindingsplaatsconcentratie zoals beschreven in hoofdstuk 4 ook relevant is voor bindingsplaats- en weefselselectiviteit. 
Voor het verloop van bindingsplaatsselectiviteit over tijd wordt vaak gezegd dat een lagere koff voor de gewenste 
bindingsplaats ten opzichte van de ongewenste bindingsplaats zorgt voor een toename van selectiviteit over tijd, ook wel 
“kinetische selectiviteit” genoemd. Uit onze simulaties blijkt dat een hoge bindingsplaats concentratie of een lage KD deze 
kinetische selectiviteit vermindert, omdat dit zorgt voor een afname van de bezettingsgraad die niet door de dissociatie 
wordt bepaald. Verder zorgt een lage KD juist voor een toename van weefselselectiviteit voor het weefsel met de hoogste 
bindingsplaats concentratie door retentie van het geneesmiddel in dit weefsel, tenzij de KD zo laag wordt dat de 
geneesmiddel retentie ook in het weefsel met de laagste bindingsplaats concentratie plaatsvindt. 
In hoofdstuk 6 laten we tenslotte zien dat deze inzichten toegepast kunnen worden op drie bestaande geneesmiddelen en 
hun selectiviteit voor de CB1 receptor. Op basis van een nieuw ontwikkelde voorspelling van de KD voor deze stoffen voor 
de CB1 receptor,  3 andere receptoren, en de receptorconcentraties in 3 verschillende hersengebieden, laten we zien dat 
de selectiviteit voor de verschillende hersengebieden wordt bepaald door de receptorconcentraties en KD waardes. 
Bovendien blijkt uit deze simulaties dat het voor stoffen met een lage KD meerdere dagen kan duren voordat een stabiele 
bezettingsgraad van de receptor bereikt wordt. We concluderen dat een lage KD waarde niet altijd wenselijk is en dat er bij 
optimalisatie van de KD en de bindingskinetiek rekening gehouden dient te worden met de concentraties van de 
bindingsplaatsen en de distributiesnelheid naar de verschillende weefsels. 
Deel 3. Simulaties, modelanalyse en experimentele validatie van de invloed van bindingskinetiek op het 
tijdsverloop van geneesmiddel effecten.  
 
Terwijl we in de voorgaande hoofdstukken vooral onderzochten hoe bindingskinetiek de bezettingsgraad van het doelwit 
beïnvloedt, beschrijven we in hoofdstuk 7 de invloed van bindingskinetiek op het tijdsverloop van een geneesmiddeleffect. 
We focussen ons in dit hoofdstuk op het verschil in het tijdsverloop van een geneesmiddeleffect tussen de situatie waar de 
distributie naar de plaats van werking langzaam is en de situatie waar de binding aan de bindingsplaats langzaam is. De 
wiskundige modellen die deze situaties beschrijven hebben we gebruikt om een bestaande collectie meetgegevenste 
analyseren van het effect van morfine op het elektro-encefalogram (EEG) in ratten. Bij deze analyse zagen we dat het lastig 
was om het verschil in de beschrijving van de meetgegevens tussen beide modellen te zien en dat alleen een kwantitatieve 
analyse van de beschrijving van de meetgegevens voor beide modellen kon laten zien dat het model voor de langzame 
distributie naar de plaats van werking de data het best beschreef. 
Om het verschil tussen beide modellen verder uit te zoeken hebben we ook geanalyseerd voor welke parameterwaardes 
het gebruik van verschillende doseringen leidt tot een verschil in de tijd tot het maximale geneesmiddeleffect in het 
bindingsmodel. Het verschuiven van de tijd tot het maximale geneesmiddeleffect is namelijk een belangrijke eigenschap 
die het verschil tussen het bindingsmodel en het distributiemodel bepaalt. Uit deze analyse bleek dat een koff die veel 
kleiner is dan de kel en een KD die veel kleiner is dan de doelwitconcentratie zorgen voor een vermindering van het 
verschuiven van de tijd tot het maximale geneesmiddeleffect. Daardoor is onder deze voorwaarden het verschil tussen 
beide modellen klein en moeilijk te identificeren. De kleine verschillen tussen het bindings- en distributiemodel zorgen 
ervoor dat een beschrijving van experimentele gegevens met één van deze modellen niet voldoende is om de relevantie 
van het gebruikte mechanisme aan te tonen, terwijl deze denkstap in de literatuur wel vaak impliciet of expliciet gemaakt 
wordt. We pleiten dan ook voor het vaker testen van het bindingsmodel, ook omdat voor dit model in vitro gegevens 
kunnen worden gebruikt en zo een betere in vitro - in vivo vertaling kan worden verkregen. Bovendien kunnen op deze 
manier ook mogelijke interacties van stoffen die binden aan dezelfde bindingsplaats beter worden gekarakteriseerd. 
In hoofdstuk 8 komen de laatste onderwerpen uit dit proefschrift aan de orde: de invloed van de bindingskinetiek van 
endogene stoffen en de rol van signaaltransductie en terugkoppelingsmechanismen. Om dit te kunnen onderzoeken is 
eerst de bindingskinetiek van dopamine en 17 verschillende dopamine antagonisten in vitro bepaald. Vervolgens zijn de 
cyclisch adenosine monofosfaat (cAMP) responsprofielen gemeten na pre-incubatie met dopamine en toevoeging van de 
antagonisten. Deze gegevens zijn gebruikt om een minimaal mechanistisch model te ontwikkelen. Dit model beschrijft de 
competitieve binding van dopamine en de antagonist aan de dopamine D2 receptor, de invloed van receptorbinding op de 
cAMP synthese en de negatieve terugkoppeling tussen cAMP en PDE (fosfodiësterase). Tenslotte beschrijven we de analyse 
van dit model middels een simulatie studie met fluctuerende dopamine concentraties. De endogene 
dopamineconcentraties fluctueren in vivo op verschillende tijdschalen variërend van seconden tot uren. Om dit na te 
bootsen hebben we de dopamineconcentraties laten variëren volgens een sinusfunctie, waarbij de frequentie van de 
sinusfunctie werd gevarieerd om zo een wijd bereik van frequenties te onderzoeken. Uit deze studie kwam naar voren dat 
voor hoge frequenties van dopamineconcentratiefluctuaties de binding van dopamine aan de receptor en de 
omzettingssnelheid van cAMP te laag zijn om deze concentratiefluctuaties om te zetten in fluctuaties van cAMP. Deze 
hoogfrequente dopaminefluctuaties resulteren in een stabiele, gemiddelde cAMP respons. Dit betekent ook dat de koff van 
de dopamine agonisten geen invloed meer heeft op de gevoeligheid voor fluctuaties in dopamine concentraties zodra deze 
koff hoger is dan de koff van dopamine of de degradatiesnelheidsconstante van cAMP. In dit hoofdstuk hebben we dus laten 
zien dat de invloed van bindingskinetiek bestudeerd moet worden in verband met de bindingskinetiek van endogene 
stoffen, signaal overdracht en terugkoppelingsmechanismen. 
In hoofdstuk 9 bespreken we de bevindingen uit de voorgaande hoofdstukken en hoe deze bevindingen zich verhouden 
met de bestaande inzichten. Verder bespreken we de mogelijkheden voor vervolgonderzoek en vatten we de belangrijkste 
conclusies van het onderzoek samen. We laten in dit hoofdstuk zien dat de kinetiek van de binding aan het doelwit alleen 
onder specifieke omstandigheden een invloed heeft op het beloop van de bezettingsgraad en het geneesmiddeleffect. 
Tevens leveren we kwantitatieve richtlijnen over de parameterwaarden die leiden tot een grote invloed van de koff op de 
werkingsduur van een geneesmiddel. In dit proefschrift hebben we ons vooral gericht op de relatie tussen bindingskinetiek, 
farmacokinetiek, competitie met endogene stoffen, signaal transductie en terugkoppelingsmechanismen. Eén van de 
onderwerpen die we wel deels hebben besproken maar nog verder onderzocht moet worden is de invloed van de 
omzettingssnelheid van het doelwit. Verder hebben we de invloed van signaaloverdracht slechts onderzocht voor één 
overdrachtssysteem met omzetting van een eerste signaalstof en negatieve terugkoppeling hierop. Dit zou verder 
onderzocht kunnen worden voor meer complexe systemen met positieve terugkoppeling en vertakte 
signaaloverdrachtssystemen. 
In dit proefschrift is steeds gebleken dat de rol van bindingskinetiek alleen begrepen kan worden als andere relevante 
factoren, zoals de farmacokinetiek, ook meegewogen worden. We hebben niet alleen laten zien dat dit nodig is maar ook 
hoe dit bepaald kan worden. We concluderen dan ook dat de rol van bindingskinetiek alleen begrepen kan worden met 
inbegrip van de gehele farmacokinetische en farmacodynamische context. Alhoewel nog steeds meer onderzoek te 
verrichten valt kunnen de inzichten die wij hier hebben verkregen gebruikt worden om de beste geneesmiddelkandidaten 
te selecteren en verder te ontwikkelen. 
 
